0001437749-16-042352.txt : 20161117 0001437749-16-042352.hdr.sgml : 20161117 20161117171947 ACCESSION NUMBER: 0001437749-16-042352 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 72 CONFORMED PERIOD OF REPORT: 20160930 FILED AS OF DATE: 20161117 DATE AS OF CHANGE: 20161117 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Interpace Diagnostics Group, Inc. CENTRAL INDEX KEY: 0001054102 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] IRS NUMBER: 222919486 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 000-24249 FILM NUMBER: 162005771 BUSINESS ADDRESS: STREET 1: MORRIS CORPORATE CENTER 1, BUILDING A STREET 2: 300 INTERPACE PARKWAY CITY: PARSIPPANY STATE: NJ ZIP: 07054 BUSINESS PHONE: 8622077800 MAIL ADDRESS: STREET 1: MORRIS CORPORATE CENTER 1, BUILDING A STREET 2: 300 INTERPACE PARKWAY CITY: PARSIPPANY STATE: NJ ZIP: 07054 FORMER COMPANY: FORMER CONFORMED NAME: PDI INC DATE OF NAME CHANGE: 20021113 FORMER COMPANY: FORMER CONFORMED NAME: PROFESSIONAL DETAILING INC DATE OF NAME CHANGE: 19980129 10-Q 1 idxg20160901_10q.htm FORM 10-Q idxg20160901_10q.htm Table Of Contents

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C.  20549


FORM 10-Q


 

(Mark One)

 

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

 For the quarterly period ended September 30, 2016

OR

 

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

 For the transition period from _______________ to _______________

 

 

Commission File Number: 000-24249


Interpace Diagnostics Group, Inc.

(Exact name of registrant as specified in its charter)

 

Delaware

 

22-2919486

(State or other jurisdiction of Incorporation or

 

(I.R.S. Employer Identification No.)

organization)    

 

Morris Corporate Center 1, Building A

300 Interpace Parkway, Parsippany, NJ 07054


(Address of principal executive offices and zip code)

(844) 405-9655


(Registrant's telephone number, including area code)

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒    No ☐

 

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes ☒    No ☐

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company.   See definitions of “large accelerated filer,” “accelerated filer,” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.  (Check one):

 

Large accelerated filer   ☐

Accelerated filer   ☐

Non-accelerated filer  ☐

Smaller reporting company  ☒

   

(Do not check if a  smaller

 
    reporting company)  

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). Yes ☐    No ☒

 

Indicate the number of shares outstanding of each of the issuer's classes of common stock, as of the latest practicable date:

 

 

 

Class

Shares Outstanding

November 10, 2016

Common stock, $0.01 par value

18,162,671

 
 

 

 

INTERPACE DIAGNOSTICS GROUP, INC.

 

FORM 10-Q FOR PERIOD ENDED SEPTEMBER 30, 2016

 

TABLE OF CONTENTS

 

   

Page No.

 

PART I - FINANCIAL INFORMATION

 
     

Item 1.

Unaudited Interim Condensed Consolidated Financial Statements

 
     
 

Condensed Consolidated Balance Sheets at September 30, 2016 (unaudited) and December 31, 2015

3

      
 

Condensed Consolidated Statements of Comprehensive Loss for the three- and nine-month periods ended September 30, 2016 and 2015 (unaudited)

4

      
 

Condensed Consolidated Statements of Cash Flows for the three- and nine-month periods ended September 30, 2016 and 2015 (unaudited)

5

      
 

Notes to Unaudited Interim Condensed Consolidated Financial Statements

6

      

Item 2.

Management's Discussion and Analysis of Financial Condition and Results of Operations

23

     

Item 4.

Controls and Procedures

35

     
     
 

PART II - OTHER INFORMATION

 
      

Item 1.

Legal Proceedings

36

Item 1A. Risk Factors 36
Item 5. Other Information 37

Item 6.

Exhibits

38

Signatures

39

 

 

INTERPACE DIAGNOSTICS GROUP, INC.

CONDENSED CONSOLIDATED BALANCE SHEETS

(in thousands, except share and per share data)

 

   

September 30,

   

December 31,

 
   

2016

   

2015

 
   

(unaudited)

         
                 

ASSETS

               

Current assets:

               

Cash and cash equivalents

  $ 1,693     $ 8,310  

Short-term investments

    -       106  

Accounts receivable, net

    2,753       2,806  

Other current assets

    2,087       2,569  

Current assets from discontinued operations

    150       5,374  

Total current assets

    6,683       19,165  

Property and equipment, net

    1,060       1,460  

Other intangible assets, net

    37,220       43,492  

Other long-term assets

    1,001       3,255  

Non-current assets from discontinued operations

    -       340  

Total assets

  $ 45,964     $ 67,712  
                 

LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT)

               

Current liabilities:

               

Accounts payable

  $ 1,365     $ 1,560  

Accrued salary and bonus

    3,089       2,424  

Other accrued expenses

    6,905       5,961  

Current portion of long-term debt, net of debt discount

    3,756       1,164  

Current liabilities from discontinued operations

    4,755       12,264  

Total current liabilities

    19,870       23,373  

Contingent consideration

    17,691       17,890  

Long-term debt, net of debt discount

    5,267       7,233  

Other long-term liabilities

    4,615       6,178  

Total liabilities

    47,443       54,674  
                 

Commitments and contingencies (Note 6)

               
                 

Stockholders’ equity:

               

Preferred stock, $.01 par value; 5,000,000 shares authorized, no shares issued and outstanding

    -       -  

Common stock, $.01 par value; 100,000,000 shares authorized; 18,705,214 shares issued; 18,162,671 and 17,662,671 shares outstanding, respectively

    187       187  

Additional paid-in capital

    125,842       132,522  

Accumulated deficit

    (125,865 )     (111,252 )

Accumulated other comprehensive income

    -       13  

Treasury stock, at cost (542,543 and 1,042,543 shares, respectively)

    (1,643 )     (8,432 )

Total stockholders' (deficit) equity

    (1,479 )     13,038  

Total liabilities and stockholders' (deficit) equity

  $ 45,964     $ 67,712  

 

The accompanying notes are an integral part of these condensed consolidated financial statements.

 

  

INTERPACE DIAGNOSTICS GROUP, INC.

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS

(unaudited, in thousands, except for per share data)

 

   

Three Months Ended

   

Nine Months Ended

 
   

September 30,

   

September 30,

 
   

2016

   

2015

   

2016

   

2015

 
                                 

Revenue, net

  $ 3,316     $ 2,506     $ 9,963     $ 6,876  

Cost of revenue (excluding amortization of $970 and $986 for the three months and $2,909 and $2,825 for the nine months, respectively)

    1,846       1,799       4,866       5,224  

Gross profit

    1,470       707       5,097       1,652  

Operating expenses:

                               

Sales and marketing

    1,282       2,876       4,186       8,387  

Research and development

    659       1,000       1,339       1,646  

General and administrative

    2,858       2,498       7,655       8,909  

Acquisition related amortization expense

    970       986       2,909       2,825  

Asset impairment

    3,363       -       3,363       -  

Change in fair value of contingent consideration

    (1,174 )     -       (1,174 )     -  

Total operating expenses

    7,958       7,360       18,278       21,767  
                                 

Operating loss

    (6,488 )     (6,653 )     (13,181 )     (20,115 )

Interest expense

    (539 )     (884 )     (1,601 )     (2,616 )

Other income (expense), net

    4       (112 )     14       (268 )

Loss from continuing operations before tax

    (7,023 )     (7,649 )     (14,768 )     (22,999 )

Provision (benefit) for income taxes

    173       (180 )     (54 )     (430 )

Loss from continuing operations

    (7,196 )     (7,469 )     (14,714 )     (22,569 )

(Loss) income from discontinued operations, net of tax

    (297 )     2,574       101       6,828  

Net loss

  $ (7,493 )   $ (4,895 )   $ (14,613 )   $ (15,741 )
                                 

Net Loss and Comprehensive Loss

  $ (7,493 )   $ (4,895 )   $ (14,613 )   $ (15,741 )
                                 

Basic and diluted (loss) income per share of common stock:

                               

From continuing operations

  $ (0.40 )   $ (0.48 )   $ (0.82 )   $ (1.48 )

From discontinued operations

    (0.02 )     0.16       0.01       0.45  

Net loss per basic and diluted share of common stock

  $ (0.41 )   $ (0.31 )   $ (0.81 )   $ (1.03 )

Weighted average number of common shares and common share equivalents outstanding:

                               

Basic

    18,163       15,654       18,029       15,301  

Diluted

    18,163       15,654       18,029       15,301  

 

The accompanying notes are an integral part of these condensed consolidated financial statements.

 

  

INTERPACE DIAGNOSTICS GROUP, INC.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(unaudited, in thousands)

 

   

Nine Months Ended

 
   

September 30,

 
   

2016

   

2015

 
                 

Cash Flows From Operating Activities

               

Net loss

  $ (14,613 )   $ (15,741 )

Adjustments to reconcile net loss to net cash used in operating activities:

               

Depreciation and amortization

    3,490       3,775  

Realignment accrual accretion

    29       104  

Interest accretion

    1,601       825  

Provision for bad debt

    482       202  

Gain on sale of discontinued operations

    -       (217 )

Stock-based compensation

    109       1,517  

Asset impairment

    3,363       -  

Change in fair value of contingent consideration

    (1,174 )     -  

Deferred taxes

    -       (634 )

Other (gains), losses and expenses, net

    (4 )     -  

Other changes in assets and liabilities:

               

Decrease (increase) in accounts receivable

    4,639       (4,257 )

Decrease in unbilled receivable

    16       702  

Decrease in other current assets

    1,272       1,084  

Decrease in other long-term assets

    754       2,137  

(Decrease) increase in accounts payable

    (761 )     200  

(Decrease) increase in unearned contract revenue

    (11 )     396  

(Decrease) increase in accrued salaries and bonus

    (685 )     2,155  

Decrease in accrued liabilities

    (4,561 )     (7,318 )

(Decrease) increase in long-term liabilities

    (563 )     1,534  

Net cash used in operating activities

    (6,617 )     (13,536 )
                 

Cash Flows From Investing Activities

               

Purchase of property and equipment

    -       (583 )

Net cash used in investing activities

    -       (583 )
                 

Cash Flows From Financing Activities

               

Cash paid for repurchase of restricted shares

    -       (37 )

Net cash used in financing activities

    -       (37 )
                 

Net increase (decrease) in cash and cash equivalents

    (6,617 )     (14,156 )

Cash and cash equivalents – beginning

    8,310       23,111  

Cash and cash equivalents – ending

  $ 1,693     $ 8,955  

Cash paid for interest

  $ -     $ 2,153  

 

The accompanying notes are an integral part of these condensed consolidated financial statements.

 

 

INTERPACE DIAGNOSTICS GROUP, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Tabular information in thousands, except per share amounts)

 

1.

BASIS OF PRESENTATION

 

The accompanying unaudited interim condensed consolidated financial statements and related notes (the interim financial statements) should be read in conjunction with the consolidated financial statements of Interpace Diagnostics Group, Inc. (the Company or Interpace), and its wholly-owned subsidiaries, Interpace Diagnostics Corporation and Interpace Diagnostics, LLC, and related notes as included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2015, as filed with the U.S. Securities and Exchange Commission (SEC) on March 30, 2016, as amended on April 29, 2016 and June 14, 2016.  The condensed interim financial statements of the Company have been prepared in accordance with generally accepted accounting principles in the United States (GAAP) for interim financial reporting and the instructions to Form 10-Q and Article 10 of Regulation S-X.  Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements.  The condensed interim financial statements include all normal recurring adjustments that, in the judgment of management, are necessary for a fair presentation of such interim financial statements.  All significant intercompany balances and transactions have been eliminated in consolidation.  Discontinued operations include the Company's wholly owned subsidiaries: Group DCA, LLC, or Group DCA; InServe Support Solutions (Pharmakon); and TVG, Inc. (TVG, dissolved December 31, 2014) and its Commercial Services (CSO) business unit. All significant intercompany balances and transactions have been eliminated in consolidation. Operating results for the three- and nine-month periods ended September 30, 2016 are not necessarily indicative of the results that may be expected for the year ending December 31, 2016.

 

2.

LIQUIDITY AND MANAGEMENT'S PLANS

  

For the nine months ended September 30, 2016, the Company incurred a net loss of $14.6 million and cash used in operating activities was $6.6 million.  The Company did not raise any capital or incur any funded debt during the first nine months of 2016, but it did enter into a Credit Agreement with SCM Specialty Finance Opportunities Fund, L.P. on September 28, 2016 as described further below, on which it has not yet drawn. The Company also anticipates operating losses to continue for the foreseeable future due to, among other things, costs related to its commercial operations, developing products and product candidates, right sizing and reorganizing its administrative organization and winding down activities and managing obligations related to its discontinued operations.

 

The accompanying condensed, consolidated financial statements have been prepared on a basis that assumes that the Company will continue as a going concern and that contemplates the continuity of operations, the realization of assets and the satisfaction of liabilities and commitments in the normal course of business. As of September 30, 2016, the Company had cash and cash equivalents of $1.7 million, net accounts receivable of $2.8 million, current assets of $6.7 million and current liabilities of $19.9 million.

 

 

INTERPACE DIAGNOSTICS GROUP, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)

(Tabular information in thousands, except per share amounts)

 

As a result of the sale of substantially all of its CSO business in December 2015, which generated net cash proceeds of $26.8 million (of which $21.6 million was used to repay long-term debt and fees), the Company focused its resources and strategic initiatives on its molecular diagnostics business. As with many companies in a similar stage, sufficient capital is required before achieving profitability. Accordingly, the Company may require additional capital in 2016 and will require additional capital in 2017 and beyond. In order to obtain such capital and fund its operations, the Company may be required to restructure all or a portion of its obligations related to the sale of its CSO business as well as obligations owed to the former equity holders of RedPath Integrated Pathology, Inc.(“RedPath”) arising out of the Company’s acquisition of RedPath. The first payment of secured debt to RedPath Equityholder Representative, LLC (the “RedPath Equityholder Representative”), as representative of the former equity holders of RedPath, has been extended several times from its original due date of October 1, 2016 and is now due December 31, 2016 unless further extended. There is no guarantee that additional capital will or can be raised or that adequate restructuring will be accomplished that are sufficient to fund the Company's operations for the rest of 2016 and beyond or that the terms of such additional capital, if available, will be acceptable to the Company. Accordingly, the Company continues to explore sales of assets and various dilutive and non-dilutive sources of funding, including equity and debt financings, strategic alliances and alternatives, business development, and other alternatives. Additionally, the Company continues to focus on increasing sales of its commercial molecular diagnostic tests, closely managing cash and further streamlining operations. If, however, the Company is unsuccessful in obtaining capital and executing its plans for the business to continue operations, when needed, including the restructuring of its debt and other liabilities, then it may be forced to sell off assets, seek protection under the U.S. Bankruptcy Code, or be forced into liquidation or substantially alter or restructure its business operations. In the event of a default on its secured note, the RedPath Equityholder Representative could foreclose on the Company’s assets, force the Company into bankruptcy or pursue other remedies. In such events, stockholders may not be able to recoup their investment. These factors, among others, raise substantial doubt about the Company’s ability to continue as a going concern.

  

During the first nine months of 2016, the Company commenced negotiations with certain of its creditors and former sales representatives and executives to restructure its current and long-term obligations related to the sale of the majority of its CSO business in December 2015. The proposed restructuring by the Company includes reducing or extending the term of certain of its obligations, converting a portion to equity and/or forgiving portions thereof. However, any such restructuring may be dependent on the Company raising additional capital. The Company believes that this proposed restructuring, if achieved, will not only improve its liquidity but also provide the flexibility for future funding. No assurance, however, can be given that the negotiations to restructure the Company’s debt and obligations will be successful.

 

At September 30, 2016, the Company had the following debt obligations that it has been seeking to restructure:

 

 

1.

Future payments and conditions related to the $10.7 million secured note payable to the former equity holders of RedPath.

 

 

2.

Severance obligations to former executives ($3.1 million, including taxes).

 

 

3.

Obligations due to former sales representatives under the CSO incentive plan (up to $1 million including taxes). To date, 343 former sales representatives have accepted the Company’s offer to pay out approximately $0.6 million in equal installments over eight months. For the period ended September 30, 2016 approximately $0.1 million was paid out under this plan.

  

 

4.

Various liabilities including trade payables, other employee severance in accrued expenses and certain liabilities from Discontinued Operations which are in the process of being renegotiated or restructured.

 

There is, however, no guarantee that the Company will be successful in restructuring its outstanding debt.

 

A summary of the Company’s most significant contractual obligations over the next 12 months are as follows:

  

   

Total

   

0 to 3

months

   

3 to 6

months

   

6 to 12

months

 

Note due Redpath Equityholders

  $ 4,001     $ 1,334     $     $ 2,667  

Severance obligations

    3,137       3,137       -       -  

DOJ settlement

    665       85       85       495  

Deferred Bonus - ERT salesforce

    800       185       308       307  

Total obligations

  $ 8,603     $ 4,741     $ 393     $ 3,469  

 

 

 

INTERPACE DIAGNOSTICS GROUP, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)

(Tabular information in thousands, except per share amounts)

 

On September 28, 2016 (the “Closing Date”), the Company and its wholly-owned direct and indirect subsidiaries, Interpace Diagnostics, LLC (“Interpace LLC”) and Interpace Diagnostics Corporation (“IDC” and together with Interpace LLC, its “Subsidiaries”), entered into a Credit Agreement (the “Credit Agreement”) with SCM Specialty Finance Opportunities Fund, L.P. (the “Lender”). Pursuant to and subject to the terms of the Credit Agreement, the Lender agreed to provide a revolving loan (the “Loan”) to the Company in the maximum principal amount of $1.2 million (“Facility Cap”). Also on the Closing Date, the Company and its Subsidiaries acknowledged and agreed to an Intercreditor Agreement (the “Intercreditor Agreement”) by and between the Lender and the RedPath Equityholder Representative pursuant to which the Lender has a first lien security interest on all of the accounts receivable (and related intangibles) of the Company and its Subsidiaries and the RedPath Equityholder Representative has a second lien security interest, subordinated to the Lender, on all the accounts receivables (and related intangibles) of the Company and its Subsidiaries. In addition, pursuant to the Intercreditor Agreement, the RedPath Equityholder Representative has a first lien security interest on all other assets of the Company and its Subsidiaries and the Lender has no lien with respect to such other assets. The maturity date of the Loan is September 28, 2018. The Loan bears interest at an annual rate equal to the Prime Rate (as defined in the Credit Agreement) plus 2.75%, payable in cash monthly in arrears. The interest rate will be increased by 5.0% in the event of a default under the Credit Agreement. Events of default under the Credit Agreement, some of which are subject to certain cure periods, include a failure to pay or perform obligations when due, the making of a material misrepresentation to the Lender, the rendering of certain judgments or decrees against the Company and its Subsidiaries and the initiation, voluntarily or involuntarily, of a bankruptcy or similar proceeding against the Company or its Subsidiaries. 

 

The Company agreed to pay certain out-of-pocket costs and expenses incurred by the Lender in connection with the Credit Agreement and related documents, the administration of the Loan and related documents and the enforcement or protection of the Lender’s rights. The Lender is also entitled to: (a) a $12,000 origination fee; (b) a monthly unused line fee equal to the amount which is one-twelfth of one percent (0.083%) of the difference between (i) the outstanding balance of the Loan during the preceding month, and (ii) the Facility Cap on the date of determination; (c) a monthly collateral management fee equal to one-sixth of one percent (0.1666%) of the average daily balance under the Credit Agreement outstanding during the preceding month; and (d) a termination fee equal to (i) two percent (2%) of the Facility Cap if the Credit Agreement is terminated before the first anniversary of the Closing Date (the “First Anniversary”), or (ii) one percent (1%) of the Facility Cap if the Credit Agreement is terminated after the First Anniversary. The Company must also pay certain fees in the event that (a) the amount outstanding under the Credit Agreement exceeds the availability under the Credit Agreement’s borrowing base, and (b) receivables are not properly deposited in the appropriate lockbox account.

  

The Credit Agreement contains customary representations and warranties in favor of the Lender and certain covenants, including, among other things, financial covenants relating to loan turnover rates, liquidity and revenue targets. 

 

As of November 17, 2016, the Company had not borrowed any funds under the Credit Agreement.

 

On September 30, 2016, the Company, Interpace LLC, and the RedPath Equityholder Representative entered into an amendment to the $10.7 million interest free secured note payable to the former equity holders of RedPath to extend by one month, until November 1, 2016, subject to the terms of the amendment, the due date for the first quarterly payment of principal under the note. Effective October 31, 2016 the Company, Interpace LLC, and the RedPath Equityholder Representative entered into a fourth amendment to the note to extend until November 20, 2016, subject to the terms of the amendment, the due date for the first quarterly payment of principal. On November 16, 2016 the Company, Interpace LLC, and the RedPath Equityholder Representative entered into a fifth amendment to the note to extend until December 31, 2016, subject to the terms of the amendment, the due date for the first quarterly payment of principal under the note. In addition, the fifth amendment also amends the note to add as an event of default the failure of the Company to maintain a minimum net cash balance from operations of no less than $400,000, excluding proceeds from borrowed money, at the end of every week. The fifth amendment also contains a reporting requirement for the Company to provide to the RedPath Equityholder Representative, on a weekly basis, a 13-week cash flow forecast commencing November 22, 2016.

 

 

INTERPACE DIAGNOSTICS GROUP, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)

(Tabular information in thousands, except per share amounts)

 

Under the note, the Company is required to make eight installment payments of principal, with each payment equal to $1,333,750, together with accrued and unpaid interest, if any. The first quarterly payment of principal under the note originally was due on October 1, 2016 and the first payment is now due on December 31, 2016. Subsequent payments are to be made on the first day of each fiscal quarter, beginning on April 1, 2017.

 

The Company currently has no means to make the first quarterly payment of principal due on December 31, 2016, and if the due date for the first quarterly payment of principal is not extended by the RedPath Equityholder Representative or other equity or debt capital is not raised, the RedPath Equityholder Representative could foreclose on the Company’s assets, force the Company into bankruptcy or pursue other remedies. Accordingly, the Company continues to explore sales of assets and various dilutive and non-dilutive sources of funding, including equity and debt financings, strategic alliances and alternatives, business development, and other alternatives.

  

3.

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

 

Accounting Estimates

 

The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts of assets and liabilities reported and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period.  Management's estimates are based on historical experience, facts and circumstances available at the time, and various other assumptions that are believed to be reasonable under the circumstances.  Significant estimates include best estimate of selling price in multiple element arrangements, valuation allowances related to deferred income taxes, self-insurance loss accruals, allowances for doubtful accounts and notes, income tax accruals, acquisition accounting, asset impairments and facilities realignment accruals.  The Company periodically reviews these matters and reflects changes in estimates as appropriate.  Actual results could materially differ from those estimates.

 

Reclassifications

 

The CSO business in the three- and nine-month periods ended September 30, 2015 has been reclassified to discontinued operations to conform to the current period presentation.

  

Receivables and Allowance for Doubtful Accounts

 

The Company’s accounts receivable are generated using its proprietary tests. The Company’s services are fulfilled upon completion of the test, review and release of the test results. In conjunction with fulfilling these services, the Company bills the third-party payor or hospital. The Company recognizes accounts receivable related to billings for Medicare, Medicare Advantage, and hospitals on an accrual basis, net of contractual adjustment, when collectability is reasonably assured. Contractual adjustments represent the difference between the list prices and the reimbursement rate set by Medicare and Medicare Advantage, or the amounts billed to hospitals. The Company records an Allowance for Doubtful accounts for PancraGen® hospital roster billings based on the collection history of this payor. Since Medicare and Medicare Advantage have fixed reimbursement rates, there is no Allowance for Doubtful Accounts associated with these payors.

 

The Company provides services to commercial insurance carriers or governmental programs that do not have a contract in place for its proprietary tests which may or may not be covered by these entities existing reimbursement policies. In addition, the Company does not enter into direct agreements with patients that commit them to pay any portion of the cost of the tests in the event that their commercial insurance carrier or governmental program does not pay the Company for its services. In the absence of an agreement with the patient, or other clearly enforceable legal right to demand payment from commercial insurance carriers or governmental agencies, no accounts receivable is recognized. The Company does not record an Allowance for Doubtful Accounts for the commercial insurance or governmental programs since the revenue is recorded mainly on a cash basis. There was approximately a $1.3 million allowance for doubtful accounts as of September 30, 2016.

 

 

INTERPACE DIAGNOSTICS GROUP, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)

(Tabular information in thousands, except per share amounts)

 

Other Current Assets

 

Other current assets consisted of the following as of September 30, 2016 and December 31, 2015: 

 

   

September 30, 2016

   

December 31, 2015

 

Indemnification assets

  $ 1,375     $ 875  

Letters of credit

    -       360  

Other receivables

    666       1,048  

Other

    46       286  
    $ 2,087     $ 2,569  

  

Other Intangible Assets, including Finite-Lived Intangible Assets

 

The Company allocates the cost of acquired companies to the identifiable tangible and intangible assets acquired and liabilities assumed, with the remaining amount classified as goodwill, if any. Since the entities the Company has acquired do not have significant tangible assets, a significant portion of the purchase price has been allocated to intangible assets and goodwill. The identification and valuation of these intangible assets and the determination of the estimated useful lives at the time of acquisition, as well as the completion of impairment tests, require significant management judgments and estimates. These estimates are made based on, among other factors, consultations with an accredited independent valuation consultant, reviews of projected future operating results and business plans, economic projections, anticipated highest and best use of future cash flows and the market participant cost of capital. The use of alternative estimates and assumptions could increase or decrease the estimated fair value of other intangible assets, and potentially result in a different impact to the Company's results of operations. Further, changes in business strategy and/or market conditions may significantly impact these judgments thereby impacting the fair value of these assets, which could result in an impairment of the intangible assets.

 

Finite-lived intangible assets are stated at cost less accumulated amortization.  Amortization of finite-lived acquired intangible assets is recognized on a straight-line basis, using the estimated useful lives of the assets of approximately two years to nine years in acquisition related amortization expense in the consolidated statements of comprehensive loss.

 

The Company reviews the recoverability of long-lived assets and finite-lived intangible assets whenever events or changes in circumstances indicate that the carrying value of such assets may not be recoverable.  If the sum of the expected future undiscounted cash flows is less than the carrying amount of the asset, an impairment loss is recognized by reducing the recorded value of the asset to its fair value measured by future discounted cash flows.  This analysis requires estimates of the amount and timing of projected cash flows and, where applicable, judgments associated with, among other factors, the market price and physical condition of the assets at measurement date.  Such estimates are critical in determining whether any impairment charge should be recorded and the amount of such charge if an impairment loss is deemed to be necessary. 

 

During the quarter ended September 30, 2016 the Company recorded an asset impairment charge of approximately $3.4 million, resulting from a decline in market value of Pancreas and Biobank assets associated with the acquisition of certain assets from Asuragen.


 
 

Discontinued Operations

 

The Company accounts for business dispositions and its businesses held for sale in accordance with ASC 205-20, Discontinued Operations. ASC 205-20 requires the results of operations of business dispositions to be segregated from continuing operations and reflected as discontinued operations in current and prior periods. See Note 11, Discontinued Operations for further information. 

 

Basic and Diluted Net Loss per Share

 

A reconciliation of the number of shares of common stock used in the calculation of basic and diluted loss per share for the three- and nine-month-periods ended September 30, 2016 and 2015 is as follows: 

 

   

Three Months Ended

   

Nine Months Ended

 
   

September 30,

   

September 30,

 
   

2016

   

2015

   

2016

   

2015

 

Basic weighted average number of  of common shares

    18,163       15,654       18,029       15,301  

Potential dilutive effect of stock-based awards

    -       -       -       -  

Diluted weighted average number of common shares

    18,163       15,654       18,029       15,301  

 

 

INTERPACE DIAGNOSTICS GROUP, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)

(Tabular information in thousands, except per share amounts)

 

The following outstanding stock-based awards were excluded from the computation of the effect of dilutive securities on loss per share for the following periods because they would have been anti-dilutive:  

 

   

Three Months Ended

   

Nine Months Ended

 
   

September 30,

   

September 30,

 
   

2016

   

2015

   

2016

   

2015

 

Options

    -       -       -       -  

Stock-settled stock appreciation rights (SARs)

    1,027       1,028       1,027       1,028  

Restricted stock and restricted stock units (RSUs)

    1,151       1,745       1,151       1,745  

Performance contingent SARs

    -       188       -       188  
      2,178       2,961       2,178       2,961  

  

4.

OTHER INTANGIBLE ASSETS

  

The net carrying value of the identifiable intangible assets as of September 30, 2016 is as follows: 

 

           

As of September 30, 2016

   

As of December 31, 2015

 
   

Life

   

Carrying

   

Carrying

 
   

(Years)

   

Amount

   

Amount

 

Diagnostic assets:

                       

Asuragen acquisition:

                       

Thyroid

    9     $ 8,519     $ 8,519  

Pancreas

    -       -       2,882  

Biobank

    -       -       1,575  

RedPath acquisition:

                       

Pancreas test

    7       16,141       16,141  

Barrett's test

    9       18,351       18,351  

Total

          $ 43,011     $ 47,468  

Diagnostic lab:

                       

CLIA Lab

    2.3     $ 609     $ 609  
                         

Accumulated Amortization

          $ (6,400 )   $ (4,585 )
                         

Net Carrying Value

          $ 37,220     $ 43,492  

 

Amortization expense was approximately $1.0 million for the three-month periods ended September 30, 2016 and 2015, respectively, and $2.9 million and $2.8 million for the nine-month periods ended September 30, 2016 and 2015, respectively. Amortization of our diagnostic assets begins upon launch of the product. Estimated amortization expense for the next five years is as follows, based on current assumptions of future product launches:  

 

2016

   

2017

   

2018

   

2019

   

2020

 
$ 3,771     $ 4,272     $ 5,292     $ 5,292     $ 5,292  

 

During the quarter ended September 30, 2016 the Company recorded an asset impairment charge of approximately $3.4 million resulting from a decline in the market value of Pancreas and Biobank assets associated with the acquisition of certain assets from Asuragen.

 

 

 

 

INTERPACE DIAGNOSTICS GROUP, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)

(Tabular information in thousands, except per share amounts)

 

5.

FAIR VALUE MEASUREMENTS

 

The Company's financial assets and liabilities reflected at fair value in the consolidated financial statements include: cash and cash equivalents; short-term investments; accounts receivable; other current assets; accounts payable; and contingent consideration. Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. In determining fair value, the Company uses various methods, including market, income and cost approaches. Based on these approaches, the Company often utilizes certain assumptions that market participants would use in pricing the asset or liability, including assumptions about risk and/or the risks inherent in the inputs to the valuation technique. These inputs can be readily observable, market-corroborated, or generally unobservable inputs. The Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs. Based upon observable inputs used in the valuation techniques, the Company is required to provide information according to the fair value hierarchy. The fair value hierarchy ranks the quality and reliability of the information used to determine fair values into three broad levels as follows:

 

 

Level 1:

Valuations for assets and liabilities traded in active markets from readily available pricing sources for market transactions involving identical assets or liabilities.

 

 

Level 2:

Valuations for assets and liabilities traded in less active dealer or broker markets. Valuations are obtained from third-party pricing services for identical or similar assets or liabilities.

 

 

Level 3:

Valuations incorporate certain assumptions and projections in determining the fair value assigned to such assets or liabilities.

 

In instances where the determination of the fair value measurement is based on inputs from different levels of the fair value hierarchy, the level in the fair value hierarchy within which the entire fair value measurement falls is based on the lowest level input that is significant to the fair value measurement in its entirety. The Company's assessment of the significance of a particular input to the fair value measurement in its entirety requires judgment, and considers factors specific to the asset or liability. The valuation methodologies used for the Company's financial instruments measured on a recurring basis at fair value, including the general classification of such instruments pursuant to the valuation hierarchy, is set forth in the tables below: 

 

   

As of September 30, 2016

   

Fair Value Measurements

 
   

Carrying

   

Fair

   

As of September 30, 2016

 
   

Amount

   

Value

   

Level 1

   

Level 2

   

Level 3

 

Assets:

                                       

Cash and cash equivalents:

                                       

Cash

  $ 1,693     $ 1,693     $ 1,693     $ -     $ -  

Money market funds

    -       -       -       -       -  
    $ 1,693     $ 1,693     $ 1,693     $ -     $ -  

Marketable securities:

                                       

U.S. Treasury securities

  $ -     $ -     $ -     $ -     $ -  

Liabilities:

                                       

Contingent consideration:

                                       

Asuragen

  $ 3,247     $ 3,247     $ -     $ -     $ 3,247  

RedPath

    14,653       14,653       -       -       14,653  
    $ 17,900     $ 17,900     $ -     $ -     $ 17,900  

 

INTERPACE DIAGNOSTICS GROUP, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)

(Tabular information in thousands, except per share amounts)

 

   

As of December 31, 2015

   

Fair Value Measurements

 
   

Carrying

   

Fair

   

As of December 31, 2015

 
   

Amount

   

Value

   

Level 1

   

Level 2

     

Level 3

 

Assets:

                                         

Cash and cash equivalents:

                                         

Cash

  $ 7,534     $ 7,534     $ 7,534     $ -  

 

  $ -  

Money market funds

    776       776       776       -         -  
    $ 8,310     $ 8,310     $ 8,310     $ -       $ -  

Marketable securities:

                                         

Money market funds

  $ 48     $ 48     $ 48     $ -       $ -  

Mutual funds

    58       58       58       -         -  

U.S. Treasury securities

    1,115       1,115       1,115       -         -  

Government agency securities

    131       131       131       -         -  
    $ 1,352     $ 1,352     $ 1,352     $ -       $ -  

Liabilities:

                                         

Contingent consideration:

                                         

Asuragen

  $ 4,628     $ 4,628     $ -     $ -       $ 4,628  

RedPath

    13,921       13,921       -       -         13,921  
    $ 18,549     $ 18,549     $ -     $ -       $ 18,549  

  

The fair value of cash and cash equivalents and marketable securities is valued using market prices in active markets (level 1). As of September 30, 2016, the Company did not have any marketable securities in less active markets (level 2) or without observable market values that would require a high level of judgment to determine fair value (level 3).

  

In connection with the acquisition of certain assets from Asuragen and the acquisition of RedPath, the Company recorded contingent consideration related to contingent payments and other revenue based payments. The Company determined the fair value of the contingent consideration based on a probability-weighted income approach derived from revenue estimates. The fair value measurement is based on significant inputs not observable in the market and thus represents a Level 3 measurement.  A rollforward of the carrying value of the contingent consideration from continuing operations from January 1, 2016 to September 30, 2016 is as follows:

 

   

2016

 
                           

Adjustments

         
   

January 1,

   

Payments

   

Accretion

   

to Fair Value

   

September 30,

 

Asuragen

  $ 4,628     $ (450 )   $ 243     $ (1,174 )   $ 3,247  

Redpath

    13,921       -       732       -       14,653  
    $ 18,549     $ (450 )   $ 975     $ (1,174 )   $ 17,900  

  

The Company considers carrying amounts of accounts receivable, accounts payable and accrued expenses to approximate fair value due to the short-term nature of these financial instruments.  There is no fair value ascribed to the letters of credit as management does not expect any material losses to result from these instruments because performance is not expected to be required.

 

Certain of the Company's non-financial assets, such as other intangible assets and goodwill, are measured at fair value when there is an indicator of impairment and recorded at fair value only when an impairment charge is recognized. 

 

6.

COMMITMENTS AND CONTINGENCIES

 

Letters of Credit

 

As of September 30, 2016, the Company had $0.3 million in letters of credit outstanding as required by its existing facility leases. These letters of credit are collateralized by certain investments. In October 2016, the letters of credit were not renewed and the balance was distributed to our landlords who now hold the funds as security deposits on the Company’s facility leases.

 

 

INTERPACE DIAGNOSTICS GROUP, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)

(Tabular information in thousands, except per share amounts)

 

Contingency

 

In connection with the acquisition of RedPath on October 31, 2014, the Company and its wholly-owned subsidiary, Interpace LLC, entered into a Contingent Consideration Agreement with the RedPath Equityholder Representative. Pursuant to the Contingent Consideration Agreement, the Company agreed to issue to the equityholders of RedPath 500,000 shares of the Company’s common stock, par value $0.01 (Common Stock), upon acceptance for publication of a specified article related to PathFinderTG® for the management of Barrett’s esophagus. The pending issuance of Common Stock was recorded as Additional paid-in capital in the Company's consolidated balance sheet as of December 31, 2014. On April 13, 2015, this milestone was reached upon acceptance for publication of new data supporting the use of BarreGen™ for predicting risk of progression from Barrett’s esophagus to esophageal cancer. On June 16, 2015, the 500,000 shares were issued from Treasury stock decreasing the balance in treasury stock by approximately $6.1 million, with a corresponding decrease in Additional paid-in capital of $6.1 million. In March 2016, 500,000 additional shares of Common Stock were issued from Treasury stock, as a result of the acceleration of the Common Stock Milestone, as defined in the Contingent Consideration Agreement, resulting from the change of control in connection with the sale of its CSO business in December 2015, decreasing the balance in treasury stock by approximately $6.8 million, with a corresponding decrease in Additional paid-in capital of $6.8 million.

 

Litigation

 

Due to the nature of the businesses in which the Company is engaged it is subject to certain risks. Such risks include, among others, risk of liability for personal injury or death to persons using products the Company promotes or commercializes. There can be no assurance that substantial claims or liabilities will not arise in the future due to the nature of the Company’s business activities and recent increases in litigation related to healthcare products. As part of the closeout of its CSO operations, the Company seeks to reduce its potential liability under its service agreements through measures such as contractual indemnification provisions with customers (the scope of which may vary from customer to customer, and the performance of which is not secured) and insurance. The Company could, however, also be held liable for errors and omissions of its employees in connection with the services it performs that are outside the scope of any indemnity or insurance policy. The Company could be materially adversely affected if it were required to pay damages or incur defense costs in connection with a claim that is outside the scope of an indemnification agreement; if the indemnity, although applicable, is not performed in accordance with its terms; or if the Company’s liability exceeds the amount of applicable insurance or indemnity.

 

The Company routinely assesses its litigation and threatened litigation as to the probability of ultimately incurring a liability, and records its best estimate of the ultimate loss in situations where the Company assesses the likelihood of loss as probable. The Company accrues for a liability when it is both probable that a liability has been incurred and the amount of the loss can be reasonably estimated. Significant judgment is required in both the determination of probability and the determination as to whether a loss is reasonably estimable. In addition, in the event the Company determines that a loss is not probable, but is reasonably possible, and it becomes possible to develop what the Company believes to be a reasonable range of possible loss, then the Company will include disclosures related to such matter as appropriate and in compliance with ASC 450. To the extent there is a reasonable possibility that the losses could exceed the amounts already accrued, the Company will, as applicable, adjust the accrual in the period the determination is made, disclose an estimate of the additional loss or range of loss, indicate that the estimate is immaterial with respect to its financial statements as a whole or, if the amount of such adjustment cannot be reasonably estimated, disclose that an estimate cannot be made. As of September 30, 2016, the Company's accrual for litigation and threatened litigation was not material to the consolidated financial statements.

 

In connection with the October 31, 2014 acquisition of RedPath, the Company assumed a liability for a January 2013 settlement agreement (the Settlement Agreement) entered into by the former owners of RedPath with the Department of Justice (“DOJ”). Under the terms of the Settlement Agreement, the Company is obligated to make payments to the DOJ for the calendar years ended December 31, 2014 through 2017, up to a maximum of $3.0 million.

 

 

INTERPACE DIAGNOSTICS GROUP, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)

(Tabular information in thousands, except per share amounts)

 

Payments are due March 31st following the calendar year that the revenue milestones are achieved. The Company has been indemnified by the former owners of RedPath for $2.5 million of the obligation and has recorded an indemnification asset of that amount within other non-current assets. In May 2016 the Company renegotiated payment terms with the DOJ related to a $250,000 payment associated with performance in fiscal 2014 that resulted in an agreement that the Company pay $85,000 on July 31, 2016, $85,000 on October 31, 2016 and $80,000 on February 28, 2017. Accordingly, $170,000 was paid to the DOJ in 2016. During the nine months ended September 30, 2016, the Company has $1.7 million recorded as its best estimate of the amount that remains to be paid under the Settlement Agreement based on its estimate of future revenues, of which $0.7 million is included in other accrued expenses and $1.0 million is included in other long-term liabilities.

 

Prolias Technologies, Inc. v. PDI, Inc.

 

On April 8, 2015, Prolias Technologies, Inc.(“Prolias”) filed a complaint (the “Complaint”) against the Company with the Superior Court of New Jersey (Morris County) in a matter entitled Prolias Technologies, Inc. v. PDI, Inc. (Docket No. MRS-L-899-15).  In the Complaint, Prolias alleges that it and the Company entered into an August 19, 2013 Collaboration Agreement and a First Amendment thereto (collectively, the “Agreement”) whereby Prolias and the Company agreed to work in good faith to commercialize a diagnostic test known as "Thymira."  Thymira is a minimally invasive diagnostic test that is being developed to detect thyroid cancer.

 

Prolias alleges in the Complaint that the Company wrongfully terminated the Agreement, breached obligations owed to it under the Agreement and committed torts by (i) failing to effectively and timely validate Thymira, (ii) purchasing a competitor of Prolias and working to commercialize the competitive product at the expense of Thymira, and (iii) interfering with a license agreement that Prolias had with Cornell University related to a license for Thymira. Prolias asserts claims against the Company for breach of contract, breach of the covenant of good faith and fair dealing, intentional interference with contract and breach of fiduciary duty and seeks to recover unspecified compensatory damages, punitive damages, interest and costs of suit.

 

On June 3, 2015, the Company filed an Answer and Counterclaim in response to the Complaint. In the Answer, the Company denied that it had any liability to Prolias for the claims raised in the Complaint. In the Counterclaim, the Company sought (a) to recover from Polias the principal amount of $500,000 plus interest that was due and owing under a March 18, 2014 promissory note that Prolias delivered to the Company and (b) to compel Prolias to execute and deliver a $1 million promissory note to memorialize Prolias’s repayment obligations of money the Company advanced under the Agreement.

 

The parties exchanged documents in the fourth quarter of 2015. On December 18, 2015, Prolias moved for temporary restraints as to an asset sale of the Company. The Court denied the temporary restraints on December 21, 2015 and, when Prolias pursued the restraints in the form of a preliminary injunction motion, the Court denied that as well on February 4, 2016. Prolias’s separate motion to disqualify the Company’s counsel was also denied by the Court on

February 4, 2016. On February 24, 2016, Prolias moved for leave to appeal the interlocutory order denying the disqualification of Company’s counsel. On May 11, 2016, the Appellate Division granted the motion for leave to appeal and then summarily affirmed the denial of Prolias’s motion to disqualify the Company’s counsel.

 

On March 29, 2016, Prolias’ counsel moved to withdraw from representing Prolias. On April 7, 2016, the Company conditionally opposed the motion to withdraw pending prompt appointment of new counsel for Prolias. On April 19, 2016, the Court denied the motion without prejudice. On April 26, 2016, Prolias’ counsel renewed its motion to withdraw. On May 27, 2016, the Court granted the motion to withdraw and ordered Prolias to retain substitute counsel within 30 days.

 

 

INTERPACE DIAGNOSTICS GROUP, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)

(Tabular information in thousands, except per share amounts)

 

On July 6, 2016, the Company moved to dismiss Prolias’ complaint and strike Prolias’ answer to the Company’s counterclaims for failure to retain substitute counsel within 30 days as required by the Court’s May 27th Order. On August 15, 2016, the Court granted the Company’s motion and dismissed Prolias’ complaint with prejudice and struck Prolias’ answer to the Company’s counterclaims. On September 22, 2016, the Court granted the Company’s request to enter default against Prolias for failure to plead or otherwise respond to the counterclaims. Thereafter, on October 13, 2016, the Company filed an application to enter final judgment and taxing of costs against Prolias. The Company requested that the Court enter final judgment against Prolias and for the Company in the amount of $621,236.16, plus ten percent interest continuing to accrue on the principal balance of $500,000.00 unless and until paid, attorneys’ fees and costs of $390,769.04, and a declaratory judgment that Prolias is deemed to have executed and delivered to the Company a promissory note in the amount of $1,000,000 under Article 10.2(a) of the Collaboration Agreement. The Company is awaiting a response from the Court on the application for entry of final judgment. 

 

Swann v. Akorn, Inc., and Interpace Diagnostics Group, Inc.

 

On May 27, 2016, Michael J. Swann, one of the Company’s former employees, filed a complaint against the Company in the Court of Common Pleas of the Fifth Judicial Circuit in South Carolina in a matter entitled Michael J. Swann v. Akorn, Inc., and Interpace Diagnostic Group Inc. (Civil Action No. 2016-CP-40-03362). In the complaint, Mr. Swann alleges, among other things, that he was discriminated against and wrongfully terminated as a member of a sales force marketing pharmaceutical products of Akorn, Inc., because of an illness suffered by Mr. Swann. Mr. Swann alleges that he was discriminated against in violation of the Americans with Disabilities Act/Americans with Disabilities Act Amendments Act and the Family Medical Leave Act and seeks damages for back pay, reinstatement, front pay, compensatory and punitive damages in an amount not less than $300,000, attorney’s fees and costs. The Company denies that it is liable to Mr. Swann for any of the claims asserted and intends to vigorously defend itself against those claims.

 

Severance

 

In 2015, in connection with the sale of the majority of the CSO business and the implementation of a broad-based program to maximize efficiencies and cut costs, the Company reduced headcount and incurred severance obligations to terminated employees that amounted to approximately $3.7 million.

 

During the first quarter ended March 31, 2016 the Company recorded additional severance obligations as it continued to right-size the organization and wind down its CSO business. The Company recorded obligations of $1.1 million, $0.5 million of which was recorded in continuing operations. The current severance liability as of September 30, 2016 is $3.1 million, of which $2.3 million resides in continuing operations and $0.8 million is in discontinued operations.

 

 

INTERPACE DIAGNOSTICS GROUP, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)

(Tabular information in thousands, except per share amounts)

 

7.

ACCRUED EXPENSES AND LONG-TERM LIABILITIES

 

Other accrued expenses consisted of the following as of September 30, 2016 and December 31, 2015: 

 

   

September 30, 2016

   

December 31, 2015

 

Accrued royalties

  $ 504     $ 111  

Self insurance and benefit accruals

    272       366  

Indemnification liability

    875       875  

Contingent consideration

    209       659  

Rent payable

    78       127  

DOJ settlement

    665       250  

Accrued professional fees

    1,320       775  

Taxes payable

    691       591  

Unclaimed property

    544       546  

Directors fees and insurance

    208       107  

All others

    1,539       1,554  
    $ 6,905     $ 5,961  

 

Long-term liabilities consisted of the following as of September 30, 2016 and December 31, 2015: 

 

   

September 30, 2016

   

December 31, 2015

 

Rent payable

  $ -     $ 52  

Uncertain tax positions

    3,556       3,425  

DOJ settlement (indemnified by RedPath)

    1,000       2,500  

Other

    59       201  
    $ 4,615     $ 6,178  

  

8.

STOCK-BASED COMPENSATION

 

Stock Incentive Plan

 

In 2015, the board of directors (the Board) and stockholders approved the Company’s Amended and Restated 2004 Stock Award and Incentive Plan, or the Amended and Restated Plan. The Amended and Restated Plan amends the Company’s pre-existing Amended and Restated 2004 Stock Award and Incentive Plan, which had replaced the 1998 Stock Option Plan, or the 1998 Plan, and the 2000 Omnibus Incentive Compensation Plan, or the 2000 Plan.  The Amended and Restated Plan authorized an additional 2,450,000 shares for new awards and combined the remaining shares available under the original Amended and Restated Plan.  Eligible participants under the Amended and Restated Plan include officers and other employees of the Company, members of the Board and outside consultants, as specified under the Amended and Restated Plan and designated by the Compensation and Management Development Committee of the Board, or the Compensation Committee.  Unless earlier terminated by action of the Board, the Amended and Restated Plan will remain in effect until such time as no stock remains available for delivery under the Amended and Restated Plan and the Company has no further rights or obligations under the Amended and Restated Plan with respect to outstanding awards thereunder. 

 

SARs are generally granted with a grant price equal to the market value of the common stock on the date of grant, vest one-third each year on the anniversary of the date of grant and expire five years from the date of grant.  The restricted shares and restricted stock units (RSU’s) granted to employees historically have had a three year cliff vesting period and are subject to accelerated vesting and forfeiture under certain circumstances. Restricted shares and restricted stock units granted to board members generally have a three year graded vesting period and are subject to accelerated vesting and forfeiture under certain circumstances.

 

 

INTERPACE DIAGNOSTICS GROUP, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)

(Tabular information in thousands, except per share amounts)

 

In February 2016, certain employees and members of the Company’s Board were granted approximately 1.3 million RSU’s at a weighted average grant price of $0.25. These shares vest one-third each year on the anniversary of the date of grant.

 

The following table provides the weighted average assumptions used in determining the fair value of the non-market based SARs awards granted during the nine month periods ended September 30, 2016 and September 30, 2015:  

 

   

Nine Months Ended

 
   

September 30,

 
   

2016

   

2015

 

Risk-free interest rate

    -       1.02 %

Expected life (years)

    -       3.5  

Expected volatility

    -       54.47 %

Dividend yield

    -       -  

 

The Company recognized approximately $0.02 million and $0.3 million of stock-based compensation expense during each of the three month periods ended September 30, 2016 and 2015, respectively, and $0.1 million and $1.0 million during each of the nine month periods ended September 30, 2016 and 2015, respectively.

 

On October 14, 2016, the Company’s Chief Executive Officer, Chief Financial Officer and certain employees were granted incentive stock options to purchase an aggregate of 878,744 shares of common stock with an exercise price of $0.16 per share and, subject generally to the executive’s or employee’s, as applicable, continued service with the Company, vest in equally monthly installments over a period of one year. 

 

9.

INCOME TAXES

 

Generally, accounting standards require companies to provide for income taxes each quarter based on their estimate of the effective tax rate for the full year. The authoritative guidance for accounting for income taxes allows use of the discrete method when it provides a better estimate of income tax expense. Due to the Company's valuation allowance position, it is the Company's position that the discrete method provides a more accurate estimate of income tax expense and therefore income tax expense for the current quarter has been presented using the discrete method.  As the year progresses, the Company refines its estimate based on the facts and circumstances by each tax jurisdiction.  The following table summarizes income tax (benefit) expense on loss from continuing operations and the effective tax rate for the three- and nine-month periods ended September 30, 2016 and 2015:  

 

   

Three Months Ended

   

Nine Months Ended

 
   

September 30,

   

September 30,

 
   

2016

   

2015

   

2016

   

2015

 

Provision (benefit) from income tax

  $ 173     $ (180 )   $ (54 )   $ (430 )

Effective income tax rate

    (2.5% )     2.4 %     0.4 %     1.9 %

 

Income tax expense and benefit for the three- and nine-month periods ended September 30, 2016 was primarily due to the reclassification of CSO as discontinued operations and the tax adjustments associated with that reclassification. Income tax benefit for the three- and nine-month periods ended September 30, 2015 was primarily due to net operating losses, partially offset by minimum state and local taxes.

 

 

INTERPACE DIAGNOSTICS GROUP, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)

(Tabular information in thousands, except per share amounts)

 

10.

SEGMENT INFORMATION

 

Effective December 31, 2015, the Company has one reporting segment: the Company's molecular diagnostics business, after the divestiture of its CSO business on December 22, 2015. The Company realigned its reporting segments due to the integration of RedPath and acquiring certain assets from Asuragen, to reflect the Company's current and going forward business strategy. The Company's current reporting segment structure is reflective of the way the Company's management views the business, makes operating decisions and assesses performance. This structure allows investors to better understand Company performance, better assess prospects for future cash flows, and make more informed decisions about the Company.

 

The Company's molecular diagnostics business focuses on developing and commercializing molecular diagnostic tests, leveraging the latest technology and personalized medicine for better patient diagnosis and management. Through the Company's molecular diagnostics business, the Company aims to provide physicians and patients with diagnostic options for detecting genetic and other molecular alterations that are associated with gastrointestinal and endocrine cancers, which are principally focused on early detection of high potential progressors to cancer. Customers in the Company's molecular diagnostics segment consist primarily of physicians, hospitals and clinics. The service offerings throughout the segment have similar long-term average gross margins, contract terms, types of customers and regulatory environments. They are promoted through one centrally managed marketing group and the chief operating decision maker views their results on a combined basis.

 

11.

DISCONTINUED OPERATIONS

 

The table below presents the significant components of CSO, Group DCA's, Pharmakon's and TVG’s results included in (Loss) Income from Discontinued Operations, Net of Tax in the consolidated statements of comprehensive loss for the three- and nine-months ended September 30, 2016 and 2015.

 

   

Three Months Ending September 30,

   

Nine Months Ending September 30,

 
   

2016

   

2015

   

2016

   

2015

 

Revenue, net

  $ -     $ 34,119     $ 1,644     $ 104,408  
                                 

(Loss) income from discontinued operations

    (414 )     2,576       (1,006 )     6,615  

Gain on sale of assets

    -       -       1,326       217  

(Loss) income from discontinued operations, before tax

    (414 )     2,576       320       6,832  

Income tax (benefit) expense

    (117 )     2       219       4  

(Loss) income from discontinued operations, net of tax

  $ (297 )   $ 2,574     $ 101     $ 6,828  

 

 

INTERPACE DIAGNOSTICS GROUP, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)

(Tabular information in thousands, except per share amounts)

 

The assets and liabilities classified as discontinued operations relate to CSO, Group DCA, Pharmakon, and TVG. As of September 30, 2016 and December 31, 2015, these assets and liabilities are in the accompanying balance sheets as follows:

 

   

For the Nine Months Ended

September 30, 2016

   

For the Year Ended

December 31, 2015

 
   

CSO

   

DCA/TVG

   

Total

   

CSO

   

DCA/TVG

   

Total

 

Accounts receivable, net

  $ -     $ -     $ -     $ 3,296     $ -     $ 3,296  

Unbilled receivable, net

    -       -       -       16       -       16  

Other

    -       150       150       2,062       -       2,062  

Current assets from discontinued operations

    -       150       150       5,374       -       5,374  

Property and equipment, net

    -       -       -       190       -       190  

Other

    -       -       -       -       150       150  

Long-term assets from discontinued operations

    -       -       -       190       150       340  

Total assets

  $ -     $ 150     $ 150     $ 5,564     $ 150     $ 5,714  
                                                 

Accounts payable

  $ 947     $ -     $ 947     $ 3,767     $ -     $ 3,767  

Unearned contract revenue

    -       -       -       11       -       11  

Accrued salary and bonus

    1,686       -       1,686       3,036       -       3,036  

Other

    2,052       70       2,122       5,092       358       5,450  

Current liabilities from discontinued operations

    4,685       70       4,755       11,906       358       12,264  

Total liabilities

  $ 4,685     $ 70     $ 4,755     $ 11,906     $ 358     $ 12,264  

 

  

12.

LONG-TERM DEBT

 

On October 31, 2014, the Company and Interpace LLC, entered into an agreement to acquire RedPath (the Transaction). In connection with the Transaction, the Company entered into a note with the RedPath Equityholder Representative, on behalf of the former equity holders of RedPath, dated October 31, 2014 (the Note).

 

The Note is $11.0 million, interest-free and payable in eight equal consecutive quarterly installments beginning October 1, 2016. On September 30, the Company and the RedPath Equityholder Representative amended the Note to extend the due date of the first installment to November 1, 2016. Effective October 31, 2016, the Company and the RedPath Equityholder Representative amended the Note to further extend the due date of the first installment to November 20, 2016. On November 16, 2016 the Company and the RedPath Equityholder Representative amended the Note to extend the due date of the first installment to December 31, 2016, to add as an event of default the failure of the Company to maintain a minimum net cash balance from operations of no less than $400,000, excluding proceeds from borrowed money, at the end of every week and to add a reporting requirement for the Company to provide to the RedPath Equityholder Representative, on a weekly basis, a 13-week cash flow forecast commencing November 22, 2016. Subsequent payments on the Note are to be made on the first day of each fiscal quarter, beginning on April 1, 2017.

 

In the second quarter of 2015, the final working capital adjustment was made, reducing the balance of the Note to approximately $10.7 million. In December 2015, pursuant to the sale of substantially all of the CSO business, the Note was amended so that the CSO sales proceeds would not have to be applied against the Note payable balance.

 

The interest rate will be 5.0% in the event of a default under the Note. The obligations of the Company under the Note are guaranteed by the Company and its subsidiaries pursuant to a Guarantee and Collateral Agreement (the “Subordinated Guarantee”) in favor of the RedPath Equityholder Representative. Pursuant to the Subordinated Guarantee, the Company and its subsidiaries also granted a security interest in substantially all of their assets, including intellectual property, to secure their obligations to the RedPath Equityholder Representative. Based on the Company's incremental borrowing rate under its Credit Agreement, the fair value of the Note at the date of issuance was $7.5 million. During the quarters ended September 30, 2016 and 2015, the Company accreted approximately $0.2 million into interest expense, respectively, for each period. During the nine months ended September 30, 2016 and 2015, the Company accreted approximately $0.6 million into interest expense, respectively, for each period. As of September 30, 2016, the balance of the Note is approximately $9.0 million and the unamortized discount is $1.7 million.

 

 

INTERPACE DIAGNOSTICS GROUP, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)

(Tabular information in thousands, except per share amounts)

 

Principal payments due related to the long-term debt, subsequent to the amendment to the Note that was entered into on November 16, 2016, over the next three years are as follows:

  

   

2016

 

2017

 

2018

Note

  $ 1,334       $ 4,001       $ 5,335    

   

The Company currently has an indemnification asset of $1.5 million relating to the DOJ settlement with the former owners of RedPath that was recorded with the acquisition of RedPath. The related DOJ liability is $1.7 million and as the Company makes payments to the DOJ, it may reduce the balance owed on the Note by the same amount.  

 

In addition, the Company entered into the Credit Agreement with SWK Funding LLC (the Agent) and the lenders party thereto in connection with the Transaction in the aggregate principal amount of $20.0 million (the Loan). The maturity date of the Loan was October 31, 2020. The Company received net proceeds of approximately $19.6 million following payment of certain fees and expenses in connection with the Credit Agreement.

 

Upon the sale of substantially all of the CSO business on December 22, 2015, the Company used a portion of the net proceeds from the transaction to pay the balance of the outstanding loan in the aggregate principal amount of $20.0 million, and an exit fee and expenses of approximately $1.6 million. In connection with the termination of the Credit Agreement, the Guarantee and Collateral Agreement, dated October 31, 2014, by the Company and certain of its subsidiaries in favor of the Agent was also terminated on December 22, 2015. 

 

13.

SUPPLEMENTAL CASH FLOW INFORMATION

 

The following table represents cash flows (used in) provided by the Company's discontinued operations for the nine months ended September 30, 2016 and 2015:

  

   

Nine Months Ended

 
   

September 30,

 
   

2016

   

2015

 

Net cash (used in) provided by operating activities of discontinued operations

  $ (1,486 )   $ 7,466  
                 

Net cash (used in) provided by investing activities of discontinued operations

  $ -     $ -  

 

14.

RECENT ACCOUNTING PRONOUNCEMENTS

  

In August 2014, the Financial Accounting Standards Board (“FASB”) issued guidance on determining when and how to disclose going-concern uncertainties in the financial statements. The new standard requires management to perform interim and annual assessments of an entity’s ability to continue as a going concern within one year of the date the financial statements are issued. An entity must provide certain disclosures if conditions or events raise substantial doubt about the entity’s ability to continue as a going concern. The guidance applies to all entities and is effective for annual periods ending after December 15, 2016, and interim periods thereafter, with early adoption permitted. The Company is evaluating the potential impact of the new guidance on its quarterly reporting process and its consolidated financial position, results of operations and related disclosures.

 

In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842), which when effective will require organizations that lease assets (e.g., through "leases") to recognize assets and liabilities for the rights and obligations created by the leases on the balance sheet. A lessee will be required to recognize assets and liabilities for leases with terms that exceed twelve months. The standard will also require disclosures to help investors and financial statement users better understand the amount, timing and uncertainty of cash flows arising from leases. The disclosures include qualitative and quantitative requirements, providing additional information about the amounts recorded in the financial statements. The guidance is effective for annual periods beginning after December 15, 2018, and interim periods within those annual periods. Early adoption is permitted. The Company is currently evaluating the impact of this standard on its consolidated financial position and results of operations.

 

 

INTERPACE DIAGNOSTICS GROUP, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)

(Tabular information in thousands, except per share amounts)

 

In May 2016, the FASB issued ASU 2016-12, "Revenue from Contract with Customers - Narrow-Scope Improvements and Practical Expedients". In April 2016, the FASB issued ASU 2016-10, "Revenue from Contracts with Customers - Identifying Performance Obligations and Licensing". In March 2016, the FASB issued ASU 2016-08, "Revenue from Contract with Customers - Principal versus Agent Considerations (Reporting Revenue Gross versus Net)". In August 2015, the FASB issued ASU 2015-14 deferring the effective date to annual and interim periods. In May 2014, the FASB issued ASU 2014-09, "Revenue from Contracts with Customers". The core principle of these ASUs are that an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. The amendments in ASU 2016-12 affect only the narrow aspects of the guidance, such as assessing the collectability criterion and accounting for contracts that do not meet the criterion, presentation of sales and other similar taxes collected from customers, non-cash consideration, and contract modifications at transition. ASU 2016-10 clarifies two aspects of the guidance: identifying performance obligations and the licensing implementation. The intention of ASU 2016-08 is to improve the operability and understandability of the implementation guidance on principal versus agent considerations. ASU 2015-14 defers the effective date to annual and interim periods beginning on or after December 15, 2017, and early adoption will be permitted, but not earlier than the original effective date of annual and interim periods beginning on or after December 15, 2016, for public entities. ASU 2014-09 is a comprehensive new revenue recognition model for revenue from contract with customers. The Company will adopt these ASUs when effective.

  

15.

OTHER SUBSEQUENT EVENTS

 

On October 4, 2016, Heinrich Dreismann, Ph.D., resigned as a member of the Board effective as of September 30, 2016. In connection with Dr. Dreismann’s resignation and to comply with Nasdaq Listing Rule 5605(c)(4)(B), on October 5, 2016, the Company notified NASDAQ that, as a result of the vacancy on the Audit Committee of the Board (the “Audit Committee”) created by Dr. Dreismann’s resignation, the Audit Committee only has two members and the Company is not in compliance with Nasdaq Listing Rule 5605(c)(2)(A), which requires the Audit Committee be comprised of at least three members. In response to the Company’s notice, NASDAQ issued a letter to the Company on October 6, 2016 acknowledging the Company’s notice that it is no longer in compliance with the audit committee requirements set forth in Nasdaq Listing Rule 5605(c)(2)(A). In its letter, NASDAQ notified the Company that it can rely on the cure period provided by Nasdaq Listing Rule 5605(c)(4), which allows the Company until the earlier of (i) its next annual meeting of stockholders or (ii) October 2, 2017 to regain compliance, or, if the next annual meeting of stockholders is held before March 29, 2017, then the Company must evidence compliance no later than March 29, 2017. The Company intends to appoint an additional independent director to the Board and to the Audit Committee prior to the end of the cure period.

 

 

INTERPACE DIAGNOSTICS GROUP, INC.

 

Item 2.  Management’s Discussion and Analysis of Financial Condition and Results of Operations

 

FORWARD-LOOKING STATEMENTS

 

 This quarterly report on Form 10-Q (Form 10-Q) contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended (the Securities Act), and Section 21E of the Securities Exchange Act of 1934. as amended (the Exchange Act).  Statements that are not historical facts, including statements about our plans, objectives, beliefs and expectations, are forward-looking statements.  Forward-looking statements include statements preceded by, followed by or that include the words “believes,” “expects,” “anticipates,” “plans,” “estimates,” “intends,” “projects,” “should,” "could," “may,” “will” or similar words and expressions.  These forward-looking statements are contained throughout this Form 10-Q.

 

Forward-looking statements are only predictions and are not guarantees of future performance.  These statements are based on current expectations and assumptions involving judgments about, among other things, future economic, competitive and market conditions and future business decisions, all of which are difficult or impossible to predict accurately and many of which are beyond our control.  These predictions are also affected by known and unknown risks, uncertainties and other factors that may cause our actual results to be materially different from those expressed or implied by any forward-looking statement.  Many of these factors are beyond our ability to control or predict.  Such factors include, but are not limited to, the following:

 

 

our ability to profitably grow our business, including our ability to finance our business on acceptable terms and successfully compete in the market;

 

our ability to obtain and maintain broad adoption of and reimbursement for our molecular diagnostic tests in a changing reimbursement environment;

 

whether we are able to successfully utilize our operating experience to sell our molecular diagnostic tests;

 

our limited operating history as a molecular diagnostics company;

 

our dependence on a concentrated selection of payors for our molecular diagnostic tests;

 

the demand for our molecular diagnostic tests from physicians and patients;

 

our reliance on our internal sales forces for business expansion;

 

our dependence on third parties for the supply of some of the materials used in our molecular diagnostic tests;

 

our ability to scale our operations, testing capacity and processing technology;

 

our ability to restructure, defer or convert into equity certain of our debt obligations and liabilities;

 

our ability to meet the legacy obligations of our CSO business previously sold or to meet the acquisition indebtedness related to acquiring our molecular diagnostics businesses;

 

our ability to find a buyer for all or a portion of our assets to forestall foreclosure proceedings in the event the RedPath Equityholder Representative does not further extend the due date of the first payment of principal on its secured note beyond December 31, 2016 or in the event the Company does not obtain further financing;

 

our ability to negotiate acceptable agreements, including amendments with our secured and unsecured creditors, sufficient to enable us to continue operations and fund our near term operations;

 

the risk of not making our first installment payment due to the RedPath Equityholder Representative by December 31, 2016 and not obtaining a further extension and the impact on our business;

 

our ability to comply with the other requirements of the secured note payable to the RedPath Equityholder Representative;

 

the risk of foreclosure by the secured creditors and the possible sale of our assets;

 

the risk of the sale of our assets not yielding sufficient proceeds to either pay the secured creditors or unsecured creditors or provide any return to stockholders;

 

the risk of filing a Chapter 7 bankruptcy proceeding after any sale of assets;

 

product liability claims against us;

 

our ability to gain sufficient stockholder support in order to potentially enter into any transaction that may further dilute our stockholders;

 

our involvement in current and future litigation against us;

 

the effect current and future laws, licensing requirements and regulation have on our business especially the changing FDA environment as it relates to molecular diagnostics;

 

 

INTERPACE DIAGNOSTICS GROUP, INC.  

 

 

our exposure to environmental liabilities as a result of our business;

 

the susceptibility of our information systems to security breaches, loss of data and other disruptions;

 

our billing practices and our ability to collect on claims for the sale of our molecular diagnostic tests;

 

our ability to attract and retain qualified sales representatives and other key employees and management personnel;

 

competition in the segment of the molecular diagnostics industry in which we operate or expect to operate;

 

our ability to obtain additional funds in order to implement our business models and strategies;

 

the results of any future impairment testing for other intangible assets;

 

our ability to successfully identify, complete and integrate any future acquisitions and the effects of any such items on our revenues, profitability and ongoing business;

 

our compliance with our license agreements and our ability to protect and defend our intellectual property rights;

 

our ability to remain listed on NASDAQ despite our having received notices of non-compliance, including for failing to have three independent audit committee members;

 

the effect our largest stockholders may have on us;

 

failure of third-party service providers to perform their obligations to us;

  our ability to comply with our line of credit covenants, if the line is utilized; and
 

the volatility of our stock price and fluctuations in our quarterly and annual revenues and earnings.

 

Please see Part I – Item 1A – “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2015, Part-II- Item 1A – “Risk Factors” of this Form 10-Q, as well as other documents we file with the U.S. Securities and Exchange Commission (SEC) from time-to-time, for other important factors that could cause our actual results to differ materially from our current expectations as expressed in the forward-looking statements discussed in this Form 10-Q.  Because of these and other risks, uncertainties and assumptions, you should not place undue reliance on these forward-looking statements. In addition, these statements speak only as of the date of the report in which they are set forth and, except as may be required by law, we undertake no obligation to revise or update publicly any forward-looking statements for any reason.

 

OVERVIEW

 

We are focused on developing and commercializing molecular diagnostic tests principally focused on early detection of high potential progressors to cancer and leveraging the latest technology and personalized medicine for patient diagnosis and management. We currently have three commercialized molecular tests: PancraGen®, a pancreatic cyst molecular test that can aid in pancreatic cyst diagnosis and pancreatic cancer risk assessment utilizing our proprietary PathFinder platform; ThyGenX®, which assesses thyroid nodules for risk of malignancy; and ThyraMIR®, which assesses thyroid nodules risk of malignancy utilizing a proprietary gene expression assay. We also have on the market, in a limited manner, an assay utilizing our PathFinder platform, for Barrett's Esophagus, an esophageal cancer risk classifier. Additionally, we have in development and are launching an assay for biliary cancer.

 

Our mission is to provide personalized medicine through molecular diagnostics and innovation to advance patient care based on rigorous science. We aim to provide physicians and patients with diagnostic options for detecting genetic and other molecular alterations that are associated with gastrointestinal and endocrine cancers. Our customers consist primarily of physicians, hospitals and clinics.

 

With the completion of the CSO transaction and wind down of related activities through September 2016, we are now concentrating our efforts principally on our molecular diagnostics business by offering solutions for determining the presence of certain cancers to clinicians and their patients as well as providing prognostic pre-cancerous information, which we believe to be an expanding market opportunity. We believe that the molecular diagnostics market offers significant growth and strong patient value given the substantial opportunity it affords to lower healthcare costs by helping to reduce unnecessary surgeries and avoiding too frequent monitoring. We are keenly focused on growing our test volumes, securing additional reimbursement, supporting our current reimbursement and supporting revenue growth for our three commercialized innovative tests as well as expanding our business by developing and promoting synergistic products in our market.

 

 

INTERPACE DIAGNOSTICS GROUP, INC.

 

In March 2016, we announced that we implemented a broad-based program to maximize efficiencies and cut costs as we focus on improving cash flows and profitability while completing our transition to a standalone molecular diagnostics business. In addition to reducing headcount, we have realigned our compensation structure, consolidated positions, eliminated programs and development plans that did not have near term benefits, and streamlined and right-sized operating systems while reducing overhead. This was done while supporting the transition of our CSO business to the buyer of that business and continuing to shut down less profitable CSO contracts that were not part of the sale of that business.

 

In August 2016, we announced that the New York State Department of Health has reviewed and approved ThyraMir, the Company's micro RNA gene-expression based test, for marketing in New York State.  New York State accounts for approximately 5% of the 600,000 Thyroid FNA biopsies performed in the U.S. annually according to Thyroid Disease Manager. New York was the final state for which we had been awaiting approval.  

 

In October 2016, we announced that the New York State Department of Health has reviewed and approved for marketing ThyGenX™, the Company's NextGen Sequencing oncogene panel for indeterminate thyroid nodules.  The New York State approval of ThyGenX, which determines whether or not specific biomarkers are present, enables Interpace LLC to market both ThyGenX and ThyraMir together in the state. ThyGenX typically precedes the running of ThyraMir, and they typically go hand in hand with 82% of ThyGenX cases warranting reflex to a more sophisticated, micro RNA assessment via ThyraMir. Of the several states that require special licensure to provide testing to patients who reside in their jurisdiction, New York was the final state to issue approval.

 

Also in October 2016, we announced completion and the validation and launch of two new thyroid services, further expanding the Company's comprehensive support of physicians and health care institutions servicing thyroid patients. Our new cytopathology service is designed to assist physicians and clinics that prefer to have the initial Fine Needle Aspirate (FNA) biopsy assessed by an independent third party versus having it performed on site.

 

We have been successfully expanding the reimbursement of our products in 2016:

 

 

In April 2016, we announced reimbursement approval by a major national managed care organization to cover ThyraMIR™, the first micro RNA classifier made available for improving the diagnosis of indeterminate thyroid nodules. This approval brings the total number of covered lives in the United States for ThyraMIR to more than 130 million. Coverage by this national plan was previously approved for ThyGenX®, our Next Gen oncogene panel used to assist physicians in distinguishing between benign and malignant thyroid nodules. 

 

In April 2016, we also announced that we received coverage for all of our products by Galaxy Health Network, a national managed care provider with over 3.5 million covered lives. Galaxy Health Network's Preferred Provider Organization includes a network of over 400,000 contracted physicians, 2,700 hospitals and 47,000 ancillary providers.

 

In April 2016, we announced new coding by Novitas Solutions for PancraGen®. Novitas Solutions has assigned a new molecular CPT code (Current Procedural Terminology) to its PancraGen® test for pancreatic cysts.  Prior to this coding change the test was covered under a miscellaneous chemistry code, which is used for billing a wide range of tests across the laboratory industry and does not effectively differentiate between technologies that have significantly different features and offer unique benefits to patients with specific diseases. 

 

In February 2016, we announced that we received Medicare approval for coverage of ThyraMIR. As a result, the ThyraMIR test is now accessible to more than 50 million Medicare covered patients nationwide effective December 14, 2015. ThyGenX® is already covered by Medicare, therefore, the addition of coverage for ThyraMIR provides Medicare covered patients the benefits of the ThyGenX/ThyraMIR combination test.

 

In January 2016, we announced that our Medicare administrative carrier, Novitas Solutions, issued a new local coverage determination (LCD) for PancraGen®. The LCD provides the specific circumstances under which PancraGen® is covered. The new policy is non-conditional and may improve the efficiency of the testing process for doctors and patients. The LCD covers approximately 55 million patients, bringing the total patients covered for PancraGen® to nearly 68 million.

 

 

INTERPACE DIAGNOSTICS GROUP, INC.

 

On January 7, 2016, we were notified by NASDAQ that we were no longer in compliance with the minimum bid price requirements of the stock exchange and that we have until July 5, 2016 to regain compliance with this requirement or face delisting. On July 6, 2016, we were notified by NASDAQ that we were eligible for an additional 180 day period, or until January 3, 2017, to regain compliance. On August 3, 2016, our stockholders voted to allow, but not require, our Board to effect a reverse stock split of the outstanding shares of common stock at any time before January 1, 2017 by a ratio of not less than one-for-five and not more than one-for-thirty, with the specific ratio to be fixed within this range by the Board in its sole discretion. The reverse split must be executed no later than ten business days prior to January 3, 2017 unless the Company’s closing bid price was at least $1.00 for a minimum of 10 business days prior to that time. This would allow us to meet the minimum listing requirements of NASDAQ and avoid delisting.

 

On October 4, 2016, Heinrich Dreismann, Ph.D., resigned as a member of our Board effective as of September 30, 2016. In connection with Dr. Dreismann’s resignation and to comply with Nasdaq Listing Rule 5605(c)(4)(B), on October 5, 2016, we notified NASDAQ that, as a result of the vacancy on the Audit Committee of our Board (the “Audit Committee”) created by Dr. Dreismann’s resignation, the Audit Committee only has two members and we are not in compliance with Nasdaq Listing Rule 5605(c)(2)(A), which requires the Audit Committee be comprised of at least three members. In response to our notice, NASDAQ issued a letter to us on October 6, 2016 acknowledging our notice that we are no longer in compliance with the audit committee requirements set forth in Nasdaq Listing Rule 5605(c)(2)(A). In its letter, NASDAQ notified us that we can rely on the cure period provided by Nasdaq Listing Rule 5605(c)(4), which allows us until the earlier of (i) our next annual meeting of stockholders or (ii) October 2, 2017 to regain compliance, or, if the next annual meeting of stockholders is held before March 29, 2017, then we must evidence compliance no later than March 29, 2017. We intend to appoint an additional independent director to our Board and to the Audit Committee prior to the end of the cure period. 

 

DESCRIPTION OF REPORTING SEGMENTS

 

We currently operate under one operating segment, which is our molecular diagnostic business. Until December 22, 2015 prior to the CSO sale, we operated under two reporting segments: Commercial Services (CSO) and Interpace Diagnostics. The CSO business in the periods ended September 30, 2016 is reported as discontinued operations and has been reclassified to discontinued operations in the periods ended September 30, 2015 to conform to the current period presentation.

 

Interpace Diagnostics

 

Interpace Diagnostics revenue is generated from the use of our proprietary tests. Our performance obligation is fulfilled upon the completion, review and release of test results. In conjunction with fulfilling these services, we bill the third-party payor or hospital. We recognize revenue related to billings for Medicare, Medicare Advantage, hospitals, and other third party payers on an accrual basis, net of contractual adjustment, when a contract is in place, a reliable pattern of collectability exists and collectability is reasonably assured. Contractual adjustments represent the difference between the list prices and the reimbursement rate set by Medicare, Medicare Advantage, insurance companies, and the contractual rate or the amounts agreed to with hospitals.

 

Until a contract has been negotiated with a commercial insurance carrier or governmental program, the services may or may not be covered by these entities' existing reimbursement policies. In addition, we do not enter into direct agreements with patients that commit them to pay any portion of the cost of the tests in the event that insurance declines to reimburse us. In the absence of an agreement with the patient or other clearly enforceable legal right to demand payment, the related revenue is only recognized upon the earlier of payment notification or cash receipt. Accordingly, we recognize revenue from commercial insurance carriers and governmental programs without contracts, when payment is received.

 

Persuasive evidence of an arrangement exists and delivery is deemed to have occurred upon completion, review, and release of the test results and we will bill the third-party payor or hospital at such time. The assessment of the fixed or determinable nature of the fees charged for diagnostic testing performed, and the collectability of those fees, requires significant judgment by our management. Our management believes that these two criteria have been met when there is contracted reimbursement coverage or a predictable pattern of collectability with individual third-party payors or hospitals and accordingly, recognizes revenue upon delivery of the test results. In the absence of contracted reimbursement coverage or a predictable pattern of collectability, we believe that the fee is fixed or determinable and collectability is reasonably assured only upon request of third-party payor notification of payment or when cash is received, and we recognize revenue at that time.

 

 

INTERPACE DIAGNOSTICS GROUP, INC.

 

Cost of services consists primarily of the costs associated with operating our laboratories and other costs directly related to our tests. Personnel costs, which constitute the largest portion of cost of services, include all labor related costs, such as salaries, bonuses, fringe benefits and payroll taxes for laboratory personnel. Other direct costs include, but are not limited to, laboratory supplies, certain consulting expenses, and facility expenses.

 

CONDENSED CONSOLIDATED RESULTS OF OPERATIONS

 

The following table sets forth, for the periods indicated, certain statements of operations data. The trends illustrated in this table may not be indicative of future results.

 

Condensed Consolidated Results of Continuing Operations for the Quarter Ended September 30, 2016 Compared to the Quarter Ended September 30, 2015 (in thousands)  

 

   

Three Months Ended

 
   

September 30,

 
   

2016

   

2016

   

2015

   

2015

 
                                 
                                 

Revenue, net

  $ 3,316       100.0 %   $ 2,506       100.0 %

Cost of revenue

    1,846       55.7 %     1,799       71.8 %

Gross profit

    1,470       44.3 %     707       28.2 %

Operating expenses:

                               

Sales and marketing

    1,282       38.7 %     2,876       114.8 %

Research and development

    659       19.9 %     1,000       39.9 %

General and administrative

    2,858       86.2 %     2,498       99.7 %

Acquisition related amortization expense

    970       29.3 %     986       39.3 %

Asset impairment

    3,363       101.4 %     -       -  

Change in fair value of contingent consideration

    (1,174 )     -35.4 %     -       -  

Total operating expenses

    7,958       240.0 %     7,360       293.7 %
                                 

Operating loss

    (6,488 )     -195.7 %     (6,653 )     -265.5 %

Interest expense

    (539 )     -16.3 %     (884 )     -35.3 %

Other income (expense), net

    4       0.1 %     (112 )     -4.5 %

Loss from continuing operations before tax

    (7,023 )     -211.8 %     (7,649 )     -305.2 %

Provision (benefit) for income tax

    173       5.2 %     (180 )     -7.2 %

Loss from continuing operations

    (7,196 )     -217.0 %     (7,469 )     -298.0 %

(Loss) income from discontinued operations, net of tax

    (297 )     -9.0 %     2,574       102.7 %

Net loss

  $ (7,493 )     -226.0 %   $ (4,895 )     -195.3 %

 

Revenue, net

 

Consolidated revenue for the three months ended September 30, 2016 increased by $0.8 million, or 32.3%, to $3.3 million, compared to $2.5 million for the three months ended September 30, 2015. This increase was principally attributable to increased test and collection volume, and an increase in amounts collected based upon Medicare coverage received for ThyraMIR® tests.

 

 

INTERPACE DIAGNOSTICS GROUP, INC.

 

Cost of revenue

 

Consolidated cost of revenue for the three months ended September 30, 2016 increased slightly by 2.6% but decreased, however, as a percentage of revenue. This decrease as a percentage of revenue was attributable to lower lab supplies expense as a percentage of revenue as part of a broad-based program to maximize efficiencies and cut costs.

 

Gross profit

 

Consolidated gross profit for the three months ended September 30, 2016 increased $0.8 million, or 107.9%, to $1.5 million, compared to $0.7 million for the three months ended September 30, 2015. This increase was related to the favorable impact of the increase in revenue along with the lower cost as a percentage of revenue described above.

 

Sales and marketing expense

 

Sales and marketing expense was $1.3 million for the three months ended September 30, 2016 and as a percentage of revenue was 38.7%. For the three months ended September 30, 2015, the sales and marketing expense was $2.9 million and 114.8% as a percentage of revenue. The decrease in sales and marketing expense principally reflects a reduction in sales personnel and the consolidation of marketing activities under a broad-based program to maximize efficiencies and cut costs and the percentage decline is also a function of the growth in revenues.

 

Research and development

 

Research and development expense was $0.7 million for the three months ended September 30, 2016 and as a percentage of revenue was 19.9%. For the three months ended September 30, 2015 the expense was $1.0 million and as a percentage of revenue was 39.9%. Effort to maximize efficiencies

 

General and administrative

 

General and administrative expense for the three months ended September 30, 2016 was $2.9 million as compared to $2.5 million for the three months ended September 30, 2015. This increase was primarily attributable to an increase in professional services fees.

 

Acquisition related amortization expense

 

During the three months ended September 30, 2016 and September 30, 2015, we recorded amortization expense of approximately $1.0 million in both periods. This relates to the amortization for RedPath and Asuragen acquired intangible assets.

 

Asset impairment

 

During the three months ended September 30, 2016, we incurred an asset impairment charge of approximately $3.4 million resulting from a decline in the market value of Pancreas and Biobank assets associated with the acquisition of certain assets from Asuragen.

 

Change in fair value of contingent consideration

  

During the three months ended September 30, 2016, there was a $1.2 million reduction in contingent consideration liability related to amounts associated with future royalty payments for the Pancreas asset acquired from Asuragen.

 

Operating loss

 

There were operating losses from continuing operations of $6.5 million and $6.7 million during the three months ended September 30, 2016 and 2015, respectively.  The decrease in operating loss for the three months ended September 30, 2016 was primarily attributable to the increase in revenue and margins in addition to the cost savings initiated under our broad-based program to maximize efficiencies and cut costs, partially offset by the asset impairment charges in the quarter.

 

Provision for income taxes

 

We had income tax expense of approximately $0.2 million for the three months ended September 30, 2016. We had an income tax benefit of approximately $0.2 million for the three months ended September 30, 2015. Income tax expense for the three months ended September 30, 2016 was primarily due to the reclassification of CSO as discontinued operations and the tax adjustments associated with that reclassification. The income tax benefit for the three months ended September 30, 2015 was primarily due to our operating loss.

 

 

INTERPACE DIAGNOSTICS GROUP, INC.

 

Income (loss) from discontinued operations, net of tax

 

We had a loss from discontinued operations of $0.3 million for the three months ended September 30, 2016 and income from discontinued operations of $2.6 million for the three months ended September 30, 2015. The loss from discontinued operations for the quarter ended September 30, 2016 was primarily related to legacy costs associated with the CSO business. The income from discontinued operations for the quarter ended September 30, 2015 was related to normal CSO operations during that period.

 

Condensed Consolidated Results of Continuing Operations for the Nine Months Ended September 30, 2016 Compared to the Nine Months Ended September 30, 2015 (in thousands) 

 

   

Nine Months Ended

 
   

September 30,

 
   

2016

   

2016

   

2015

   

2015

 
                                 
                                 

Revenue, net

  $ 9,963       100.0 %   $ 6,876       100.0 %

Cost of revenue

    4,866       48.8 %     5,224       76.0 %

Gross profit

    5,097       51.2 %     1,652       24.0 %

Operating expenses:

                               

Sales and marketing

    4,186       42.0 %     8,387       122.0 %

Research and development

    1,339       13.4 %     1,646       23.9 %

General and administrative

    7,655       76.8 %     8,909       129.6 %

Acquisition related amortization expense

    2,909       29.2 %     2,825       41.1 %

Asset impairment

    3,363       33.8 %     -       -  

Change in fair value of contingent consideration

    (1,174 )     -11.8 %     -       -  

Total operating expenses

    18,278       183.5 %     21,767       316.6 %
                                 

Operating loss

    (13,181 )     -132.3 %     (20,115 )     -292.5 %

Interest expense

    (1,601 )     -16.1 %     (2,616 )     -38.0 %

Other income (expense), net

    14       0.1 %     (268 )     -3.9 %

Loss from continuing operations before tax

    (14,768 )     -148.2 %     (22,999 )     -334.5 %

Benefit for income tax

    (54 )     -0.5 %     (430 )     -6.3 %

Loss from continuing operations

    (14,714 )     -147.7 %     (22,569 )     -328.2 %

(Loss) income from discontinued operations, net of tax

    101       1.0 %     6,828       99.3 %

Net loss

  $ (14,613 )     -146.7 %   $ (15,741 )     -228.9 %

  

Revenue, net

 

Consolidated revenue for the nine months ended September 30, 2016 increased by $3.1 million, or 44.9%, to $10.0 million, compared to $6.9 million for the nine months ended September 30, 2015. This increase was principally attributable to increased test and collection volume of ThyGenX® and ThyraMIR®, and an increase in amounts collected based upon Medicare coverage received for ThyraMIR® tests.

 

Cost of revenue

 

Consolidated cost of revenue for the nine months ended September 30, 2016 decreased $0.4 million in spite of the increase in revenue, by 6.9%, to $4.9 million, compared to $5.2 million for the nine months ended September 30, 2015. This decrease was attributable to lower lab supplies expense and improved efficiencies as part of a broad-based program to maximize efficiencies and cut costs.

 

 

INTERPACE DIAGNOSTICS GROUP, INC.

 

Gross profit

 

Consolidated gross profit for the nine months ended September 30, 2016 increased $3.4 million, or 208.5%, to $5.1 million, compared to $1.7 million for the nine months ended September 30, 2015. This increase was related to the favorable impact of the increase in revenue along with the lower cost of revenue described above.

 

Sales and marketing expense

 

Sales and marketing expense was $4.2 million for the nine months ended September 30, 2016 and as a percentage of revenue was 42.0%. For the nine months ended September 30, 2015, sales and marketing expense was $8.4 million and as a percentage of revenue was 122.0%.. The decrease in sales and marketing expense principally reflects a reduction in sales personnel and the consolidation of marketing activities under a broad-based program to maximize efficiencies and cut costs.

 

Research and development

 

Research and development expense was $1.3 million for the nine months ended September 30, 2016 and as a percentage of revenue was 13.4%. For the nine months ended September 30, 2015, research and development expense was $1.6 million and as a percentage of revenue was 23.9%.

 

General and administrative

 

General and administrative expense for the nine months ended September 30, 2016 was $7.4 million as compared to $8.9 million for the nine months ended September 30, 2015. This decrease was primarily attributable to downsizing of systems, infrastructure and personnel related to operating a smaller molecular diagnostics business under a broad-based program to maximize efficiencies and cut costs.

 

Acquisition related amortization expense

 

During the nine months ended September 30, 2016 and June 30, 2015, we recorded amortization expense of approximately $2.9 million and $2.8 million, respectively. This relates to the amortization for RedPath and Asuragen acquired intangible assets.

 

Asset impairment

 

During the nine months ended September 30, 2016, we incurred an asset impairment charge of approximately $3.4 million resulting from a decline in the market value of Pancreas and Biobank assets associated with the acquisition of certain assets from Asuragen.

 

Change in fair value of contingent consideration

  

During the nine months ended September 30, 2016, there was a $1.2 million reduction in contingent consideration liability related to amounts associated with future royalty payments for the Pancreas asset acquired from Asuragen.

 

Operating loss

 

There were operating losses from continuing operations of $13.2 million and $20.1 million during the nine months ended September 30, 2016 and 2015, respectively.  The decrease in operating loss for the nine months ended September 30, 2016 was primarily attributable to the increase in revenue and margins in addition to the cost savings initiated under our broad-based program to maximize efficiencies and cut costs.

 

Provision for income taxes

 

We had an income tax benefit of approximately $0.1 million for the nine months ended September 30, 2016. We had an income tax benefit of approximately $0.4 million for the nine months ended September 30, 2015. Income tax benefit for the nine months ended September 30, 2016 was primarily due to the reclassification of CSO as discontinued operations and the tax adjustments associated with that reclassification. The income tax benefit for the nine months ended September 30, 2015 was primarily due to our operating loss.

 

Income (loss) from discontinued operations, net of tax

 

We had income from discontinued operations of $0.1 million for the nine months ended September 30, 2016 as compared to income from discontinued operations of $6.8 million for the nine months ended September 30, 2015. The income from discontinued operations for the nine months ended September 30, 2016 was primarily related to the gain on sale of $1.3 million related to the final working capital adjustment regarding the sale of the CSO business in December of 2015 partially offset by expenses relating to the winding down of CSO. The income from discontinued operations for the nine months ended September 30, 2015 was related to normal CSO operations during that period.

 

 

INTERPACE DIAGNOSTICS GROUP, INC.

 

LIQUIDITY AND CAPITAL RESOURCES 

 

For the nine months ended September 30, 2016, the Company incurred a net loss of $14.6 million and cash used in operating activities was $6.6 million.  The Company did not raise any capital or incur any funded debt during the first nine months of 2016, but it did enter into a Credit Agreement with SCM Specialty Finance Opportunities Fund, L.P. on September 28, 2015 as described further below, on which it has not yet drawn. The Company also anticipates operating losses to continue for the foreseeable future due to, among other things, costs related to its commercial operations, developing products and product candidates, right sizing and reorganizing its administrative organization and winding down activities and managing obligations related to its discontinued operations.

 

The accompanying condensed, consolidated financial statements have been prepared on a basis that assumes that the Company will continue as a going concern and that contemplates the continuity of operations, the realization of assets and the satisfaction of liabilities and commitments in the normal course of business. As of September 30, 2016, the Company had cash and cash equivalents of $1.7 million, net accounts receivable of $2.8 million, current assets of $6.7 million and current liabilities of $19.9 million.

 

As a result of the sale of substantially all of its CSO business in December 2015, which generated net cash proceeds of $26.8 million (of which $21.6 million was used to repay long-term debt and fees), the Company focused its resources and strategic initiatives on its molecular diagnostics business. As with many companies in a similar stage, sufficient capital is required before achieving profitability. Accordingly, the Company may require additional capital in 2016 and will require additional capital beyond 2016. In order to obtain such capital and fund its operations, the Company may be required to restructure all or a portion of its obligations related to the sale of its CSO business as well as obligations owed to the former equity holders of RedPath Integrated Pathology, Inc.(“RedPath”) arising out of the Company’s acquisition of RedPath. The first payment of secured debt to RedPath Equity Holder Representative, LLC (the “Equityholder Representative”), as representative of the former equity holders of RedPath, has been extended several times from its original due date of October 1, 2016 and is now due December 31, 2016 unless further extended. There is no guarantee that additional capital will or can be raised or that adequate restructuring will be accomplished that are sufficient to fund the Company's operations for the rest of 2016 and beyond or that the terms of such additional capital, if available, will be acceptable to the Company. Accordingly, the Company continues to explore sales of assets and various dilutive and non-dilutive sources of funding, including equity and debt financings, strategic alliances and alternatives, business development, and other alternatives. Additionally, the Company continues to focus on increasing sales of its commercial molecular diagnostic tests, closely managing cash and further streamlining operations. If, however, the Company is unsuccessful in obtaining capital and executing its plans for the business to continue operations, when needed, including the restructuring of its debt and other liabilities, then it may be forced to sell off assets, seek protection under the U.S. Bankruptcy Code, or be forced into liquidation or substantially alter or restructure its business operations. In the event of a default on its secured note, the RedPath Equityholder Representative could foreclose on the Company’s assets, force the Company into bankruptcy or pursue other remedies. In such events, stockholders are not likely to recoup their investment in the Company. These factors, among others, raise substantial doubt about the Company’s ability to continue as a going concern.

 

During the first nine months of 2016, the Company commenced negotiations with certain of its creditors and former sales representatives and executives to restructure its current and long-term obligations related to the sale of the majority of its CSO business in December 2015. The proposed restructuring by the Company includes reducing or extending the term of certain of its obligations, converting a portion to equity and/or forgiving portions thereof. However, any such restructuring may be dependent on the Company raising additional capital. The Company believes that this proposed restructuring, if achieved, will not only improve its liquidity but also provide the flexibility for future funding. No assurance, however, can be given that the negotiations to restructure the Company’s debt and obligations will be successful.

 

 

INTERPACE DIAGNOSTICS GROUP, INC.

 

At September 30, 2016, the Company had the following debt obligations that it has been seeking to restructure:

 

 

1.

Future payments and conditions related to the $10.7 million secured note payable to the former equity holders of RedPath.

 

 

2.

Severance obligations to former executives ($3.1 million, including taxes).

 

 

3.

Obligations due to former sales representatives under the CSO incentive plan (up to $1 million including taxes). To date, 343 former sales representatives have accepted the Company’s offer to pay out approximately $0.6 million in equal installments over eight months. For the period ended September 30, 2016 approximately $0.1 million was paid out under this plan.

  

 

4.

Various liabilities including trade payables, other employee severance in accrued expenses and certain liabilities from Discontinued Operations which are in the process of being renegotiated or restructured.

 

There is, however, no guarantee that the Company will be successful in restructuring its outstanding debt. 

 

A summary of the Company’s most significant contractual obligations over the next 12 months are as follows: 

 

   

Total

   

0 to 3 months

   

3 to 6 months

   

6 to 12 months

 

Note due Redpath Equityholders

  $ 4,001     $ 1,334     $ -     $ 2,667  

Severance obligations

    3,137       3,137       -       -  

DOJ settlement

    665       85       85       495  

Deferred Bonus - ERT salesforce

    800       185       308       307  

Total obligations

  $ 8,603     $ 4,741     $ 393     $ 3,469  

  

On September 28, 2016 (the “Closing Date”), the Company and its wholly-owned direct and indirect subsidiaries, Interpace Diagnostics, LLC (“Interpace LLC”) and Interpace Diagnostics Corporation (“IDC” and together with Interpace LLC, its “Subsidiaries”), entered into a Credit Agreement (the “Credit Agreement”) with SCM Specialty Finance Opportunities Fund, L.P. (the “Lender”). Pursuant to and subject to the terms of the Credit Agreement, the Lender agreed to provide a revolving loan (the “Loan”) to the Company in the maximum principal amount of $1.2 million (“Facility Cap”). Also on the Closing Date, the Company and its Subsidiaries acknowledged and agreed to an Intercreditor Agreement (the “Intercreditor Agreement”) by and between the Lender and the RedPath Equityholder Representative pursuant to which the Lender has a first lien security interest on all of the accounts receivable (and related intangibles) of the Company and its Subsidiaries and the RedPath Equityholder Representative has a second lien security interest, subordinated to the Lender, on all the accounts receivables (and related intangibles) of the Company and its Subsidiaries. In addition, pursuant to the Intercreditor Agreement, the RedPath Equityholder Representative has a first lien security interest on all other assets of the Company and its Subsidiaries and the Lender has no lien with respect to such other assets. The maturity date of the Loan is September 28, 2018. The Loan bears interest at an annual rate equal to the Prime Rate (as defined in the Credit Agreement) plus 2.75%, payable in cash monthly in arrears. The interest rate will be increased by 5.0% in the event of a default under the Credit Agreement. Events of default under the Credit Agreement, some of which are subject to certain cure periods, include a failure to pay or perform obligations when due, the making of a material misrepresentation to the Lender, the rendering of certain judgments or decrees against the Company and its Subsidiaries and the initiation, voluntarily or involuntarily, of a bankruptcy or similar proceeding against the Company or its Subsidiaries.

 

The Company agreed to pay certain out-of-pocket costs and expenses incurred by the Lender in connection with the Credit Agreement and related documents, the administration of the Loan and related documents and the enforcement or protection of the Lender’s rights. The Lender is also entitled to: (a) a $12,000 origination fee; (b) a monthly unused line fee equal to the amount which is one-twelfth of one percent (0.083%) of the difference between (i) the outstanding balance of the Loan during the preceding month, and (ii) the Facility Cap on the date of determination; (c) a monthly collateral management fee equal to one-sixth of one percent (0.1666%) of the average daily balance under the Credit Agreement outstanding during the preceding month; and (d) a termination fee equal to (i) two percent (2%) of the Facility Cap if the Credit Agreement is terminated before the first anniversary of the Closing Date (the “First Anniversary”), or (ii) one percent (1%) of the Facility Cap if the Credit Agreement is terminated after the First Anniversary. The Company must also pay certain fees in the event that (a) the amount outstanding under the Credit Agreement exceeds the availability under the Credit Agreement’s borrowing base, and (b) receivables are not properly deposited in the appropriate lockbox account.

 

 

INTERPACE DIAGNOSTICS GROUP, INC.

 

The Credit Agreement contains customary representations and warranties in favor of the Lender and certain covenants, including, among other things, financial covenants relating to loan turnover rates, liquidity and revenue targets. 

 

As of November 17, 2016, the Company had not borrowed any funds under the Credit Agreement.

 

On September 30, 2016, the Company, Interpace LLC and the RedPath Equityholder Representative entered into an amendment to the $10.7 million interest free secured note payable to the former equity holders of RedPath to extend by one month, until November 1, 2016, subject to the terms of the amendment, the due date for the first quarterly payment of principal under the note. Effective October 31, 2016, the Company, Interpace LLC and the RedPath Equityholder Representative entered into a fourth amendment to the note to extend until November 20, 2016, subject to the terms of the amendment, the due date for the first quarterly payment of principal. On November 16, 2016 the Company, Interpace LLC and the RedPath Equityholder Representative entered into a fifth amendment to the note to, among other things, extend until December 31, 2016, subject to the terms of the amendment, the due date for the first quarterly payment. Under the note, the Company is required to make eight installment payments of principal, with each payment equal to $1,333,750, together with accrued and unpaid interest, if any. The first payment is now due on December 31, 2016, and subsequent payments are to be made on the first day of each fiscal quarter, beginning on April 1, 2017. The first quarterly payment of principal under the note originally was due on October 1, 2016.

  

The Company currently has no means to make the first quarterly payment of principal due on December 31, 2016, and if the due date for the first quarterly payment of principal is not extended by the RedPath Equityholder Representative or equity capital or debt is not raised, the RedPath Equityholder Representative could foreclose on our assets. Accordingly, the Company continues to explore sales of assets and various dilutive and non-dilutive sources of funding, including equity and debt financings, strategic alliances and alternatives, business development, and other alternatives.

 

During the nine months ended September 30, 2016, net cash used in operating activities was $6.6 million, of which $5.1 million was used in continuing operations and $1.5 million was used in discontinued operations.  The main component of cash used in operating activities during the nine months ended September 30, 2016 was our loss from continuing operations of $14.7 million. During the nine months ended September 30, 2015, net cash used in operating activities was $13.5 million, of which $21.0 million was used in continuing operations and $7.5 million was provided by discontinued operations. The main component of cash used in operating activities during the nine months ended September 30, 2015 was our loss from continuing operations of $22.6 million.

 

For the nine months ended September 30, 2016, there was no net cash from investing activities. For the nine months ended September 30, 2015, net cash used in investing activities was $0.6 million and consisted of purchases of property plant and equipment.

 

For the nine months ended September 30, 2016, there was no net cash used in financing. For the nine months ended September 30, 2015, the net cash used by financing activities of $0.03 million related to the repurchase of restricted stock shares.

 

As of September 30, 2016, we had total assets and total liabilities of $46.0 million and $47.4 million, respectively, and current assets and current liabilities of $6.7 million and $19.9 million, respectively.

 

We had standby letters of credit of approximately $0.3 million and $1.4 million at September 30, 2016 and 2015, respectively, as collateral for our existing insurance policies and our facility leases. In October 2016, the letters of credit were not renewed and the balance was distributed to our landlords who now hold it as security deposits on our facility leases.

 

 

INTERPACE DIAGNOSTICS GROUP, INC.

 

Inflation

 

We do not believe that inflation had a significant impact on our results of operations for the periods presented. On an ongoing basis, we attempt to minimize any effects of inflation on our operating results by controlling operating costs and whenever possible, seeking to insure that billing rates reflect increases in costs due to inflation.

 

Off-Balance Sheet Arrangements

 

None.

 

 

INTERPACE DIAGNOSTICS GROUP, INC.

 

Item 4.  Controls and Procedures

 

Evaluation of disclosure controls and procedures

 

Our management, with the participation of our Chief Executive Officer and Chief Financial Officer, evaluated the effectiveness of our disclosure controls and procedures pursuant to Rule 13a-15 under the Exchange Act as of the end of the period covered by this Form 10-Q. In designing and evaluating the disclosure controls and procedures, management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives including that information we are required to disclose in reports that we file or submit under the Exchange Act is recorded, processed, summarized, and reported within the time periods specified in the SEC rules and forms, and that such information is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure. In addition, management is required to apply its judgment in evaluating the benefits of possible disclosure controls and procedures relative to their costs to implement and maintain.

 

Based on our evaluation, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures were not effective as of September 30, 2016 as a result of the continuing existence of the material weakness in our controls related to our identification and accounting for contingent consideration and related interest costs associated with seller financing and a material weakness identified related to our accounting for, review of, and disclosure of the completeness and accuracy of transaction that we enter into. Specifically, as of September 30, 2016, the following material weaknesses existed:

  

 

We did not have adequate controls in place to properly identify and account for contingent consideration and related interest costs associated with seller financing related primarily to our purchase of the assets of RedPath whereby such analysis has historically been updated at year-end with the assistance of third party valuation experts. However, if material, such analysis is required to be updated quarterly. The financial impact of this material weakness resulted in an increase in the fair value of the contingent consideration of approximately $0.4 million during the period ended June 30, 2016, resulting from the accretion of interest over time and amounting to $0.7 million, partially offset by the Company making payments of $0.3 million in the second quarter of 2016.

 

 

We lack the quantity of resources to appropriately account for, review, and disclose the completeness and accuracy of transactions entered into by the Company. The financial impact of this material weakness during the period ended September 30, 2016 resulted in an increase in expense of approximately $0.6 million related to the accounting for the valuation of accounts receivable and an increase in general and administrative expense by approximately $0.3 million for an insurance letter of credit which was contractually disbursed to an insurance carrier for the payment of outstanding claims.

 

Management believes that the material weaknesses noted are due in part to the small size of the staff resulting from staff downsizing and cost containment.  As part of our remediation plan, we intend to take steps to improve our financial reporting and implement new policies, procedures and controls in addition to seeking external assistance with a review of transactions recorded and classified in the financial statements, as well as the accounting and related disclosures for complex accounting matters when necessary.

 

Changes in internal controls

 

There has been no change in our internal control over financial reporting (as defined in Rule 13a-15(f) and 15d-15(f) under the Exchange Act) that occurred during the quarter covered by this report that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

 

 

INTERPACE DIAGNOSTICS GROUP, INC.

 

PART II.  OTHER INFORMATION

 

Item 1.  Legal Proceedings

 

“Item 3- Legal Proceedings” of our most recent Annual Report on Form 10-K filed on March 30, 2016, as amended on April 29, 2016 and June 14, 2016, “Item 1 – Legal Proceedings” to Part II of our Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2016 filed on May 12, 2016 and “Item 1 – Legal Proceedings” to Part II of our Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2016 filed on August 15, 2016 include a discussion of our legal proceedings as does Note 6 to the accompanying condensed consolidated financial statements. During the three months ended September 30, 2016, there have been no material changes from the proceedings discussed in our Form 10-K and our Quarterly Reports on Form 10-Q referenced above, except as follows:

 

Prolias Technologies, Inc. v. PDI, Inc. 

 

On July 6, 2016, we moved to dismiss Prolias’ complaint and strike Prolias’ answer to our counterclaims for failure to retain substitute counsel within 30 days as required by the Court’s May 27th Order. On August 15, 2016, the Court granted our motion and dismissed Prolias’ complaint with prejudice and struck Prolias’ answer to our counterclaims. On September 22, 2016, the Court granted our request to enter default judgment against Prolias for failure to plead or otherwise respond to the counterclaims. Thereafter, on October 13, 2016, we filed an application to enter final judgment and taxing of costs against Prolias. We requested that the Court enter final judgment against Prolias and for us in the amount of $621,236.16, plus ten percent interest continuing to accrue on the principal balance of $500,000.00 unless and until paid, attorneys’ fees and costs of $390,769.04, and a declaratory judgment that Prolias is deemed to have executed and delivered to us a promissory note in the amount of $1,000,000 under Article 10.2(a) of the Collaboration Agreement. We are awaiting a response from the Court on the application for entry of final judgment.

 

Item 1A. Risk Factors.

 

Other than the risk factor below, there have been no material changes during the period covered by this Form 10-Q to the risk factors previously disclosed in Item 1A to Part I of the Company’s Annual Report on Form 10-K filed on March 30, 2016, as amended on April 29, 2016 and June 14, 2016.

 

In the event that the RedPath Equityholder Representative does not grant further extensions of the $1.3 million first principal payment on its secured promissory note now due December 31, 2016, or if we do not raise sufficient equity or debt capital, we will not be able to make such payment and may therefore face foreclosure and/or bankruptcy proceedings in which event stockholders will likely not be able to recover their investments in us.

 

 

INTERPACE DIAGNOSTICS GROUP, INC.

 

In connection with the Company’s acquisition of RedPath on October 31, 2014, the Company entered into an $11.0 million secured promissory note payable in equal consecutive quarterly installments beginning October 1, 2016. On September 30, 2016, the note was amended to extend by one month, until November 1, 2016, subject to the terms of the amendment, the due date for the first quarterly payment of principal under the note. Effective October 31, 2016, the note was amended to extend until November 20, 2016, subject to the terms of the amendment, the due date for the first quarterly payment of principal. On November 16, 2016, the note was further amended to, among other things, extend the due date for the first quarterly payment until December 31, 2016. Subsequent payments are to be made on the first day of each fiscal quarter, beginning on April 1, 2017. The Company currently does not have the funds to make the December 31, 2016 payment or any subsequent payments. The Company is actively looking for buyers of its assets. In the event the Company does not raise sufficient equity or debt capital or positive indications of a sale of its assets do not materialize by December 31, 2016, the RedPath Equityholder Representative may determine to begin foreclosure proceedings, bankruptcy proceedings or similar proceedings or pursue other remedies available to it. In the event of an asset sale, foreclosure, bankruptcy or similar proceedings, due to the amount of secured and unsecured debt outstanding, it is likely that stockholders will not be able to recoup their investment in the Company.

 

 

Item 5. Other Information

 

On November 16, 2016, the Company, Interpace LLC and the RedPath Equityholder Representative entered into a Fifth Amendment To Non-Negotiable Subordinated Secured Promissory Note (the “Fifth Amendment”) to extend until December 31, 2016, subject to the terms of the Fifth Amendment, the due date for the first quarterly payment of principal under that certain Non-Negotiable Subordinated Secured Promissory Note, dated as of October 31, 2014 (as amended, the “Note”) by the Company and Interpace LLC, in favor of the RedPath Equityholder Representative, on behalf of the former equity holders of RedPath.

 

The Note, which was entered into in connection with the Company’s acquisition of RedPath on October 31, 2014, is for the principal amount of $10.67 million, is interest-free and, prior to the Fifth Amendment, was to be paid in eight equal consecutive quarterly installments beginning November 20, 2016. The interest rate will be 5.0% in the event of a default under the Note, which include the failure to make any payment of principal due under the Note within ten business days after the date such payment is due (subject to certain exceptions), the making of an assignment for the benefit of creditors generally and suffering proceedings under any law related to bankruptcy, insolvency, liquidation and such proceeding is not dismissed or stayed within 60 days. The obligations of the Company under the Note are guaranteed by the Company and its subsidiaries pursuant to a Guarantee and Collateral Agreement pursuant to which the Company and its subsidiaries also granted a security interest in substantially all of their respective assets, including intellectual property, to secure their obligations to the RedPath Equityholder Representative.

 

Pursuant to the Fifth Amendment, the Company is required to make eight installment payments of principal, with each payment equal to $1,333,750, together with accrued and unpaid interest, if any. The first payment is due on December 31, 2016, and subsequent payments are to be made on the first day of each fiscal quarter, beginning on April 1, 2017. If not paid sooner, all principal and accrued interest will be due and payable on October 1, 2018.

 

The Fifth Amendment also amends the Note to add as an event of default the failure of the Company to maintain a minimum net cash balance from operations of no less than $400,000, excluding proceeds from borrowed money, at the end of every week. The Fifth Amendment provides that so long as an event of default does not exist and would not exist under the Note or under the Credit Agreement, after giving effect to any draw on the Credit Agreement, and the Company has maintained a minimum net cash balance from operations of no less than $400,000, excluding proceeds from borrowed money, at the end of every week at the time of any such draw, the Company shall have the right to make borrowings under the Credit Agreement, provided the RedPath Equityholder Representative is given notice of any draw at least one business day prior to such draw. The Fifth Amendment also contains a reporting requirement for the Company to provide to the RedPath Equityholder Representative, on a weekly basis, a 13-week cash flow forecast commencing November 22, 2016.

 

The foregoing summary of the Fifth Amendment is not complete and is subject to and qualified in its entirety by reference to the Fifth Amendment, a copy of which is filed as Exhibit 10.11 to this Form 10-Q and is incorporated herein by reference.

 

Commerce Health Ventures, L.P., an affiliate of NewSpring Capital, was a stockholder of RedPath and serves as the RedPath Equityholder Representative. In connection with the Company’s acquisition of RedPath, the Company entered into a Contingent Consideration Agreement with the RedPath Equityholder Representative, the Company issued the Note, and the Company assumed a liability for a January 2013 settlement agreement entered into by RedPath with the Department of Justice. From October 30, 2015 to September 13, 2016, Kapila Ratnam, a partner at NewSpring Capital, served as a director of the Company. Additional information regarding these transactions can be found in the Company’s filings with the U.S. Securities and Exchange Commission.

 

 
37

 

 

Item 6.  Exhibits

 

Exhibit No.

 

Description

     

10.1

 

Form of Indemnification Agreement by and between Interpace Diagnostics Group, Inc. and its directors and executive officers is incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K filed with the SEC on August 8, 2016.

 

   

10.2

 

Credit Agreement and Security Agreement, dated as of September 28, 2016, by and among Interpace Diagnostics Group, Inc., Interpace Diagnostics Corporation, Interpace Diagnostics, LLC and SCM Specialty Finance Opportunities Fund, L.P. is incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K filed with the SEC on October 4, 2016.

     

10.3

 

Intercreditor Agreement, dated as of September 28, 2016, by and between SCM Specialty Finance Opportunities Fund, L.P. and RedPath Equityholder Representative, LLC and acknowledged and agreed to by Interpace Diagnostics Group, Inc., Interpace Diagnostics, LLC and Interpace Diagnostics Corporation is incorporated by reference to Exhibit 10.2 to the Company’s Current Report on Form 8-K filed with the SEC on October 4, 2016.

     

10.4

 

Third Amendment To Non-Negotiable Subordinated Secured Promissory Note, dated as of September 30, 2016, by and among Interpace Diagnostics Group, Inc., Interpace Diagnostics, LLC and RedPath Equityholder Representative, LLC is incorporated by reference to Exhibit 10.3 to the Company’s Current Report on Form 8-K filed with the SEC on October 4, 2016.

     

10.5*

 

Management Engagement Letter, effective as of October 11, 2016, by and between Early Financial Consulting, LLC and Interpace Diagnostics Group, Inc. is incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K filed with the SEC on October 14, 2016.

     

10.6*

 

Incentive Stock Option Agreement between Interpace Diagnostics Group, Inc. and Jack E. Stover is incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K filed with the SEC on October 20, 2016.

     

10.7*

 

Incentive Stock Option Agreement between Interpace Diagnostics Group, Inc. and James Early is incorporated by reference to Exhibit 10.2 to the Company’s Current Report on Form 8-K filed with the SEC on October 20, 2016.

 

   

10.8*

 

Form of Incentive Stock Option Agreement is incorporated by reference to Exhibit 10.3 to the Company’s Current Report on Form 8-K filed with the SEC on October 20, 2016.

     

10.9

 

Fourth Amendment To Non-Negotiable Subordinated Secured Promissory Note, dated as of October 31, 2016, by and among Interpace Diagnostics Group, Inc., Interpace Diagnostics, LLC and RedPath Equityholder Representative, LLC is incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K filed with the SEC on November 3, 2016.

     

10.10*

 

Employment Agreement, dated as of October 28, 2016, by and between Interpace Diagnostics Group, Inc. and Jack E. Stover is incorporated by reference to Exhibit 10.2 to the Company’s Current Report on Form 8-K filed with the SEC on November 3, 2016.

     

10.11

 

Fifth Amendment To Non-Negotiable Subordinated Secured Promissory Note, dated as of November 16, 2016, by and among Interpace Diagnostics Group, Inc., Interpace Diagnostics, LLC and RedPath Equityholder Representative, LLC is filed herewith

 

   

31.1

 

Certification of Chief Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002, filed herewith.

     

31.2

 

Certification of Chief Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002, filed herewith.

     

32.1+

 

Certification of Chief Executive Officer Pursuant to 18 U.S.C. Section 1350, as adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, furnished herewith.

     

32.2+

 

Certification of Chief Financial Officer Pursuant to 18 U.S.C. Section 1350, as adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, furnished herewith.

     

101

 

The following financial information from this Quarterly Report on Form 10-Q for the fiscal quarter ended September 30, 2016 formatted in XBRL (Extensible Business Reporting Language) and furnished electronically herewith: (i) the Condensed Consolidated Balance Sheets; (ii) the Condensed Consolidated Statements of Operations; (iii) the Condensed Consolidated Statements of Cash Flows; and (iv) the Notes to Condensed Consolidated Financial Statements.

 

* Denotes compensatory plan, compensation arrangement or management contract.

+ Exhibits 32.1 and 32.2 are being furnished and shall not be deemed to be “filed” for purposes of Section 18 of the Exchange Act or otherwise subject to the liability of that section, nor shall such exhibits be deemed to be incorporated by reference to any registration statement or other document filed under the Securities Act or the Exchange Act, except as otherwise stated in any such filing.

 

 

INTERPACE DIAGNOSTICS GROUP, INC.

 

SIGNATURES

 

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

Date:  November 17, 2016

 Interpace Diagnostics Group, Inc.

 
 

(Registrant)

 
     
 

/s/ Jack E. Stover

 
 

Jack E. Stover

 
 

President and Chief Executive Officer

 
     
 

(Principal Executive Officer)

 
     
 

/s/ James Early

 
 

James Early

 
 

Chief Financial Officer

 
     
 

(Principal Financial Officer and Principal Accounting Officer)

 

 39

EX-10.11 2 ex10-11.htm EXHIBIT 10.11 ex10-11.htm

Exhibit 10.11

 

FIFTH AMENDMENT TO NON-NEGOTIABLE SUBORDINATED SECURED PROMISSORY NOTE

 

THIS FIFTH AMENDMENT TO NON-NEGOTIABLE SUBORDINATED SECURED PROMISSORY NOTE (this "Fifth Amendment") is entered into as of November 16, 2016 between INTERPACE DIAGNOSTICS GROUP, INC., a Delaware corporation formerly known as PDI, INC., a Delaware corporation (“IDG”), INTERPACE DIAGNOSTICS, LLC, a Delaware limited liability company (“Parent”, together with IDG, the “IDG Parties” or “Borrower Parties”) and REDPATH EQUITYHOLDER REPRESENTATIVE, LLC ("Lender").

 

W I T N E S S E T H:

 

WHEREAS, the IDG Parties and Lender have entered into that certain Non-Negotiable Subordinated Secured Promissory Note dated October 31, 2014 as amended by that certain Amendment No. 1 to Note dated as of July 30, 2015 as further amended by that certain Limited Waiver, Consent and Amendment No. 2 to the Note dated as of October 30, 2015 as further amended by that certain Third Amendment to Non-Negotiable Subordinated Secured Promissory Note dated as of September 30, 2016 and as further amended by that certain Fourth Amendment to Non-Negotiable Secured Promissory Note dated as of October 31, 2016 (as the same may be further amended, modified, supplemented, extended or restated from time to time, the "Note");

 

WHEREAS, pursuant to the Note, Lender agreed to extend to the IDG Parties, and the IDG Parties agreed to repay, financing in the original principal amount of $11,000,000.00 which was subsequently reduced to $10,670,000 (the “Loan”).

 

WHEREAS, repayment of the Loan is secured by, among other things, (1) that certain Guarantee and Collateral Agreement dated as of October 31, 2014 (as amended or modified from time to time, the “Guaranty”) executed by IDG, Parent, Group DCA, LLC, PDI BioPharma, LLC f/k/a Interpace BioPharma, LLC, Interpace Diagnostics Lab Inc. f/k/a JS Genetics, Inc., and Interpace Diagnostics Corporation, successor-by-merger to Redpath Acquisition Sub, Inc. (“Interpace Diagnostics Corporation” and collectively, the “Guaranty Parties”) in favor of Lender, and (2) that certain Intellectual Property Security Agreement dated November 1, 2014 (“IP Security Agreement”) executed by Interpace Diagnostics Corporation in favor of Lender.

 

WHEREAS, the Note, Guaranty, and IP Security Agreement, together with all other documents relating to or governing the Loan shall be referred to as the “Loan Documents.”

 

WHEREAS, the IDG Parties have requested that Lender modify terms set forth in the Note, including, among other things, an extension of the due date for the first installment payment due under the Note, and in connection therewith, the IDG Parties and Lender have agreed to amend the Note on the terms and conditions set forth in this Fourth Amendment, in the manner hereinafter set forth;

 

WHEREAS, the IDG Parties have confirmed to Lender that the IDG Parties have no defenses to or offsets of any kind against any of the indebtedness due under the Note; and

 

 
1

 

 

WHEREAS, this Fifth Amendment shall amend and continue to evidence the indebtedness outstanding under the Note but not be a payment, satisfaction, cancellation or novation of the Note.

 

NOW, THEREFORE, the parties hereto, for good and valuable consideration, the receipt and sufficiency thereof being hereby acknowledged, and intending to be legally bound hereby, covenant and agree as follows, to be effective as of the Effective Date:

 

1.     The Recitals set forth above are hereby incorporated herein by reference.

 

2.     Any initially capitalized terms used in this Fifth Amendment without definition shall have the meanings assigned to those terms in the Note. To the extent that any term or provision of this Amendment is or may be inconsistent with any term or provision in the Note, the terms and provisions of this Fifth Amendment shall control.

 

3.     Amendments to Note.

 

(a)     Section 4 of the Note is amended and restated as follows:

 

“Payments. Subject to Section 8 of this Note, PDI shall make (8) installment payments of principal, each equal to One Million Three Hundred Thirty-Three Thousand Seven Hundred Fifty Dollars ($1,333,750) together with accrued and unpaid interest thereon as computed under Section 2 herein, if any. The first payment shall be due on December 31, 2016, and subsequent payments shall be made on the first day of each fiscal quarter, beginning on April 1, 2017. If not paid sooner, all principal and accrued interest herein shall be due and payable on October 1, 2018.”

 

(b)     Section 10 of the Note is amended to add a new subpart (g) as follows:

 

“(g)     the PDI Parties (defined below), together with their successors, subsidiaries and affiliates, shall fail at any time to maintain a minimum net, cash balance from operations of no less than $400,000 (excluding proceeds from borrowed money) at the end of every week as reflected on the 13-Week Cash Flow Forecast (as defined below). Notwithstanding the foregoing, so long as an Event of Default does not exist and would not exist under this Note or under that certain Credit and Security Agreement , dated as of September 28, 2016 (the “A/R Line of Credit”), by and between SCM Specialty Finance Opportunities Fund, L.P., a Delaware limited partnership, as lender, the IDG Parties and Interpace Diagnostics Corporation, a Delaware corporation (“IDC” and together with the IDG Parties, collectively, the “PDI Parties”), as borrowers, after giving effect to any draw on the A/R Line of Credit, and the PDI Parties are in compliance with this Section 10(g) at the time of any such draw, the PDI Parties shall have the right to make borrowings under the A/R Line of Credit, provided that the PDI Parties shall provide the Lender with notice of any draw under the A/R Line of Credit at least one business day prior to such draw.”

 

 
2

 

 

(c)     The Note is hereby amended to add a new Section 21 as follows:

 

“21.     13-Week Cash Flow Forecast. On or before Tuesday of each week, commencing November 22, 2016, the PDI Parties shall provide the Lender with a rolling 13-week cash flow forecast together with a variance report to budget for the immediately preceding week.”

 

4.     The IDG Parties hereby represent and warrant that all security interests and liens in the collateral as security for the obligations of the IDG Parties to Lender under Note and Loan Documents related thereto, including the liens, security interests, mortgages, and pledges granted by the IDG Parties under the Guaranty and IP Security Agreement, are valid and enforceable and shall continue unimpaired and in full force and effect, and shall continue to cover and secure all of the IDG Parties’ existing and future obligations to Lender, as modified by this Fifth Amendment.

 

5.     Nothing contained herein shall operate to release any Borrower Party, any Guarantor Party or any other person or persons from their liability to keep and perform the provisions, conditions, obligations, and agreements contained in the Note and the related Loan Documents, except as herein modified, and each Borrower Party and each Guarantor Party, by its joinder hereto, hereby reaffirms that each and every provision, condition, obligation, and agreement in the Loan Documents shall continue in full force and effect, except as herein modified. This Fifth Amendment shall not constitute or be construed as a waiver of any Event of Default or event which with the giving of notice or the passage of time or both would constitute an Event of Default by Borrowers under any of the existing Loan Documents or any of Lender's rights and remedies with respect thereto. The validity, priority and perfection of all security interests and other liens granted or created by the Loan Documents is hereby acknowledged and confirmed, and the Loan Documents shall continue to secure the Loans, as amended by this Amendment, without any change, loss or impairment of the priority of such security interests or other liens.

 

6.     This Fifth Amendment may be signed in any number of counterpart copies and by the parties to this Fifth Amendment on separate counterparts, but all such copies shall constitute one and the same instrument. Delivery of an executed counterpart of a signature page to this Fifth Amendment by facsimile or by .pdf transmission shall be effective as delivery of a manually executed counterpart. Any party so executing this Fifth Amendment by facsimile transmission shall promptly deliver a manually executed counterpart, provided that any failure to do so shall not affect the validity of the counterpart executed by facsimile transmission.

 

7.     This Fifth Amendment will be binding upon and inure to the benefit of the IDG Parties and Lender and their respective heirs, executors, administrators, successors and assigns.

 

8.     Guarantor Consent. By executing this Fifth Amendment, the Guarantor Parties expressly consent to the amendments herein and reaffirm all guarantees and security agreements, including, without limitation, the Guaranty and the IP Security Agreement, executed by Guarantor Parties in favor of Lender which are related to debts owed by the IDG Parties to Lender.

 

[signature pages follow]

 

 
3

 

 

IN WITNESS WHEREOF, the parties have caused this Fifth Amendment to be executed by their duly authorized officers as of the date shown above.

 

 

BORROWER PARTIES:

 

INTERPACE DIAGNOSTICS GROUP, INC., a Delaware corporation, formerly known as PDI, INC., a Delaware Corporation

 

 

By:           /s/ Jack E. Stover     

Name: Jack E. Stover

Title: President & CEO

 

INTERPACE DIAGNOSTICS, LLC, a Delaware limited liability corporation

 

 

By:           /s/ Jack E. Stover     

Name: Jack E. Stover

Title: President & CEO

 

 

GUARANTOR PARTIES:

 

GROUP DCA, LLC, a Delaware limited liability company

 

 

By:           /s/ Jack E. Stover     

Name: Jack E. Stover

Title: President & CEO

 

 

PDI BioPharma, LLC, a New Jersey limited liability company, f/k/a Interpace BioPharma, LLC, a New Jersey limited liability company

 

 

By:           /s/ Jack E. Stover     

Name: Jack E. Stover

Title: President & CEO

 

 

[signatures continued on following page]

 

 
4

 

 

[signatures continued from previous page]

 

 

INTERPACE DIAGNOSTICS LAB INC., a Delaware corporation, f/k/a/ JS Genetics, Inc., a Delaware corporation

 

 

 

By:           /s/ Jack E. Stover     

Name: Jack E. Stover

Title: President & CEO

 

INTERPACE DIAGNOSTICS CORPORATION, a Delaware corporation, successor-by-merger to Redpath Acquisition Sub, Inc., a Delaware corporation

 

 

By:           /s/ Jack E. Stover     

Name: Jack E. Stover

Title: President & CEO

 

 
5

 

 

[signatures continued from previous page]

 

 

LENDER:

 

REDPATH EQUITYHOLDER REPRESENTATIVE, LLC, a Delaware LLC

 

By:           /s/ Jon Schwartz     

Name: Jon Schwartz

Title: CFO

 

 

6

EX-31.1 3 ex31-1.htm EXHIBIT 31.1 idxg20160901_10q.htm

Exhibit 31.1

 

CERTIFICATION PURSUANT TO SECTION 302

OF THE SARBANES-OXLEY ACT OF 2002

 

I, Jack E. Stover, certify that:

 

 

1.

I have reviewed this Quarterly Report on Form 10-Q for the quarter ended September 30, 2016 of Interpace Diagnostics Group, Inc. (the “registrant”);

 

 

2.

Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

 

3.

Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

 

 

4.

The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

 

a.

Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

 

b.

Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

 

c.

Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

 

d.

Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

 

 

5.

The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

 

 

a.

All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

 

 

b.

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

 

 

Date:

November 17, 2016

/s/ Jack E. Stover

 

 

Chief Executive Officer

 

 

(Principal Executive Officer)

 

 

 

EX-31.2 4 ex31-2.htm EXHIBIT 31.2 idxg20160901_10q.htm

Exhibit 31.2

 

CERTIFICATION PURSUANT TO SECTION 302

OF THE SARBANES-OXLEY ACT OF 2002

 

I, James Early, certify that:

 

 

1.

I have reviewed this Quarterly Report on Form 10-Q for the quarter ended September 30, 2016 of Interpace Diagnostics Group, Inc. (the “registrant”);

 

 

2.

Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

 

3.

Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

 

 

4.

The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

 

a.

Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

 

b.

Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

 

c.

Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

 

d.

Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

 

 

5.

The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

 

 

a.

All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

 

 

b.

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

 

 

Date:

November 17, 2016

/s/ James Early

 

 

Chief Financial Officer

 

 

(Principal Financial Officer)

 

 

 

 

EX-32.1 5 ex32-1.htm EXHIBIT 32.1 idxg20160901_10q.htm

 

Exhibit 32.1

 

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

 

In connection with the Quarterly Report of Interpace Diagnostics Group, Inc. (the “Company”) on form 10-Q for the period ended September 30, 2016 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Jack E. Stover, as Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, to the best of my knowledge, that:

 

 

(1)

The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and

 

 

(2)

The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

 

 

Date:

November 17, 2016

/s/ Jack E. Stover

 

 

Chief Executive Officer

 

 

(Principal Executive Officer)

 

EX-32.2 6 ex32-2.htm EXHIBIT 32.2 idxg20160901_10q.htm

Exhibit 32.2

 

 

 

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

 

In connection with the Quarterly Report of Interpace Diagnostics Group, Inc. (the “Company”) on form 10-Q for the period ended September 30, 2016 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, James Early, as Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, to the best of my knowledge, that:

 

 

(1)

The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and

 

 

(2)

The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

 

 

Date:

November 17, 2016

/s/ James Early

 

 

Chief Financial Officer

 

 

(Principal Financial Officer)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

EX-101.INS 7 idxg-20160930.xml EXHIBIT 101.INS false --12-31 Q3 2016 2016-09-30 10-Q 0001054102 18162671 Yes Smaller Reporting Company Interpace Diagnostics Group, Inc. No No idxg 208000 107000 85000 308000 393000 2667000 495000 307000 3469000 1334000 3137000 85000 185000 4741000 400000 400000 P91D 0.05 8 0.001666 0.00083 0.01 0.02 <div style="display: inline; font-family: times new roman; font-size: 10pt"><table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 100%; TEXT-INDENT: 0px;; width: 700px;" cellspacing="0" cellpadding="0" border="0"> <tr> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center" colspan="10"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">For the Nine Months Ended </div></div> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">September 30, 2016</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center" colspan="10"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">For the Year Ended </div></div> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">December 31, 2015</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px">&nbsp;</td> </tr> <tr> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center" colspan="2"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">CSO</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center" colspan="2"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">DCA/TVG</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center" colspan="2"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Total</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center" colspan="2"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">CSO</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center" colspan="2"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">DCA/TVG</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center" colspan="2"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Total</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 28%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Accounts receivable, net</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">- </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">- </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">- </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">3,296 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">- </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">3,296 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #ffffff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Unbilled receivable, net</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">- </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">- </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">- </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">16 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">- </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">16 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Other</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 9%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">- </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 9%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">150 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 9%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">150 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 9%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">2,062 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 9%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">- </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 9%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">2,062 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #ffffff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Current assets from discontinued operations</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">- </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">150 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">150 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">5,374 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">- </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">5,374 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Property and equipment, net</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">- </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">- </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">- </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">190 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">- </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">190 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #ffffff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Other </div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 9%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">- </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 9%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">- </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 9%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">- </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 9%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">- </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 9%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">150 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 9%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">150 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Long-term assets from discontinued operations</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 9%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">- </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 9%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">- </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 9%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">- </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 9%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">190 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 9%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">150 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 9%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">340 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #ffffff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; PADDING-LEFT: 18pt; BACKGROUND-COLOR: #ffffff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Total assets</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; BACKGROUND-COLOR: #ffffff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 9%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">- </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; BACKGROUND-COLOR: #ffffff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 9%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">150 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; BACKGROUND-COLOR: #ffffff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 9%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">150 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; BACKGROUND-COLOR: #ffffff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 9%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">5,564 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; BACKGROUND-COLOR: #ffffff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 9%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">150 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; BACKGROUND-COLOR: #ffffff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 9%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">5,714 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="BACKGROUND-COLOR: #cceeff">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #ffffff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Accounts payable</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">947 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">- </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">947 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">3,767 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">- </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">3,767 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Unearned contract revenue</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">- </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">- </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">- </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">11 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">- </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">11 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #ffffff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Accrued salary and bonus</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">1,686 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">- </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">1,686 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">3,036 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">- </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">3,036 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Other</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 9%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">2,052 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 9%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">70 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 9%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">2,122 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 9%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">5,092 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 9%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">358 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 9%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">5,450 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #ffffff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Current liabilities from discontinued operations</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 9%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">4,685 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 9%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">70 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 9%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">4,755 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 9%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">11,906 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 9%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">358 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 9%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">12,264 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; PADDING-LEFT: 18pt; BACKGROUND-COLOR: #cceeff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Total liabilities</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 9%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">4,685 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 9%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">70 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 9%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">4,755 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 9%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">11,906 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 9%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">358 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 9%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">12,264 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> </tr> </table></div> 1686000 1686000 3036000 3036000 243000 732000 975000 360000 390769.04 0.1 250000 <div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" TEXT-ALIGN: justify; MARGIN: 0pt 0pt 0pt 36pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-style: italic;">Other Current Assets</div></div></div><div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div><div style=" TEXT-ALIGN: justify; MARGIN: 0pt 0pt 0pt 36pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Other current assets consisted of the following as of September 30, 2016 and December 31, 2015:</div><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; FONT-SIZE: 10pt; FONT-STYLE: normal; BACKGROUND-COLOR: yellow"></div></div>&nbsp;</div><div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div><div> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 80%; MARGIN-LEFT: 10%; MARGIN-RIGHT: 10%; TEXT-INDENT: 0px; width: 700px;" cellspacing="0" cellpadding="0" border="0"> <tr> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center" colspan="2"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">September 30, 2016</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; PADDING-BOTTOM: 1px">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center" colspan="2"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">December 31, 2015</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; PADDING-BOTTOM: 1px">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 62%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Indemnification assets</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">1,375 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">875 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #ffffff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Letters of credit</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">- </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">360 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Other receivables</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">666 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 0px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">1,048 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 0px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #ffffff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Other</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">46 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">286 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">2,087 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">2,569 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> </tr> </table> </div></div></div></div></div></div></div></div> <div style="display: inline; font-family: times new roman; font-size: 10pt"><table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 95%; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 5%; TEXT-INDENT: 0px;; width: 700px;" cellspacing="0" cellpadding="0" border="0"> <tr> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 36%">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 17%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center" colspan="6"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Three Months Ending September 30,</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 17%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center" colspan="6"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Nine Months Ending September 30,</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px">&nbsp;</td> </tr> <tr> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 36%">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center" colspan="2"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">2016 </div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center" colspan="2"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">2015 </div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center" colspan="2"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">2016 </div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center" colspan="2"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">2015 </div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 36%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Revenue, net</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 13%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">- </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 13%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">34,119 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 13%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">1,644 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 13%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">104,408 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #ffffff"> <td style="WIDTH: 36%; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="WIDTH: 13%; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="WIDTH: 13%; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="WIDTH: 13%; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="WIDTH: 13%; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 36%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">(Loss) income from discontinued operations</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 13%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">(414</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">)</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 13%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">2,576 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 13%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">(1,006</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">)</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 13%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">6,615 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #ffffff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 36%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Gain on sale of assets</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 13%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">- </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 13%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">- </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 13%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">1,326 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 13%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">217 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 36%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">(Loss) income from discontinued operations, before tax</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 13%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">(414</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">)</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 13%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">2,576 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 13%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">320 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 13%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">6,832 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #ffffff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 36%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Income tax (benefit) expense</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 13%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">(117</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">)</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 13%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">2 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 13%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">219 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 13%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">4 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 36%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">(Loss) income from discontinued operations, net of tax</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 13%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">(297</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">)</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 13%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">2,574 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 13%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">101 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 13%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">6,828 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> </tr> </table></div> 544000 546000 1365000 1560000 2753000 2806000 29000 104000 1601000 825000 6905000 5961000 1320000 775000 504000 111000 13000 125842000 132522000 970000 986000 2909000 2825000 -6100000 -6800000 20000 300000 100000 1000000 1300000 986000 970000 2909000 2825000 1027000 1028000 1027000 1028000 1151000 1745000 1151000 1745000 188000 188000 2178000 2961000 2178000 2961000 3363000 3363000 45964000 67712000 6683000 19165000 150000 150000 5564000 150000 5714000 150000 150000 5374000 5374000 <div style="display: inline; font-family: times new roman; font-size: 10pt"><table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 100%; TEXT-INDENT: 0px; width: 700px;" cellspacing="0" cellpadding="0" border="0"> <tr> <td style="WIDTH: 36pt; VERTICAL-ALIGN: top"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">3.</div><div style="display: inline; font-weight: bold;"></div></div></div></td> <td style="VERTICAL-ALIGN: top"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;"></div><div style="display: inline; font-weight: bold;">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES </div></div></div></td> </tr> </table> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt 0pt 0pt 36pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-style: italic;">Accounting Estimates</div></div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt 0pt 0pt 36pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt 0pt 0pt 36pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts of assets and liabilities reported and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period.&nbsp;&nbsp;Management's estimates are based on historical experience, facts and circumstances available at the time, and various other assumptions that are believed to be reasonable under the circumstances.&nbsp;&nbsp;Significant estimates include best estimate of selling price in multiple element arrangements, valuation allowances related to deferred income taxes, self-insurance loss accruals, allowances for doubtful accounts and notes, income tax accruals, acquisition accounting, asset impairments and facilities realignment accruals. &nbsp;The Company periodically reviews these matters and reflects changes in estimates as appropriate.&nbsp;&nbsp;Actual results could materially differ from those estimates.</div></div> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt 0pt 0pt 36pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-style: italic;">Reclassifications</div></div></div> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt 0pt 0pt 36pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">The CSO business in the three- and nine-month periods ended September 30, 2015 has been reclassified to discontinued operations to conform to the current period presentation.</div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt 0pt 0pt 36pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-style: italic;">&nbsp;</div></div><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt 0pt 0pt 36pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-style: italic;">Receivables and Allowance for Doubtful Accounts </div></div></div> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt 0pt 0pt 36pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">The Company&#x2019;s accounts receivable are generated using its proprietary tests. The Company&#x2019;s services are fulfilled upon completion of the test, review and release of the test results. In conjunction with fulfilling these services, the Company bills the third-party payor or hospital. The Company recognizes accounts receivable related to billings for Medicare, Medicare Advantage, and hospitals on an accrual basis, net of contractual adjustment, when collectability is reasonably assured. Contractual adjustments represent the difference between the list prices and the reimbursement rate set by Medicare and Medicare Advantage, or the amounts billed to hospitals. The Company records an Allowance for Doubtful accounts for PancraGen&reg; hospital roster billings based on the collection history of this payor. Since Medicare and Medicare Advantage have fixed reimbursement rates, there is no Allowance for Doubtful Accounts associated with these payors.</div></div> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt 0pt 0pt 36pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">The Company provides services to commercial insurance carriers or governmental programs that do not have a contract in place for its proprietary tests which may or may not be covered by these entities existing reimbursement policies. In addition, the Company does not enter into direct agreements with patients that commit them to pay any portion of the cost of the tests in the event that their commercial insurance carrier or governmental program does not pay the Company for its services. In the absence of an agreement with the patient, or other clearly enforceable legal right to demand payment from commercial insurance carriers or governmental agencies, no accounts receivable is recognized. The Company does not record an Allowance for Doubtful Accounts for the commercial insurance or governmental programs since the revenue is recorded mainly on a cash basis. There was approximately a $1.3 million allowance for doubtful accounts as of September 30, 2016.</div></div> <div style=" TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; font-weight: bold;"></div>&nbsp;</div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt 0pt 0pt 36pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-style: italic;">Other Current Assets</div></div></div> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt 0pt 0pt 36pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Other current assets consisted of the following as of September 30, 2016 and December 31, 2015:</div><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; FONT-SIZE: 10pt; FONT-STYLE: normal; BACKGROUND-COLOR: yellow"></div></div>&nbsp;</div> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div> <div> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 80%; MARGIN-LEFT: 10%; MARGIN-RIGHT: 10%; TEXT-INDENT: 0px; width: 700px;" cellspacing="0" cellpadding="0" border="0"> <tr> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center" colspan="2"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">September 30, 2016</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; PADDING-BOTTOM: 1px">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center" colspan="2"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">December 31, 2015</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; PADDING-BOTTOM: 1px">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 62%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Indemnification assets</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">1,375 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">875 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #ffffff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Letters of credit</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">- </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">360 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Other receivables</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">666 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 0px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">1,048 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 0px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #ffffff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Other</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">46 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">286 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">2,087 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">2,569 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> </tr> </table> </div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt 0pt 0pt 36pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"></div>&nbsp;&nbsp;</div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt 0pt 0pt 36pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-style: italic;">Other Intangible Assets, including Finite-Lived Intangible Assets</div></div></div> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt 0pt 0pt 36pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">The Company allocates the cost of acquired companies to the identifiable tangible and intangible assets acquired and liabilities assumed, with the remaining amount classified as goodwill, if any. Since the entities the Company has acquired do not have significant tangible assets, a significant portion of the purchase price has been allocated to intangible assets and goodwill. The identification and valuation of these intangible assets and the determination of the estimated useful lives at the time of acquisition, as well as the completion of impairment tests, require significant management judgments and estimates. These estimates are made based on, among other factors, consultations with an accredited independent valuation consultant, reviews of projected future operating results and business plans, economic projections, anticipated highest and best use of future cash flows and the market participant cost of capital. The use of alternative estimates and assumptions could increase or decrease the estimated fair value of other intangible assets, and potentially result in a different impact to the Company's results of operations. Further, changes in business strategy and/or market conditions may significantly impact these judgments thereby impacting the fair value of these assets, which could result in an impairment of the intangible assets.</div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt 0pt 0pt 36pt; LINE-HEIGHT: 1.25">&nbsp;</div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt 0pt 0pt 36pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Finite-lived intangible assets are stated at cost less accumulated amortization.&nbsp;&nbsp;Amortization of finite-lived acquired intangible assets is recognized on a straight-line basis, using the estimated useful lives of the assets of approximately two years to nine years in acquisition related amortization expense in the consolidated statements of comprehensive loss.</div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt 0pt 0pt 36pt; LINE-HEIGHT: 1.25">&nbsp;</div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt 0pt 0pt 36pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">The Company reviews the recoverability of long-lived assets and finite-lived intangible assets whenever events or changes in circumstances indicate that the carrying value of such assets may not be recoverable.&nbsp;&nbsp;If the sum of the expected future undiscounted cash flows is less than the carrying amount of the asset, an impairment loss is recognized by reducing the recorded value of the asset to its fair value measured by future discounted cash flows.&nbsp;&nbsp;This analysis requires estimates of the amount and timing of projected cash flows and, where applicable, judgments associated with, among other factors, the market price and physical condition of the assets at measurement date.&nbsp;&nbsp;Such estimates are critical in determining whether any impairment charge should be recorded and the amount of such charge if an impairment loss is deemed to be necessary.&nbsp;</div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt 0pt 0pt 36pt; LINE-HEIGHT: 1.25">&nbsp;</div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt 0pt 0pt 36pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">During the quarter ended September 30, 2016 the Company recorded an asset impairment charge of approximately $3.4 million, resulting from a decline in market value of Pancreas and Biobank assets associated with the acquisition of certain assets from Asuragen.</div></div> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><br />&nbsp;</div><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"></div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt 0pt 0pt 36pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-style: italic;">Discontinued Operations</div></div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt 0pt 0pt 36pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-style: italic;">&nbsp;</div></div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt 0pt 0pt 36pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">The Company accounts for business dispositions and its businesses held for sale in accordance with ASC&nbsp;205-20, Discontinued Operations. ASC 205-20 requires the results of operations of business dispositions to be segregated from continuing operations and reflected as discontinued operations in current and prior periods. See Note&nbsp;11, <div style="display: inline; font-style: italic;">Discontinued Operations</div> for further information.</div><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-style: italic;">&nbsp;</div></div></div> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt 0pt 0pt 36pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-style: italic;">Basic and Diluted Net Loss per Share</div></div></div> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt 0pt 0pt 36pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">A reconciliation of the number of shares of common stock used in the calculation of basic and diluted loss per share for the three- and nine-month-periods ended September 30, 2016 and 2015 is as follows:</div><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div> <div style=" TEXT-ALIGN: center; MARGIN: 0pt 0pt 0pt 36pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; FONT-SIZE: 10pt; FONT-STYLE: normal; BACKGROUND-COLOR: yellow"></div></div>&nbsp;</div> <div> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 95%; MARGIN-LEFT: 36pt; MARGIN-RIGHT: 5%; TEXT-INDENT: 0px; width: 700px;" cellspacing="0" cellpadding="0" border="0"> <tr> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: center" colspan="6"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Three Months Ended</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: center" colspan="6"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Nine Months Ended</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</td> </tr> <tr> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center" colspan="6"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">September 30,</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center" colspan="6"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">September 30,</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px">&nbsp;</td> </tr> <tr> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center" colspan="2"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">2016</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center" colspan="2"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">2015</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center" colspan="2"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">2016</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center" colspan="2"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">2015</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; PADDING-LEFT: 9pt; BACKGROUND-COLOR: #cceeff; TEXT-INDENT: -9pt"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Basic weighted average number of&nbsp; of common shares</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">18,163 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">15,654 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">18,029 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">15,301 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #ffffff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Potential dilutive effect of stock-based awards</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">- </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">- </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">- </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">- </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; PADDING-LEFT: 9pt; BACKGROUND-COLOR: #cceeff; TEXT-INDENT: -9pt"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Diluted weighted average number of common shares</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">18,163 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">15,654 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">18,029 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">15,301 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> </tr> </table> </div> <div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <div style=" TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; font-weight: bold;"></div>&nbsp;</div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt 0pt 0pt 36pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">The following outstanding stock-based awards were excluded from the computation of the effect of dilutive securities on loss per share for the following periods because they would have been anti-dilutive:</div><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div> <div style=" TEXT-ALIGN: center; MARGIN: 0pt 0pt 0pt 36pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-style: italic;"><div style="display: inline; FONT-SIZE: 10pt; FONT-STYLE: normal; BACKGROUND-COLOR: yellow"></div></div></div>&nbsp;</div> <div> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 90%; MARGIN-LEFT: 36pt; MARGIN-RIGHT: 10%; TEXT-INDENT: 0px; width: 700px;" cellspacing="0" cellpadding="0" border="0"> <tr> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 44%">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 15%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: center" colspan="6"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Three Months Ended</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 15%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: center" colspan="6"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Nine Months Ended</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%">&nbsp;</td> </tr> <tr> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 44%">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 15%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center" colspan="6"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">September 30,</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 15%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center" colspan="6"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">September 30,</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px">&nbsp;</td> </tr> <tr> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 44%">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center" colspan="2"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">2016</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center" colspan="2"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">2015</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center" colspan="2"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">2016</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center" colspan="2"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">2015</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 44%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Options</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">- </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">- </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">- </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">- </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #ffffff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 44%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Stock-settled stock appreciation rights (SARs)</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">1,027 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">1,028 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">1,027 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">1,028 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 44%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Restricted stock and restricted stock units (RSUs)</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">1,151 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">1,745 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">1,151 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">1,745 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #ffffff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 44%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Performance contingent SARs</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 11%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">- </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 11%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">188 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 11%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">- </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 11%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">188 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 44%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 11%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">2,178 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 11%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">2,961 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 11%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">2,178 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 11%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">2,961 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> </tr> </table> </div></div> 500000 500000 500000 7500000 -1174000 -1174000 3247000 3247000 3247000 14653000 14653000 14653000 17900000 17900000 17900000 4628000 4628000 4628000 13921000 13921000 13921000 18549000 18549000 18549000 209000 659000 17691000 17890000 2500000 1500000 1693000 8310000 23111000 8955000 1693000 1693000 1693000 1693000 1693000 1693000 7534000 7534000 7534000 776000 776000 776000 8310000 8310000 8310000 -6617000 -14156000 <div style="display: inline; font-family: times new roman; font-size: 10pt"><table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 100%; TEXT-INDENT: 0px; width: 700px;" cellspacing="0" cellpadding="0" border="0"> <tr> <td style="WIDTH: 36pt; VERTICAL-ALIGN: top"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">13. </div></div></div></td> <td style="VERTICAL-ALIGN: top"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">SUPPLEMENTAL CASH FLOW INFORMATION</div></div></div></td> </tr> </table> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div> <div style=" TEXT-ALIGN: left; MARGIN: 0pt 0pt 0pt 36pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">The following table represents cash flows (used in) provided by the Company's discontinued operations for the nine months ended September 30, 2016 and 2015:</div></div> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div>&nbsp;</div> <div> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 90%; MARGIN-LEFT: 36pt; MARGIN-RIGHT: 10%; TEXT-INDENT: 0px; width: 700px;" cellspacing="0" cellpadding="0" border="0"> <tr> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: center" colspan="6"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">Nine Months Ended</div></div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> </tr> <tr> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center" colspan="6"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">September 30,</div></div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> </tr> <tr> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center" colspan="2"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">2016</div></div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center" colspan="2"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">2015</div></div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 66%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Net cash (used in) provided by operating activities of discontinued operations</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 14%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">(1,486</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">)</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 14%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">7,466 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #ffffff"> <td style="BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="BACKGROUND-COLOR: #ffffff">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Net cash (used in) provided by investing activities of discontinued operations</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 14%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">- </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 14%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">- </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> </tr> </table> </div></div> -1486000 7466000 <div style="display: inline; font-family: times new roman; font-size: 10pt"><table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 100%; TEXT-INDENT: 0px; width: 700px;" cellspacing="0" cellpadding="0" border="0"> <tr> <td style="WIDTH: 36pt; VERTICAL-ALIGN: top"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">6</div><div style="display: inline; font-weight: bold;">.</div></div></div></td> <td style="VERTICAL-ALIGN: top"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;"></div><div style="display: inline; font-weight: bold;">COMMITMENTS AND CONTINGENCIES </div></div></div></td> </tr> </table> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt 0pt 0pt 36pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-style: italic;">Letters of Credit</div></div></div> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt 0pt 0pt 36pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">As of September 30, 2016, the Company had $0.3 million in letters of credit outstanding as required by its existing facility leases. These letters of credit are collateralized by certain investments. In October 2016, the letters of credit were not renewed and the balance was distributed to our landlords who now hold the funds as security deposits on the Company&#x2019;s facility leases.</div></div> <div style=" MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px">&nbsp;</div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt 0pt 0pt 36pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-style: italic;">Contingency</div></div></div> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt 0pt 0pt 36pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">In connection with the acquisition of RedPath on October 31, 2014, the Company and its wholly-owned subsidiary, Interpace LLC, entered into a Contingent Consideration Agreement with the RedPath Equityholder Representative. Pursuant to the Contingent Consideration Agreement, the Company agreed to issue to the equityholders of RedPath 500,000 shares of the Company&#x2019;s common stock, par value $0.01 (Common Stock), upon acceptance for publication of a specified article related to PathFinderTG&reg; for the management of Barrett&#x2019;s esophagus. The pending issuance of Common Stock was recorded as Additional paid-in capital in the Company's consolidated balance sheet as of December 31, 2014. On April 13, 2015, this milestone was reached upon acceptance for publication of new data supporting the use of BarreGen&#x2122; for predicting risk of progression from Barrett&#x2019;s esophagus to esophageal cancer. On June 16, 2015, the 500,000 shares were issued from Treasury stock decreasing the balance in treasury stock by approximately $6.1 million, with a corresponding decrease in Additional paid-in capital of $6.1 million. In March 2016, 500,000 additional shares of Common Stock were issued from Treasury stock, as a result of the acceleration of the Common Stock Milestone, as defined in the Contingent Consideration Agreement, resulting from the change of control in connection with the sale of its CSO business in December 2015, decreasing the balance in treasury stock by approximately $6.8 million, with a corresponding decrease in Additional paid-in capital of $6.8 million.</div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt 0pt 0pt 36pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt 0pt 0pt 36pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-style: italic;">Litigation</div></div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt 0pt 0pt 36pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt 0pt 0pt 36pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Due to the nature of the businesses in which the Company is engaged it is subject to certain risks. Such risks include, among others, risk of liability for personal injury or death to persons using products the Company promotes or commercializes. There can be no assurance that substantial claims or liabilities will not arise in the future due to the nature of the Company&#x2019;s business activities and recent increases in litigation related to healthcare products. As part of the closeout of its CSO operations, the Company seeks to reduce its potential liability under its service agreements through measures such as contractual indemnification provisions with customers (the scope of which may vary from customer to customer, and the performance of which is not secured) and insurance. The Company could, however, also be held liable for errors and omissions of its employees in connection with the services it performs that are outside the scope of any indemnity or insurance policy. The Company could be materially adversely affected if it were required to pay damages or incur defense costs in connection with a claim that is outside the scope of an indemnification agreement; if the indemnity, although applicable, is not performed in accordance with its terms; or if the Company&#x2019;s liability exceeds the amount of applicable insurance or indemnity.</div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt 0pt 0pt 36pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt 0pt 0pt 36pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">The Company routinely assesses its litigation and threatened litigation as to the probability of ultimately incurring a liability, and records its best estimate of the ultimate loss in situations where the Company assesses the likelihood of loss as probable. The Company accrues for a liability when it is both probable that a liability has been incurred and the amount of the loss can be reasonably estimated. Significant judgment is required in both the determination of probability and the determination as to whether a loss is reasonably estimable. In addition, in the event the Company determines that a loss is not probable, but is reasonably possible, and it becomes possible to develop what the Company believes to be a reasonable range of possible loss, then the Company will include disclosures related to such matter as appropriate and in compliance with ASC 450. To the extent there is a reasonable possibility that the losses could exceed the amounts already accrued, the Company will, as applicable, adjust the accrual in the period the determination is made, disclose an estimate of the additional loss or range of loss, indicate that the estimate is immaterial with respect to its financial statements as a whole or, if the amount of such adjustment cannot be reasonably estimated, disclose that an estimate cannot be made. As of September 30, 2016, the Company's accrual for litigation and threatened litigation was not material to the consolidated financial statements.</div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt 0pt 0pt 36pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt 0pt 0pt 36pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">In connection with the October 31, 2014 acquisition of RedPath, the Company assumed a liability for a January 2013 settlement agreement (the Settlement Agreement) entered into by the former owners of RedPath with the Department of Justice (&#x201c;DOJ&#x201d;). Under the terms of the Settlement Agreement, the Company is obligated to make payments to the DOJ for the calendar years ended December 31, 2014 through 2017, up to a maximum of $3.0 million.</div></div> <div style=" TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; font-weight: bold;"></div>&nbsp;</div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt 0pt 0pt 36pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Payments are due March 31st following the calendar year that the revenue milestones are achieved. The Company has been indemnified by the former owners of RedPath for $2.5 million of the obligation and has recorded an indemnification asset of that amount within other non-current assets. In May 2016 the Company renegotiated payment terms with the DOJ related to a $250,000 payment associated with performance in fiscal 2014 that resulted in an agreement that the Company pay $85,000 on July 31, 2016, $85,000 on October 31, 2016 and $80,000 on February 28, 2017. Accordingly, $170,000 was paid to the DOJ in 2016. During the nine months ended September 30, 2016, the Company has $1.7 million recorded as its best estimate of the amount that remains to be paid under the Settlement Agreement based on its estimate of future revenues, of which $0.7 million is included in<div style="display: inline; font-style: italic;"> other accrued expenses</div> and $1.0 million is included in <div style="display: inline; font-style: italic;">other long-term liabilities</div>.</div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt 0pt 0pt 36pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div> <div style=" TEXT-ALIGN: left; MARGIN: 0pt 0pt 0pt 36pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-style: italic;">Prolias Technologies, Inc. v. PDI, Inc. </div></div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt 0pt 0pt 36pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt 0pt 0pt 36pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">On April 8, 2015, Prolias Technologies, Inc.(&#x201c;Prolias&#x201d;) filed a complaint (the &#x201c;Complaint&#x201d;) against the Company with the Superior Court of New Jersey (Morris County) in a matter entitled&nbsp;Prolias Technologies, Inc. v. PDI, Inc.&nbsp;(Docket No. MRS-L-899-15). &nbsp;In the Complaint, Prolias alleges that it and the Company entered into an August 19, 2013 Collaboration Agreement and a First Amendment thereto (collectively, the &#x201c;Agreement&#x201d;) whereby Prolias and the Company agreed to work in good faith to commercialize a diagnostic test known as &quot;Thymira.&quot; &nbsp;Thymira is a minimally invasive diagnostic test that is being developed to detect thyroid cancer.</div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt 0pt 0pt 36pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt 0pt 0pt 36pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Prolias alleges in the Complaint that the Company wrongfully terminated the Agreement, breached obligations owed to it under the Agreement and committed torts by (i) failing to effectively and timely validate Thymira, (ii) purchasing a competitor of Prolias and working to commercialize the competitive product at the expense of Thymira, and (iii) interfering with a license agreement that Prolias had with Cornell University related to a license for Thymira. Prolias asserts claims against the Company for breach of contract, breach of the covenant of good faith and fair dealing, intentional interference with contract and breach of fiduciary duty and seeks to recover unspecified compensatory damages, punitive damages, interest and costs of suit.</div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt 0pt 0pt 36pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt 0pt 0pt 36pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">On June 3, 2015, the Company filed an Answer and Counterclaim in response to the Complaint. In the Answer, the Company denied that it had any liability to Prolias for the claims raised in the Complaint. In the Counterclaim, the Company sought (a) to recover from Polias the principal amount of $500,000 plus interest that was due and owing under a March 18, 2014 promissory note that Prolias delivered to the Company and (b) to compel Prolias to execute and deliver a $1 million promissory note to memorialize Prolias&#x2019;s repayment obligations of money the Company advanced under the Agreement. </div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt 0pt 0pt 36pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt 0pt 0pt 36pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">The parties exchanged documents in the fourth quarter of 2015. On December 18, 2015, Prolias moved for temporary restraints as to an asset sale of the Company. The Court denied the temporary restraints on December 21, 2015 and, when Prolias pursued the restraints in the form of a preliminary injunction motion, the Court denied that as well on February 4, 2016. Prolias&#x2019;s separate motion to disqualify the Company&#x2019;s counsel was also denied by the Court on</div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt 0pt 0pt 36pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">February 4, 2016. On February 24, 2016, Prolias moved for leave to appeal the interlocutory order denying the disqualification of Company&#x2019;s counsel. On May 11, 2016, the Appellate Division granted the motion for leave to appeal and then summarily affirmed the denial of Prolias&#x2019;s motion to disqualify the Company&#x2019;s counsel. </div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt 0pt 0pt 36pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt 0pt 0pt 36pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">On March 29, 2016, Prolias&#x2019; counsel moved to withdraw from representing Prolias. On April 7, 2016, the Company conditionally opposed the motion to withdraw pending prompt appointment of new counsel for Prolias. On April 19, 2016, the Court denied the motion without prejudice. On April 26, 2016, Prolias&#x2019; counsel renewed its motion to withdraw. On May 27, 2016, the Court granted the motion to withdraw and ordered Prolias to retain substitute counsel within 30 days. </div></div> <div style=" TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; font-weight: bold;"></div>&nbsp;</div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt 0pt 0pt 36pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">On July 6, 2016, the Company moved to dismiss Prolias&#x2019; complaint and strike Prolias&#x2019; answer to the Company&#x2019;s counterclaims for failure to retain substitute counsel within 30 days as required by the Court&#x2019;s May 27th Order. On August 15, 2016, the Court granted the Company&#x2019;s motion and dismissed Prolias&#x2019; complaint with prejudice and struck Prolias&#x2019; answer to the Company&#x2019;s counterclaims. On September 22, 2016, the Court granted the Company&#x2019;s request to enter default against Prolias for failure to plead or otherwise respond to the counterclaims. Thereafter, on October 13, 2016, the Company filed an application to enter final judgment and taxing of costs against Prolias. The Company requested that the Court enter final judgment against Prolias and for the Company in the amount of $621,236.16, plus ten percent interest continuing to accrue on the principal balance of $500,000.00 unless and until paid, attorneys&#x2019; fees and costs of $390,769.04, and a declaratory judgment that Prolias is deemed to have executed and delivered to the Company a promissory note in the amount of $1,000,000 under Article 10.2(a) of the Collaboration Agreement. The Company is awaiting a response from the Court on the application for entry of final judgment.</div><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt 0pt 0pt 36pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt 0pt 0pt 36pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-style: italic;">Swann v. Akorn, Inc., and Interpace Diagnostics Group, Inc.</div></div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt 0pt 0pt 36pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-style: italic;"></div></div>&nbsp;</div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt 0pt 0pt 36pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">On May 27, 2016, Michael J. Swann, one of the Company&#x2019;s former employees, filed a complaint against the Company in the Court of Common Pleas of the Fifth Judicial Circuit in South Carolina in a matter entitled Michael J. Swann v. Akorn, Inc., and Interpace Diagnostic Group Inc. (Civil Action No. 2016-CP-40-03362). In the complaint, Mr. Swann alleges, among other things, that he was discriminated against and wrongfully terminated as a member of a sales force marketing pharmaceutical products of Akorn, Inc., because of an illness suffered by Mr. Swann. Mr. Swann alleges that he was discriminated against in violation of the Americans with Disabilities Act/Americans with Disabilities Act Amendments Act and the Family Medical Leave Act and seeks damages for back pay, reinstatement, front pay, compensatory and punitive damages in an amount not less than $300,000, attorney&#x2019;s fees and costs. The Company denies that it is liable to Mr. Swann for any of the claims asserted and intends to vigorously defend itself against those claims.</div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt 0pt 0pt 36pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div> <div style=" TEXT-ALIGN: left; MARGIN: 0pt 0pt 0pt 36pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-style: italic;">Severance</div></div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt 0pt 0pt 36pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-style: italic;">&nbsp;</div></div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt 0pt 0pt 36pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">In 2015, in connection with the sale of the majority of the CSO business and the implementation of a broad-based program to maximize efficiencies and cut costs, the Company reduced headcount and incurred severance obligations to terminated employees that amounted to approximately $3.7 million. </div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt 0pt 0pt 36pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt 0pt 0pt 36pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">During the first quarter ended March 31, 2016 the Company recorded additional severance obligations as it continued to right-size the organization and wind down its CSO business. The Company recorded obligations of $1.1 million, $0.5 million of which was recorded in continuing operations. The current severance liability as of September 30, 2016 is $3.1 million, of which $2.3 million resides in continuing operations and $0.8 million is in discontinued operations.</div></div></div> 0.01 0.01 0.01 100000000 100000000 18705214 18705214 18162671 17662671 187000 187000 -7493000 -4895000 -14613000 -15741000 10700000 3100000 1000000 600000 4001000 3137000 665000 800000 8603000 <div style="display: inline; font-family: times new roman; font-size: 10pt"><table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 95%; MARGIN-LEFT: 36pt; MARGIN-RIGHT: 5%; TEXT-INDENT: 0px;; width: 700px;" cellspacing="0" cellpadding="0" border="0"> <tr> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center" colspan="2"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Total</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center" colspan="2"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">0 to 3 </div></div> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">months</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center" colspan="2"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">3 to 6 </div></div> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">months</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center" colspan="2"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">6 to 12 </div></div> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">months</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 48%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Note due Redpath Equityholders</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">4,001 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">1,334 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">-&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">2,667 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #ffffff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Severance obligations</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">3,137 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">3,137 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">- </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">- </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">DOJ settlement</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">665 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">85 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">85 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">495 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #ffffff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Deferred Bonus - ERT salesforce</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">800 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">185 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">308 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">307 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; PADDING-LEFT: 9pt; BACKGROUND-COLOR: #cceeff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Total obligations</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">8,603 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">4,741 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">393</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">3,469 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> </tr> </table></div> 1846000 1799000 4866000 5224000 0.0275 11000000 20000000 12000 0.05 1333750 1700000 -634000 78000 127000 52000 3490000 3775000 <div style="display: inline; font-family: times new roman; font-size: 10pt"><table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 100%; TEXT-INDENT: 0px; width: 700px;" cellspacing="0" cellpadding="0" border="0"> <tr> <td style="WIDTH: 36pt; VERTICAL-ALIGN: top"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">8</div><div style="display: inline; font-weight: bold;">.</div></div></div></td> <td style="VERTICAL-ALIGN: top"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;"></div><div style="display: inline; font-weight: bold;">STOCK-BASED COMPENSATION</div></div></div></td> </tr> </table> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt 0pt 0pt 36pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-style: italic;">Stock Incentive Plan</div></div></div> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt 0pt 0pt 36pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">In 2015, the board of directors (the Board) and stockholders approved the Company&#x2019;s Amended and Restated 2004 Stock Award and Incentive Plan, or the Amended and Restated Plan. The Amended and Restated Plan amends the Company&#x2019;s pre-existing Amended and Restated 2004 Stock Award and Incentive Plan, which had replaced the 1998 Stock Option Plan, or the 1998 Plan, and the 2000 Omnibus Incentive Compensation Plan, or the 2000 Plan.&nbsp;&nbsp;The Amended and Restated Plan authorized an additional 2,450,000 shares for new awards and combined the remaining shares available under the original Amended and Restated Plan.&nbsp;&nbsp;Eligible participants under the Amended and Restated Plan include officers and other employees of the Company, members of the Board and outside consultants, as specified under the Amended and Restated Plan and designated by the Compensation and Management Development Committee of the Board, or the Compensation Committee.&nbsp;&nbsp;Unless earlier terminated by action of the Board, the Amended and Restated Plan will remain in effect until such time as no stock remains available for delivery under the Amended and Restated Plan and the Company has no further rights or obligations under the Amended and Restated Plan with respect to outstanding awards thereunder.&nbsp;</div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt 0pt 0pt 36pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt 0pt 0pt 36pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">SARs are generally granted with a grant price equal to the market value of the common stock on the date of grant, vest one-third each year on the anniversary of the date of grant and expire five years from the date of grant.&nbsp;&nbsp;The restricted shares and restricted stock units (RSU&#x2019;s) granted to employees historically have had a three year cliff vesting period and are subject to accelerated vesting and forfeiture under certain circumstances. Restricted shares and restricted stock units granted to board members generally have a three year graded vesting period and are subject to accelerated vesting and forfeiture under certain circumstances.</div></div> <div style=" TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; font-weight: bold;"></div>&nbsp;</div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt 0pt 0pt 36pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">In February 2016, certain employees and members of the Company&#x2019;s Board were granted approximately 1.3 million RSU&#x2019;s at a weighted average grant price of $0.25.&nbsp;These shares vest one-third each year on the anniversary of the date of grant.</div></div> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt 0pt 0pt 36pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">The following table provides the weighted average assumptions used in determining the fair value of the non-market based SARs awards granted during the nine month periods ended September 30, 2016 and September 30, 2015:&nbsp;</div><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div> <div style=" TEXT-ALIGN: center; MARGIN: 0pt 0pt 0pt 36pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; FONT-SIZE: 10pt; FONT-STYLE: normal; BACKGROUND-COLOR: yellow"></div></div>&nbsp;</div> <div> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 80%; MARGIN-LEFT: 126pt; MARGIN-RIGHT: 20%; TEXT-INDENT: 0px; width: 700px;" cellspacing="0" cellpadding="0" border="0"> <tr> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: center" colspan="6"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Nine Months Ended</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</td> </tr> <tr> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center" colspan="6"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">September 30,</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px">&nbsp;</td> </tr> <tr> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center" colspan="2"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">2016</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center" colspan="2"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">2015</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px">&nbsp;</td> </tr> <tr> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 62%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Risk-free interest rate</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">- </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">1.02</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">%</td> </tr> <tr> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Expected life (years)</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">- </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: center; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="TEXT-ALIGN: right">3.5</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BACKGROUND-COLOR: #ffffff">&nbsp;</td> </tr> <tr> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Expected volatility</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">- </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">54.47</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">%</td> </tr> <tr> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Dividend yield</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">- </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">- </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> </tr> </table> </div> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt 0pt 0pt 36pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">The Company recognized approximately $0.02 million and $0.3 million of stock-based compensation expense during each of the three month periods ended September 30, 2016 and 2015, respectively, and $0.1 million and $1.0 million during each of the nine month periods ended September 30, 2016 and 2015, respectively.</div></div> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt 0pt 0pt 36pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">On October 14, 2016, the Company&#x2019;s Chief Executive Officer, Chief Financial Officer and certain employees were granted incentive stock options to purchase an aggregate of 878,744 shares of common stock with an exercise price of $0.16 per share and, subject generally to the executive&#x2019;s or employee&#x2019;s, as applicable, continued service with the Company, vest in equally monthly installments over a period of one year.</div><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"></div></div></div> 1326000 217000 -414000 2576000 320000 6832000 -117000 2000 219000 4000 <div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" TEXT-ALIGN: justify; MARGIN: 0pt 0pt 0pt 36pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-style: italic;">Discontinued Operations</div></div></div><div style=" TEXT-ALIGN: justify; MARGIN: 0pt 0pt 0pt 36pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-style: italic;">&nbsp;</div></div></div><div style=" TEXT-ALIGN: justify; MARGIN: 0pt 0pt 0pt 36pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">The Company accounts for business dispositions and its businesses held for sale in accordance with ASC&nbsp;205-20, Discontinued Operations. ASC 205-20 requires the results of operations of business dispositions to be segregated from continuing operations and reflected as discontinued operations in current and prior periods. See Note&nbsp;11, <div style="display: inline; font-style: italic;">Discontinued Operations</div> for further information.</div><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-style: italic;">&nbsp;</div></div></div></div></div></div></div></div></div></div> 16000 16000 947000 947000 3767000 3767000 190000 150000 340000 11000 11000 -414000 2576000 -1006000 6615000 150000 150000 2062000 2062000 2052000 70000 2122000 5092000 358000 5450000 150000 150000 190000 190000 34119000 1644000 104408000 217000 <div style="display: inline; font-family: times new roman; font-size: 10pt"><table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 100%; TEXT-INDENT: 0px; width: 700px;" cellspacing="0" cellpadding="0" border="0"> <tr> <td style="WIDTH: 36pt; VERTICAL-ALIGN: top"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">11.</div></div></div></td> <td style="VERTICAL-ALIGN: top"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">DISCONTINUED OPERATIONS</div></div></div></td> </tr> </table> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt 0pt 0pt 36pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">The table below presents the significant components of CSO, Group DCA's, Pharmakon's and TVG&#x2019;s results included in (Loss)&nbsp;Income from Discontinued Operations, Net of Tax in the consolidated statements of comprehensive loss for the three- and nine-months ended September 30, 2016 and 2015.</div></div> <div style=" TEXT-ALIGN: left; MARGIN: 0pt 0pt 0pt 18pt; LINE-HEIGHT: 1.25">&nbsp;</div> <div> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 95%; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 5%; TEXT-INDENT: 0px; width: 700px;" cellspacing="0" cellpadding="0" border="0"> <tr> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 36%">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 17%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center" colspan="6"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Three Months Ending September 30,</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 17%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center" colspan="6"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Nine Months Ending September 30,</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px">&nbsp;</td> </tr> <tr> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 36%">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center" colspan="2"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">2016 </div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center" colspan="2"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">2015 </div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center" colspan="2"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">2016 </div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center" colspan="2"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">2015 </div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 36%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Revenue, net</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 13%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">- </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 13%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">34,119 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 13%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">1,644 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 13%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">104,408 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #ffffff"> <td style="WIDTH: 36%; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="WIDTH: 13%; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="WIDTH: 13%; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="WIDTH: 13%; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="WIDTH: 13%; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 36%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">(Loss) income from discontinued operations</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 13%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">(414</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">)</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 13%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">2,576 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 13%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">(1,006</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">)</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 13%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">6,615 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #ffffff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 36%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Gain on sale of assets</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 13%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">- </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 13%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">- </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 13%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">1,326 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 13%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">217 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 36%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">(Loss) income from discontinued operations, before tax</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 13%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">(414</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">)</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 13%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">2,576 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 13%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">320 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 13%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">6,832 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #ffffff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 36%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Income tax (benefit) expense</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 13%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">(117</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">)</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 13%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">2 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 13%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">219 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 13%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">4 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 36%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">(Loss) income from discontinued operations, net of tax</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 13%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">(297</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">)</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 13%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">2,574 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 13%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">101 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 13%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">6,828 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> </tr> </table> </div> <div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <div style=" TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; font-weight: bold;"></div>&nbsp;</div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt 0pt 0pt 36pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">The assets and liabilities classified as discontinued operations relate to CSO, Group DCA, Pharmakon, and TVG. As of September 30, 2016 and December&nbsp;31, 2015, these assets and liabilities are in the accompanying balance sheets as follows:</div></div> <div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;"><div style="display: inline; FONT-SIZE: 10pt; FONT-STYLE: normal; BACKGROUND-COLOR: yellow"></div></div></div>&nbsp;</div> <div> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 100%; TEXT-INDENT: 0px; width: 700px;" cellspacing="0" cellpadding="0" border="0"> <tr> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center" colspan="10"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">For the Nine Months Ended </div></div> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">September 30, 2016</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center" colspan="10"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">For the Year Ended </div></div> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">December 31, 2015</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px">&nbsp;</td> </tr> <tr> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center" colspan="2"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">CSO</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center" colspan="2"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">DCA/TVG</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center" colspan="2"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Total</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center" colspan="2"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">CSO</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center" colspan="2"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">DCA/TVG</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center" colspan="2"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Total</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 28%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Accounts receivable, net</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">- </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">- </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">- </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">3,296 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">- </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">3,296 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #ffffff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Unbilled receivable, net</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">- </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">- </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">- </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">16 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">- </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">16 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Other</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 9%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">- </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 9%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">150 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 9%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">150 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 9%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">2,062 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 9%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">- </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 9%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">2,062 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #ffffff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Current assets from discontinued operations</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">- </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">150 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">150 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">5,374 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">- </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">5,374 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Property and equipment, net</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">- </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">- </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">- </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">190 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">- </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">190 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #ffffff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Other </div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 9%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">- </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 9%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">- </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 9%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">- </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 9%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">- </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 9%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">150 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 9%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">150 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Long-term assets from discontinued operations</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 9%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">- </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 9%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">- </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 9%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">- </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 9%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">190 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 9%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">150 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 9%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">340 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #ffffff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; PADDING-LEFT: 18pt; BACKGROUND-COLOR: #ffffff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Total assets</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; BACKGROUND-COLOR: #ffffff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 9%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">- </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; BACKGROUND-COLOR: #ffffff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 9%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">150 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; BACKGROUND-COLOR: #ffffff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 9%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">150 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; BACKGROUND-COLOR: #ffffff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 9%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">5,564 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; BACKGROUND-COLOR: #ffffff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 9%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">150 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; BACKGROUND-COLOR: #ffffff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 9%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">5,714 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="BACKGROUND-COLOR: #cceeff">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #ffffff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Accounts payable</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">947 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">- </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">947 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">3,767 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">- </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">3,767 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Unearned contract revenue</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">- </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">- </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">- </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">11 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">- </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">11 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #ffffff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Accrued salary and bonus</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">1,686 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">- </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">1,686 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">3,036 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">- </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">3,036 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Other</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 9%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">2,052 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 9%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">70 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 9%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">2,122 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 9%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">5,092 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 9%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">358 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 9%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">5,450 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #ffffff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Current liabilities from discontinued operations</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 9%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">4,685 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 9%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">70 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 9%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">4,755 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 9%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">11,906 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 9%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">358 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 9%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">12,264 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; PADDING-LEFT: 18pt; BACKGROUND-COLOR: #cceeff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Total liabilities</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 9%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">4,685 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 9%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">70 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 9%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">4,755 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 9%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">11,906 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 9%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">358 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 9%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">12,264 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> </tr> </table> </div></div> -0.41 -0.31 -0.81 -1.03 <div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" TEXT-ALIGN: justify; MARGIN: 0pt 0pt 0pt 36pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-style: italic;">Basic and Diluted Net Loss per Share</div></div></div><div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div><div style=" TEXT-ALIGN: justify; MARGIN: 0pt 0pt 0pt 36pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">A reconciliation of the number of shares of common stock used in the calculation of basic and diluted loss per share for the three- and nine-month-periods ended September 30, 2016 and 2015 is as follows:</div><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div><div style=" TEXT-ALIGN: center; MARGIN: 0pt 0pt 0pt 36pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; FONT-SIZE: 10pt; FONT-STYLE: normal; BACKGROUND-COLOR: yellow"></div></div>&nbsp;</div><div> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 95%; MARGIN-LEFT: 36pt; MARGIN-RIGHT: 5%; TEXT-INDENT: 0px; width: 700px;" cellspacing="0" cellpadding="0" border="0"> <tr> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: center" colspan="6"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Three Months Ended</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: center" colspan="6"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Nine Months Ended</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</td> </tr> <tr> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center" colspan="6"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">September 30,</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center" colspan="6"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">September 30,</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px">&nbsp;</td> </tr> <tr> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center" colspan="2"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">2016</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center" colspan="2"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">2015</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center" colspan="2"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">2016</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center" colspan="2"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">2015</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; PADDING-LEFT: 9pt; BACKGROUND-COLOR: #cceeff; TEXT-INDENT: -9pt"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Basic weighted average number of&nbsp; of common shares</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">18,163 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">15,654 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">18,029 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">15,301 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #ffffff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Potential dilutive effect of stock-based awards</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">- </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">- </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">- </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">- </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; PADDING-LEFT: 9pt; BACKGROUND-COLOR: #cceeff; TEXT-INDENT: -9pt"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Diluted weighted average number of common shares</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">18,163 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">15,654 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">18,029 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">15,301 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> </tr> </table> </div><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <div style=" TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; font-weight: bold;"></div>&nbsp;</div></div><div style=" TEXT-ALIGN: justify; MARGIN: 0pt 0pt 0pt 36pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">The following outstanding stock-based awards were excluded from the computation of the effect of dilutive securities on loss per share for the following periods because they would have been anti-dilutive:</div><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div><div style=" TEXT-ALIGN: center; MARGIN: 0pt 0pt 0pt 36pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-style: italic;"><div style="display: inline; FONT-SIZE: 10pt; FONT-STYLE: normal; BACKGROUND-COLOR: yellow"></div></div></div>&nbsp;</div><div> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 90%; MARGIN-LEFT: 36pt; MARGIN-RIGHT: 10%; TEXT-INDENT: 0px; width: 700px;" cellspacing="0" cellpadding="0" border="0"> <tr> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 44%">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 15%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: center" colspan="6"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Three Months Ended</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 15%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: center" colspan="6"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Nine Months Ended</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%">&nbsp;</td> </tr> <tr> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 44%">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 15%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center" colspan="6"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">September 30,</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 15%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center" colspan="6"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">September 30,</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px">&nbsp;</td> </tr> <tr> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 44%">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center" colspan="2"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">2016</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center" colspan="2"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">2015</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center" colspan="2"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">2016</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center" colspan="2"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">2015</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 44%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Options</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">- </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">- </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">- </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">- </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #ffffff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 44%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Stock-settled stock appreciation rights (SARs)</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">1,027 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">1,028 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">1,027 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">1,028 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 44%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Restricted stock and restricted stock units (RSUs)</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">1,151 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">1,745 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">1,151 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">1,745 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #ffffff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 44%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Performance contingent SARs</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 11%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">- </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 11%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">188 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 11%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">- </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 11%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">188 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 44%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 11%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">2,178 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 11%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">2,961 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 11%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">2,178 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 11%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">2,961 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> </tr> </table> </div></div></div></div></div></div></div></div> -0.025 0.024 0.004 0.019 3089000 2424000 <div style="display: inline; font-family: times new roman; font-size: 10pt"><table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 95%; MARGIN-RIGHT: 5%; TEXT-INDENT: 0px;; width: 700px;" cellspacing="0" cellpadding="0" border="0"> <tr> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 35%; VERTICAL-ALIGN: bottom">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center" colspan="18"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">2016</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 1px">&nbsp;</td> </tr> <tr> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 35%; VERTICAL-ALIGN: bottom">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: center">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: center">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: center">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: center" colspan="2"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Adjustments</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: center">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom">&nbsp;</td> </tr> <tr> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 35%; VERTICAL-ALIGN: bottom">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center" colspan="2"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">January 1,</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 1px">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center" colspan="2"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Payments</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 1px">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center" colspan="2"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Accretion</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 1px">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center" colspan="2"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">to Fair Value</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 1px">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center" colspan="2"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">September 30,</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 1px">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 35%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Asuragen</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">4,628 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">(450</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">)</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">243 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">(1,174</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">)</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">3,247 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #ffffff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 35%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Redpath</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">13,921 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">- </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">732 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">- </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">14,653 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 35%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">18,549 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">(450</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">)</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">975 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">(1,174</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">)</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">17,900 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> </tr> </table></div> <div style="display: inline; font-family: times new roman; font-size: 10pt"><table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 95%; MARGIN-LEFT: 36pt; MARGIN-RIGHT: 5%; TEXT-INDENT: 0px;; width: 700px;" cellspacing="0" cellpadding="0" border="0"> <tr> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center" colspan="6"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">As of September 30, 2016</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 1px">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: center" colspan="10"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Fair Value Measurements</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 1px">&nbsp;</td> </tr> <tr> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: center" colspan="2"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Carrying</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 0px">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: center" colspan="2"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Fair</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 0px">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center" colspan="10"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">As of September 30, 2016</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 0px">&nbsp;</td> </tr> <tr> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center" colspan="2"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Amount</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 1px">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center" colspan="2"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Value</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 1px">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center" colspan="2"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Level 1</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 1px">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center" colspan="2"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Level 2</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 1px">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center" colspan="2"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Level 3</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 1px">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 35%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">Assets:</div></div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> </tr> <tr style="BACKGROUND-COLOR: #ffffff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Cash and cash equivalents:</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; PADDING-LEFT: 9pt; BACKGROUND-COLOR: #cceeff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Cash</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">1,693 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">1,693 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">1,693 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">- </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">- </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #ffffff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; PADDING-LEFT: 9pt; BACKGROUND-COLOR: #ffffff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Money market funds</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">- </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">- </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">- </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">- </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">- </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">1,693 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">1,693 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">1,693 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">- </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">- </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #ffffff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Marketable securities:</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; BACKGROUND-COLOR: #ffffff">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; PADDING-LEFT: 9pt; BACKGROUND-COLOR: #cceeff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">U.S. Treasury securities</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">- </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">- </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">- </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">- </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">- </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #ffffff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">Liabilities:</div></div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Contingent consideration:</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #ffffff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; PADDING-LEFT: 9pt; BACKGROUND-COLOR: #ffffff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Asuragen</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">3,247 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">3,247 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">- </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">- </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">3,247 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; PADDING-LEFT: 9pt; BACKGROUND-COLOR: #cceeff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">RedPath</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">14,653 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">14,653 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">- </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">- </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">14,653 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #ffffff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; BACKGROUND-COLOR: #ffffff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">17,900 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; BACKGROUND-COLOR: #ffffff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">17,900 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; BACKGROUND-COLOR: #ffffff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">- </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; BACKGROUND-COLOR: #ffffff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">- </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; BACKGROUND-COLOR: #ffffff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">17,900 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> </tr> </table></div><div style="display: inline; font-family: times new roman; font-size: 10pt"><table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 95%; MARGIN-LEFT: 36pt; MARGIN-RIGHT: 5%; TEXT-INDENT: 0px;; width: 700px;" cellspacing="0" cellpadding="0" border="0"> <tr> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 35%">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 14%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center" colspan="6"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">As of December 31, 2015</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 0px">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 27%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center" colspan="11"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Fair Value Measurements</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 0px">&nbsp;</td> </tr> <tr> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 35%">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: center" colspan="2"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Carrying</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 0px">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: center" colspan="2"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Fair</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 0px">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 27%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: center" colspan="11"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">As of December 31, 2015</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 0px">&nbsp;</td> </tr> <tr> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 35%">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center" colspan="2"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Amount</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center" colspan="2"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Value</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center" colspan="2"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Level 1</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center" colspan="2"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Level 2</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 0%">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center" colspan="2"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Level 3</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 35%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">Assets:</div></div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 0%; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> </tr> <tr style="BACKGROUND-COLOR: #ffffff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 35%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Cash and cash equivalents:</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 0%; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 35%; VERTICAL-ALIGN: bottom; PADDING-LEFT: 9pt; BACKGROUND-COLOR: #cceeff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Cash</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">7,534 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">7,534 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">7,534 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">- </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: right; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"></div>&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 0%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">- </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #ffffff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 35%; VERTICAL-ALIGN: bottom; PADDING-LEFT: 9pt; BACKGROUND-COLOR: #ffffff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Money market funds</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">776 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">776 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">776 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">- </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 0%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">- </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 35%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">8,310 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">8,310 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">8,310 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">- </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 0%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">- </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #ffffff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 35%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Marketable securities:</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 0%; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 35%; VERTICAL-ALIGN: bottom; PADDING-LEFT: 9pt; BACKGROUND-COLOR: #cceeff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Money market funds</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">48 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">48 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">48 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">- </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 0%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">- </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #ffffff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 35%; VERTICAL-ALIGN: bottom; PADDING-LEFT: 9pt; BACKGROUND-COLOR: #ffffff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Mutual funds</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">58 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">58 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">58 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">- </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 0%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">- </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 35%; VERTICAL-ALIGN: bottom; PADDING-LEFT: 9pt; BACKGROUND-COLOR: #cceeff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">U.S. Treasury securities</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">1,115 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">1,115 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">1,115 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">- </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 0%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">- </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #ffffff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 35%; VERTICAL-ALIGN: bottom; PADDING-LEFT: 9pt; BACKGROUND-COLOR: #ffffff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Government agency securities</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">131 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">131 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">131 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">- </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 0%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">- </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 35%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">1,352 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">1,352 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">1,352 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">- </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 0%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">- </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #ffffff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 35%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">Liabilities:</div></div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #ffffff"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #ffffff"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #ffffff"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #ffffff"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #ffffff"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #ffffff"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #ffffff"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #ffffff"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #ffffff"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #ffffff"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #ffffff"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #ffffff"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #ffffff"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 0%; BACKGROUND-COLOR: #ffffff"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #ffffff"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #ffffff"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 35%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Contingent consideration:</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 0%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #ffffff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 35%; VERTICAL-ALIGN: bottom; PADDING-LEFT: 9pt; BACKGROUND-COLOR: #ffffff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Asuragen</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">4,628 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">4,628 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">- </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">- </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 0%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">4,628 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 35%; VERTICAL-ALIGN: bottom; PADDING-LEFT: 9pt; BACKGROUND-COLOR: #cceeff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">RedPath</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">13,921 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">13,921 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">- </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">- </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 0%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">13,921 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #ffffff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 35%; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; BACKGROUND-COLOR: #ffffff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">18,549 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; BACKGROUND-COLOR: #ffffff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">18,549 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; BACKGROUND-COLOR: #ffffff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">- </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; BACKGROUND-COLOR: #ffffff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">- </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 0%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; BACKGROUND-COLOR: #ffffff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">18,549 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> </tr> </table></div> <div style="display: inline; font-family: times new roman; font-size: 10pt"><table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 100%; TEXT-INDENT: 0px; width: 700px;" cellspacing="0" cellpadding="0" border="0"> <tr> <td style="WIDTH: 36pt; VERTICAL-ALIGN: top"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">5.</div></div></div></td> <td style="VERTICAL-ALIGN: top"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">FAIR VALUE MEASUREMENTS</div></div></div></td> </tr> </table> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt 0pt 0pt 36pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">The Company's financial assets and liabilities reflected at fair value in the consolidated financial statements include: cash and cash equivalents; short-term investments; accounts receivable; other current assets; accounts payable; and contingent consideration. Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. In determining fair value, the Company uses various methods, including market, income and cost approaches. Based on these approaches, the Company often utilizes certain assumptions that market participants would use in pricing the asset or liability, including assumptions about risk and/or the risks inherent in the inputs to the valuation technique. These inputs can be readily observable, market-corroborated, or generally unobservable inputs. The Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs. Based upon observable inputs used in the valuation techniques, the Company is required to provide information according to the fair value hierarchy. The fair value hierarchy ranks the quality and reliability of the information used to determine fair values into three broad levels as follows:</div></div> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 100%; TEXT-INDENT: 0px; width: 700px;" cellspacing="0" cellpadding="0" border="0"> <tr> <td style="WIDTH: 68pt">&nbsp;</td> <td style="WIDTH: 40pt; VERTICAL-ALIGN: top"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: justify; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Level 1:</div></div></td> <td style="VERTICAL-ALIGN: top"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: justify; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Valuations for assets and liabilities traded in active markets from readily available pricing sources for market transactions involving identical assets or liabilities.</div></div></td> </tr> </table> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 100%; TEXT-INDENT: 0px; width: 700px;" cellspacing="0" cellpadding="0" border="0"> <tr> <td style="WIDTH: 68pt">&nbsp;</td> <td style="WIDTH: 40pt; VERTICAL-ALIGN: top"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: justify; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Level 2:</div></div></td> <td style="VERTICAL-ALIGN: top"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: justify; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Valuations for assets and liabilities traded in less active dealer or broker markets. Valuations are obtained from third-party pricing services for identical or similar assets or liabilities.</div></div></td> </tr> </table> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 100%; TEXT-INDENT: 0px; width: 700px;" cellspacing="0" cellpadding="0" border="0"> <tr> <td style="WIDTH: 68pt">&nbsp;</td> <td style="WIDTH: 40pt; VERTICAL-ALIGN: top"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: justify; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Level 3:</div></div></td> <td style="VERTICAL-ALIGN: top"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: justify; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Valuations incorporate certain assumptions and projections in determining the fair value assigned to such assets or liabilities.</div></div></td> </tr> </table> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt 0pt 0pt 36pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">In instances where the determination of the fair value measurement is based on inputs from different levels of the fair value hierarchy, the level in the fair value hierarchy within which the entire fair value measurement falls is based on the lowest level input that is significant to the fair value measurement in its entirety. The Company's assessment of the significance of a particular input to the fair value measurement in its entirety requires judgment, and considers factors specific to the asset or liability. The valuation methodologies used for the Company's financial instruments measured on a recurring basis at fair value, including the general classification of such instruments pursuant to the valuation hierarchy, is set forth in the tables below:</div><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; FONT-SIZE: 10pt; FONT-STYLE: normal; BACKGROUND-COLOR: yellow"></div></div>&nbsp;</div> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div> <div> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 95%; MARGIN-LEFT: 36pt; MARGIN-RIGHT: 5%; TEXT-INDENT: 0px; width: 700px;" cellspacing="0" cellpadding="0" border="0"> <tr> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center" colspan="6"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">As of September 30, 2016</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 1px">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: center" colspan="10"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Fair Value Measurements</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 1px">&nbsp;</td> </tr> <tr> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: center" colspan="2"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Carrying</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 0px">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: center" colspan="2"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Fair</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 0px">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center" colspan="10"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">As of September 30, 2016</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 0px">&nbsp;</td> </tr> <tr> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center" colspan="2"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Amount</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 1px">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center" colspan="2"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Value</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 1px">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center" colspan="2"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Level 1</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 1px">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center" colspan="2"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Level 2</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 1px">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center" colspan="2"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Level 3</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 1px">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 35%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">Assets:</div></div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> </tr> <tr style="BACKGROUND-COLOR: #ffffff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Cash and cash equivalents:</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; PADDING-LEFT: 9pt; BACKGROUND-COLOR: #cceeff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Cash</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">1,693 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">1,693 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">1,693 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">- </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">- </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #ffffff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; PADDING-LEFT: 9pt; BACKGROUND-COLOR: #ffffff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Money market funds</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">- </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">- </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">- </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">- </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">- </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">1,693 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">1,693 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">1,693 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">- </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">- </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #ffffff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Marketable securities:</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; BACKGROUND-COLOR: #ffffff">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; PADDING-LEFT: 9pt; BACKGROUND-COLOR: #cceeff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">U.S. Treasury securities</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">- </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">- </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">- </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">- </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">- </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #ffffff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">Liabilities:</div></div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Contingent consideration:</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #ffffff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; PADDING-LEFT: 9pt; BACKGROUND-COLOR: #ffffff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Asuragen</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">3,247 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">3,247 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">- </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">- </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">3,247 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; PADDING-LEFT: 9pt; BACKGROUND-COLOR: #cceeff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">RedPath</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">14,653 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">14,653 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">- </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">- </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">14,653 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #ffffff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; BACKGROUND-COLOR: #ffffff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">17,900 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; BACKGROUND-COLOR: #ffffff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">17,900 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; BACKGROUND-COLOR: #ffffff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">- </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; BACKGROUND-COLOR: #ffffff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">- </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; BACKGROUND-COLOR: #ffffff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">17,900 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> </tr> </table> </div> <div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> </div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt 0pt 0pt 36pt; LINE-HEIGHT: 1.25">&nbsp;</div> <div> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 95%; MARGIN-LEFT: 36pt; MARGIN-RIGHT: 5%; TEXT-INDENT: 0px; width: 700px;" cellspacing="0" cellpadding="0" border="0"> <tr> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 35%">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 14%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center" colspan="6"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">As of December 31, 2015</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 0px">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 27%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center" colspan="11"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Fair Value Measurements</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 0px">&nbsp;</td> </tr> <tr> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 35%">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: center" colspan="2"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Carrying</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 0px">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: center" colspan="2"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Fair</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 0px">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 27%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: center" colspan="11"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">As of December 31, 2015</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 0px">&nbsp;</td> </tr> <tr> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 35%">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center" colspan="2"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Amount</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center" colspan="2"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Value</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center" colspan="2"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Level 1</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center" colspan="2"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Level 2</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 0%">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center" colspan="2"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Level 3</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 35%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">Assets:</div></div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 0%; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> </tr> <tr style="BACKGROUND-COLOR: #ffffff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 35%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Cash and cash equivalents:</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 0%; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 35%; VERTICAL-ALIGN: bottom; PADDING-LEFT: 9pt; BACKGROUND-COLOR: #cceeff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Cash</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">7,534 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">7,534 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">7,534 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">- </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: right; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"></div>&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 0%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">- </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #ffffff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 35%; VERTICAL-ALIGN: bottom; PADDING-LEFT: 9pt; BACKGROUND-COLOR: #ffffff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Money market funds</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">776 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">776 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">776 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">- </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 0%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">- </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 35%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">8,310 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">8,310 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">8,310 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">- </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 0%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">- </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #ffffff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 35%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Marketable securities:</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 0%; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 35%; VERTICAL-ALIGN: bottom; PADDING-LEFT: 9pt; BACKGROUND-COLOR: #cceeff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Money market funds</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">48 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">48 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">48 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">- </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 0%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">- </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #ffffff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 35%; VERTICAL-ALIGN: bottom; PADDING-LEFT: 9pt; BACKGROUND-COLOR: #ffffff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Mutual funds</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">58 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">58 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">58 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">- </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 0%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">- </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 35%; VERTICAL-ALIGN: bottom; PADDING-LEFT: 9pt; BACKGROUND-COLOR: #cceeff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">U.S. Treasury securities</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">1,115 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">1,115 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">1,115 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">- </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 0%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">- </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #ffffff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 35%; VERTICAL-ALIGN: bottom; PADDING-LEFT: 9pt; BACKGROUND-COLOR: #ffffff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Government agency securities</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">131 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">131 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">131 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">- </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 0%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">- </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 35%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">1,352 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">1,352 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">1,352 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">- </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 0%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">- </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #ffffff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 35%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">Liabilities:</div></div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #ffffff"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #ffffff"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #ffffff"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #ffffff"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #ffffff"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #ffffff"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #ffffff"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #ffffff"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #ffffff"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #ffffff"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #ffffff"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #ffffff"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #ffffff"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 0%; BACKGROUND-COLOR: #ffffff"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #ffffff"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #ffffff"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 35%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Contingent consideration:</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 0%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #ffffff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 35%; VERTICAL-ALIGN: bottom; PADDING-LEFT: 9pt; BACKGROUND-COLOR: #ffffff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Asuragen</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">4,628 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">4,628 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">- </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">- </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 0%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">4,628 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 35%; VERTICAL-ALIGN: bottom; PADDING-LEFT: 9pt; BACKGROUND-COLOR: #cceeff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">RedPath</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">13,921 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">13,921 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">- </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">- </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 0%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">13,921 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #ffffff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 35%; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; BACKGROUND-COLOR: #ffffff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">18,549 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; BACKGROUND-COLOR: #ffffff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">18,549 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; BACKGROUND-COLOR: #ffffff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">- </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; BACKGROUND-COLOR: #ffffff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">- </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 0%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; BACKGROUND-COLOR: #ffffff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">18,549 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> </tr> </table> </div> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt 0pt 0pt 36pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">The fair value of cash and cash equivalents and marketable securities is valued using market prices in active markets (level 1). As of September 30, 2016, the Company did not have any marketable securities in less active markets (level 2) or without observable market values that would require a high level of judgment to determine fair value (level 3). </div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt 0pt 0pt 36pt; LINE-HEIGHT: 1.25">&nbsp;&nbsp;<div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"></div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt 0pt 0pt 36pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">In connection with the acquisition of certain assets from Asuragen and the acquisition of RedPath, the Company recorded contingent consideration related to contingent payments and other revenue based payments. The Company determined the fair value of the contingent consideration based on a probability-weighted income approach derived from revenue estimates. The fair value measurement is based on significant inputs not observable in the market and thus represents a Level&nbsp;3 measurement. &nbsp;A rollforward of the carrying value of the contingent consideration from continuing operations from January 1, 2016 to September 30, 2016 is as follows:</div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt 0pt 0pt 36pt; LINE-HEIGHT: 1.25">&nbsp;</div> <div> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 95%; MARGIN-RIGHT: 5%; TEXT-INDENT: 0px; width: 700px;" cellspacing="0" cellpadding="0" border="0"> <tr> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 35%; VERTICAL-ALIGN: bottom">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center" colspan="18"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">2016</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 1px">&nbsp;</td> </tr> <tr> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 35%; VERTICAL-ALIGN: bottom">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: center">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: center">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: center">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: center" colspan="2"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Adjustments</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: center">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom">&nbsp;</td> </tr> <tr> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 35%; VERTICAL-ALIGN: bottom">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center" colspan="2"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">January 1,</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 1px">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center" colspan="2"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Payments</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 1px">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center" colspan="2"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Accretion</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 1px">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center" colspan="2"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">to Fair Value</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 1px">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center" colspan="2"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">September 30,</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 1px">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 35%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Asuragen</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">4,628 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">(450</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">)</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">243 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">(1,174</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">)</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">3,247 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #ffffff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 35%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Redpath</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">13,921 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">- </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">732 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">- </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">14,653 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 35%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">18,549 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">(450</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">)</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">975 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">(1,174</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">)</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">17,900 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> </tr> </table> </div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt 0pt 0pt 36pt; LINE-HEIGHT: 1.25">&nbsp;<div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt 0pt 0pt 36pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">The Company considers carrying amounts of accounts receivable, accounts payable and accrued expenses to approximate fair value due to the short-term nature of these financial instruments.&nbsp;&nbsp;There is no fair value ascribed to the letters of credit as management does not expect any material losses to result from these instruments because performance is not expected to be required.</div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt 0pt 0pt 36pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt 0pt 0pt 36pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Certain of the Company's non-financial assets, such as other intangible assets and goodwill, are measured at fair value when there is an indicator of impairment and recorded at fair value only when an impairment charge is recognized.</div><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div></div> -1174000 -1174000 450000 450000 4628000 3247000 13921000 14653000 18549000 17900000 P2Y P9Y P9Y P7Y P9Y P2Y109D 6400000 4585000 3771000 5292000 5292000 5292000 4272000 8519000 8519000 2882000 1575000 16141000 16141000 18351000 18351000 43011000 47468000 609000 609000 37220000 43492000 2858000 2498000 7655000 8909000 <div style="display: inline; font-family: times new roman; font-size: 10pt"><table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 100%; TEXT-INDENT: 0px; width: 700px;" cellspacing="0" cellpadding="0" border="0"> <tr> <td style="WIDTH: 36pt; VERTICAL-ALIGN: top"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">4.</div><div style="display: inline; font-weight: bold;"></div></div></div></td> <td style="VERTICAL-ALIGN: top"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;"></div><div style="display: inline; font-weight: bold;">OTHER INTANGIBLE ASSETS</div></div></div></td> </tr> </table> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">&nbsp;</div></div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 36pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">The net carrying value of the identifiable intangible assets as of September 30, 2016 is as follows:&nbsp;</div></div> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div> <div> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 85%; MARGIN-LEFT: 7.5%; MARGIN-RIGHT: 7.5%; TEXT-INDENT: 0px; width: 700px;" cellspacing="0" cellpadding="0" border="0"> <tr> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; TEXT-ALIGN: center">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; PADDING-BOTTOM: 1px">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center" colspan="2"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">As of September 30, 2016</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; PADDING-BOTTOM: 1px">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left" colspan="2"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">As of December 31, 2015</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; PADDING-BOTTOM: 1px">&nbsp;</td> </tr> <tr> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: center" colspan="2"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Life</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: center" colspan="2"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Carrying</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: center" colspan="2"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Carrying</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</td> </tr> <tr> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center" colspan="2"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">(Years)</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; PADDING-BOTTOM: 1px">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center" colspan="2"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Amount</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; PADDING-BOTTOM: 1px">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center" colspan="2"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Amount</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; PADDING-BOTTOM: 1px">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 46%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">Diagnostic assets:</div></div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> </tr> <tr style="BACKGROUND-COLOR: #ffffff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Asuragen acquisition:</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BACKGROUND-COLOR: #ffffff">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; PADDING-LEFT: 9pt; BACKGROUND-COLOR: #cceeff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Thyroid</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 15%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: center; BACKGROUND-COLOR: #cceeff">9</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 15%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">8,519 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 15%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">8,519 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #ffffff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; PADDING-LEFT: 9pt; BACKGROUND-COLOR: #ffffff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Pancreas</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 15%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: center; BACKGROUND-COLOR: #ffffff">- </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 15%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">- </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 15%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">2,882 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; PADDING-LEFT: 9pt; BACKGROUND-COLOR: #cceeff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Biobank</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 15%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: center; BACKGROUND-COLOR: #cceeff">- </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 15%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">- </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 15%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">1,575 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #ffffff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">RedPath acquisition:</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; TEXT-ALIGN: center; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BACKGROUND-COLOR: #ffffff">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Pancreas test</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 15%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: center; BACKGROUND-COLOR: #cceeff">7</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 15%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">16,141 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 15%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">16,141 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #ffffff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Barrett's test</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 15%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: center; BACKGROUND-COLOR: #ffffff">9</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 15%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">18,351 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 15%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">18,351 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Total</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; PADDING-BOTTOM: 3px; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 15%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">43,011 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 15%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">47,468 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #ffffff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">Diagnostic lab:</div></div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BACKGROUND-COLOR: #ffffff"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BACKGROUND-COLOR: #ffffff"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BACKGROUND-COLOR: #ffffff"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BACKGROUND-COLOR: #ffffff"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BACKGROUND-COLOR: #ffffff"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BACKGROUND-COLOR: #ffffff"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BACKGROUND-COLOR: #ffffff"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BACKGROUND-COLOR: #ffffff"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BACKGROUND-COLOR: #ffffff"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">CLIA Lab</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 15%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: center; BACKGROUND-COLOR: #cceeff">2.3</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 15%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">609 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 15%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">609 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #ffffff"> <td style="BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="BACKGROUND-COLOR: #ffffff">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Accumulated Amortization</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 15%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">(6,400</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">)</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 15%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">(4,585</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">)</td> </tr> <tr style="BACKGROUND-COLOR: #ffffff"> <td style="BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="PADDING-BOTTOM: 1px; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; BACKGROUND-COLOR: #ffffff">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Net Carrying Value</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; PADDING-BOTTOM: 3px; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 15%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">37,220 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 15%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">43,492 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> </tr> </table> </div> <div style=" TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"></div><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt 0pt 0pt 36pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Amortization expense was approximately $1.0 million for the three-month periods ended September 30, 2016 and 2015, respectively, and $2.9 million and $2.8 million for the nine-month periods ended September 30, 2016 and 2015, respectively. Amortization of our diagnostic assets begins upon launch of the product. Estimated amortization expense for the next five years is as follows, based on current assumptions of future product launches:&nbsp;</div><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt 0pt 0pt 36pt; LINE-HEIGHT: 1.25">&nbsp;</div> <div> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 80%; MARGIN-LEFT: 10%; MARGIN-RIGHT: 10%; TEXT-INDENT: 0px; width: 700px;" cellspacing="0" cellpadding="0" border="0"> <tr> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid" colspan="2"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">2016</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; PADDING-BOTTOM: 1px">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center" colspan="2"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">2017</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; PADDING-BOTTOM: 1px">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center" colspan="2"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">2018</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; PADDING-BOTTOM: 1px">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center" colspan="2"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">2019</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; PADDING-BOTTOM: 1px">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center" colspan="2"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">2020</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; PADDING-BOTTOM: 1px">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 13%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">3,771 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 13%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">4,272 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 13%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">5,292 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 13%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">5,292 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 13%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">5,292 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> </tr> </table> </div> <div style=" MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&nbsp;</div><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"></div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt 0pt 0pt 36pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">During the quarter ended September 30, 2016 the Company recorded an asset impairment charge of approximately $3.4 million resulting from a decline in the&nbsp;market value of Pancreas and Biobank assets associated with the acquisition of certain assets from Asuragen.</div></div></div> <div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" TEXT-ALIGN: justify; MARGIN: 0pt 0pt 0pt 36pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-style: italic;">Other Intangible Assets, including Finite-Lived Intangible Assets</div></div></div><div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div><div style=" TEXT-ALIGN: justify; MARGIN: 0pt 0pt 0pt 36pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">The Company allocates the cost of acquired companies to the identifiable tangible and intangible assets acquired and liabilities assumed, with the remaining amount classified as goodwill, if any. Since the entities the Company has acquired do not have significant tangible assets, a significant portion of the purchase price has been allocated to intangible assets and goodwill. The identification and valuation of these intangible assets and the determination of the estimated useful lives at the time of acquisition, as well as the completion of impairment tests, require significant management judgments and estimates. These estimates are made based on, among other factors, consultations with an accredited independent valuation consultant, reviews of projected future operating results and business plans, economic projections, anticipated highest and best use of future cash flows and the market participant cost of capital. The use of alternative estimates and assumptions could increase or decrease the estimated fair value of other intangible assets, and potentially result in a different impact to the Company's results of operations. Further, changes in business strategy and/or market conditions may significantly impact these judgments thereby impacting the fair value of these assets, which could result in an impairment of the intangible assets.</div></div><div style=" TEXT-ALIGN: justify; MARGIN: 0pt 0pt 0pt 36pt; LINE-HEIGHT: 1.25">&nbsp;</div><div style=" TEXT-ALIGN: justify; MARGIN: 0pt 0pt 0pt 36pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Finite-lived intangible assets are stated at cost less accumulated amortization.&nbsp;&nbsp;Amortization of finite-lived acquired intangible assets is recognized on a straight-line basis, using the estimated useful lives of the assets of approximately two years to nine years in acquisition related amortization expense in the consolidated statements of comprehensive loss.</div></div><div style=" TEXT-ALIGN: justify; MARGIN: 0pt 0pt 0pt 36pt; LINE-HEIGHT: 1.25">&nbsp;</div><div style=" TEXT-ALIGN: justify; MARGIN: 0pt 0pt 0pt 36pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">The Company reviews the recoverability of long-lived assets and finite-lived intangible assets whenever events or changes in circumstances indicate that the carrying value of such assets may not be recoverable.&nbsp;&nbsp;If the sum of the expected future undiscounted cash flows is less than the carrying amount of the asset, an impairment loss is recognized by reducing the recorded value of the asset to its fair value measured by future discounted cash flows.&nbsp;&nbsp;This analysis requires estimates of the amount and timing of projected cash flows and, where applicable, judgments associated with, among other factors, the market price and physical condition of the assets at measurement date.&nbsp;&nbsp;Such estimates are critical in determining whether any impairment charge should be recorded and the amount of such charge if an impairment loss is deemed to be necessary.&nbsp;</div></div><div style=" TEXT-ALIGN: justify; MARGIN: 0pt 0pt 0pt 36pt; LINE-HEIGHT: 1.25">&nbsp;</div><div style=" TEXT-ALIGN: justify; MARGIN: 0pt 0pt 0pt 36pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">During the quarter ended September 30, 2016 the Company recorded an asset impairment charge of approximately $3.4 million, resulting from a decline in market value of Pancreas and Biobank assets associated with the acquisition of certain assets from Asuragen.</div></div></div></div></div></div></div></div></div> 1470000 707000 5097000 1652000 -7196000 -7469000 -14714000 -22569000 -7023000 -7649000 -14768000 -22999000 -0.40 -0.48 -0.82 -1.48 -297000 2574000 101000 6828000 -0.02 0.16 0.01 0.45 <div style="display: inline; font-family: times new roman; font-size: 10pt"><table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 100%; TEXT-INDENT: 0px; width: 700px;" cellspacing="0" cellpadding="0" border="0"> <tr> <td style="WIDTH: 36pt; VERTICAL-ALIGN: top"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">9.</div></div></div></td> <td style="VERTICAL-ALIGN: top"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">INCOME TAXES</div></div></div></td> </tr> </table> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt 0pt 0pt 36pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Generally, accounting standards require companies to provide for income taxes each quarter based on their estimate of the effective tax rate for the full year. The authoritative guidance for accounting for income taxes allows use of the discrete method when it provides a better estimate of income tax expense. Due to the Company's valuation allowance position, it is the Company's position that the discrete method provides a more accurate estimate of income tax expense and therefore income tax expense for the current quarter has been presented using the discrete method.&nbsp; As the year progresses, the Company refines its estimate based on the facts and circumstances by each tax jurisdiction.&nbsp; The following table summarizes income tax (benefit) expense on loss from continuing operations and the effective tax rate for the three- and nine-month periods ended September 30, 2016 and 2015:&nbsp;</div><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; FONT-SIZE: 10pt; FONT-STYLE: normal; BACKGROUND-COLOR: yellow"></div></div>&nbsp;</div> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div> <div> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 95%; MARGIN-LEFT: 36pt; MARGIN-RIGHT: 5%; TEXT-INDENT: 0px; width: 700px;" cellspacing="0" cellpadding="0" border="0"> <tr> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: center" colspan="6"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Three Months Ended </div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: center" colspan="6"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Nine Months Ended </div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</td> </tr> <tr> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center" colspan="6"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">September 30,</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; PADDING-BOTTOM: 1px">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center" colspan="6"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">September 30,</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; PADDING-BOTTOM: 1px">&nbsp;</td> </tr> <tr> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center" colspan="2"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">2016</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; PADDING-BOTTOM: 1px">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center" colspan="2"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">2015</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; PADDING-BOTTOM: 1px">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center" colspan="2"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">2016</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; PADDING-BOTTOM: 1px">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center" colspan="2"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">2015</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; PADDING-BOTTOM: 1px">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 48%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Provision (benefit) from income tax</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">173 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">(180</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">)</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">(54</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">)</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">(430</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">)</td> </tr> <tr style="BACKGROUND-COLOR: #ffffff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Effective income tax rate </div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">(2.5%</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">)</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">2.4</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">% </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">0.4</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">% </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">1.9</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">% </td> </tr> </table> </div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt 0pt 0pt 36pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"></div>&nbsp;</div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt 0pt 0pt 36pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Income tax expense and benefit for the three- and nine-month periods ended September 30, 2016 was primarily due to the reclassification of CSO as discontinued operations and the tax adjustments associated with that reclassification</div><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">. Income tax benefit for the three- and nine-month periods ended September 30, 2015 was primarily due to net operating losses, partially offset by minimum state and local taxes.</div></div></div> 173000 -180000 -54000 -430000 -761000 200000 -4639000 4257000 -4561000 -7318000 -685000 2155000 -11000 396000 -1272000 -1084000 -754000 -2137000 -563000 1534000 -16000 -702000 200000 600000 600000 200000 539000 884000 1601000 2616000 2153000 48000 48000 48000 58000 58000 58000 1115000 1115000 1115000 131000 131000 131000 1352000 1352000 1352000 300000 47443000 54674000 45964000 67712000 19870000 23373000 4685000 70000 4755000 11906000 358000 12264000 4685000 70000 4755000 11906000 358000 12264000 4615000 6178000 875000 875000 3556000 3425000 0 1200000 3000000 500000 10700000 9000000 3756000 1164000 5335000 4001000 1334000 5267000 7233000 <div style="display: inline; font-family: times new roman; font-size: 10pt"><table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 100%; TEXT-INDENT: 0px; width: 700px;" cellspacing="0" cellpadding="0" border="0"> <tr> <td style="WIDTH: 36pt; VERTICAL-ALIGN: top"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">12.</div></div></div></td> <td style="VERTICAL-ALIGN: top"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">LONG-TERM DEBT </div></div></div></td> </tr> </table> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt 0pt 0pt 36pt; LINE-HEIGHT: 1.25">&nbsp;</div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt 0pt 0pt 36pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">On October 31, 2014, the Company and Interpace LLC, entered into an agreement to acquire RedPath (the Transaction). In connection with the Transaction, the Company entered into a note with the RedPath Equityholder Representative, on behalf of the former equity holders of RedPath, dated October 31, 2014 (the Note).</div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt 0pt 0pt 36pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt 0pt 0pt 36pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">The Note is $11.0 million, interest-free and payable in eight equal consecutive quarterly installments beginning October&nbsp;1, 2016. On September 30, the Company and the RedPath Equityholder Representative amended the Note to extend the due date of the first installment to November 1, 2016. Effective October 31, 2016, the Company and the RedPath Equityholder Representative amended the Note to further extend the due date of the first installment to November 20, 2016. On November 16, 2016 the Company and the RedPath Equityholder Representative amended the Note to extend the due date of the first installment to December 31, 2016, to add as an event of default the failure of the Company to maintain a minimum net cash balance from operations of no less than $400,000, excluding proceeds from borrowed money, at the end of every week and to add a reporting requirement for the Company to provide to the RedPath Equityholder Representative, on a weekly basis, a 13-week cash flow forecast commencing November 22, 2016. Subsequent payments on the Note are to be made on the first day of each fiscal quarter, beginning on April 1, 2017. </div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt 0pt 0pt 36pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt 0pt 0pt 36pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">In the second quarter of 2015, the final working capital adjustment was made, reducing the balance of the Note to approximately $10.7 million. In December 2015, pursuant to the sale of substantially all of the CSO business, the Note was amended so that the CSO sales proceeds would not have to be applied against the Note payable balance. </div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt 0pt 0pt 36pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt 0pt 0pt 36pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">The interest rate will be 5.0% in the event of a default under the Note. The obligations of the Company under the Note are guaranteed by the Company and its subsidiaries pursuant to a Guarantee and Collateral Agreement (the &#x201c;Subordinated Guarantee&#x201d;) in favor of the RedPath Equityholder Representative. Pursuant to the Subordinated Guarantee, the Company and its subsidiaries also granted a security interest in substantially all of their assets, including intellectual property, to secure their obligations to the RedPath Equityholder Representative. Based on the Company's incremental borrowing rate under its Credit Agreement, the fair value of the Note at the date of issuance was $7.5 million. During the quarters ended September 30, 2016 and 2015, the Company accreted approximately $0.2 million into interest expense, respectively, for each period. During the nine months ended September 30, 2016 and 2015, the Company accreted approximately $0.6 million into interest expense, respectively, for each period. As of September 30, 2016, the balance of the Note is approximately $9.0 million and the unamortized discount is $1.7 million.</div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt 0pt 0pt 36pt; LINE-HEIGHT: 1.25">&nbsp;</div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt 0pt 0pt 36pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Principal payments due related to the long-term debt, subsequent to the amendment to the Note that was entered into on November 16, 2016, over the next three years are as follows:</div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt 0pt 0pt 18pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div> <div> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 80%; MARGIN-LEFT: 10%; MARGIN-RIGHT: 10%; TEXT-INDENT: 0px; width: 700px;" cellspacing="0" cellpadding="0" border="0"> <tr> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; MARGIN-LEFT: 0pt" colspan="4"> <div style=" TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">2016</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; MARGIN-LEFT: 0pt" colspan="4"> <div style=" TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">2017</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; MARGIN-LEFT: 0pt" colspan="4"> <div style=" TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">2018</div></div></td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 39.4%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Note</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff">1,334</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff">4,001</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff">5,335</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; BACKGROUND-COLOR: #cceeff">&nbsp;</td> </tr> </table> </div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt 0pt 0pt 36pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"></div><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt 0pt 0pt 36pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">The Company currently has an indemnification asset of $1.5 million relating to the DOJ settlement with the former owners of RedPath that was recorded with the acquisition of RedPath. The related DOJ liability is $1.7 million and as the Company makes payments to the DOJ, it may reduce the balance owed on the Note by the same amount. </div><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt 0pt 0pt 18pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt 0pt 0pt 36pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">In addition, the Company entered into the Credit Agreement with SWK Funding LLC (the Agent) and the lenders party thereto in connection with the Transaction in the aggregate principal amount of $20.0 million (the Loan). The maturity date of the Loan was October&nbsp;31, 2020. The Company received net proceeds of approximately $19.6 million following payment of certain fees and expenses in connection with the Credit Agreement. </div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt 0pt 0pt 36pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt 0pt 0pt 36pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Upon the sale of substantially all of the CSO business on December 22, 2015, the Company used a portion of the net proceeds from the transaction to pay the balance of the outstanding loan in the aggregate principal amount of $20.0 million, and an exit fee and expenses of approximately $1.6 million. In connection with the termination of the Credit Agreement, the Guarantee and Collateral Agreement, dated October 31, 2014, by the Company and certain of its subsidiaries in favor of the Agent was also terminated on December 22, 2015.</div><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div></div> 85000 85000 80000 170000 500000 -621236.16 300000 -37000 -583000 -6617000 -13536000 -14613000 -15741000 -7493000 -4895000 <div style="display: inline; font-family: times new roman; font-size: 10pt"><table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 100%; TEXT-INDENT: 0px; width: 700px;" cellspacing="0" cellpadding="0" border="0"> <tr> <td style="WIDTH: 36pt; VERTICAL-ALIGN: top"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">14. </div><div style="display: inline; font-weight: bold;"></div></div></div></td> <td style="VERTICAL-ALIGN: top"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;"></div><div style="display: inline; font-weight: bold;">RECENT ACCOUNTING PRONOUNCEMENTS</div></div></div></td> </tr> </table> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt 0pt 0pt 36pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">In August 2014, the Financial Accounting Standards Board (&#x201c;FASB&#x201d;) issued guidance on determining when and how to disclose going-concern uncertainties in the financial statements. The new standard requires management to perform interim and annual assessments of an entity&#x2019;s ability to continue as a going concern within one year of the date the financial statements are issued. An entity must provide certain disclosures if conditions or events raise substantial doubt about the entity&#x2019;s ability to continue as&nbsp;</div><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">a going concern. The guidance applies to all entities and is effective for annual periods ending after December 15, 2016, and interim periods thereafter, with early adoption permitted. The Company is evaluating the potential impact of the new guidance on its quarterly reporting process and its </div><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">consolidated financial position, results of operations and related disclosures.</div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt 0pt 0pt 36pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt 0pt 0pt 36pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842), which when effective will require organizations that lease assets (e.g., through &quot;leases&quot;) to recognize assets and liabilities for the rights and obligations created by the leases on the balance sheet. A lessee will be required to recognize assets and liabilities for leases with terms that exceed twelve months. The standard will also require disclosures to help investors and financial statement users better understand the amount, timing and uncertainty of cash flows arising from leases. The disclosures include qualitative and quantitative requirements, providing additional information about the amounts recorded in the financial statements. The guidance is effective for annual periods beginning after December 15, 2018, and interim periods within those annual periods. Early adoption is permitted. The Company is currently evaluating the impact of this standard on its consolidated financial position and results of operations.</div></div> <div style=" TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt 0pt 0pt 36pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">In May 2016, the FASB issued ASU 2016-12, &quot;Revenue from Contract with Customers - Narrow-Scope Improvements and Practical Expedients&quot;. In April 2016, the&nbsp;FASB issued ASU 2016-10, &quot;Revenue from Contracts with Customers - Identifying Performance Obligations and Licensing&quot;. In March 2016, the FASB issued ASU 2016-08, &quot;Revenue from Contract with Customers - Principal versus Agent Considerations (Reporting Revenue Gross versus Net)&quot;. In August 2015, the FASB issued ASU 2015-14 deferring the effective date to annual and interim periods. In May 2014, the FASB issued ASU 2014-09, &quot;Revenue from Contracts with Customers&quot;. The core principle of these ASUs are that an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. The amendments in ASU 2016-12 affect only the narrow aspects of the guidance, such as assessing the collectability criterion and accounting for contracts that do not meet the criterion, presentation of sales and other similar taxes collected from customers, non-cash consideration, and contract modifications at transition. ASU 2016-10 clarifies two aspects of the guidance: identifying performance obligations and the licensing implementation. The intention of ASU 2016-08 is to improve the operability and understandability of the implementation guidance on principal versus agent considerations. ASU 2015-14 defers the effective date to annual and interim periods beginning on or after December 15, 2017, and early adoption will be permitted, but not earlier than the original effective date of annual and interim periods beginning on or after December 15, 2016, for public entities. ASU 2014-09 is a comprehensive new revenue recognition model for revenue from contract with customers. The Company will adopt these ASUs when effective.</div></div></div> 1000000 1 7958000 7360000 18278000 21767000 -6488000 -6653000 -13181000 -20115000 <div style="display: inline; font-family: times new roman; font-size: 10pt"><table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 100%; TEXT-INDENT: 0px; width: 700px;" cellspacing="0" cellpadding="0" border="0"> <tr> <td style="WIDTH: 36pt; VERTICAL-ALIGN: top"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">1.</div></div></div></td> <td style="VERTICAL-ALIGN: top"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">BASIS OF PRESENTATION </div></div></div></td> </tr> </table> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt 0pt 0pt 36pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">The accompanying unaudited interim condensed consolidated financial statements and related notes (the interim financial statements) should be read in conjunction with the consolidated financial statements of Interpace Diagnostics Group, Inc. </div><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">(the Company or Interpace), and its wholly-owned subsidiaries, Interpace Diagnostics Corporation and Interpace Diagnostics, LLC, </div><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">and related notes as included in the Company&#x2019;s Annual Report on Form 10-K for the year ended December&nbsp;31, 2015, as filed with the U.S. Securities and Exchange Commission (SEC) on March 30, 2016, as amended on April 29, 2016 and June 14, 2016.&nbsp;&nbsp;The condensed interim financial statements of the Company have been prepared in accordance with generally accepted accounting principles in the United States (GAAP) for interim financial reporting and the instructions to Form 10-Q and Article 10 of Regulation S-X.&nbsp;&nbsp;Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements.&nbsp;&nbsp;The condensed interim financial statements include all normal recurring adjustments that, in the judgment of management, are necessary for a fair presentation of such interim financial statements.&nbsp;&nbsp;All significant intercompany balances and transactions have been eliminated in consolidation.&nbsp;&nbsp;Discontinued operations include the Company's wholly owned subsidiaries: Group DCA, LLC, or Group DCA; InServe Support Solutions (Pharmakon); and TVG, Inc. (TVG, dissolved December 31, 2014) and its Commercial Services (CSO) business unit. All significant intercompany balances and transactions have been eliminated in consolidation. </div><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Operating results for the three- and nine-month periods ended September 30, 2016 are not necessarily indicative of the results that may be expected for the year ending December&nbsp;31, 2016.</div></div></div> 1539000 1554000 46000 286000 2087000 2569000 1001000 3255000 37220000 43492000 <div style="display: inline; font-family: times new roman; font-size: 10pt"><table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 100%; TEXT-INDENT: 0px; width: 700px;" cellspacing="0" cellpadding="0" border="0"> <tr> <td style="WIDTH: 36pt; VERTICAL-ALIGN: top"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">7.</div></div></div></td> <td style="VERTICAL-ALIGN: top"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">ACCRUED EXPENSES AND LONG-TERM LIABILITIES</div></div></div></td> </tr> </table> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt 0pt 0pt 36pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Other accrued expenses consisted of the following as of September 30, 2016 and December&nbsp;31, 2015:</div><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div> <div style=" TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; FONT-SIZE: 10pt; FONT-STYLE: normal; BACKGROUND-COLOR: yellow"></div></div>&nbsp;</div> <div> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 90%; MARGIN-LEFT: 63pt; MARGIN-RIGHT: 10%; TEXT-INDENT: 0px; width: 700px;" cellspacing="0" cellpadding="0" border="0"> <tr> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right" colspan="2"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">September 30, 2016</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right" colspan="2"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">December 31, 2015</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 66%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Accrued royalties</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 14%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">504 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 14%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">111 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #ffffff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Self insurance and benefit accruals</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 14%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">272 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 14%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">366 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Indemnification liability</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 14%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">875 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 14%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">875 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #ffffff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Contingent consideration</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 14%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">209 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 14%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">659 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Rent payable</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 14%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">78 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 14%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">127 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #ffffff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">DOJ settlement </div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 14%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">665 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 14%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">250 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Accrued professional fees</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 14%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">1,320 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 14%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">775 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #ffffff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Taxes payable</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 14%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">691 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 14%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">591 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Unclaimed property</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 14%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">544 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 14%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">546 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #ffffff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Directors fees and insurance</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 14%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">208 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 14%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">107 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">All others</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 14%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">1,539 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 14%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">1,554 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #ffffff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; BACKGROUND-COLOR: #ffffff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 14%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">6,905 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; BACKGROUND-COLOR: #ffffff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 14%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">5,961 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> </tr> </table> </div> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 36pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Long-term liabilities consisted of the following as of September 30, 2016 and December&nbsp;31, 2015:</div><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div> <div style=" TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; FONT-SIZE: 10pt; FONT-STYLE: normal; BACKGROUND-COLOR: yellow"></div></div>&nbsp;</div> <div> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 90%; MARGIN-LEFT: 63pt; MARGIN-RIGHT: 10%; TEXT-INDENT: 0px; width: 700px;" cellspacing="0" cellpadding="0" border="0"> <tr> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center" colspan="2"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">September 30, 2016</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center" colspan="2"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">December 31, 2015</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 66%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Rent payable</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 14%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">- </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 14%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">52 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #ffffff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Uncertain tax positions</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 14%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">3,556 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 14%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">3,425 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">DOJ settlement (indemnified by RedPath)</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 14%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">1,000 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 14%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">2,500 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #ffffff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Other</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 14%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">59 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 14%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">201 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 14%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">4,615 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 14%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">6,178 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> </tr> </table> </div></div> 59000 201000 4000 4000 -112000 14000 -268000 666000 1048000 1600000 37000 100000 583000 0.01 0.01 5000000 5000000 0 0 0 0 0 0 <div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" TEXT-ALIGN: justify; MARGIN: 0pt 0pt 0pt 36pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-style: italic;">Reclassifications</div></div></div><div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div><div style=" TEXT-ALIGN: justify; MARGIN: 0pt 0pt 0pt 36pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">The CSO business in the three- and nine-month periods ended September 30, 2015 has been reclassified to discontinued operations to conform to the current period presentation.</div></div></div></div></div></div></div></div></div> 26800000 19600000 1060000 1460000 482000 202000 1375000 875000 1700000 700000 1000000 1700000 1000000 2500000 21600000 659000 1000000 1339000 1646000 343 -125865000 -111252000 3316000 2506000 9963000 6876000 <div style="display: inline; font-family: times new roman; font-size: 10pt"><table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 90%; MARGIN-LEFT: 63pt; MARGIN-RIGHT: 10%; TEXT-INDENT: 0px;; width: 700px;" cellspacing="0" cellpadding="0" border="0"> <tr> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right" colspan="2"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">September 30, 2016</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right" colspan="2"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">December 31, 2015</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 66%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Accrued royalties</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 14%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">504 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 14%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">111 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #ffffff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Self insurance and benefit accruals</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 14%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">272 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 14%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">366 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Indemnification liability</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 14%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">875 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 14%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">875 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #ffffff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Contingent consideration</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 14%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">209 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 14%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">659 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Rent payable</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 14%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">78 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 14%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">127 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #ffffff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">DOJ settlement </div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 14%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">665 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 14%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">250 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Accrued professional fees</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 14%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">1,320 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 14%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">775 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #ffffff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Taxes payable</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 14%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">691 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 14%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">591 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Unclaimed property</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 14%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">544 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 14%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">546 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #ffffff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Directors fees and insurance</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 14%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">208 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 14%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">107 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">All others</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 14%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">1,539 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 14%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">1,554 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #ffffff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; BACKGROUND-COLOR: #ffffff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 14%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">6,905 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; BACKGROUND-COLOR: #ffffff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 14%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">5,961 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> </tr> </table></div> <div style="display: inline; font-family: times new roman; font-size: 10pt"><table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 85%; MARGIN-LEFT: 7.5%; MARGIN-RIGHT: 7.5%; TEXT-INDENT: 0px;; width: 700px;" cellspacing="0" cellpadding="0" border="0"> <tr> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; TEXT-ALIGN: center">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; PADDING-BOTTOM: 1px">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center" colspan="2"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">As of September 30, 2016</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; PADDING-BOTTOM: 1px">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left" colspan="2"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">As of December 31, 2015</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; PADDING-BOTTOM: 1px">&nbsp;</td> </tr> <tr> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: center" colspan="2"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Life</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: center" colspan="2"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Carrying</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: center" colspan="2"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Carrying</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</td> </tr> <tr> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center" colspan="2"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">(Years)</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; PADDING-BOTTOM: 1px">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center" colspan="2"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Amount</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; PADDING-BOTTOM: 1px">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center" colspan="2"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Amount</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; PADDING-BOTTOM: 1px">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 46%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">Diagnostic assets:</div></div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> </tr> <tr style="BACKGROUND-COLOR: #ffffff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Asuragen acquisition:</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BACKGROUND-COLOR: #ffffff">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; PADDING-LEFT: 9pt; BACKGROUND-COLOR: #cceeff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Thyroid</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 15%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: center; BACKGROUND-COLOR: #cceeff">9</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 15%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">8,519 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 15%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">8,519 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #ffffff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; PADDING-LEFT: 9pt; BACKGROUND-COLOR: #ffffff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Pancreas</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 15%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: center; BACKGROUND-COLOR: #ffffff">- </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 15%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">- </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 15%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">2,882 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; PADDING-LEFT: 9pt; BACKGROUND-COLOR: #cceeff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Biobank</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 15%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: center; BACKGROUND-COLOR: #cceeff">- </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 15%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">- </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 15%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">1,575 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #ffffff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">RedPath acquisition:</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; TEXT-ALIGN: center; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BACKGROUND-COLOR: #ffffff">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Pancreas test</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 15%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: center; BACKGROUND-COLOR: #cceeff">7</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 15%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">16,141 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 15%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">16,141 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #ffffff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Barrett's test</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 15%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: center; BACKGROUND-COLOR: #ffffff">9</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 15%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">18,351 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 15%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">18,351 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Total</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; PADDING-BOTTOM: 3px; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 15%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">43,011 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 15%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">47,468 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #ffffff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">Diagnostic lab:</div></div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BACKGROUND-COLOR: #ffffff"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BACKGROUND-COLOR: #ffffff"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BACKGROUND-COLOR: #ffffff"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BACKGROUND-COLOR: #ffffff"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BACKGROUND-COLOR: #ffffff"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BACKGROUND-COLOR: #ffffff"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BACKGROUND-COLOR: #ffffff"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BACKGROUND-COLOR: #ffffff"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BACKGROUND-COLOR: #ffffff"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">CLIA Lab</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 15%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: center; BACKGROUND-COLOR: #cceeff">2.3</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 15%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">609 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 15%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">609 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #ffffff"> <td style="BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="BACKGROUND-COLOR: #ffffff">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Accumulated Amortization</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 15%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">(6,400</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">)</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 15%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">(4,585</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">)</td> </tr> <tr style="BACKGROUND-COLOR: #ffffff"> <td style="BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="PADDING-BOTTOM: 1px; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; BACKGROUND-COLOR: #ffffff">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Net Carrying Value</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; PADDING-BOTTOM: 3px; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 15%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">37,220 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 15%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">43,492 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> </tr> </table></div> <div style="display: inline; font-family: times new roman; font-size: 10pt"><table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 90%; MARGIN-LEFT: 36pt; MARGIN-RIGHT: 10%; TEXT-INDENT: 0px;; width: 700px;" cellspacing="0" cellpadding="0" border="0"> <tr> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 44%">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 15%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: center" colspan="6"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Three Months Ended</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 15%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: center" colspan="6"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Nine Months Ended</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%">&nbsp;</td> </tr> <tr> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 44%">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 15%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center" colspan="6"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">September 30,</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 15%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center" colspan="6"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">September 30,</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px">&nbsp;</td> </tr> <tr> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 44%">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center" colspan="2"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">2016</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center" colspan="2"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">2015</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center" colspan="2"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">2016</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center" colspan="2"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">2015</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 44%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Options</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">- </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">- </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">- </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">- </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #ffffff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 44%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Stock-settled stock appreciation rights (SARs)</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">1,027 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">1,028 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">1,027 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">1,028 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 44%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Restricted stock and restricted stock units (RSUs)</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">1,151 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">1,745 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">1,151 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">1,745 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #ffffff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 44%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Performance contingent SARs</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 11%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">- </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 11%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">188 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 11%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">- </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 11%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">188 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 44%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 11%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">2,178 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 11%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">2,961 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 11%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">2,178 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 11%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">2,961 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> </tr> </table></div> <div style="display: inline; font-family: times new roman; font-size: 10pt"><table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 90%; MARGIN-LEFT: 36pt; MARGIN-RIGHT: 10%; TEXT-INDENT: 0px;; width: 700px;" cellspacing="0" cellpadding="0" border="0"> <tr> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: center" colspan="6"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">Nine Months Ended</div></div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> </tr> <tr> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center" colspan="6"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">September 30,</div></div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> </tr> <tr> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center" colspan="2"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">2016</div></div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center" colspan="2"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">2015</div></div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 66%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Net cash (used in) provided by operating activities of discontinued operations</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 14%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">(1,486</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">)</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 14%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">7,466 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #ffffff"> <td style="BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="BACKGROUND-COLOR: #ffffff">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Net cash (used in) provided by investing activities of discontinued operations</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 14%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">- </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 14%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">- </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> </tr> </table></div> <div style="display: inline; font-family: times new roman; font-size: 10pt"><table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 80%; MARGIN-LEFT: 10%; MARGIN-RIGHT: 10%; TEXT-INDENT: 0px;; width: 700px;" cellspacing="0" cellpadding="0" border="0"> <tr> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; MARGIN-LEFT: 0pt" colspan="4"> <div style=" TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">2016</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; MARGIN-LEFT: 0pt" colspan="4"> <div style=" TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">2017</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; MARGIN-LEFT: 0pt" colspan="4"> <div style=" TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">2018</div></div></td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 39.4%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Note</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff">1,334</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff">4,001</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff">5,335</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; BACKGROUND-COLOR: #cceeff">&nbsp;</td> </tr> </table></div> <div style="display: inline; font-family: times new roman; font-size: 10pt"><table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 95%; MARGIN-LEFT: 36pt; MARGIN-RIGHT: 5%; TEXT-INDENT: 0px;; width: 700px;" cellspacing="0" cellpadding="0" border="0"> <tr> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: center" colspan="6"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Three Months Ended </div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: center" colspan="6"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Nine Months Ended </div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</td> </tr> <tr> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center" colspan="6"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">September 30,</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; PADDING-BOTTOM: 1px">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center" colspan="6"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">September 30,</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; PADDING-BOTTOM: 1px">&nbsp;</td> </tr> <tr> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center" colspan="2"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">2016</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; PADDING-BOTTOM: 1px">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center" colspan="2"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">2015</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; PADDING-BOTTOM: 1px">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center" colspan="2"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">2016</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; PADDING-BOTTOM: 1px">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center" colspan="2"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">2015</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; PADDING-BOTTOM: 1px">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 48%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Provision (benefit) from income tax</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">173 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">(180</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">)</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">(54</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">)</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">(430</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">)</td> </tr> <tr style="BACKGROUND-COLOR: #ffffff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Effective income tax rate </div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">(2.5%</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">)</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">2.4</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">% </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">0.4</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">% </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">1.9</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">% </td> </tr> </table></div> <div style="display: inline; font-family: times new roman; font-size: 10pt"><table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 90%; MARGIN-LEFT: 63pt; MARGIN-RIGHT: 10%; TEXT-INDENT: 0px;; width: 700px;" cellspacing="0" cellpadding="0" border="0"> <tr> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center" colspan="2"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">September 30, 2016</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center" colspan="2"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">December 31, 2015</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 66%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Rent payable</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 14%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">- </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 14%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">52 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #ffffff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Uncertain tax positions</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 14%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">3,556 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 14%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">3,425 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">DOJ settlement (indemnified by RedPath)</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 14%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">1,000 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 14%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">2,500 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #ffffff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Other</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 14%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">59 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 14%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">201 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 14%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">4,615 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 14%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">6,178 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> </tr> </table></div> <div style="display: inline; font-family: times new roman; font-size: 10pt"><table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 80%; MARGIN-LEFT: 10%; MARGIN-RIGHT: 10%; TEXT-INDENT: 0px;; width: 700px;" cellspacing="0" cellpadding="0" border="0"> <tr> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center" colspan="2"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">September 30, 2016</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; PADDING-BOTTOM: 1px">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center" colspan="2"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">December 31, 2015</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; PADDING-BOTTOM: 1px">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 62%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Indemnification assets</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">1,375 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">875 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #ffffff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Letters of credit</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">- </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">360 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Other receivables</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">666 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 0px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">1,048 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 0px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #ffffff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Other</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">46 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">286 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">2,087 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">2,569 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> </tr> </table></div> <div style="display: inline; font-family: times new roman; font-size: 10pt"><table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 80%; MARGIN-LEFT: 126pt; MARGIN-RIGHT: 20%; TEXT-INDENT: 0px;; width: 700px;" cellspacing="0" cellpadding="0" border="0"> <tr> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: center" colspan="6"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Nine Months Ended</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</td> </tr> <tr> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center" colspan="6"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">September 30,</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px">&nbsp;</td> </tr> <tr> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center" colspan="2"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">2016</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center" colspan="2"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">2015</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px">&nbsp;</td> </tr> <tr> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 62%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Risk-free interest rate</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">- </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">1.02</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">%</td> </tr> <tr> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Expected life (years)</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">- </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: center; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="TEXT-ALIGN: right">3.5</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BACKGROUND-COLOR: #ffffff">&nbsp;</td> </tr> <tr> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Expected volatility</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">- </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">54.47</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">%</td> </tr> <tr> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Dividend yield</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">- </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">- </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> </tr> </table></div> <div style="display: inline; font-family: times new roman; font-size: 10pt"><table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 95%; MARGIN-LEFT: 36pt; MARGIN-RIGHT: 5%; TEXT-INDENT: 0px;; width: 700px;" cellspacing="0" cellpadding="0" border="0"> <tr> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: center" colspan="6"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Three Months Ended</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: center" colspan="6"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Nine Months Ended</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</td> </tr> <tr> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center" colspan="6"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">September 30,</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center" colspan="6"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">September 30,</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px">&nbsp;</td> </tr> <tr> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center" colspan="2"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">2016</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center" colspan="2"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">2015</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center" colspan="2"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">2016</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center" colspan="2"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">2015</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; PADDING-LEFT: 9pt; BACKGROUND-COLOR: #cceeff; TEXT-INDENT: -9pt"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Basic weighted average number of&nbsp; of common shares</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">18,163 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">15,654 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">18,029 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">15,301 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #ffffff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Potential dilutive effect of stock-based awards</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">- </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">- </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">- </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">- </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; PADDING-LEFT: 9pt; BACKGROUND-COLOR: #cceeff; TEXT-INDENT: -9pt"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Diluted weighted average number of common shares</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">18,163 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">15,654 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">18,029 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">15,301 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> </tr> </table></div> <div style="display: inline; font-family: times new roman; font-size: 10pt"><table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 80%; MARGIN-LEFT: 10%; MARGIN-RIGHT: 10%; TEXT-INDENT: 0px;; width: 700px;" cellspacing="0" cellpadding="0" border="0"> <tr> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid" colspan="2"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">2016</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; PADDING-BOTTOM: 1px">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center" colspan="2"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">2017</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; PADDING-BOTTOM: 1px">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center" colspan="2"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">2018</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; PADDING-BOTTOM: 1px">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center" colspan="2"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">2019</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; PADDING-BOTTOM: 1px">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center" colspan="2"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">2020</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; PADDING-BOTTOM: 1px">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 13%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">3,771 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 13%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">4,272 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 13%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">5,292 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 13%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">5,292 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 13%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">5,292 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> </tr> </table></div> <div style="display: inline; font-family: times new roman; font-size: 10pt"><table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 100%; TEXT-INDENT: 0px; width: 700px;" cellspacing="0" cellpadding="0" border="0"> <tr> <td style="WIDTH: 36pt; VERTICAL-ALIGN: top"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">10.</div></div></div></td> <td style="VERTICAL-ALIGN: top"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">SEGMENT INFORMATION</div></div></div></td> </tr> </table> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt 0pt 0pt 36pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Effective December&nbsp;31, 2015, the Company has one reporting segment: the Company's molecular diagnostics business, after the divestiture of its CSO business on December 22, 2015. The Company realigned its reporting segments due to the integration of RedPath and acquiring certain assets from Asuragen, to reflect the Company's current and going forward business strategy. The Company's current reporting segment structure is reflective of the way the Company's management views the business, makes operating decisions and assesses performance. This structure allows investors to better understand Company performance, better assess prospects for future cash flows, and make more informed decisions about the Company.</div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt 0pt 0pt 36pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt 0pt 0pt 36pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">The Company's molecular diagnostics business&nbsp;focuses on developing and commercializing molecular diagnostic tests, leveraging the latest technology and personalized medicine for better patient diagnosis and management. Through the Company's molecular diagnostics business, the Company aims to provide physicians and patients with diagnostic options for detecting genetic and other molecular alterations that are associated with gastrointestinal and endocrine cancers, which are principally focused on early detection of high potential progressors to cancer. Customers in the Company's molecular diagnostics segment consist primarily of physicians, hospitals and clinics. The service offerings throughout the segment have similar long-term average gross margins, contract terms, types of customers and regulatory environments. They are promoted through one centrally managed marketing group and the chief operating decision maker views their results on a combined basis.</div></div></div> 272000 366000 1282000 2876000 4186000 8387000 665000 250000 3700000 1100000 500000 3100000 2300000 800000 109000 1517000 P3Y P3Y P1Y 1300000 0.25 0 0.5447 0.0102 2450000 878744 0.16 0.3333 0.3333 P5Y P3Y182D 106000 6100000 6800000 -1479000 13038000 <div style="display: inline; font-family: times new roman; font-size: 10pt"><table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 100%; TEXT-INDENT: 0px; width: 700px;" cellspacing="0" cellpadding="0" border="0"> <tr> <td style="WIDTH: 36pt; VERTICAL-ALIGN: top"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">15.</div><div style="display: inline; font-weight: bold;"></div></div></div></td> <td style="VERTICAL-ALIGN: top"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;"></div><div style="display: inline; font-weight: bold;">OTHER SUBSEQUENT EVENTS</div></div></div></td> </tr> </table> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt 0pt 0pt 36pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">On October 4, 2016, Heinrich Dreismann, Ph.D., resigned as a member of the Board effective as of September 30, 2016. In connection with Dr. Dreismann&#x2019;s resignation and to comply with Nasdaq Listing Rule 5605(c)(4)(B), on October 5, 2016, the Company notified NASDAQ that, as a result of the vacancy on the Audit Committee of the Board (the &#x201c;Audit Committee&#x201d;) created by Dr. Dreismann&#x2019;s resignation, the Audit Committee only has two members and the Company is not in compliance with Nasdaq Listing Rule 5605(c)(2)(A), which requires the Audit Committee be comprised of at least three members. In response to the Company&#x2019;s notice, NASDAQ issued a letter to the Company on October 6, 2016 acknowledging the Company&#x2019;s notice that it is no longer in compliance with the audit committee requirements set forth in Nasdaq Listing Rule 5605(c)(2)(A). In its letter, NASDAQ notified the Company that it can rely on the cure period provided by Nasdaq Listing Rule 5605(c)(4), which allows the Company until the earlier of (i) its next annual meeting of stockholders or (ii) October 2, 2017 to regain compliance, or, if the next annual meeting of stockholders is held before March 29, 2017, then the Company must evidence compliance no later than March 29, 2017. The Company intends to appoint an additional independent director to the Board and to the Audit Committee prior to the end of the cure period.</div></div></div> <div style="display: inline; font-family: times new roman; font-size: 10pt"><table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 100%; TEXT-INDENT: 0px; width: 700px;" cellspacing="0" cellpadding="0" border="0"> <tr> <td style="WIDTH: 36pt; VERTICAL-ALIGN: top"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">2.</div><div style="display: inline; font-weight: bold;"></div></div></div></td> <td style="VERTICAL-ALIGN: top"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;"></div><div style="display: inline; font-weight: bold;">LIQUIDITY AND MANAGEMENT'S PLANS </div></div></div></td> </tr> </table> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"></div>&nbsp;&nbsp;</div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt 0pt 0pt 36pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">For the nine months ended September 30, 2016, the Company incurred a net loss of $14.6 million and cash used in operating activities was $6.6 million. &nbsp;The Company did not raise any capital or incur any funded debt during the first nine months of 2016, but it did enter into a Credit Agreement with SCM Specialty Finance Opportunities Fund, L.P. on September 28, 2016 as described further below, on which it has not yet drawn. The Company also anticipates operating losses to continue for the foreseeable future due to, among other things, costs related to its commercial operations, developing products and product candidates, right sizing and reorganizing its administrative organization and winding down activities and managing obligations related to its discontinued operations. </div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt 0pt 0pt 36pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt 0pt 0pt 36pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">The accompanying condensed, consolidated financial statements have been prepared on a basis that assumes that the Company will continue as a going concern and that contemplates the continuity of operations, the realization of assets and the satisfaction of liabilities and commitments in the normal course of business. As of September 30, 2016, the Company had cash and cash equivalents of $1.7 million, net accounts receivable of $2.8 million, current assets of $6.7 million and current liabilities of $19.9 million. </div></div> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"></div>&nbsp;</div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt 0pt 0pt 36pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">As a result of the sale of substantially all of its CSO business in December 2015, which generated net cash proceeds of $26.8 million (of which $21.6 million was used to repay long-term debt and fees), the Company focused its resources and strategic initiatives on its molecular diagnostics business. As with many companies in a similar stage, sufficient capital is required before achieving profitability. Accordingly, the Company may require additional capital in 2016 and will require additional capital in 2017 and beyond. In order to obtain such capital and fund its operations, the Company may be required to restructure all or a portion of its obligations related to the sale of its CSO business as well as obligations owed to the former equity holders of RedPath Integrated Pathology, Inc.(&#x201c;RedPath&#x201d;) arising out of the Company&#x2019;s acquisition of RedPath. The first payment of secured debt to RedPath Equityholder Representative, LLC (the &#x201c;RedPath Equityholder Representative&#x201d;), as representative of the former equity holders of RedPath, has been extended several times from its original due date of October 1, 2016 and is now due December 31, 2016 unless further extended. There is no guarantee that additional capital will or can be raised or that adequate restructuring will be accomplished that are sufficient to fund the Company's operations for the rest of 2016 and beyond or that the terms of such additional capital, if available, will be acceptable to the Company. Accordingly, the Company continues to explore sales of assets and various dilutive and non-dilutive sources of funding, including equity and debt financings, strategic alliances and alternatives, business development, and other alternatives. Additionally, the Company continues to focus on increasing sales of its commercial molecular diagnostic tests, closely managing cash and further streamlining operations. If, however, the Company is unsuccessful in obtaining capital and executing its plans for the business to continue operations, when needed, including the restructuring of its debt and other liabilities, then it may be forced to sell off assets, seek protection under the U.S. Bankruptcy Code, or be forced into liquidation or substantially alter or restructure its business operations. In the event of a default on its secured note, the RedPath Equityholder Representative could foreclose on the Company&#x2019;s assets, force the Company into bankruptcy or pursue other remedies. In such events, stockholders may not be able to recoup their investment. These factors, among others, raise substantial doubt about the Company&#x2019;s ability to continue as a going concern.</div></div> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div>&nbsp;</div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt 0pt 0pt 36pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">During the first nine months of 2016, the Company commenced negotiations with certain of its creditors and former sales representatives and executives to restructure its current and long-term obligations related to the sale of the majority of its CSO business in December 2015. The proposed restructuring by the Company includes reducing or extending the term of certain of its obligations, converting a portion to equity and/or forgiving portions thereof. However, any such restructuring may be dependent on the Company raising additional capital. The Company believes that this proposed restructuring, if achieved, will not only improve its liquidity but also provide the flexibility for future funding. No assurance, however, can be given that the negotiations to restructure the Company&#x2019;s debt and obligations will be successful. </div></div> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"></div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt 0pt 0pt 36pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">At September 30, 2016, the Company had the following debt obligations that it has been seeking to restructure:</div></div> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"></div>&nbsp;</div> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 100%; TEXT-INDENT: 0px; width: 700px;" cellspacing="0" cellpadding="0" border="0"> <tr> <td style="WIDTH: 54pt">&nbsp;</td> <td style="WIDTH: 18pt; VERTICAL-ALIGN: top"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: justify; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">1.</div></div></td> <td style="VERTICAL-ALIGN: top"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: justify; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Future payments and conditions related to the $10.7 million secured note payable to the former equity holders of RedPath.</div></div></td> </tr> </table> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 100%; TEXT-INDENT: 0px; width: 700px;" cellspacing="0" cellpadding="0" border="0"> <tr> <td style="WIDTH: 54pt">&nbsp;</td> <td style="WIDTH: 18pt; VERTICAL-ALIGN: top"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: justify; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">2.</div></div></td> <td style="VERTICAL-ALIGN: top"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: justify; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Severance obligations to former executives ($3.1 million, including taxes).</div></div></td> </tr> </table> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 100%; TEXT-INDENT: 0px; width: 700px;" cellspacing="0" cellpadding="0" border="0"> <tr> <td style="WIDTH: 54pt">&nbsp;</td> <td style="WIDTH: 18pt; VERTICAL-ALIGN: top"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">3.</div></div></td> <td style="VERTICAL-ALIGN: top"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Obligations due to former sales representatives under the CSO incentive plan (up to $1 million including taxes). To date, 343 former sales representatives have accepted the Company&#x2019;s offer to pay out approximately $0.6 million in equal installments over eight months. For the period ended September 30, 2016 approximately $0.1 million was paid out under this plan.</div></div></td> </tr> </table> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt 0pt 0pt 72pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"></div>&nbsp;&nbsp;</div> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 100%; TEXT-INDENT: 0px; width: 700px;" cellspacing="0" cellpadding="0" border="0"> <tr> <td style="WIDTH: 54pt"> <div style=" MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div></td> <td style="WIDTH: 18pt; VERTICAL-ALIGN: top"> <div style=""><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">4.</div></div></td> <td style="MARGIN-BOTTOM: 0px; VERTICAL-ALIGN: top; MARGIN-TOP: 0px"> <div style=" MARGIN-BOTTOM: 0px; TEXT-ALIGN: justify; MARGIN-TOP: 0px"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Various liabilities including trade payables, other employee severance in accrued expenses and certain liabilities from Discontinued Operations which are in the process of being renegotiated or restructured.</div></div></td> </tr> </table> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt 0pt 0pt 72pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"></div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt 0pt 0pt 36pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">There is, however, no guarantee that the Company will be successful in restructuring its outstanding debt.</div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt 0pt 0pt 36pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"></div>&nbsp;</div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt 0pt 0pt 36pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">A summary of the Company&#x2019;s most significant contractual obligations over the next 12 months are as follows:</div></div> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div>&nbsp;</div> <div> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 95%; MARGIN-LEFT: 36pt; MARGIN-RIGHT: 5%; TEXT-INDENT: 0px; width: 700px;" cellspacing="0" cellpadding="0" border="0"> <tr> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center" colspan="2"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Total</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center" colspan="2"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">0 to 3 </div></div> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">months</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center" colspan="2"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">3 to 6 </div></div> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">months</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center" colspan="2"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">6 to 12 </div></div> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">months</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 48%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Note due Redpath Equityholders</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">4,001 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">1,334 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">-&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">2,667 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #ffffff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Severance obligations</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">3,137 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">3,137 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">- </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">- </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">DOJ settlement</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">665 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">85 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">85 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">495 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #ffffff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Deferred Bonus - ERT salesforce</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">800 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">185 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">308 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">307 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; PADDING-LEFT: 9pt; BACKGROUND-COLOR: #cceeff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Total obligations</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">8,603 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">4,741 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">393</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">3,469 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> </tr> </table> </div> <div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <div style=" TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; font-weight: bold;"></div>&nbsp;</div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt 0pt 0pt 36pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">On September 28, 2016 (the &#x201c;Closing Date&#x201d;), the Company and its wholly-owned direct and indirect subsidiaries, Interpace Diagnostics, LLC (&#x201c;Interpace LLC&#x201d;) and Interpace Diagnostics Corporation (&#x201c;IDC&#x201d; and together with Interpace LLC, its &#x201c;Subsidiaries&#x201d;), entered into a Credit Agreement (the &#x201c;Credit Agreement&#x201d;) with SCM Specialty Finance Opportunities Fund, L.P. (the &#x201c;Lender&#x201d;). Pursuant to and subject to the terms of the Credit Agreement, the Lender agreed to provide a revolving loan (the &#x201c;Loan&#x201d;) to the Company in the maximum principal amount of $1.2 million (&#x201c;Facility Cap&#x201d;). Also on the Closing Date, the Company and its Subsidiaries acknowledged and agreed to an Intercreditor Agreement (the &#x201c;Intercreditor Agreement&#x201d;) by and between the Lender and the RedPath Equityholder Representative pursuant to which the Lender has a first lien security interest on all of the accounts receivable (and related intangibles) of the Company and its Subsidiaries and the RedPath Equityholder Representative has a second lien security interest, subordinated to the Lender, on all the accounts receivables (and related intangibles) of the Company and its Subsidiaries. In addition, pursuant to the Intercreditor Agreement, the RedPath Equityholder Representative has a first lien security interest on all other assets of the Company and its Subsidiaries and the Lender has no lien with respect to such other assets. The maturity date of the Loan is September 28, 2018. The Loan bears interest at an annual rate equal to the Prime Rate (as defined in the Credit Agreement) plus 2.75%, payable in cash monthly in arrears. The interest rate will be increased by 5.0% in the event of a default under the Credit Agreement. Events of default under the Credit Agreement, some of which are subject to certain cure periods, include a failure to pay or perform obligations when due, the making of a material misrepresentation to the Lender, the rendering of certain judgments or decrees against the Company and its Subsidiaries and the initiation, voluntarily or involuntarily, of a bankruptcy or similar proceeding against the Company or its Subsidiaries.</div><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt 0pt 0pt 36pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">The Company agreed to pay certain out-of-pocket costs and expenses incurred by the Lender in connection with the Credit Agreement and related documents, the administration of the Loan and related documents and the enforcement or protection of the Lender&#x2019;s rights. The Lender is also entitled to: (a) a $12,000 origination fee; (b) a monthly unused line fee equal to the amount which is one-twelfth of one percent (0.083%) of the difference between (i) the outstanding balance of the Loan during the preceding month, and (ii) the Facility Cap on the date of determination; (c) a monthly collateral management fee equal to one-sixth of one percent (0.1666%) of the average daily balance under the Credit Agreement outstanding during the preceding month; and (d) a termination fee equal to (i) two percent (2%) of the Facility Cap if the Credit Agreement is terminated before the first anniversary of the Closing Date (the &#x201c;First Anniversary&#x201d;), or (ii) one percent (1%) of the Facility Cap if the Credit Agreement is terminated after the First Anniversary. The Company must also pay certain fees in the event that (a) the amount outstanding under the Credit Agreement exceeds the availability under the Credit Agreement&#x2019;s borrowing base, and (b) receivables are not properly deposited in the appropriate lockbox account.</div></div> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt 0pt 0pt 36pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">The Credit Agreement contains customary representations and warranties in favor of the Lender and certain covenants, including, among other things, financial covenants relating to loan turnover rates, liquidity and revenue targets.&nbsp;</div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt 0pt 0pt 36pt; LINE-HEIGHT: 1.25">&nbsp;</div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt 0pt 0pt 36pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">As of November 17, 2016, the Company had not borrowed any funds under the Credit Agreement. </div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt 0pt 0pt 36pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt 0pt 0pt 36pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">On September 30, 2016, the Company, Interpace LLC, and the RedPath Equityholder Representative entered into an amendment to the $10.7 million interest free secured note payable to the former equity holders of RedPath to extend by one month, until November 1, 2016, subject to the terms of the amendment, the due date for the first quarterly payment of principal under the note. Effective October 31, 2016 the Company, Interpace LLC, and the RedPath Equityholder Representative entered into a fourth amendment to the note to extend until November 20, 2016, subject to the terms of the amendment, the due date for the first quarterly payment of principal. On November 16, 2016 the Company, Interpace LLC, and the RedPath Equityholder Representative entered into a fifth amendment to the note to extend until December 31, 2016, subject to the terms of the amendment, the due date for the first quarterly payment of principal under the note. In addition, the fifth amendment also amends the note to add as an event of default the failure of the Company to maintain a minimum net cash balance from operations of no less than $400,000, excluding proceeds from borrowed money, at the end of every week. The fifth amendment also contains a reporting requirement for the Company to provide to the RedPath Equityholder Representative, on a weekly basis, a 13-week cash flow forecast commencing November 22, 2016.</div></div> <div style=" MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px; LINE-HEIGHT: 1.25">&nbsp;</div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt 0pt 0pt 36pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Under the note, the Company is required to make eight installment payments of principal, with each payment equal to $1,333,750, together with accrued and unpaid interest, if any. The first quarterly payment of principal under the note originally was due on October 1, 2016 and the first payment is now due on December 31, 2016. Subsequent payments are to be made on the first day of each fiscal quarter, beginning on April 1, 2017. </div></div> <div style=" MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px; LINE-HEIGHT: 1.25">&nbsp;</div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt 0pt 0pt 36pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">The Company currently has no means to make the first quarterly payment of principal due on December 31, 2016, and if the due date for the first quarterly payment of principal is not extended by the RedPath Equityholder Representative or other equity or debt capital is not raised, the RedPath Equityholder Representative could foreclose on the Company&#x2019;s assets, force the Company into bankruptcy or pursue other remedies. Accordingly, the Company continues to explore sales of assets and various dilutive and non-dilutive sources of funding, including equity and debt financings, strategic alliances and alternatives, business development, and other alternatives. </div></div></div> 691000 591000 <div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" TEXT-ALIGN: justify; MARGIN: 0pt 0pt 0pt 36pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-style: italic;">Receivables and Allowance for Doubtful Accounts </div></div></div><div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div><div style=" TEXT-ALIGN: justify; MARGIN: 0pt 0pt 0pt 36pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">The Company&#x2019;s accounts receivable are generated using its proprietary tests. The Company&#x2019;s services are fulfilled upon completion of the test, review and release of the test results. In conjunction with fulfilling these services, the Company bills the third-party payor or hospital. The Company recognizes accounts receivable related to billings for Medicare, Medicare Advantage, and hospitals on an accrual basis, net of contractual adjustment, when collectability is reasonably assured. Contractual adjustments represent the difference between the list prices and the reimbursement rate set by Medicare and Medicare Advantage, or the amounts billed to hospitals. The Company records an Allowance for Doubtful accounts for PancraGen&reg; hospital roster billings based on the collection history of this payor. Since Medicare and Medicare Advantage have fixed reimbursement rates, there is no Allowance for Doubtful Accounts associated with these payors.</div></div><div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div><div style=" TEXT-ALIGN: justify; MARGIN: 0pt 0pt 0pt 36pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">The Company provides services to commercial insurance carriers or governmental programs that do not have a contract in place for its proprietary tests which may or may not be covered by these entities existing reimbursement policies. In addition, the Company does not enter into direct agreements with patients that commit them to pay any portion of the cost of the tests in the event that their commercial insurance carrier or governmental program does not pay the Company for its services. In the absence of an agreement with the patient, or other clearly enforceable legal right to demand payment from commercial insurance carriers or governmental agencies, no accounts receivable is recognized. The Company does not record an Allowance for Doubtful Accounts for the commercial insurance or governmental programs since the revenue is recorded mainly on a cash basis. There was approximately a $1.3 million allowance for doubtful accounts as of September 30, 2016.</div></div></div></div></div></div></div></div></div> 3296000 3296000 542543 1042543 1643000 8432000 <div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" TEXT-ALIGN: justify; MARGIN: 0pt 0pt 0pt 36pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-style: italic;">Accounting Estimates</div></div></div><div style=" TEXT-ALIGN: justify; MARGIN: 0pt 0pt 0pt 36pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div><div style=" TEXT-ALIGN: justify; MARGIN: 0pt 0pt 0pt 36pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts of assets and liabilities reported and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period.&nbsp;&nbsp;Management's estimates are based on historical experience, facts and circumstances available at the time, and various other assumptions that are believed to be reasonable under the circumstances.&nbsp;&nbsp;Significant estimates include best estimate of selling price in multiple element arrangements, valuation allowances related to deferred income taxes, self-insurance loss accruals, allowances for doubtful accounts and notes, income tax accruals, acquisition accounting, asset impairments and facilities realignment accruals. &nbsp;The Company periodically reviews these matters and reflects changes in estimates as appropriate.&nbsp;&nbsp;Actual results could materially differ from those estimates.</div></div></div></div></div></div></div></div></div> 18163000 15654000 18029000 15301000 18163000 15654000 18029000 15301000 xbrli:shares xbrli:pure iso4217:USD iso4217:USD xbrli:shares 0001054102 2014-10-31 2014-10-31 0001054102 idxg:RedpathIntegratedPathologyIncMember idxg:TheNoteMember us-gaap:NotesPayableOtherPayablesMember 2014-10-31 2014-10-31 0001054102 idxg:RedpathIntegratedPathologyIncMember us-gaap:LoansPayableMember 2014-10-31 2014-10-31 0001054102 2015-01-01 2015-09-30 0001054102 us-gaap:EmployeeStockOptionMember 2015-01-01 2015-09-30 0001054102 us-gaap:PerformanceSharesMember 2015-01-01 2015-09-30 0001054102 us-gaap:RestrictedStockUnitsRSUMember 2015-01-01 2015-09-30 0001054102 us-gaap:StockAppreciationRightsSARSMember 2015-01-01 2015-09-30 0001054102 idxg:RedpathIntegratedPathologyIncMember idxg:TheNoteMember us-gaap:NotesPayableOtherPayablesMember 2015-01-01 2015-09-30 0001054102 2015-01-01 2015-12-31 0001054102 idxg:RsusAndRestrictedStockMember 2015-01-01 2015-12-31 0001054102 idxg:RsusAndRestrictedStockMember us-gaap:DirectorMember 2015-01-01 2015-12-31 0001054102 us-gaap:StockAppreciationRightsSARSMember 2015-01-01 2015-12-31 0001054102 idxg:CompanysCounterclaimAgainstProliasMember 2015-06-03 2015-06-03 0001054102 2015-06-16 2015-06-16 0001054102 2015-07-01 2015-09-30 0001054102 us-gaap:EmployeeStockOptionMember 2015-07-01 2015-09-30 0001054102 us-gaap:PerformanceSharesMember 2015-07-01 2015-09-30 0001054102 us-gaap:RestrictedStockUnitsRSUMember 2015-07-01 2015-09-30 0001054102 us-gaap:StockAppreciationRightsSARSMember 2015-07-01 2015-09-30 0001054102 idxg:RedpathIntegratedPathologyIncMember idxg:TheNoteMember us-gaap:NotesPayableOtherPayablesMember 2015-07-01 2015-09-30 0001054102 2015-12-01 2015-12-31 0001054102 idxg:CSOMember 2015-12-01 2015-12-31 0001054102 2015-12-22 2015-12-22 0001054102 2016-01-01 2016-03-31 0001054102 us-gaap:SegmentContinuingOperationsMember 2016-01-01 2016-03-31 0001054102 2016-01-01 2016-09-30 0001054102 us-gaap:EmployeeStockOptionMember 2016-01-01 2016-09-30 0001054102 us-gaap:PerformanceSharesMember 2016-01-01 2016-09-30 0001054102 us-gaap:RestrictedStockUnitsRSUMember 2016-01-01 2016-09-30 0001054102 us-gaap:StockAppreciationRightsSARSMember 2016-01-01 2016-09-30 0001054102 idxg:AsuragenMember idxg:ContingentConsiderationMember 2016-01-01 2016-09-30 0001054102 idxg:AsuragenMember idxg:DiagnosticTestBiobankMember 2016-01-01 2016-09-30 0001054102 idxg:AsuragenMember idxg:DiagnosticTestPancreasMember 2016-01-01 2016-09-30 0001054102 idxg:AsuragenMember idxg:DiagnosticTestThyroidMember 2016-01-01 2016-09-30 0001054102 idxg:RedPathMember idxg:ContingentConsiderationMember 2016-01-01 2016-09-30 0001054102 idxg:RedPathMember idxg:DiagnosticTestBarrettsRedpathMember 2016-01-01 2016-09-30 0001054102 idxg:RedPathMember idxg:DiagnosticTestPancreasMember 2016-01-01 2016-09-30 0001054102 idxg:RedpathIntegratedPathologyIncMember idxg:TheNoteMember us-gaap:NotesPayableOtherPayablesMember 2016-01-01 2016-09-30 0001054102 idxg:ContingentConsiderationMember 2016-01-01 2016-09-30 0001054102 idxg:CLIADiagnosticLabMember 2016-01-01 2016-09-30 0001054102 us-gaap:MaximumMember 2016-01-01 2016-09-30 0001054102 us-gaap:MinimumMember 2016-01-01 2016-09-30 0001054102 idxg:ObligationsToFormerSalesRepresentativesUnderTheCsoIncentivePlanMember 2016-01-01 2016-09-30 0001054102 us-gaap:SegmentContinuingOperationsMember 2016-01-01 2016-09-30 0001054102 us-gaap:SegmentDiscontinuedOperationsMember 2016-01-01 2016-09-30 0001054102 idxg:FormerOwnersOfRedpathMember us-gaap:SubsequentEventMember 2016-01-01 2016-10-31 0001054102 idxg:RsusAndRestrictedStockMember us-gaap:DirectorMember 2016-02-01 2016-02-29 0001054102 2016-03-01 2016-03-31 0001054102 idxg:DOJMember 2016-05-01 2016-05-31 0001054102 idxg:SwannVsAkornIncAndInterpaceDiagnosticsGroupIncMember 2016-05-27 2016-05-27 0001054102 2016-07-01 2016-09-30 0001054102 us-gaap:EmployeeStockOptionMember 2016-07-01 2016-09-30 0001054102 us-gaap:PerformanceSharesMember 2016-07-01 2016-09-30 0001054102 us-gaap:RestrictedStockUnitsRSUMember 2016-07-01 2016-09-30 0001054102 us-gaap:StockAppreciationRightsSARSMember 2016-07-01 2016-09-30 0001054102 idxg:RedpathIntegratedPathologyIncMember idxg:TheNoteMember us-gaap:NotesPayableOtherPayablesMember 2016-07-01 2016-09-30 0001054102 idxg:DOJMember 2016-07-31 2016-07-31 0001054102 us-gaap:RevolvingCreditFacilityMember idxg:CreditAgreementMember idxg:SCMSpecialtyFinanceOpportunitiesFundLPMember 2016-09-28 2016-09-28 0001054102 us-gaap:RevolvingCreditFacilityMember idxg:CreditAgreementMember idxg:SCMSpecialtyFinanceOpportunitiesFundLPMember us-gaap:PrimeRateMember 2016-09-28 2016-09-28 0001054102 idxg:SecuredNotePayableToRedPathEquityRepresentativeMember 2016-09-30 2016-09-30 0001054102 idxg:CompanysCounterclaimAgainstProliasMember us-gaap:SubsequentEventMember 2016-10-13 2016-10-13 0001054102 us-gaap:EmployeeStockOptionMember us-gaap:SubsequentEventMember idxg:CeoCfoAndCertainEmployeesMember 2016-10-14 2016-10-14 0001054102 us-gaap:SubsequentEventMember idxg:CeoCfoAndCertainEmployeesMember 2016-10-14 2016-10-14 0001054102 idxg:DOJMember us-gaap:SubsequentEventMember 2016-10-31 2016-10-31 0001054102 idxg:RedpathIntegratedPathologyIncMember idxg:TheNoteMember us-gaap:NotesPayableOtherPayablesMember 2016-11-14 2016-11-14 0001054102 idxg:DOJMember us-gaap:ScenarioForecastMember 2017-02-28 2017-02-28 0001054102 2014-10-31 0001054102 idxg:RedpathIntegratedPathologyIncMember idxg:TheNoteMember us-gaap:NotesPayableOtherPayablesMember 2014-10-31 0001054102 idxg:RedpathIntegratedPathologyIncMember us-gaap:LoansPayableMember 2014-10-31 0001054102 idxg:FormerOwnersOfRedpathMember 2014-10-31 0001054102 2014-12-31 0001054102 idxg:RedpathIntegratedPathologyIncMember idxg:TheNoteMember us-gaap:NotesPayableOtherPayablesMember 2015-06-30 0001054102 2015-09-30 0001054102 2015-12-31 0001054102 idxg:AsuragenMember us-gaap:FairValueInputsLevel1Member 2015-12-31 0001054102 idxg:AsuragenMember us-gaap:FairValueInputsLevel2Member 2015-12-31 0001054102 idxg:AsuragenMember us-gaap:FairValueInputsLevel3Member 2015-12-31 0001054102 idxg:AsuragenMember idxg:ContingentConsiderationMember 2015-12-31 0001054102 idxg:AsuragenMember us-gaap:CarryingReportedAmountFairValueDisclosureMember 2015-12-31 0001054102 idxg:AsuragenMember us-gaap:EstimateOfFairValueFairValueDisclosureMember 2015-12-31 0001054102 idxg:AsuragenMember idxg:DiagnosticTestBiobankMember 2015-12-31 0001054102 idxg:AsuragenMember idxg:DiagnosticTestPancreasMember 2015-12-31 0001054102 idxg:AsuragenMember idxg:DiagnosticTestThyroidMember 2015-12-31 0001054102 idxg:RedPathMember 2015-12-31 0001054102 idxg:RedPathMember us-gaap:FairValueInputsLevel1Member 2015-12-31 0001054102 idxg:RedPathMember us-gaap:FairValueInputsLevel2Member 2015-12-31 0001054102 idxg:RedPathMember us-gaap:FairValueInputsLevel3Member 2015-12-31 0001054102 idxg:RedPathMember idxg:ContingentConsiderationMember 2015-12-31 0001054102 idxg:RedPathMember us-gaap:CarryingReportedAmountFairValueDisclosureMember 2015-12-31 0001054102 idxg:RedPathMember us-gaap:EstimateOfFairValueFairValueDisclosureMember 2015-12-31 0001054102 idxg:RedPathMember idxg:DiagnosticTestBarrettsRedpathMember 2015-12-31 0001054102 idxg:RedPathMember idxg:DiagnosticTestPancreasMember 2015-12-31 0001054102 us-gaap:CashMember us-gaap:FairValueInputsLevel1Member 2015-12-31 0001054102 us-gaap:CashMember us-gaap:FairValueInputsLevel2Member 2015-12-31 0001054102 us-gaap:CashMember us-gaap:FairValueInputsLevel3Member 2015-12-31 0001054102 us-gaap:CashMember us-gaap:CarryingReportedAmountFairValueDisclosureMember 2015-12-31 0001054102 us-gaap:CashMember us-gaap:EstimateOfFairValueFairValueDisclosureMember 2015-12-31 0001054102 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member 2015-12-31 0001054102 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel2Member 2015-12-31 0001054102 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel3Member 2015-12-31 0001054102 us-gaap:MoneyMarketFundsMember us-gaap:CarryingReportedAmountFairValueDisclosureMember 2015-12-31 0001054102 us-gaap:MoneyMarketFundsMember us-gaap:EstimateOfFairValueFairValueDisclosureMember 2015-12-31 0001054102 us-gaap:FairValueInputsLevel1Member 2015-12-31 0001054102 us-gaap:FairValueInputsLevel1Member idxg:GovernmentAgencySecuritiesMember 2015-12-31 0001054102 us-gaap:FairValueInputsLevel1Member idxg:MarketableSecuritiesMoneyMarketFundsMember 2015-12-31 0001054102 us-gaap:FairValueInputsLevel1Member idxg:MutualFundsMember 2015-12-31 0001054102 us-gaap:FairValueInputsLevel1Member us-gaap:USTreasurySecuritiesMember 2015-12-31 0001054102 us-gaap:FairValueInputsLevel2Member 2015-12-31 0001054102 us-gaap:FairValueInputsLevel2Member idxg:GovernmentAgencySecuritiesMember 2015-12-31 0001054102 us-gaap:FairValueInputsLevel2Member idxg:MarketableSecuritiesMoneyMarketFundsMember 2015-12-31 0001054102 us-gaap:FairValueInputsLevel2Member idxg:MutualFundsMember 2015-12-31 0001054102 us-gaap:FairValueInputsLevel2Member us-gaap:USTreasurySecuritiesMember 2015-12-31 0001054102 us-gaap:FairValueInputsLevel3Member 2015-12-31 0001054102 us-gaap:FairValueInputsLevel3Member idxg:GovernmentAgencySecuritiesMember 2015-12-31 0001054102 us-gaap:FairValueInputsLevel3Member idxg:MarketableSecuritiesMoneyMarketFundsMember 2015-12-31 0001054102 us-gaap:FairValueInputsLevel3Member idxg:MutualFundsMember 2015-12-31 0001054102 us-gaap:FairValueInputsLevel3Member us-gaap:USTreasurySecuritiesMember 2015-12-31 0001054102 idxg:ContingentConsiderationMember 2015-12-31 0001054102 us-gaap:CarryingReportedAmountFairValueDisclosureMember 2015-12-31 0001054102 us-gaap:CarryingReportedAmountFairValueDisclosureMember idxg:GovernmentAgencySecuritiesMember 2015-12-31 0001054102 us-gaap:CarryingReportedAmountFairValueDisclosureMember idxg:MarketableSecuritiesMoneyMarketFundsMember 2015-12-31 0001054102 us-gaap:CarryingReportedAmountFairValueDisclosureMember idxg:MutualFundsMember 2015-12-31 0001054102 us-gaap:CarryingReportedAmountFairValueDisclosureMember us-gaap:USTreasurySecuritiesMember 2015-12-31 0001054102 us-gaap:EstimateOfFairValueFairValueDisclosureMember 2015-12-31 0001054102 us-gaap:EstimateOfFairValueFairValueDisclosureMember idxg:GovernmentAgencySecuritiesMember 2015-12-31 0001054102 us-gaap:EstimateOfFairValueFairValueDisclosureMember idxg:MarketableSecuritiesMoneyMarketFundsMember 2015-12-31 0001054102 us-gaap:EstimateOfFairValueFairValueDisclosureMember idxg:MutualFundsMember 2015-12-31 0001054102 us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:USTreasurySecuritiesMember 2015-12-31 0001054102 idxg:CLIADiagnosticLabMember 2015-12-31 0001054102 idxg:CommercialServicesMember 2015-12-31 0001054102 idxg:OtherDiscontinuedOperationsMember 2015-12-31 0001054102 us-gaap:RevolvingCreditFacilityMember idxg:CreditAgreementMember idxg:SCMSpecialtyFinanceOpportunitiesFundLPMember 2016-09-28 0001054102 2016-09-30 0001054102 idxg:OtherAccruedExpensesMember 2016-09-30 0001054102 us-gaap:OtherNoncurrentLiabilitiesMember 2016-09-30 0001054102 idxg:AsuragenMember us-gaap:FairValueInputsLevel1Member 2016-09-30 0001054102 idxg:AsuragenMember us-gaap:FairValueInputsLevel2Member 2016-09-30 0001054102 idxg:AsuragenMember us-gaap:FairValueInputsLevel3Member 2016-09-30 0001054102 idxg:AsuragenMember idxg:ContingentConsiderationMember 2016-09-30 0001054102 idxg:AsuragenMember us-gaap:CarryingReportedAmountFairValueDisclosureMember 2016-09-30 0001054102 idxg:AsuragenMember us-gaap:EstimateOfFairValueFairValueDisclosureMember 2016-09-30 0001054102 idxg:AsuragenMember idxg:DiagnosticTestBiobankMember 2016-09-30 0001054102 idxg:AsuragenMember idxg:DiagnosticTestPancreasMember 2016-09-30 0001054102 idxg:AsuragenMember idxg:DiagnosticTestThyroidMember 2016-09-30 0001054102 idxg:InterpaceDiagnosticsLLCMember 2016-09-30 0001054102 idxg:RedPathMember 2016-09-30 0001054102 idxg:RedPathMember us-gaap:FairValueInputsLevel1Member 2016-09-30 0001054102 idxg:RedPathMember us-gaap:FairValueInputsLevel2Member 2016-09-30 0001054102 idxg:RedPathMember us-gaap:FairValueInputsLevel3Member 2016-09-30 0001054102 idxg:RedPathMember idxg:ContingentConsiderationMember 2016-09-30 0001054102 idxg:RedPathMember us-gaap:CarryingReportedAmountFairValueDisclosureMember 2016-09-30 0001054102 idxg:RedPathMember us-gaap:EstimateOfFairValueFairValueDisclosureMember 2016-09-30 0001054102 idxg:RedPathMember idxg:DiagnosticTestBarrettsRedpathMember 2016-09-30 0001054102 idxg:RedPathMember idxg:DiagnosticTestPancreasMember 2016-09-30 0001054102 idxg:RedpathIntegratedPathologyIncMember 2016-09-30 0001054102 idxg:RedpathIntegratedPathologyIncMember idxg:TheNoteMember us-gaap:NotesPayableOtherPayablesMember 2016-09-30 0001054102 us-gaap:CashMember us-gaap:FairValueInputsLevel1Member 2016-09-30 0001054102 us-gaap:CashMember us-gaap:FairValueInputsLevel2Member 2016-09-30 0001054102 us-gaap:CashMember us-gaap:FairValueInputsLevel3Member 2016-09-30 0001054102 us-gaap:CashMember us-gaap:CarryingReportedAmountFairValueDisclosureMember 2016-09-30 0001054102 us-gaap:CashMember us-gaap:EstimateOfFairValueFairValueDisclosureMember 2016-09-30 0001054102 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member 2016-09-30 0001054102 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel2Member 2016-09-30 0001054102 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel3Member 2016-09-30 0001054102 us-gaap:MoneyMarketFundsMember us-gaap:CarryingReportedAmountFairValueDisclosureMember 2016-09-30 0001054102 us-gaap:MoneyMarketFundsMember us-gaap:EstimateOfFairValueFairValueDisclosureMember 2016-09-30 0001054102 idxg:ObligationsToFormerSalesRepresentativesUnderTheCsoIncentivePlanMember 2016-09-30 0001054102 idxg:ObligationsToFormerSalesRepresentativesUnderTheCsoIncentivePlanMember us-gaap:MaximumMember 2016-09-30 0001054102 us-gaap:FairValueInputsLevel1Member 2016-09-30 0001054102 us-gaap:FairValueInputsLevel1Member us-gaap:CarryingReportedAmountFairValueDisclosureMember 2016-09-30 0001054102 us-gaap:FairValueInputsLevel1Member us-gaap:USTreasurySecuritiesMember 2016-09-30 0001054102 us-gaap:FairValueInputsLevel2Member 2016-09-30 0001054102 us-gaap:FairValueInputsLevel2Member us-gaap:CarryingReportedAmountFairValueDisclosureMember 2016-09-30 0001054102 us-gaap:FairValueInputsLevel2Member us-gaap:USTreasurySecuritiesMember 2016-09-30 0001054102 us-gaap:FairValueInputsLevel3Member 2016-09-30 0001054102 us-gaap:FairValueInputsLevel3Member us-gaap:CarryingReportedAmountFairValueDisclosureMember 2016-09-30 0001054102 us-gaap:FairValueInputsLevel3Member us-gaap:USTreasurySecuritiesMember 2016-09-30 0001054102 idxg:ContingentConsiderationMember 2016-09-30 0001054102 us-gaap:CarryingReportedAmountFairValueDisclosureMember 2016-09-30 0001054102 us-gaap:CarryingReportedAmountFairValueDisclosureMember us-gaap:USTreasurySecuritiesMember 2016-09-30 0001054102 us-gaap:EstimateOfFairValueFairValueDisclosureMember 2016-09-30 0001054102 us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:USTreasurySecuritiesMember 2016-09-30 0001054102 idxg:CLIADiagnosticLabMember 2016-09-30 0001054102 idxg:CommercialServicesMember 2016-09-30 0001054102 idxg:OtherDiscontinuedOperationsMember 2016-09-30 0001054102 idxg:DojSettlementMember 2016-09-30 0001054102 idxg:SecuredNotePayableToRedPathEquityRepresentativeMember 2016-09-30 0001054102 us-gaap:EmployeeSeveranceMember 2016-09-30 0001054102 idxg:ObligationsToFormerSalesRepresentativesUnderTheCsoIncentivePlanMember 2016-09-30 0001054102 idxg:CompanysCounterclaimAgainstProliasMember us-gaap:SubsequentEventMember 2016-10-13 0001054102 2016-11-10 0001054102 us-gaap:RevolvingCreditFacilityMember idxg:CreditAgreementMember idxg:SCMSpecialtyFinanceOpportunitiesFundLPMember us-gaap:SubsequentEventMember 2016-11-14 EX-101.SCH 8 idxg-20160930.xsd EXHIBIT 101.SCH 000 - Document - Document And Entity Information link:calculationLink link:definitionLink link:presentationLink 001 - Statement - Condensed Consolidated Balance Sheets (Current Period Unaudited) link:calculationLink link:definitionLink link:presentationLink 002 - Statement - Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) link:calculationLink link:definitionLink link:presentationLink 003 - Statement - Condensed Consolidated Statements of Comprehensive Loss (Unaudited) link:calculationLink link:definitionLink link:presentationLink 004 - Statement - Condensed Consolidated Statements of Comprehensive Loss (Unaudited) (Parentheticals) link:calculationLink link:definitionLink link:presentationLink 005 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) link:calculationLink link:definitionLink link:presentationLink 006 - Disclosure - Note 1 - Basis of Presentation link:calculationLink link:definitionLink link:presentationLink 007 - Disclosure - Note 2 - Liquidity and Management's Plans link:calculationLink link:definitionLink link:presentationLink 008 - Disclosure - Note 3 - Summary of Significant Accounting Policies link:calculationLink link:definitionLink link:presentationLink 009 - Disclosure - Note 4 - Other Intangible Assets link:calculationLink link:definitionLink link:presentationLink 010 - Disclosure - Note 5 - Fair Value Measurements link:calculationLink link:definitionLink link:presentationLink 011 - Disclosure - Note 6 - Commitments and Contingencies link:calculationLink link:definitionLink link:presentationLink 012 - Disclosure - Note 7 - Accrued Expenses and Long-term Liabilities link:calculationLink link:definitionLink link:presentationLink 013 - Disclosure - Note 8 - Stock-based Compensation link:calculationLink link:definitionLink link:presentationLink 014 - Disclosure - Note 9 - Income Taxes link:calculationLink link:definitionLink link:presentationLink 015 - Disclosure - Note 10 - Segment Information link:calculationLink link:definitionLink link:presentationLink 016 - Disclosure - Note 11 - Discontinued Operations link:calculationLink link:definitionLink link:presentationLink 017 - Disclosure - Note 12 - Long-term Debt link:calculationLink link:definitionLink link:presentationLink 018 - Disclosure - Note 13 - Supplemental Cash Flow Information link:calculationLink link:definitionLink link:presentationLink 019 - Disclosure - Note 14 - Recent Accounting Pronouncements link:calculationLink link:definitionLink link:presentationLink 020 - Document - Note 15 - Other Subsequent Events link:calculationLink link:definitionLink link:presentationLink 021 - Disclosure - Significant Accounting Policies (Policies) link:calculationLink link:definitionLink link:presentationLink 022 - Disclosure - Note 2 - Liquidity and Management's Plans (Tables) link:calculationLink link:definitionLink link:presentationLink 023 - Disclosure - Note 3 - Summary of Significant Accounting Policies (Tables) link:calculationLink link:definitionLink link:presentationLink 024 - Disclosure - Note 4 - Other Intangible Assets (Tables) link:calculationLink link:definitionLink link:presentationLink 025 - Disclosure - Note 5 - Fair Value Measurements (Tables) link:calculationLink link:definitionLink link:presentationLink 026 - Disclosure - Note 7 - Accrued Expenses and Long-term Liabilities (Tables) link:calculationLink link:definitionLink link:presentationLink 027 - Disclosure - Note 8 - Stock-based Compensation (Tables) link:calculationLink link:definitionLink link:presentationLink 028 - Disclosure - Note 9 - Income Taxes (Tables) link:calculationLink link:definitionLink link:presentationLink 029 - Disclosure - Note 11 - Discontinued Operations (Tables) link:calculationLink link:definitionLink link:presentationLink 030 - Disclosure - Note 12 - Long-term Debt (Tables) link:calculationLink link:definitionLink link:presentationLink 031 - Disclosure - Note 13 - Supplemental Cash Flow Information (Tables) link:calculationLink link:definitionLink link:presentationLink 032 - Disclosure - Note 2 - Liquidity and Management's Plans (Details Textual) link:calculationLink link:definitionLink link:presentationLink 033 - Disclosure - Note 2 - Liquidity and Management's Plan - Contractual Obligations Due in the Next 12 Months (Details) link:calculationLink link:definitionLink link:presentationLink 034 - Disclosure - Note 3 - Summary of Significant Accounting Policies (Details Textual) link:calculationLink link:definitionLink link:presentationLink 035 - Disclosure - Note 3 - Summary of Significant Accounting Policies - Other Current Assets (Details) link:calculationLink link:definitionLink link:presentationLink 036 - Disclosure - Note 3 - Summary of Significant Accounting Policies - Reconciliation of the Number of Shares Used in Basic and Diluted Earnings Per Share (Details) link:calculationLink link:definitionLink link:presentationLink 037 - Disclosure - Note 3 - Summary of Significant Accounting Policies - Stock Awards Excluded from the Computation of the Effect of Dilutive Securities (Details) link:calculationLink link:definitionLink link:presentationLink 038 - Disclosure - Note 4 - Other Intangible Assets (Details Textual) link:calculationLink link:definitionLink link:presentationLink 039 - Disclosure - Note 4 - Other Intangible Assets - Identifiable Intangible Assets Carrying Value (Details) link:calculationLink link:definitionLink link:presentationLink 040 - Disclosure - Note 4 - Other Intangible Assets - Future Estimated Amortization Expense (Details) link:calculationLink link:definitionLink link:presentationLink 041 - Disclosure - Note 5 - Fair Value Measurements - Financial Instruments (Details) link:calculationLink link:definitionLink link:presentationLink 042 - Disclosure - Note 5 - Fair Value Measurements - Roll-forward of the Carrying Value of the Contingent Consideration (Details) link:calculationLink link:definitionLink link:presentationLink 043 - Disclosure - Note 6 - Commitments and Contingencies (Details Textual) link:calculationLink link:definitionLink link:presentationLink 044 - Disclosure - Note 7 - Accrued Expenses and Long-term Liabilities - Accrued Expenses (Details) link:calculationLink link:definitionLink link:presentationLink 045 - Disclosure - Note 7 - Accrued Expenses and Long-term Liabilities - Other Long-term Liabilities (Details) link:calculationLink link:definitionLink link:presentationLink 046 - Disclosure - Note 8 - Stock-based Compensation (Details Textual) link:calculationLink link:definitionLink link:presentationLink 047 - Disclosure - Note 8 - Stock-based Compensation - Weighted Average Assumptions (Details) link:calculationLink link:definitionLink link:presentationLink 048 - Disclosure - Note 9 - Income Taxes - Income Taxes (Details) link:calculationLink link:definitionLink link:presentationLink 049 - Disclosure - Note 10 - Segment Information (Details Textual) link:calculationLink link:definitionLink link:presentationLink 050 - Disclosure - Note 11 - Discontinued Operations - Results Included in Loss From Discontinued Operations, Net of Tax (Details) link:calculationLink link:definitionLink link:presentationLink 051 - Disclosure - Note 11 - Discontinued Operations - Assets and Liabilities Classified as Discontinued Operations (Details) link:calculationLink link:definitionLink link:presentationLink 052 - Disclosure - Note 12 - Long-term Debt (Details Textual) link:calculationLink link:definitionLink link:presentationLink 053 - Disclosure - Note 12 - Long-term Debt - Long-term Debt Future Principal Payments (Details) link:calculationLink link:definitionLink link:presentationLink 054 - Disclosure - Note 13 - Supplemental Cash Flow Information - Supplemental Cash Flow Information (Details) link:calculationLink link:definitionLink link:presentationLink EX-101.CAL 9 idxg-20160930_cal.xml EXHIBIT 101.CAL EX-101.DEF 10 idxg-20160930_def.xml EXHIBIT 101.DEF EX-101.LAB 11 idxg-20160930_lab.xml EXHIBIT 101.LAB Document And Entity Information Note To Financial Statement Details Textual statementsignificantaccountingpoliciespolicies statementnote2liquidityandmanagementsplanstables statementnote3summaryofsignificantaccountingpoliciestables statementnote4otherintangibleassetstables statementnote5fairvaluemeasurementstables us-gaap_InterestExpenseDebt Interest Expense, Debt Interest expense statementnote7accruedexpensesandlongtermliabilitiestables Segment Reporting Disclosure [Text Block] statementnote8stockbasedcompensationtables statementnote9incometaxestables statementnote11discontinuedoperationstables statementnote12longtermdebttables statementnote13supplementalcashflowinformationtables statementnote2liquidityandmanagementsplancontractualobligationsdueinthenext12monthsdetails us-gaap_IncreaseDecreaseInDeferredRevenue (Decrease) increase in unearned contract revenue statementnote3summaryofsignificantaccountingpoliciesothercurrentassetsdetails statementnote3summaryofsignificantaccountingpoliciesreconciliationofthenumberofsharesusedinbasicanddilutedearningspersharedetails statementnote3summaryofsignificantaccountingpoliciesstockawardsexcludedfromthecomputationoftheeffectofdilutivesecuritiesdetails Other intangible assets, net statementnote4otherintangibleassetsidentifiableintangibleassetscarryingvaluedetails statementnote4otherintangibleassetsfutureestimatedamortizationexpensedetails DOJ Settlement [Member] Contractual obligation to pay the Department of Justice as agreed upon in the settlement agreement. statementnote5fairvaluemeasurementsfinancialinstrumentsdetails statementnote5fairvaluemeasurementsrollforwardofthecarryingvalueofthecontingentconsiderationdetails us-gaap_IncreaseDecreaseInAccruedLiabilities Decrease in accrued liabilities Credit Agreement [Member] Represents the Credit Agreement. statementnote7accruedexpensesandlongtermliabilitiesaccruedexpensesdetails CSO [Member] Represents the Commercial Services business (CSO). Contractual Obligations, Due in 3 to 6 Months Amount of contractual obligation due in four to six months. statementnote7accruedexpensesandlongtermliabilitiesotherlongtermliabilitiesdetails Contractual Obligations, Due in 0 to 3 Months Amount of contractual obligation due in zero to three months. statementnote8stockbasedcompensationweightedaverageassumptionsdetails statementnote9incometaxesincometaxesdetails idxg_DebtInstrumentPercentageUsedToDetermineMonthlyUnusedLineFee Debt Instrument, Percentage Used to Determine Monthly Unused Line Fee The percentage used to determine the monthly unused line fee by multiplying this by the difference of the outstanding balance of the loan during the preceding month and the facility cap on the date of determination. Contractual Obligations, Due in 6 to 12 Months Amount of contractual obligation due in seven to twelve months statementnote11discontinuedoperationsresultsincludedinlossfromdiscontinuedoperationsnetoftaxdetails SCM Specialty Finance Opportunities Fund, L.P. [Member] Represents the lender, SCM Specialty Finance Opportunities Fund, L.P. statementnote11discontinuedoperationsassetsandliabilitiesclassifiedasdiscontinuedoperationsdetails statementnote12longtermdebtlongtermdebtfutureprincipalpaymentsdetails idxg_DebtInstrumentPercentageUsedToDetermineTerminationFeeAfterFirstAnniversary Debt Instrument, Percentage Used to Determine Termination Fee, After First Anniversary The percentage used to determine the termination fee by multiplying this by the facility cap if the credit agreement is terminated after the first anniversary of the closing date. Former Owners of RedPath [Member] Represents former owners of RedPath that has indemnified assets. statementnote13supplementalcashflowinformationsupplementalcashflowinformationdetails idxg_DebtInstrumentNumberOfPeriodicPaymentsPrincipal Debt Instrument, Number of Periodic Payments, Principal Represents the number of installment payments of principal the Company is required to make. Notes To Financial Statements idxg_DebtInstrumentPercentageUsedToDetermineMonthlyCollateralManagementFee Debt Instrument, Percentage Used to Determine Monthly Collateral Management Fee The percentage used to determine the monthly collateral management fee by multiplying this by the average daily balance under the credit agreement outstanding during the preceding month. Notes To Financial Statements [Abstract] idxg_DebtInstrumentPercentageUsedToDetermineTerminationFeeBeforeFirstAnniversary Debt Instrument, Percentage Used to Determine Termination Fee, Before First Anniversary The percentage used to determine the termination fee by multiplying this by the facility cap if the credit agreement is terminated before the first anniversary of the closing date. us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour 2019 us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive 2020 us-gaap_IncreaseDecreaseInAccruedSalaries (Decrease) increase in accrued salaries and bonus us-gaap_PolicyTextBlockAbstract Accounting Policies us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo 2017 us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree 2018 us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths 2016 us-gaap_IncreaseDecreaseInAccountsPayable (Decrease) increase in accounts payable Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block] Schedule of Acquired Finite-Lived Intangible Assets by Major Class [Table Text Block] idxg_LossContingencyInterestOnSettlement Loss Contingency, Interest on Settlement The interest rate applied to a judgement amount passed against the defendant. Schedule of Cash Flow, Supplemental Disclosures [Table Text Block] idxg_LossContingencyRenegotiatedAmount Loss Contingency, Renegotiated, Amount The amount of loss contingency that was subsequently renegotiated. Finite-lived intangible asset, useful life Finite-Lived Intangible Asset, Useful Life Cash Flow, Supplemental Disclosures [Text Block] Directors fees and insurance Amount of fees and insurance due to certain employees within one year or the normal operating cycle, if longer. Net Loss and Comprehensive Loss CEO, CFO, and Certain Employees [Member] Related to the chief executive officer, chief financial officer, and certain other employees. Operating expenses: us-gaap_RegulatoryLiabilities Regulatory Liabilities Preferred Stock, Shares Outstanding (in shares) us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities (Decrease) increase in long-term liabilities Estimate of Fair Value Measurement [Member] Common Stock, Shares, Outstanding (in shares) Portion at Fair Value Measurement [Member] Measurement Basis [Axis] Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value Cash and cash equivalents – beginning Cash and cash equivalents – ending Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block] us-gaap_AllocatedShareBasedCompensationExpense Allocated Share-based Compensation Expense RSU's and Restricted Stock [Member] Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met and stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met. us-gaap_AdjustmentsToAdditionalPaidInCapitalOther Adjustments to Additional Paid in Capital, Other us-gaap_LettersOfCreditOutstandingAmount Letters of Credit Outstanding, Amount Other Liabilities Disclosure [Text Block] us-gaap_TreasuryStockValue Treasury stock, at cost (542,543 and 1,042,543 shares, respectively) Companys Counter-claim Against Prolias [Member] Related to the company's counter-claim against Prolias. idxg_DebtInstrumentInterestRateIncreaseInEventOfDefault Debt Instrument, Interest Rate, Increase in Event of Default The amount of increase in the debt instrument interest rate in the event of a default occcuring. DOJ [Member] Related to settlements reached the Department of Justice. idxg_LossContingencyDamagesSoughtValueAttorneyFees Loss Contingency Damages Sought, Value, Attorney Fees The value of attorney fees sought in related to a loss contingency. us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued Stock Issued During Period, Value, Treasury Stock Reissued Revenue, net us-gaap_IncreaseDecreaseInUnbilledReceivables Decrease in unbilled receivable Contingent Consideration [Member] Related to the contingent consideration. Accretion Amount of accretion of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing. us-gaap_IncreaseDecreaseInAccountsReceivable Decrease (increase) in accounts receivable Fair Value, by Balance Sheet Grouping [Table Text Block] Fair Value Disclosures [Text Block] us-gaap_IncreaseDecreaseInOtherNoncurrentAssets Decrease in other long-term assets us-gaap_IncreaseDecreaseInOtherCurrentAssets Decrease in other current assets Earnings Per Share, Policy [Policy Text Block] us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross Discontinued Operations, Policy [Policy Text Block] us-gaap_LiabilitiesAndStockholdersEquity Total liabilities and stockholders' (deficit) equity Accumulated deficit Accumulated other comprehensive income idxg_DebtInstrumentCovenantTermRollingNetCashFlowAnalysis Debt Instrument, Covenant Term, Rolling Net Cash Flow Analysis The term of rolling net cash flow analysis, updated weekly, required to be provided by the company as part of the terms of the debt agreement. idxg_DebtInstrumentCovenantTermNetCashBalanceAmount Debt Instrument, Covenant Term, Net Cash Balance, Amount The minimum net cash balance the company must keep within a specified period in accordance with the terms of the debt agreement. Long-term assets from discontinued operations us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrent Property and equipment, net The Note [Member] Represents information pertaining to a note with the Equityholder Representative, on behalf of the former equity holders of RedPath, dated October 31, 2014. The Note is interest-free. Other changes in assets and liabilities: us-gaap_OtherNoncashIncomeExpense Other (gains), losses and expenses, net us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentAssets Other Deferred taxes Investments, fair value disclosure Cash and cash equivalents, fair value disclosure us-gaap_PaymentsForRestructuring Payments for Restructuring Stock-based compensation Other long-term assets Diagnostic Test, Pancreas [Member] Represents the business segment that generates sales from the pancreas diagnostics product line. Interpace Diagnostics, LLC [Member] Reporting entity's wholly-owned subsidiary. Diagnostic Test, Thyroid [Member] Represents the segment that generates net sales from the thyroid diagnostics product line. Treasury Stock, Shares (in shares) Cost of Revenue, Amortization Common stock, $.01 par value; 100,000,000 shares authorized; 18,705,214 shares issued; 18,162,671 and 17,662,671 shares outstanding, respectively us-gaap_TableTextBlock Notes Tables us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedInceptionToDate Restructuring and Related Cost, Number of Positions Eliminated, Inception to Date RedPath [Member] Represents RedPath Integrated Pathology, Inc ("RedPath"). Common Stock, Shares, Issued (in shares) Common Stock, Shares Authorized (in shares) Diagnostic Test, Barrett's RedPath [Member] Represents the diagnostic test Barrett's RedPath. Amendment Flag Depreciation and amortization Common Stock, Par or Stated Value Per Share (in dollars per share) Common Stock, Par or Stated Value Per Share US Treasury Securities [Member] us-gaap_AssetsCurrent Assets, Current Total current assets Restructuring Plan [Axis] Restructuring Plan [Domain] Change in fair value of contingent consideration Other income (expense), net Goodwill and Intangible Assets, Policy [Policy Text Block] Employee Severance [Member] Type of Restructuring [Domain] Preferred stock, $.01 par value; 5,000,000 shares authorized, no shares issued and outstanding Current Fiscal Year End Date Restructuring Type [Axis] Preferred Stock, Shares Issued (in shares) us-gaap_ContractualObligation Contractual Obligation Adjustments to reconcile net loss to net cash used in operating activities: Statement of Financial Position [Abstract] Preferred Stock, Shares Authorized (in shares) Document Fiscal Period Focus Document Fiscal Year Focus Current assets from discontinued operations Asuragen [Member] Represents Asuragen. Preferred Stock, Par or Stated Value Per Share (in dollars per share) Document Period End Date Government Agency Securities [Member] Represents government agency securities. Contractual Obligations, Due us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentAssets Other Mutual Funds [Member] Represents mutual funds. Document Type Statement of Cash Flows [Abstract] us-gaap_OperatingIncomeLoss Operating loss us-gaap_GrossProfit Gross profit Document Information [Line Items] us-gaap_PaymentsForFees Payments for Other Fees Cost of revenue (excluding amortization of $970 and $986 for the three months and $2,909 and $2,825 for the nine months, respectively) Document Information [Table] Cash paid for interest Entity Filer Category Entity Current Reporting Status Entity Voluntary Filers Unclaimed property Represents unclaimed property. Entity Well-known Seasoned Issuer Other current assets Other, liabilities us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities Unearned contract revenue 2016 us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent Accounts payable Entity Central Index Key us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo 2017 Entity Registrant Name us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree 2018 Entity [Domain] Business Acquisition, Acquiree [Domain] us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss (Loss) income from discontinued operations Diagnostic Test, Biobank [Member] Represents the diagnostic tests for Biobank. Legal Entity [Axis] Business Acquisition [Axis] CLIA Diagnostic Lab [Member] Represents CLIA Diagnostic Lab. Contractual Obligation, Fiscal Year Maturity Schedule [Table Text Block] Additional paid-in capital Swann vs. Akorn, Inc, and Interpace Diagnostics Group, Inc. [Member] Represents information pertaining to the litigation case of Swann vs. Akorn, Inc. and Interpace Diagnostics Group, Inc. us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue Revenue, net Disposal Group Name [Domain] Discontinued Operation, Schedule of Amounts Recognized in Balance Sheet [Table Text Block] Tabular disclosure of the amounts from discontinued operations that are recognized in the balance sheet (or statement of financial position) for pension plans and/or other employee benefit plans, showing separately the assets and current and noncurrent liabilities (if applicable) recognized. Stockholders’ equity: Disposal Group Name [Axis] Schedule of Components of Loss from Discontinued Operations [Table Text Block] Tabular disclosure of the components of the loss from the entity's discontinued operations. Disposal Groups, Including Discontinued Operations, Disclosure [Text Block] Entity Common Stock, Shares Outstanding (in shares) Secured Note Payable to RedPath Equity Representative [Member] Represents the secured note payable to the RedPath Equityholder Representative, LLC ("RedPath Equityholder Representative"). Letters of credit Letters of credit that the company has extended to customers. Cash Flows From Operating Activities Statement [Line Items] us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued Business Acquisition, Equity Interest Issued or Issuable, Number of Shares Trading Symbol Accounts receivable, net Accounts Receivable, Net, Current us-gaap_EffectiveIncomeTaxRateContinuingOperations Effective income tax rate us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent Allowance for Doubtful Accounts Receivable, Current us-gaap_Liabilities Total liabilities Commitments and contingencies (Note 6) Total liabilities Short-term investments Fair Value, Inputs, Level 2 [Member] Fair Value, Inputs, Level 3 [Member] Fair Value Hierarchy [Domain] Obligations to Former Sales Representatives, Under the CSO Incentive Plan [Member] Represents information pertaining to the obligations to former sales representatives that fall under the CSO Incentive Plan. Fair Value, Inputs, Level 1 [Member] Fair Value, Hierarchy [Axis] ASSETS us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease Net increase (decrease) in cash and cash equivalents Net cash (used in) provided by investing activities of discontinued operations Net cash (used in) provided by operating activities of discontinued operations Taxes payable us-gaap_NetCashProvidedByUsedInFinancingActivities Net cash used in financing activities us-gaap_BusinessCombinationIndemnificationAssetsAmountAsOfAcquisitionDate Business Combination, Indemnification Assets, Amount as of Acquisition Date Accrued professional fees us-gaap_PaymentsForRepurchaseOfCommonStock Cash paid for repurchase of restricted shares us-gaap_StockholdersEquity Total stockholders' (deficit) equity Marketable Securities, Money Market Funds [Member] Represents money market funds under the category of marketable securities. Equity Components [Axis] Equity Component [Domain] Dividend yield us-gaap_LitigationSettlementAmount Litigation Settlement, Amount Risk-free interest rate us-gaap_LongTermDebt Long-term Debt Other Noncurrent Liabilities [Member] Expected volatility Expected life (years) us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred Business Combination, Consideration Transferred, Liabilities Incurred us-gaap_LineOfCredit Long-term Line of Credit Trade and Other Accounts Receivable, Policy [Policy Text Block] us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value Income Tax Disclosure [Text Block] Accounting Policies [Abstract] us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest Loss from continuing operations before tax us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period us-gaap_RepaymentsOfLongTermDebt Repayments of Long-term Debt Balance Sheet Location [Domain] us-gaap_DebtInstrumentUnamortizedDiscount Debt Instrument, Unamortized Discount Balance Sheet Location [Axis] Revolving Credit Facility [Member] Credit Facility [Domain] Credit Facility [Axis] Other receivables us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Maximum [Member] Minimum [Member] Range [Axis] Range [Domain] us-gaap_TradeReceivablesHeldForSaleNetNotPartOfDisposalGroup Accounts receivable, net Goodwill and Intangible Assets Disclosure [Text Block] us-gaap_LossContingencyAccrualPayments Loss Contingency Accrual, Payments us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized Commercial Services [Member] Disposal group. us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period us-gaap_LossContingencyDamagesSoughtValue Loss Contingency, Damages Sought, Value Potential dilutive effect of stock-based awards (in shares) Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount (in shares) idxg_DisposalGroupIncludingDiscontinuedOperationAccruedSalaryAndBonus Accrued salary and bonus Represents Disposal Group, Including Discontinued Operation, Accrued Salary and Bonus. Diluted (in shares) Diluted weighted average number of common shares (in shares) Other Discontinued Operations [Member] Represents all other disposal groups. us-gaap_EarningsPerShareBasicAndDiluted Net loss per basic and diluted share of common stock (in dollars per share) Award Type [Axis] Contingent consideration, deferred payments Equity Award [Domain] Basic and diluted (loss) income per share of common stock: Finite-Lived Intangible Assets by Major Class [Axis] Finite-Lived Intangible Assets, Major Class Name [Domain] Discontinued Operations [Member] Operating Activities [Domain] us-gaap_ProceedsFromIssuanceOfDebt Proceeds from Issuance of Debt Scenario, Forecast [Member] Continuing Operations [Member] Scenario, Unspecified [Domain] Basic weighted average number of of common shares (in shares) Operating Activities [Axis] Scenario [Axis] From continuing operations (in dollars per share) From discontinued operations (in dollars per share) Disclosure of Compensation Related Costs, Share-based Payments [Text Block] Schedule of Accrued Liabilities [Table Text Block] Statement [Table] Litigation Case [Domain] Litigation Case [Axis] Commitments and Contingencies Disclosure [Text Block] Contingent consideration Other long-term liabilities Other Liabilities Noncurrent Income Statement [Abstract] RedPath Integrated Pathology, Inc [Member] Acquired entity. DOJ settlement (indemnified by RedPath) us-gaap_NetCashProvidedByUsedInInvestingActivities Net cash used in investing activities Cash Flows From Financing Activities Uncertain tax positions Long-term Debt, Type [Axis] Long-term Debt, Type [Domain] Schedule of Effective Income Tax Rate Reconciliation [Table Text Block] us-gaap_DeferredRentCreditNoncurrent Rent payable Director [Member] Title of Individual [Axis] New Accounting Pronouncements and Changes in Accounting Principles [Text Block] us-gaap_ProceedsFromDivestitureOfBusinesses Proceeds from Divestiture of Businesses Relationship to Entity [Domain] Loans Payable [Member] Investment Type [Axis] Investments [Domain] Notes Payable, Other Payables [Member] us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation Income tax (benefit) expense us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax (Loss) income from discontinued operations, before tax Long-term debt, net of debt discount us-gaap_DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax Gain on sale of assets Provision (benefit) for income taxes Provision (benefit) from income tax us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal Gain on sale of discontinued operations us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent Contingent consideration us-gaap_LiabilitiesCurrent Liabilities, Current Total current liabilities Self insurance and benefit accruals Other Accrued Expenses [Member] Primary balance sheet location. Current liabilities from discontinued operations Class of Stock [Axis] Indemnification liability Schedule of Weighted Average Number of Shares [Table Text Block] Rent payable Current portion of long-term debt, net of debt discount Counterparty Name [Domain] Counterparty Name [Axis] Schedule of Debt [Table Text Block] Schedule of Other Assets [Table Text Block] Schedule of Other Assets and Other Liabilities [Table Text Block] us-gaap_DebtInstrumentPeriodicPaymentPrincipal Debt Instrument, Periodic Payment, Principal Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] Indemnification assets us-gaap_DebtInstrumentBasisSpreadOnVariableRate1 Debt Instrument, Basis Spread on Variable Rate us-gaap_DebtInstrumentInterestRateStatedPercentage Debt Instrument, Interest Rate, Stated Percentage Other Current Assets, Policy [Policy Text Block] Disclosure of accounting policy for other current assets. us-gaap_OperatingExpenses Total operating expenses General and administrative us-gaap_DebtInstrumentFaceAmount Debt Instrument, Face Amount us-gaap_NotesIssued1 Notes Issued Substantial Doubt about Going Concern [Text Block] Accrued salary and bonus us-gaap_DebtInstrumentFeeAmount Debt Instrument, Fee Amount Accounts payable Other accrued expenses Subsequent Event [Member] DOJ settlement Subsequent Event Type [Axis] Subsequent Event Type [Domain] Subsequent Events [Text Block] Interest accretion Realignment accrual accretion Debt Instrument [Axis] Debt Instrument, Name [Domain] Prime Rate [Member] All others Variable Rate [Axis] Variable Rate [Domain] Accrued royalties Liability Class [Axis] Fair Value by Liability Class [Domain] Basis of Presentation and Significant Accounting Policies [Text Block] us-gaap_PaymentsToAcquirePropertyPlantAndEquipment Purchase of property and equipment LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT) Adjustments to Fair Value us-gaap_Assets Total assets Asset impairment Asset Impairment Charges Total assets Long-term Debt [Text Block] us-gaap_SeveranceCosts1 Severance Costs Unbilled receivable, net Weighted average number of common shares and common share equivalents outstanding: Reported Value Measurement [Member] us-gaap_OtherAssets Other Acquisition related amortization expense Amortization of Intangible Assets us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity Line of Credit Facility, Maximum Borrowing Capacity us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization Finite-Lived Intangible Assets, Accumulated Amortization Money Market Funds [Member] Finite-Lived Intangible Assets, Net Cash and Cash Equivalents [Domain] us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue Beginning Balance Ending Balance Cash [Member] Cash and Cash Equivalents [Axis] us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements Payments Net loss Net Income (Loss) Attributable to Parent Net loss us-gaap_IncomeLossFromContinuingOperations Loss from continuing operations (Loss) income from discontinued operations, net of tax (Loss) income from discontinued operations, net of tax Lender Name [Axis] Line of Credit Facility, Lender [Domain] Stock Appreciation Rights (SARs) [Member] Restricted Stock Units (RSUs) [Member] Performance Shares [Member] Property and equipment, net Employee Stock Option [Member] Antidilutive Securities, Name [Domain] Antidilutive Securities [Axis] Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block] Provision for bad debt Sales and marketing us-gaap_DisclosureTextBlockAbstract Notes to Financial Statements Use of Estimates, Policy [Policy Text Block] us-gaap_NetCashProvidedByUsedInOperatingActivities Net Cash Provided by (Used in) Operating Activities Net cash used in operating activities Reclassification, Policy [Policy Text Block] us-gaap_NumberOfReportableSegments Number of Reportable Segments Cash Flows From Investing Activities Research and development EX-101.PRE 12 idxg-20160930_pre.xml EXHIBIT 101.PRE XML 13 R1.htm IDEA: XBRL DOCUMENT v3.5.0.2
Document And Entity Information - shares
9 Months Ended
Sep. 30, 2016
Nov. 10, 2016
Document Information [Line Items]    
Entity Registrant Name Interpace Diagnostics Group, Inc.  
Entity Central Index Key 0001054102  
Trading Symbol idxg  
Current Fiscal Year End Date --12-31  
Entity Filer Category Smaller Reporting Company  
Entity Current Reporting Status Yes  
Entity Voluntary Filers No  
Entity Well-known Seasoned Issuer No  
Entity Common Stock, Shares Outstanding (in shares)   18,162,671
Document Type 10-Q  
Document Period End Date Sep. 30, 2016  
Document Fiscal Year Focus 2016  
Document Fiscal Period Focus Q3  
Amendment Flag false  
XML 14 R2.htm IDEA: XBRL DOCUMENT v3.5.0.2
Condensed Consolidated Balance Sheets (Current Period Unaudited) - USD ($)
Sep. 30, 2016
Dec. 31, 2015
ASSETS    
Cash and cash equivalents $ 1,693,000 $ 8,310,000
Short-term investments 106,000
Accounts receivable, net 2,753,000 2,806,000
Other current assets 2,087,000 2,569,000
Current assets from discontinued operations 150,000 5,374,000
Total current assets 6,683,000 19,165,000
Property and equipment, net 1,060,000 1,460,000
Other intangible assets, net 37,220,000 43,492,000
Other long-term assets 1,001,000 3,255,000
Long-term assets from discontinued operations 340,000
Total assets 45,964,000 67,712,000
LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT)    
Accounts payable 1,365,000 1,560,000
Accrued salary and bonus 3,089,000 2,424,000
Other accrued expenses 6,905,000 5,961,000
Current portion of long-term debt, net of debt discount 3,756,000 1,164,000
Current liabilities from discontinued operations 4,755,000 12,264,000
Total current liabilities 19,870,000 23,373,000
Contingent consideration 17,691,000 17,890,000
Long-term debt, net of debt discount 5,267,000 7,233,000
Other long-term liabilities 4,615,000 6,178,000
Total liabilities 47,443,000 54,674,000
Commitments and contingencies (Note 6)
Stockholders’ equity:    
Preferred stock, $.01 par value; 5,000,000 shares authorized, no shares issued and outstanding 0 0
Common stock, $.01 par value; 100,000,000 shares authorized; 18,705,214 shares issued; 18,162,671 and 17,662,671 shares outstanding, respectively 187,000 187,000
Additional paid-in capital 125,842,000 132,522,000
Accumulated deficit (125,865,000) (111,252,000)
Accumulated other comprehensive income 13,000
Treasury stock, at cost (542,543 and 1,042,543 shares, respectively) (1,643,000) (8,432,000)
Total stockholders' (deficit) equity (1,479,000) 13,038,000
Total liabilities and stockholders' (deficit) equity $ 45,964,000 $ 67,712,000
XML 15 R3.htm IDEA: XBRL DOCUMENT v3.5.0.2
Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) - $ / shares
Sep. 30, 2016
Dec. 31, 2015
Preferred Stock, Par or Stated Value Per Share (in dollars per share) $ 0.01 $ 0.01
Preferred Stock, Shares Authorized (in shares) 5,000,000 5,000,000
Preferred Stock, Shares Issued (in shares) 0 0
Preferred Stock, Shares Outstanding (in shares) 0 0
Common Stock, Par or Stated Value Per Share (in dollars per share) $ 0.01 $ 0.01
Common Stock, Shares Authorized (in shares) 100,000,000 100,000,000
Common Stock, Shares, Issued (in shares) 18,705,214 18,705,214
Common Stock, Shares, Outstanding (in shares) 18,162,671 17,662,671
Treasury Stock, Shares (in shares) 542,543 1,042,543
XML 16 R4.htm IDEA: XBRL DOCUMENT v3.5.0.2
Condensed Consolidated Statements of Comprehensive Loss (Unaudited) - USD ($)
shares in Thousands, $ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2016
Sep. 30, 2015
Sep. 30, 2016
Sep. 30, 2015
Revenue, net $ 3,316 $ 2,506 $ 9,963 $ 6,876
Cost of revenue (excluding amortization of $970 and $986 for the three months and $2,909 and $2,825 for the nine months, respectively) 1,846 1,799 4,866 5,224
Gross profit 1,470 707 5,097 1,652
Operating expenses:        
Sales and marketing 1,282 2,876 4,186 8,387
Research and development 659 1,000 1,339 1,646
General and administrative 2,858 2,498 7,655 8,909
Acquisition related amortization expense 970 986 2,909 2,825
Asset impairment 3,363 3,363
Change in fair value of contingent consideration (1,174) (1,174)
Total operating expenses 7,958 7,360 18,278 21,767
Operating loss (6,488) (6,653) (13,181) (20,115)
Interest expense (539) (884) (1,601) (2,616)
Other income (expense), net 4 (112) 14 (268)
Loss from continuing operations before tax (7,023) (7,649) (14,768) (22,999)
Provision (benefit) for income taxes 173 (180) (54) (430)
Loss from continuing operations (7,196) (7,469) (14,714) (22,569)
(Loss) income from discontinued operations, net of tax (297) 2,574 101 6,828
Net loss (7,493) (4,895) (14,613) (15,741)
Net Loss and Comprehensive Loss $ (7,493) $ (4,895) $ (14,613) $ (15,741)
Basic and diluted (loss) income per share of common stock:        
From continuing operations (in dollars per share) $ (0.40) $ (0.48) $ (0.82) $ (1.48)
From discontinued operations (in dollars per share) (0.02) 0.16 0.01 0.45
Net loss per basic and diluted share of common stock (in dollars per share) $ (0.41) $ (0.31) $ (0.81) $ (1.03)
Weighted average number of common shares and common share equivalents outstanding:        
Basic weighted average number of of common shares (in shares) 18,163 15,654 18,029 15,301
Diluted (in shares) 18,163 15,654 18,029 15,301
XML 17 R5.htm IDEA: XBRL DOCUMENT v3.5.0.2
Condensed Consolidated Statements of Comprehensive Loss (Unaudited) (Parentheticals) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2016
Sep. 30, 2015
Sep. 30, 2016
Sep. 30, 2015
Cost of Revenue, Amortization $ 970 $ 986 $ 2,909 $ 2,825
XML 18 R6.htm IDEA: XBRL DOCUMENT v3.5.0.2
Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)
9 Months Ended
Sep. 30, 2016
Sep. 30, 2015
Cash Flows From Operating Activities    
Net loss $ (14,613,000) $ (15,741,000)
Adjustments to reconcile net loss to net cash used in operating activities:    
Depreciation and amortization 3,490,000 3,775,000
Realignment accrual accretion 29,000 104,000
Interest accretion 1,601,000 825,000
Provision for bad debt 482,000 202,000
Gain on sale of discontinued operations (217,000)
Stock-based compensation 109,000 1,517,000
Asset impairment 3,363,000
Change in fair value of contingent consideration (1,174,000)
Deferred taxes (634,000)
Other (gains), losses and expenses, net (4,000)
Other changes in assets and liabilities:    
Decrease (increase) in accounts receivable 4,639,000 (4,257,000)
Decrease in unbilled receivable 16,000 702,000
Decrease in other current assets 1,272,000 1,084,000
Decrease in other long-term assets 754,000 2,137,000
(Decrease) increase in accounts payable (761,000) 200,000
(Decrease) increase in unearned contract revenue (11,000) 396,000
(Decrease) increase in accrued salaries and bonus (685,000) 2,155,000
Decrease in accrued liabilities (4,561,000) (7,318,000)
(Decrease) increase in long-term liabilities (563,000) 1,534,000
Net cash used in operating activities (6,617,000) (13,536,000)
Cash Flows From Investing Activities    
Purchase of property and equipment (583,000)
Net cash used in investing activities (583,000)
Cash Flows From Financing Activities    
Cash paid for repurchase of restricted shares (37,000)
Net cash used in financing activities (37,000)
Net increase (decrease) in cash and cash equivalents (6,617,000) (14,156,000)
Cash and cash equivalents – beginning 8,310,000 23,111,000
Cash and cash equivalents – ending 1,693,000 8,955,000
Cash paid for interest $ 2,153,000
XML 19 R7.htm IDEA: XBRL DOCUMENT v3.5.0.2
Note 1 - Basis of Presentation
9 Months Ended
Sep. 30, 2016
Notes to Financial Statements  
Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]
1.
BASIS OF PRESENTATION
 
The accompanying unaudited interim condensed consolidated financial statements and related notes (the interim financial statements) should be read in conjunction with the consolidated financial statements of Interpace Diagnostics Group, Inc.
(the Company or Interpace), and its wholly-owned subsidiaries, Interpace Diagnostics Corporation and Interpace Diagnostics, LLC,
and related notes as included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2015, as filed with the U.S. Securities and Exchange Commission (SEC) on March 30, 2016, as amended on April 29, 2016 and June 14, 2016.  The condensed interim financial statements of the Company have been prepared in accordance with generally accepted accounting principles in the United States (GAAP) for interim financial reporting and the instructions to Form 10-Q and Article 10 of Regulation S-X.  Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements.  The condensed interim financial statements include all normal recurring adjustments that, in the judgment of management, are necessary for a fair presentation of such interim financial statements.  All significant intercompany balances and transactions have been eliminated in consolidation.  Discontinued operations include the Company's wholly owned subsidiaries: Group DCA, LLC, or Group DCA; InServe Support Solutions (Pharmakon); and TVG, Inc. (TVG, dissolved December 31, 2014) and its Commercial Services (CSO) business unit. All significant intercompany balances and transactions have been eliminated in consolidation.
Operating results for the three- and nine-month periods ended September 30, 2016 are not necessarily indicative of the results that may be expected for the year ending December 31, 2016.
XML 20 R8.htm IDEA: XBRL DOCUMENT v3.5.0.2
Note 2 - Liquidity and Management's Plans
9 Months Ended
Sep. 30, 2016
Notes to Financial Statements  
Substantial Doubt about Going Concern [Text Block]
2.
LIQUIDITY AND MANAGEMENT'S PLANS
  
For the nine months ended September 30, 2016, the Company incurred a net loss of $14.6 million and cash used in operating activities was $6.6 million.  The Company did not raise any capital or incur any funded debt during the first nine months of 2016, but it did enter into a Credit Agreement with SCM Specialty Finance Opportunities Fund, L.P. on September 28, 2016 as described further below, on which it has not yet drawn. The Company also anticipates operating losses to continue for the foreseeable future due to, among other things, costs related to its commercial operations, developing products and product candidates, right sizing and reorganizing its administrative organization and winding down activities and managing obligations related to its discontinued operations.
 
The accompanying condensed, consolidated financial statements have been prepared on a basis that assumes that the Company will continue as a going concern and that contemplates the continuity of operations, the realization of assets and the satisfaction of liabilities and commitments in the normal course of business. As of September 30, 2016, the Company had cash and cash equivalents of $1.7 million, net accounts receivable of $2.8 million, current assets of $6.7 million and current liabilities of $19.9 million.
 
As a result of the sale of substantially all of its CSO business in December 2015, which generated net cash proceeds of $26.8 million (of which $21.6 million was used to repay long-term debt and fees), the Company focused its resources and strategic initiatives on its molecular diagnostics business. As with many companies in a similar stage, sufficient capital is required before achieving profitability. Accordingly, the Company may require additional capital in 2016 and will require additional capital in 2017 and beyond. In order to obtain such capital and fund its operations, the Company may be required to restructure all or a portion of its obligations related to the sale of its CSO business as well as obligations owed to the former equity holders of RedPath Integrated Pathology, Inc.(“RedPath”) arising out of the Company’s acquisition of RedPath. The first payment of secured debt to RedPath Equityholder Representative, LLC (the “RedPath Equityholder Representative”), as representative of the former equity holders of RedPath, has been extended several times from its original due date of October 1, 2016 and is now due December 31, 2016 unless further extended. There is no guarantee that additional capital will or can be raised or that adequate restructuring will be accomplished that are sufficient to fund the Company's operations for the rest of 2016 and beyond or that the terms of such additional capital, if available, will be acceptable to the Company. Accordingly, the Company continues to explore sales of assets and various dilutive and non-dilutive sources of funding, including equity and debt financings, strategic alliances and alternatives, business development, and other alternatives. Additionally, the Company continues to focus on increasing sales of its commercial molecular diagnostic tests, closely managing cash and further streamlining operations. If, however, the Company is unsuccessful in obtaining capital and executing its plans for the business to continue operations, when needed, including the restructuring of its debt and other liabilities, then it may be forced to sell off assets, seek protection under the U.S. Bankruptcy Code, or be forced into liquidation or substantially alter or restructure its business operations. In the event of a default on its secured note, the RedPath Equityholder Representative could foreclose on the Company’s assets, force the Company into bankruptcy or pursue other remedies. In such events, stockholders may not be able to recoup their investment. These factors, among others, raise substantial doubt about the Company’s ability to continue as a going concern.
 
 
During the first nine months of 2016, the Company commenced negotiations with certain of its creditors and former sales representatives and executives to restructure its current and long-term obligations related to the sale of the majority of its CSO business in December 2015. The proposed restructuring by the Company includes reducing or extending the term of certain of its obligations, converting a portion to equity and/or forgiving portions thereof. However, any such restructuring may be dependent on the Company raising additional capital. The Company believes that this proposed restructuring, if achieved, will not only improve its liquidity but also provide the flexibility for future funding. No assurance, however, can be given that the negotiations to restructure the Company’s debt and obligations will be successful.
 
At September 30, 2016, the Company had the following debt obligations that it has been seeking to restructure:
 
 
1.
Future payments and conditions related to the $10.7 million secured note payable to the former equity holders of RedPath.
 
 
2.
Severance obligations to former executives ($3.1 million, including taxes).
 
 
3.
Obligations due to former sales representatives under the CSO incentive plan (up to $1 million including taxes). To date, 343 former sales representatives have accepted the Company’s offer to pay out approximately $0.6 million in equal installments over eight months. For the period ended September 30, 2016 approximately $0.1 million was paid out under this plan.
  
 
4.
Various liabilities including trade payables, other employee severance in accrued expenses and certain liabilities from Discontinued Operations which are in the process of being renegotiated or restructured.
 
There is, however, no guarantee that the Company will be successful in restructuring its outstanding debt.
 
A summary of the Company’s most significant contractual obligations over the next 12 months are as follows:
 
 
   
Total
   
0 to 3
months
   
3 to 6
months
   
6 to 12
months
 
Note due Redpath Equityholders
  $ 4,001     $ 1,334     $     $ 2,667  
Severance obligations
    3,137       3,137       -       -  
DOJ settlement
    665       85       85       495  
Deferred Bonus - ERT salesforce
    800       185       308       307  
Total obligations
  $ 8,603     $ 4,741     $ 393     $ 3,469  
 
On September 28, 2016 (the “Closing Date”), the Company and its wholly-owned direct and indirect subsidiaries, Interpace Diagnostics, LLC (“Interpace LLC”) and Interpace Diagnostics Corporation (“IDC” and together with Interpace LLC, its “Subsidiaries”), entered into a Credit Agreement (the “Credit Agreement”) with SCM Specialty Finance Opportunities Fund, L.P. (the “Lender”). Pursuant to and subject to the terms of the Credit Agreement, the Lender agreed to provide a revolving loan (the “Loan”) to the Company in the maximum principal amount of $1.2 million (“Facility Cap”). Also on the Closing Date, the Company and its Subsidiaries acknowledged and agreed to an Intercreditor Agreement (the “Intercreditor Agreement”) by and between the Lender and the RedPath Equityholder Representative pursuant to which the Lender has a first lien security interest on all of the accounts receivable (and related intangibles) of the Company and its Subsidiaries and the RedPath Equityholder Representative has a second lien security interest, subordinated to the Lender, on all the accounts receivables (and related intangibles) of the Company and its Subsidiaries. In addition, pursuant to the Intercreditor Agreement, the RedPath Equityholder Representative has a first lien security interest on all other assets of the Company and its Subsidiaries and the Lender has no lien with respect to such other assets. The maturity date of the Loan is September 28, 2018. The Loan bears interest at an annual rate equal to the Prime Rate (as defined in the Credit Agreement) plus 2.75%, payable in cash monthly in arrears. The interest rate will be increased by 5.0% in the event of a default under the Credit Agreement. Events of default under the Credit Agreement, some of which are subject to certain cure periods, include a failure to pay or perform obligations when due, the making of a material misrepresentation to the Lender, the rendering of certain judgments or decrees against the Company and its Subsidiaries and the initiation, voluntarily or involuntarily, of a bankruptcy or similar proceeding against the Company or its Subsidiaries.
 
 
The Company agreed to pay certain out-of-pocket costs and expenses incurred by the Lender in connection with the Credit Agreement and related documents, the administration of the Loan and related documents and the enforcement or protection of the Lender’s rights. The Lender is also entitled to: (a) a $12,000 origination fee; (b) a monthly unused line fee equal to the amount which is one-twelfth of one percent (0.083%) of the difference between (i) the outstanding balance of the Loan during the preceding month, and (ii) the Facility Cap on the date of determination; (c) a monthly collateral management fee equal to one-sixth of one percent (0.1666%) of the average daily balance under the Credit Agreement outstanding during the preceding month; and (d) a termination fee equal to (i) two percent (2%) of the Facility Cap if the Credit Agreement is terminated before the first anniversary of the Closing Date (the “First Anniversary”), or (ii) one percent (1%) of the Facility Cap if the Credit Agreement is terminated after the First Anniversary. The Company must also pay certain fees in the event that (a) the amount outstanding under the Credit Agreement exceeds the availability under the Credit Agreement’s borrowing base, and (b) receivables are not properly deposited in the appropriate lockbox account.
 
 
The Credit Agreement contains customary representations and warranties in favor of the Lender and certain covenants, including, among other things, financial covenants relating to loan turnover rates, liquidity and revenue targets. 
 
As of November 17, 2016, the Company had not borrowed any funds under the Credit Agreement.
 
On September 30, 2016, the Company, Interpace LLC, and the RedPath Equityholder Representative entered into an amendment to the $10.7 million interest free secured note payable to the former equity holders of RedPath to extend by one month, until November 1, 2016, subject to the terms of the amendment, the due date for the first quarterly payment of principal under the note. Effective October 31, 2016 the Company, Interpace LLC, and the RedPath Equityholder Representative entered into a fourth amendment to the note to extend until November 20, 2016, subject to the terms of the amendment, the due date for the first quarterly payment of principal. On November 16, 2016 the Company, Interpace LLC, and the RedPath Equityholder Representative entered into a fifth amendment to the note to extend until December 31, 2016, subject to the terms of the amendment, the due date for the first quarterly payment of principal under the note. In addition, the fifth amendment also amends the note to add as an event of default the failure of the Company to maintain a minimum net cash balance from operations of no less than $400,000, excluding proceeds from borrowed money, at the end of every week. The fifth amendment also contains a reporting requirement for the Company to provide to the RedPath Equityholder Representative, on a weekly basis, a 13-week cash flow forecast commencing November 22, 2016.
 
Under the note, the Company is required to make eight installment payments of principal, with each payment equal to $1,333,750, together with accrued and unpaid interest, if any. The first quarterly payment of principal under the note originally was due on October 1, 2016 and the first payment is now due on December 31, 2016. Subsequent payments are to be made on the first day of each fiscal quarter, beginning on April 1, 2017.
 
The Company currently has no means to make the first quarterly payment of principal due on December 31, 2016, and if the due date for the first quarterly payment of principal is not extended by the RedPath Equityholder Representative or other equity or debt capital is not raised, the RedPath Equityholder Representative could foreclose on the Company’s assets, force the Company into bankruptcy or pursue other remedies. Accordingly, the Company continues to explore sales of assets and various dilutive and non-dilutive sources of funding, including equity and debt financings, strategic alliances and alternatives, business development, and other alternatives.
XML 21 R9.htm IDEA: XBRL DOCUMENT v3.5.0.2
Note 3 - Summary of Significant Accounting Policies
9 Months Ended
Sep. 30, 2016
Notes to Financial Statements  
Basis of Presentation and Significant Accounting Policies [Text Block]
3.
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
 
Accounting Estimates
 
The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts of assets and liabilities reported and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period.  Management's estimates are based on historical experience, facts and circumstances available at the time, and various other assumptions that are believed to be reasonable under the circumstances.  Significant estimates include best estimate of selling price in multiple element arrangements, valuation allowances related to deferred income taxes, self-insurance loss accruals, allowances for doubtful accounts and notes, income tax accruals, acquisition accounting, asset impairments and facilities realignment accruals.  The Company periodically reviews these matters and reflects changes in estimates as appropriate.  Actual results could materially differ from those estimates.
 
Reclassifications
 
The CSO business in the three- and nine-month periods ended September 30, 2015 has been reclassified to discontinued operations to conform to the current period presentation.
 
 
Receivables and Allowance for Doubtful Accounts
 
The Company’s accounts receivable are generated using its proprietary tests. The Company’s services are fulfilled upon completion of the test, review and release of the test results. In conjunction with fulfilling these services, the Company bills the third-party payor or hospital. The Company recognizes accounts receivable related to billings for Medicare, Medicare Advantage, and hospitals on an accrual basis, net of contractual adjustment, when collectability is reasonably assured. Contractual adjustments represent the difference between the list prices and the reimbursement rate set by Medicare and Medicare Advantage, or the amounts billed to hospitals. The Company records an Allowance for Doubtful accounts for PancraGen® hospital roster billings based on the collection history of this payor. Since Medicare and Medicare Advantage have fixed reimbursement rates, there is no Allowance for Doubtful Accounts associated with these payors.
 
The Company provides services to commercial insurance carriers or governmental programs that do not have a contract in place for its proprietary tests which may or may not be covered by these entities existing reimbursement policies. In addition, the Company does not enter into direct agreements with patients that commit them to pay any portion of the cost of the tests in the event that their commercial insurance carrier or governmental program does not pay the Company for its services. In the absence of an agreement with the patient, or other clearly enforceable legal right to demand payment from commercial insurance carriers or governmental agencies, no accounts receivable is recognized. The Company does not record an Allowance for Doubtful Accounts for the commercial insurance or governmental programs since the revenue is recorded mainly on a cash basis. There was approximately a $1.3 million allowance for doubtful accounts as of September 30, 2016.
 
Other Current Assets
 
Other current assets consisted of the following as of September 30, 2016 and December 31, 2015:
 
 
   
September 30, 2016
   
December 31, 2015
 
Indemnification assets
  $ 1,375     $ 875  
Letters of credit
    -       360  
Other receivables
    666       1,048  
Other
    46       286  
    $ 2,087     $ 2,569  
  
Other Intangible Assets, including Finite-Lived Intangible Assets
 
The Company allocates the cost of acquired companies to the identifiable tangible and intangible assets acquired and liabilities assumed, with the remaining amount classified as goodwill, if any. Since the entities the Company has acquired do not have significant tangible assets, a significant portion of the purchase price has been allocated to intangible assets and goodwill. The identification and valuation of these intangible assets and the determination of the estimated useful lives at the time of acquisition, as well as the completion of impairment tests, require significant management judgments and estimates. These estimates are made based on, among other factors, consultations with an accredited independent valuation consultant, reviews of projected future operating results and business plans, economic projections, anticipated highest and best use of future cash flows and the market participant cost of capital. The use of alternative estimates and assumptions could increase or decrease the estimated fair value of other intangible assets, and potentially result in a different impact to the Company's results of operations. Further, changes in business strategy and/or market conditions may significantly impact these judgments thereby impacting the fair value of these assets, which could result in an impairment of the intangible assets.
 
Finite-lived intangible assets are stated at cost less accumulated amortization.  Amortization of finite-lived acquired intangible assets is recognized on a straight-line basis, using the estimated useful lives of the assets of approximately two years to nine years in acquisition related amortization expense in the consolidated statements of comprehensive loss.
 
The Company reviews the recoverability of long-lived assets and finite-lived intangible assets whenever events or changes in circumstances indicate that the carrying value of such assets may not be recoverable.  If the sum of the expected future undiscounted cash flows is less than the carrying amount of the asset, an impairment loss is recognized by reducing the recorded value of the asset to its fair value measured by future discounted cash flows.  This analysis requires estimates of the amount and timing of projected cash flows and, where applicable, judgments associated with, among other factors, the market price and physical condition of the assets at measurement date.  Such estimates are critical in determining whether any impairment charge should be recorded and the amount of such charge if an impairment loss is deemed to be necessary. 
 
During the quarter ended September 30, 2016 the Company recorded an asset impairment charge of approximately $3.4 million, resulting from a decline in market value of Pancreas and Biobank assets associated with the acquisition of certain assets from Asuragen.

 
 
Discontinued Operations
 
The Company accounts for business dispositions and its businesses held for sale in accordance with ASC 205-20, Discontinued Operations. ASC 205-20 requires the results of operations of business dispositions to be segregated from continuing operations and reflected as discontinued operations in current and prior periods. See Note 11,
Discontinued Operations
for further information.
 
 
Basic and Diluted Net Loss per Share
 
A reconciliation of the number of shares of common stock used in the calculation of basic and diluted loss per share for the three- and nine-month-periods ended September 30, 2016 and 2015 is as follows:
 
 
   
Three Months Ended
   
Nine Months Ended
 
   
September 30,
   
September 30,
 
   
2016
   
2015
   
2016
   
2015
 
Basic weighted average number of  of common shares
    18,163       15,654       18,029       15,301  
Potential dilutive effect of stock-based awards
    -       -       -       -  
Diluted weighted average number of common shares
    18,163       15,654       18,029       15,301  
 
The following outstanding stock-based awards were excluded from the computation of the effect of dilutive securities on loss per share for the following periods because they would have been anti-dilutive:
 
 
 
   
Three Months Ended
   
Nine Months Ended
 
   
September 30,
   
September 30,
 
   
2016
   
2015
   
2016
   
2015
 
Options
    -       -       -       -  
Stock-settled stock appreciation rights (SARs)
    1,027       1,028       1,027       1,028  
Restricted stock and restricted stock units (RSUs)
    1,151       1,745       1,151       1,745  
Performance contingent SARs
    -       188       -       188  
      2,178       2,961       2,178       2,961  
XML 22 R10.htm IDEA: XBRL DOCUMENT v3.5.0.2
Note 4 - Other Intangible Assets
9 Months Ended
Sep. 30, 2016
Notes to Financial Statements  
Goodwill and Intangible Assets Disclosure [Text Block]
4.
OTHER INTANGIBLE ASSETS
 
 
The net carrying value of the identifiable intangible assets as of September 30, 2016 is as follows: 
 
           
As of September 30, 2016
   
As of December 31, 2015
 
   
Life
   
Carrying
   
Carrying
 
   
(Years)
   
Amount
   
Amount
 
Diagnostic assets:
 
 
 
 
 
 
 
 
 
 
 
 
Asuragen acquisition:
                       
Thyroid
    9     $ 8,519     $ 8,519  
Pancreas
    -       -       2,882  
Biobank
    -       -       1,575  
RedPath acquisition:
                       
Pancreas test
    7       16,141       16,141  
Barrett's test
    9       18,351       18,351  
Total
          $ 43,011     $ 47,468  
Diagnostic lab:
 
 
 
 
 
 
 
 
 
 
 
 
CLIA Lab
    2.3     $ 609     $ 609  
                         
Accumulated Amortization
          $ (6,400 )   $ (4,585 )
                         
Net Carrying Value
          $ 37,220     $ 43,492  
 
Amortization expense was approximately $1.0 million for the three-month periods ended September 30, 2016 and 2015, respectively, and $2.9 million and $2.8 million for the nine-month periods ended September 30, 2016 and 2015, respectively. Amortization of our diagnostic assets begins upon launch of the product. Estimated amortization expense for the next five years is as follows, based on current assumptions of future product launches: 
 
 
2016
   
2017
   
2018
   
2019
   
2020
 
$ 3,771     $ 4,272     $ 5,292     $ 5,292     $ 5,292  
 
During the quarter ended September 30, 2016 the Company recorded an asset impairment charge of approximately $3.4 million resulting from a decline in the market value of Pancreas and Biobank assets associated with the acquisition of certain assets from Asuragen.
XML 23 R11.htm IDEA: XBRL DOCUMENT v3.5.0.2
Note 5 - Fair Value Measurements
9 Months Ended
Sep. 30, 2016
Notes to Financial Statements  
Fair Value Disclosures [Text Block]
5.
FAIR VALUE MEASUREMENTS
 
The Company's financial assets and liabilities reflected at fair value in the consolidated financial statements include: cash and cash equivalents; short-term investments; accounts receivable; other current assets; accounts payable; and contingent consideration. Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. In determining fair value, the Company uses various methods, including market, income and cost approaches. Based on these approaches, the Company often utilizes certain assumptions that market participants would use in pricing the asset or liability, including assumptions about risk and/or the risks inherent in the inputs to the valuation technique. These inputs can be readily observable, market-corroborated, or generally unobservable inputs. The Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs. Based upon observable inputs used in the valuation techniques, the Company is required to provide information according to the fair value hierarchy. The fair value hierarchy ranks the quality and reliability of the information used to determine fair values into three broad levels as follows:
 
 
Level 1:
Valuations for assets and liabilities traded in active markets from readily available pricing sources for market transactions involving identical assets or liabilities.
 
 
Level 2:
Valuations for assets and liabilities traded in less active dealer or broker markets. Valuations are obtained from third-party pricing services for identical or similar assets or liabilities.
 
 
Level 3:
Valuations incorporate certain assumptions and projections in determining the fair value assigned to such assets or liabilities.
 
In instances where the determination of the fair value measurement is based on inputs from different levels of the fair value hierarchy, the level in the fair value hierarchy within which the entire fair value measurement falls is based on the lowest level input that is significant to the fair value measurement in its entirety. The Company's assessment of the significance of a particular input to the fair value measurement in its entirety requires judgment, and considers factors specific to the asset or liability. The valuation methodologies used for the Company's financial instruments measured on a recurring basis at fair value, including the general classification of such instruments pursuant to the valuation hierarchy, is set forth in the tables below:
 
 
   
As of September 30, 2016
   
Fair Value Measurements
 
   
Carrying
   
Fair
   
As of September 30, 2016
 
   
Amount
   
Value
   
Level 1
   
Level 2
   
Level 3
 
Assets:
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cash and cash equivalents:
                                       
Cash
  $ 1,693     $ 1,693     $ 1,693     $ -     $ -  
Money market funds
    -       -       -       -       -  
    $ 1,693     $ 1,693     $ 1,693     $ -     $ -  
Marketable securities:
                                       
U.S. Treasury securities
  $ -     $ -     $ -     $ -     $ -  
Liabilities:
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Contingent consideration:
                                       
Asuragen
  $ 3,247     $ 3,247     $ -     $ -     $ 3,247  
RedPath
    14,653       14,653       -       -       14,653  
    $ 17,900     $ 17,900     $ -     $ -     $ 17,900  
 
   
As of December 31, 2015
   
Fair Value Measurements
 
   
Carrying
   
Fair
   
As of December 31, 2015
 
   
Amount
   
Value
   
Level 1
   
Level 2
     
Level 3
 
Assets:
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cash and cash equivalents:
                                         
Cash
  $ 7,534     $ 7,534     $ 7,534     $ -  
 
  $ -  
Money market funds
    776       776       776       -         -  
    $ 8,310     $ 8,310     $ 8,310     $ -       $ -  
Marketable securities:
                                         
Money market funds
  $ 48     $ 48     $ 48     $ -       $ -  
Mutual funds
    58       58       58       -         -  
U.S. Treasury securities
    1,115       1,115       1,115       -         -  
Government agency securities
    131       131       131       -         -  
    $ 1,352     $ 1,352     $ 1,352     $ -       $ -  
Liabilities:
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Contingent consideration:
                                         
Asuragen
  $ 4,628     $ 4,628     $ -     $ -       $ 4,628  
RedPath
    13,921       13,921       -       -         13,921  
    $ 18,549     $ 18,549     $ -     $ -       $ 18,549  
 
 
The fair value of cash and cash equivalents and marketable securities is valued using market prices in active markets (level 1). As of September 30, 2016, the Company did not have any marketable securities in less active markets (level 2) or without observable market values that would require a high level of judgment to determine fair value (level 3).
  
In connection with the acquisition of certain assets from Asuragen and the acquisition of RedPath, the Company recorded contingent consideration related to contingent payments and other revenue based payments. The Company determined the fair value of the contingent consideration based on a probability-weighted income approach derived from revenue estimates. The fair value measurement is based on significant inputs not observable in the market and thus represents a Level 3 measurement.  A rollforward of the carrying value of the contingent consideration from continuing operations from January 1, 2016 to September 30, 2016 is as follows:
 
   
2016
 
                           
Adjustments
         
   
January 1,
   
Payments
   
Accretion
   
to Fair Value
   
September 30,
 
Asuragen
  $ 4,628     $ (450 )   $ 243     $ (1,174 )   $ 3,247  
Redpath
    13,921       -       732       -       14,653  
    $ 18,549     $ (450 )   $ 975     $ (1,174 )   $ 17,900  
 
 
The Company considers carrying amounts of accounts receivable, accounts payable and accrued expenses to approximate fair value due to the short-term nature of these financial instruments.  There is no fair value ascribed to the letters of credit as management does not expect any material losses to result from these instruments because performance is not expected to be required.
 
Certain of the Company's non-financial assets, such as other intangible assets and goodwill, are measured at fair value when there is an indicator of impairment and recorded at fair value only when an impairment charge is recognized.
 
XML 24 R12.htm IDEA: XBRL DOCUMENT v3.5.0.2
Note 6 - Commitments and Contingencies
9 Months Ended
Sep. 30, 2016
Notes to Financial Statements  
Commitments and Contingencies Disclosure [Text Block]
6
.
COMMITMENTS AND CONTINGENCIES
 
Letters of Credit
 
As of September 30, 2016, the Company had $0.3 million in letters of credit outstanding as required by its existing facility leases. These letters of credit are collateralized by certain investments. In October 2016, the letters of credit were not renewed and the balance was distributed to our landlords who now hold the funds as security deposits on the Company’s facility leases.
 
Contingency
 
In connection with the acquisition of RedPath on October 31, 2014, the Company and its wholly-owned subsidiary, Interpace LLC, entered into a Contingent Consideration Agreement with the RedPath Equityholder Representative. Pursuant to the Contingent Consideration Agreement, the Company agreed to issue to the equityholders of RedPath 500,000 shares of the Company’s common stock, par value $0.01 (Common Stock), upon acceptance for publication of a specified article related to PathFinderTG® for the management of Barrett’s esophagus. The pending issuance of Common Stock was recorded as Additional paid-in capital in the Company's consolidated balance sheet as of December 31, 2014. On April 13, 2015, this milestone was reached upon acceptance for publication of new data supporting the use of BarreGen™ for predicting risk of progression from Barrett’s esophagus to esophageal cancer. On June 16, 2015, the 500,000 shares were issued from Treasury stock decreasing the balance in treasury stock by approximately $6.1 million, with a corresponding decrease in Additional paid-in capital of $6.1 million. In March 2016, 500,000 additional shares of Common Stock were issued from Treasury stock, as a result of the acceleration of the Common Stock Milestone, as defined in the Contingent Consideration Agreement, resulting from the change of control in connection with the sale of its CSO business in December 2015, decreasing the balance in treasury stock by approximately $6.8 million, with a corresponding decrease in Additional paid-in capital of $6.8 million.
 
Litigation
 
Due to the nature of the businesses in which the Company is engaged it is subject to certain risks. Such risks include, among others, risk of liability for personal injury or death to persons using products the Company promotes or commercializes. There can be no assurance that substantial claims or liabilities will not arise in the future due to the nature of the Company’s business activities and recent increases in litigation related to healthcare products. As part of the closeout of its CSO operations, the Company seeks to reduce its potential liability under its service agreements through measures such as contractual indemnification provisions with customers (the scope of which may vary from customer to customer, and the performance of which is not secured) and insurance. The Company could, however, also be held liable for errors and omissions of its employees in connection with the services it performs that are outside the scope of any indemnity or insurance policy. The Company could be materially adversely affected if it were required to pay damages or incur defense costs in connection with a claim that is outside the scope of an indemnification agreement; if the indemnity, although applicable, is not performed in accordance with its terms; or if the Company’s liability exceeds the amount of applicable insurance or indemnity.
 
The Company routinely assesses its litigation and threatened litigation as to the probability of ultimately incurring a liability, and records its best estimate of the ultimate loss in situations where the Company assesses the likelihood of loss as probable. The Company accrues for a liability when it is both probable that a liability has been incurred and the amount of the loss can be reasonably estimated. Significant judgment is required in both the determination of probability and the determination as to whether a loss is reasonably estimable. In addition, in the event the Company determines that a loss is not probable, but is reasonably possible, and it becomes possible to develop what the Company believes to be a reasonable range of possible loss, then the Company will include disclosures related to such matter as appropriate and in compliance with ASC 450. To the extent there is a reasonable possibility that the losses could exceed the amounts already accrued, the Company will, as applicable, adjust the accrual in the period the determination is made, disclose an estimate of the additional loss or range of loss, indicate that the estimate is immaterial with respect to its financial statements as a whole or, if the amount of such adjustment cannot be reasonably estimated, disclose that an estimate cannot be made. As of September 30, 2016, the Company's accrual for litigation and threatened litigation was not material to the consolidated financial statements.
 
In connection with the October 31, 2014 acquisition of RedPath, the Company assumed a liability for a January 2013 settlement agreement (the Settlement Agreement) entered into by the former owners of RedPath with the Department of Justice (“DOJ”). Under the terms of the Settlement Agreement, the Company is obligated to make payments to the DOJ for the calendar years ended December 31, 2014 through 2017, up to a maximum of $3.0 million.
 
Payments are due March 31st following the calendar year that the revenue milestones are achieved. The Company has been indemnified by the former owners of RedPath for $2.5 million of the obligation and has recorded an indemnification asset of that amount within other non-current assets. In May 2016 the Company renegotiated payment terms with the DOJ related to a $250,000 payment associated with performance in fiscal 2014 that resulted in an agreement that the Company pay $85,000 on July 31, 2016, $85,000 on October 31, 2016 and $80,000 on February 28, 2017. Accordingly, $170,000 was paid to the DOJ in 2016. During the nine months ended September 30, 2016, the Company has $1.7 million recorded as its best estimate of the amount that remains to be paid under the Settlement Agreement based on its estimate of future revenues, of which $0.7 million is included in
other accrued expenses
and $1.0 million is included in
other long-term liabilities
.
 
Prolias Technologies, Inc. v. PDI, Inc.
 
On April 8, 2015, Prolias Technologies, Inc.(“Prolias”) filed a complaint (the “Complaint”) against the Company with the Superior Court of New Jersey (Morris County) in a matter entitled Prolias Technologies, Inc. v. PDI, Inc. (Docket No. MRS-L-899-15).  In the Complaint, Prolias alleges that it and the Company entered into an August 19, 2013 Collaboration Agreement and a First Amendment thereto (collectively, the “Agreement”) whereby Prolias and the Company agreed to work in good faith to commercialize a diagnostic test known as "Thymira."  Thymira is a minimally invasive diagnostic test that is being developed to detect thyroid cancer.
 
Prolias alleges in the Complaint that the Company wrongfully terminated the Agreement, breached obligations owed to it under the Agreement and committed torts by (i) failing to effectively and timely validate Thymira, (ii) purchasing a competitor of Prolias and working to commercialize the competitive product at the expense of Thymira, and (iii) interfering with a license agreement that Prolias had with Cornell University related to a license for Thymira. Prolias asserts claims against the Company for breach of contract, breach of the covenant of good faith and fair dealing, intentional interference with contract and breach of fiduciary duty and seeks to recover unspecified compensatory damages, punitive damages, interest and costs of suit.
 
On June 3, 2015, the Company filed an Answer and Counterclaim in response to the Complaint. In the Answer, the Company denied that it had any liability to Prolias for the claims raised in the Complaint. In the Counterclaim, the Company sought (a) to recover from Polias the principal amount of $500,000 plus interest that was due and owing under a March 18, 2014 promissory note that Prolias delivered to the Company and (b) to compel Prolias to execute and deliver a $1 million promissory note to memorialize Prolias’s repayment obligations of money the Company advanced under the Agreement.
 
The parties exchanged documents in the fourth quarter of 2015. On December 18, 2015, Prolias moved for temporary restraints as to an asset sale of the Company. The Court denied the temporary restraints on December 21, 2015 and, when Prolias pursued the restraints in the form of a preliminary injunction motion, the Court denied that as well on February 4, 2016. Prolias’s separate motion to disqualify the Company’s counsel was also denied by the Court on
February 4, 2016. On February 24, 2016, Prolias moved for leave to appeal the interlocutory order denying the disqualification of Company’s counsel. On May 11, 2016, the Appellate Division granted the motion for leave to appeal and then summarily affirmed the denial of Prolias’s motion to disqualify the Company’s counsel.
 
On March 29, 2016, Prolias’ counsel moved to withdraw from representing Prolias. On April 7, 2016, the Company conditionally opposed the motion to withdraw pending prompt appointment of new counsel for Prolias. On April 19, 2016, the Court denied the motion without prejudice. On April 26, 2016, Prolias’ counsel renewed its motion to withdraw. On May 27, 2016, the Court granted the motion to withdraw and ordered Prolias to retain substitute counsel within 30 days.
 
On July 6, 2016, the Company moved to dismiss Prolias’ complaint and strike Prolias’ answer to the Company’s counterclaims for failure to retain substitute counsel within 30 days as required by the Court’s May 27th Order. On August 15, 2016, the Court granted the Company’s motion and dismissed Prolias’ complaint with prejudice and struck Prolias’ answer to the Company’s counterclaims. On September 22, 2016, the Court granted the Company’s request to enter default against Prolias for failure to plead or otherwise respond to the counterclaims. Thereafter, on October 13, 2016, the Company filed an application to enter final judgment and taxing of costs against Prolias. The Company requested that the Court enter final judgment against Prolias and for the Company in the amount of $621,236.16, plus ten percent interest continuing to accrue on the principal balance of $500,000.00 unless and until paid, attorneys’ fees and costs of $390,769.04, and a declaratory judgment that Prolias is deemed to have executed and delivered to the Company a promissory note in the amount of $1,000,000 under Article 10.2(a) of the Collaboration Agreement. The Company is awaiting a response from the Court on the application for entry of final judgment.
 
 
Swann v. Akorn, Inc., and Interpace Diagnostics Group, Inc.
 
On May 27, 2016, Michael J. Swann, one of the Company’s former employees, filed a complaint against the Company in the Court of Common Pleas of the Fifth Judicial Circuit in South Carolina in a matter entitled Michael J. Swann v. Akorn, Inc., and Interpace Diagnostic Group Inc. (Civil Action No. 2016-CP-40-03362). In the complaint, Mr. Swann alleges, among other things, that he was discriminated against and wrongfully terminated as a member of a sales force marketing pharmaceutical products of Akorn, Inc., because of an illness suffered by Mr. Swann. Mr. Swann alleges that he was discriminated against in violation of the Americans with Disabilities Act/Americans with Disabilities Act Amendments Act and the Family Medical Leave Act and seeks damages for back pay, reinstatement, front pay, compensatory and punitive damages in an amount not less than $300,000, attorney’s fees and costs. The Company denies that it is liable to Mr. Swann for any of the claims asserted and intends to vigorously defend itself against those claims.
 
Severance
 
In 2015, in connection with the sale of the majority of the CSO business and the implementation of a broad-based program to maximize efficiencies and cut costs, the Company reduced headcount and incurred severance obligations to terminated employees that amounted to approximately $3.7 million.
 
During the first quarter ended March 31, 2016 the Company recorded additional severance obligations as it continued to right-size the organization and wind down its CSO business. The Company recorded obligations of $1.1 million, $0.5 million of which was recorded in continuing operations. The current severance liability as of September 30, 2016 is $3.1 million, of which $2.3 million resides in continuing operations and $0.8 million is in discontinued operations.
XML 25 R13.htm IDEA: XBRL DOCUMENT v3.5.0.2
Note 7 - Accrued Expenses and Long-term Liabilities
9 Months Ended
Sep. 30, 2016
Notes to Financial Statements  
Other Liabilities Disclosure [Text Block]
7.
ACCRUED EXPENSES AND LONG-TERM LIABILITIES
 
Other accrued expenses consisted of the following as of September 30, 2016 and December 31, 2015:
 
 
   
September 30, 2016
   
December 31, 2015
 
Accrued royalties
  $ 504     $ 111  
Self insurance and benefit accruals
    272       366  
Indemnification liability
    875       875  
Contingent consideration
    209       659  
Rent payable
    78       127  
DOJ settlement
    665       250  
Accrued professional fees
    1,320       775  
Taxes payable
    691       591  
Unclaimed property
    544       546  
Directors fees and insurance
    208       107  
All others
    1,539       1,554  
    $ 6,905     $ 5,961  
 
Long-term liabilities consisted of the following as of September 30, 2016 and December 31, 2015:
 
 
   
September 30, 2016
   
December 31, 2015
 
Rent payable
  $ -     $ 52  
Uncertain tax positions
    3,556       3,425  
DOJ settlement (indemnified by RedPath)
    1,000       2,500  
Other
    59       201  
    $ 4,615     $ 6,178  
XML 26 R14.htm IDEA: XBRL DOCUMENT v3.5.0.2
Note 8 - Stock-based Compensation
9 Months Ended
Sep. 30, 2016
Notes to Financial Statements  
Disclosure of Compensation Related Costs, Share-based Payments [Text Block]
8
.
STOCK-BASED COMPENSATION
 
Stock Incentive Plan
 
In 2015, the board of directors (the Board) and stockholders approved the Company’s Amended and Restated 2004 Stock Award and Incentive Plan, or the Amended and Restated Plan. The Amended and Restated Plan amends the Company’s pre-existing Amended and Restated 2004 Stock Award and Incentive Plan, which had replaced the 1998 Stock Option Plan, or the 1998 Plan, and the 2000 Omnibus Incentive Compensation Plan, or the 2000 Plan.  The Amended and Restated Plan authorized an additional 2,450,000 shares for new awards and combined the remaining shares available under the original Amended and Restated Plan.  Eligible participants under the Amended and Restated Plan include officers and other employees of the Company, members of the Board and outside consultants, as specified under the Amended and Restated Plan and designated by the Compensation and Management Development Committee of the Board, or the Compensation Committee.  Unless earlier terminated by action of the Board, the Amended and Restated Plan will remain in effect until such time as no stock remains available for delivery under the Amended and Restated Plan and the Company has no further rights or obligations under the Amended and Restated Plan with respect to outstanding awards thereunder. 
 
SARs are generally granted with a grant price equal to the market value of the common stock on the date of grant, vest one-third each year on the anniversary of the date of grant and expire five years from the date of grant.  The restricted shares and restricted stock units (RSU’s) granted to employees historically have had a three year cliff vesting period and are subject to accelerated vesting and forfeiture under certain circumstances. Restricted shares and restricted stock units granted to board members generally have a three year graded vesting period and are subject to accelerated vesting and forfeiture under certain circumstances.
 
In February 2016, certain employees and members of the Company’s Board were granted approximately 1.3 million RSU’s at a weighted average grant price of $0.25. These shares vest one-third each year on the anniversary of the date of grant.
 
The following table provides the weighted average assumptions used in determining the fair value of the non-market based SARs awards granted during the nine month periods ended September 30, 2016 and September 30, 2015: 
 
 
   
Nine Months Ended
 
   
September 30,
 
   
2016
   
2015
 
Risk-free interest rate
    -       1.02 %
Expected life (years)
    -       3.5  
Expected volatility
    -       54.47 %
Dividend yield
    -       -  
 
The Company recognized approximately $0.02 million and $0.3 million of stock-based compensation expense during each of the three month periods ended September 30, 2016 and 2015, respectively, and $0.1 million and $1.0 million during each of the nine month periods ended September 30, 2016 and 2015, respectively.
 
On October 14, 2016, the Company’s Chief Executive Officer, Chief Financial Officer and certain employees were granted incentive stock options to purchase an aggregate of 878,744 shares of common stock with an exercise price of $0.16 per share and, subject generally to the executive’s or employee’s, as applicable, continued service with the Company, vest in equally monthly installments over a period of one year.
 
XML 27 R15.htm IDEA: XBRL DOCUMENT v3.5.0.2
Note 9 - Income Taxes
9 Months Ended
Sep. 30, 2016
Notes to Financial Statements  
Income Tax Disclosure [Text Block]
9.
INCOME TAXES
 
Generally, accounting standards require companies to provide for income taxes each quarter based on their estimate of the effective tax rate for the full year. The authoritative guidance for accounting for income taxes allows use of the discrete method when it provides a better estimate of income tax expense. Due to the Company's valuation allowance position, it is the Company's position that the discrete method provides a more accurate estimate of income tax expense and therefore income tax expense for the current quarter has been presented using the discrete method.  As the year progresses, the Company refines its estimate based on the facts and circumstances by each tax jurisdiction.  The following table summarizes income tax (benefit) expense on loss from continuing operations and the effective tax rate for the three- and nine-month periods ended September 30, 2016 and 2015: 
 
 
   
Three Months Ended
   
Nine Months Ended
 
   
September 30,
   
September 30,
 
   
2016
   
2015
   
2016
   
2015
 
Provision (benefit) from income tax
  $ 173     $ (180 )   $ (54 )   $ (430 )
Effective income tax rate
    (2.5% )     2.4 %     0.4 %     1.9 %
 
Income tax expense and benefit for the three- and nine-month periods ended September 30, 2016 was primarily due to the reclassification of CSO as discontinued operations and the tax adjustments associated with that reclassification
. Income tax benefit for the three- and nine-month periods ended September 30, 2015 was primarily due to net operating losses, partially offset by minimum state and local taxes.
XML 28 R16.htm IDEA: XBRL DOCUMENT v3.5.0.2
Note 10 - Segment Information
9 Months Ended
Sep. 30, 2016
Notes to Financial Statements  
Segment Reporting Disclosure [Text Block]
10.
SEGMENT INFORMATION
 
Effective December 31, 2015, the Company has one reporting segment: the Company's molecular diagnostics business, after the divestiture of its CSO business on December 22, 2015. The Company realigned its reporting segments due to the integration of RedPath and acquiring certain assets from Asuragen, to reflect the Company's current and going forward business strategy. The Company's current reporting segment structure is reflective of the way the Company's management views the business, makes operating decisions and assesses performance. This structure allows investors to better understand Company performance, better assess prospects for future cash flows, and make more informed decisions about the Company.
 
The Company's molecular diagnostics business focuses on developing and commercializing molecular diagnostic tests, leveraging the latest technology and personalized medicine for better patient diagnosis and management. Through the Company's molecular diagnostics business, the Company aims to provide physicians and patients with diagnostic options for detecting genetic and other molecular alterations that are associated with gastrointestinal and endocrine cancers, which are principally focused on early detection of high potential progressors to cancer. Customers in the Company's molecular diagnostics segment consist primarily of physicians, hospitals and clinics. The service offerings throughout the segment have similar long-term average gross margins, contract terms, types of customers and regulatory environments. They are promoted through one centrally managed marketing group and the chief operating decision maker views their results on a combined basis.
XML 29 R17.htm IDEA: XBRL DOCUMENT v3.5.0.2
Note 11 - Discontinued Operations
9 Months Ended
Sep. 30, 2016
Notes to Financial Statements  
Disposal Groups, Including Discontinued Operations, Disclosure [Text Block]
11.
DISCONTINUED OPERATIONS
 
The table below presents the significant components of CSO, Group DCA's, Pharmakon's and TVG’s results included in (Loss) Income from Discontinued Operations, Net of Tax in the consolidated statements of comprehensive loss for the three- and nine-months ended September 30, 2016 and 2015.
 
   
Three Months Ending September 30,
   
Nine Months Ending September 30,
 
   
2016
   
2015
   
2016
   
2015
 
Revenue, net
  $ -     $ 34,119     $ 1,644     $ 104,408  
                                 
(Loss) income from discontinued operations
    (414 )     2,576       (1,006 )     6,615  
Gain on sale of assets
    -       -       1,326       217  
(Loss) income from discontinued operations, before tax
    (414 )     2,576       320       6,832  
Income tax (benefit) expense
    (117 )     2       219       4  
(Loss) income from discontinued operations, net of tax
  $ (297 )   $ 2,574     $ 101     $ 6,828  
 
The assets and liabilities classified as discontinued operations relate to CSO, Group DCA, Pharmakon, and TVG. As of September 30, 2016 and December 31, 2015, these assets and liabilities are in the accompanying balance sheets as follows:
 
   
For the Nine Months Ended
September 30, 2016
   
For the Year Ended
December 31, 2015
 
   
CSO
   
DCA/TVG
   
Total
   
CSO
   
DCA/TVG
   
Total
 
Accounts receivable, net
  $ -     $ -     $ -     $ 3,296     $ -     $ 3,296  
Unbilled receivable, net
    -       -       -       16       -       16  
Other
    -       150       150       2,062       -       2,062  
Current assets from discontinued operations
    -       150       150       5,374       -       5,374  
Property and equipment, net
    -       -       -       190       -       190  
Other
    -       -       -       -       150       150  
Long-term assets from discontinued operations
    -       -       -       190       150       340  
Total assets
  $ -     $ 150     $ 150     $ 5,564     $ 150     $ 5,714  
                                                 
Accounts payable
  $ 947     $ -     $ 947     $ 3,767     $ -     $ 3,767  
Unearned contract revenue
    -       -       -       11       -       11  
Accrued salary and bonus
    1,686       -       1,686       3,036       -       3,036  
Other
    2,052       70       2,122       5,092       358       5,450  
Current liabilities from discontinued operations
    4,685       70       4,755       11,906       358       12,264  
Total liabilities
  $ 4,685     $ 70     $ 4,755     $ 11,906     $ 358     $ 12,264  
XML 30 R18.htm IDEA: XBRL DOCUMENT v3.5.0.2
Note 12 - Long-term Debt
9 Months Ended
Sep. 30, 2016
Notes to Financial Statements  
Long-term Debt [Text Block]
12.
LONG-TERM DEBT
 
On October 31, 2014, the Company and Interpace LLC, entered into an agreement to acquire RedPath (the Transaction). In connection with the Transaction, the Company entered into a note with the RedPath Equityholder Representative, on behalf of the former equity holders of RedPath, dated October 31, 2014 (the Note).
 
The Note is $11.0 million, interest-free and payable in eight equal consecutive quarterly installments beginning October 1, 2016. On September 30, the Company and the RedPath Equityholder Representative amended the Note to extend the due date of the first installment to November 1, 2016. Effective October 31, 2016, the Company and the RedPath Equityholder Representative amended the Note to further extend the due date of the first installment to November 20, 2016. On November 16, 2016 the Company and the RedPath Equityholder Representative amended the Note to extend the due date of the first installment to December 31, 2016, to add as an event of default the failure of the Company to maintain a minimum net cash balance from operations of no less than $400,000, excluding proceeds from borrowed money, at the end of every week and to add a reporting requirement for the Company to provide to the RedPath Equityholder Representative, on a weekly basis, a 13-week cash flow forecast commencing November 22, 2016. Subsequent payments on the Note are to be made on the first day of each fiscal quarter, beginning on April 1, 2017.
 
In the second quarter of 2015, the final working capital adjustment was made, reducing the balance of the Note to approximately $10.7 million. In December 2015, pursuant to the sale of substantially all of the CSO business, the Note was amended so that the CSO sales proceeds would not have to be applied against the Note payable balance.
 
The interest rate will be 5.0% in the event of a default under the Note. The obligations of the Company under the Note are guaranteed by the Company and its subsidiaries pursuant to a Guarantee and Collateral Agreement (the “Subordinated Guarantee”) in favor of the RedPath Equityholder Representative. Pursuant to the Subordinated Guarantee, the Company and its subsidiaries also granted a security interest in substantially all of their assets, including intellectual property, to secure their obligations to the RedPath Equityholder Representative. Based on the Company's incremental borrowing rate under its Credit Agreement, the fair value of the Note at the date of issuance was $7.5 million. During the quarters ended September 30, 2016 and 2015, the Company accreted approximately $0.2 million into interest expense, respectively, for each period. During the nine months ended September 30, 2016 and 2015, the Company accreted approximately $0.6 million into interest expense, respectively, for each period. As of September 30, 2016, the balance of the Note is approximately $9.0 million and the unamortized discount is $1.7 million.
 
Principal payments due related to the long-term debt, subsequent to the amendment to the Note that was entered into on November 16, 2016, over the next three years are as follows:
 
 
   
2016
 
2017
 
2018
Note
  $ 1,334       $ 4,001       $ 5,335    
 
 
 
The Company currently has an indemnification asset of $1.5 million relating to the DOJ settlement with the former owners of RedPath that was recorded with the acquisition of RedPath. The related DOJ liability is $1.7 million and as the Company makes payments to the DOJ, it may reduce the balance owed on the Note by the same amount.
 
 
In addition, the Company entered into the Credit Agreement with SWK Funding LLC (the Agent) and the lenders party thereto in connection with the Transaction in the aggregate principal amount of $20.0 million (the Loan). The maturity date of the Loan was October 31, 2020. The Company received net proceeds of approximately $19.6 million following payment of certain fees and expenses in connection with the Credit Agreement.
 
Upon the sale of substantially all of the CSO business on December 22, 2015, the Company used a portion of the net proceeds from the transaction to pay the balance of the outstanding loan in the aggregate principal amount of $20.0 million, and an exit fee and expenses of approximately $1.6 million. In connection with the termination of the Credit Agreement, the Guarantee and Collateral Agreement, dated October 31, 2014, by the Company and certain of its subsidiaries in favor of the Agent was also terminated on December 22, 2015.
 
XML 31 R19.htm IDEA: XBRL DOCUMENT v3.5.0.2
Note 13 - Supplemental Cash Flow Information
9 Months Ended
Sep. 30, 2016
Notes to Financial Statements  
Cash Flow, Supplemental Disclosures [Text Block]
13.
SUPPLEMENTAL CASH FLOW INFORMATION
 
The following table represents cash flows (used in) provided by the Company's discontinued operations for the nine months ended September 30, 2016 and 2015:
 
 
 
 
Nine Months Ended
 
 
 
September 30,
 
 
 
2016
 
 
2015
 
Net cash (used in) provided by operating activities of discontinued operations
  $ (1,486 )   $ 7,466  
                 
Net cash (used in) provided by investing activities of discontinued operations
  $ -     $ -  
XML 32 R20.htm IDEA: XBRL DOCUMENT v3.5.0.2
Note 14 - Recent Accounting Pronouncements
9 Months Ended
Sep. 30, 2016
Notes to Financial Statements  
New Accounting Pronouncements and Changes in Accounting Principles [Text Block]
14.
RECENT ACCOUNTING PRONOUNCEMENTS
 
 
In August 2014, the Financial Accounting Standards Board (“FASB”) issued guidance on determining when and how to disclose going-concern uncertainties in the financial statements. The new standard requires management to perform interim and annual assessments of an entity’s ability to continue as a going concern within one year of the date the financial statements are issued. An entity must provide certain disclosures if conditions or events raise substantial doubt about the entity’s ability to continue as 
a going concern. The guidance applies to all entities and is effective for annual periods ending after December 15, 2016, and interim periods thereafter, with early adoption permitted. The Company is evaluating the potential impact of the new guidance on its quarterly reporting process and its
consolidated financial position, results of operations and related disclosures.
 
In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842), which when effective will require organizations that lease assets (e.g., through "leases") to recognize assets and liabilities for the rights and obligations created by the leases on the balance sheet. A lessee will be required to recognize assets and liabilities for leases with terms that exceed twelve months. The standard will also require disclosures to help investors and financial statement users better understand the amount, timing and uncertainty of cash flows arising from leases. The disclosures include qualitative and quantitative requirements, providing additional information about the amounts recorded in the financial statements. The guidance is effective for annual periods beginning after December 15, 2018, and interim periods within those annual periods. Early adoption is permitted. The Company is currently evaluating the impact of this standard on its consolidated financial position and results of operations.
 
In May 2016, the FASB issued ASU 2016-12, "Revenue from Contract with Customers - Narrow-Scope Improvements and Practical Expedients". In April 2016, the FASB issued ASU 2016-10, "Revenue from Contracts with Customers - Identifying Performance Obligations and Licensing". In March 2016, the FASB issued ASU 2016-08, "Revenue from Contract with Customers - Principal versus Agent Considerations (Reporting Revenue Gross versus Net)". In August 2015, the FASB issued ASU 2015-14 deferring the effective date to annual and interim periods. In May 2014, the FASB issued ASU 2014-09, "Revenue from Contracts with Customers". The core principle of these ASUs are that an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. The amendments in ASU 2016-12 affect only the narrow aspects of the guidance, such as assessing the collectability criterion and accounting for contracts that do not meet the criterion, presentation of sales and other similar taxes collected from customers, non-cash consideration, and contract modifications at transition. ASU 2016-10 clarifies two aspects of the guidance: identifying performance obligations and the licensing implementation. The intention of ASU 2016-08 is to improve the operability and understandability of the implementation guidance on principal versus agent considerations. ASU 2015-14 defers the effective date to annual and interim periods beginning on or after December 15, 2017, and early adoption will be permitted, but not earlier than the original effective date of annual and interim periods beginning on or after December 15, 2016, for public entities. ASU 2014-09 is a comprehensive new revenue recognition model for revenue from contract with customers. The Company will adopt these ASUs when effective.
XML 33 R21.htm IDEA: XBRL DOCUMENT v3.5.0.2
Note 15 - Other Subsequent Events
9 Months Ended
Sep. 30, 2016
Notes to Financial Statements  
Subsequent Events [Text Block]
15.
OTHER SUBSEQUENT EVENTS
 
On October 4, 2016, Heinrich Dreismann, Ph.D., resigned as a member of the Board effective as of September 30, 2016. In connection with Dr. Dreismann’s resignation and to comply with Nasdaq Listing Rule 5605(c)(4)(B), on October 5, 2016, the Company notified NASDAQ that, as a result of the vacancy on the Audit Committee of the Board (the “Audit Committee”) created by Dr. Dreismann’s resignation, the Audit Committee only has two members and the Company is not in compliance with Nasdaq Listing Rule 5605(c)(2)(A), which requires the Audit Committee be comprised of at least three members. In response to the Company’s notice, NASDAQ issued a letter to the Company on October 6, 2016 acknowledging the Company’s notice that it is no longer in compliance with the audit committee requirements set forth in Nasdaq Listing Rule 5605(c)(2)(A). In its letter, NASDAQ notified the Company that it can rely on the cure period provided by Nasdaq Listing Rule 5605(c)(4), which allows the Company until the earlier of (i) its next annual meeting of stockholders or (ii) October 2, 2017 to regain compliance, or, if the next annual meeting of stockholders is held before March 29, 2017, then the Company must evidence compliance no later than March 29, 2017. The Company intends to appoint an additional independent director to the Board and to the Audit Committee prior to the end of the cure period.
XML 34 R22.htm IDEA: XBRL DOCUMENT v3.5.0.2
Significant Accounting Policies (Policies)
9 Months Ended
Sep. 30, 2016
Accounting Policies [Abstract]  
Use of Estimates, Policy [Policy Text Block]
Accounting Estimates
 
The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts of assets and liabilities reported and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period.  Management's estimates are based on historical experience, facts and circumstances available at the time, and various other assumptions that are believed to be reasonable under the circumstances.  Significant estimates include best estimate of selling price in multiple element arrangements, valuation allowances related to deferred income taxes, self-insurance loss accruals, allowances for doubtful accounts and notes, income tax accruals, acquisition accounting, asset impairments and facilities realignment accruals.  The Company periodically reviews these matters and reflects changes in estimates as appropriate.  Actual results could materially differ from those estimates.
Reclassification, Policy [Policy Text Block]
Reclassifications
 
The CSO business in the three- and nine-month periods ended September 30, 2015 has been reclassified to discontinued operations to conform to the current period presentation.
Trade and Other Accounts Receivable, Policy [Policy Text Block]
Receivables and Allowance for Doubtful Accounts
 
The Company’s accounts receivable are generated using its proprietary tests. The Company’s services are fulfilled upon completion of the test, review and release of the test results. In conjunction with fulfilling these services, the Company bills the third-party payor or hospital. The Company recognizes accounts receivable related to billings for Medicare, Medicare Advantage, and hospitals on an accrual basis, net of contractual adjustment, when collectability is reasonably assured. Contractual adjustments represent the difference between the list prices and the reimbursement rate set by Medicare and Medicare Advantage, or the amounts billed to hospitals. The Company records an Allowance for Doubtful accounts for PancraGen® hospital roster billings based on the collection history of this payor. Since Medicare and Medicare Advantage have fixed reimbursement rates, there is no Allowance for Doubtful Accounts associated with these payors.
 
The Company provides services to commercial insurance carriers or governmental programs that do not have a contract in place for its proprietary tests which may or may not be covered by these entities existing reimbursement policies. In addition, the Company does not enter into direct agreements with patients that commit them to pay any portion of the cost of the tests in the event that their commercial insurance carrier or governmental program does not pay the Company for its services. In the absence of an agreement with the patient, or other clearly enforceable legal right to demand payment from commercial insurance carriers or governmental agencies, no accounts receivable is recognized. The Company does not record an Allowance for Doubtful Accounts for the commercial insurance or governmental programs since the revenue is recorded mainly on a cash basis. There was approximately a $1.3 million allowance for doubtful accounts as of September 30, 2016.
Other Current Assets, Policy [Policy Text Block]
Other Current Assets
 
Other current assets consisted of the following as of September 30, 2016 and December 31, 2015:
 
 
   
September 30, 2016
   
December 31, 2015
 
Indemnification assets
  $ 1,375     $ 875  
Letters of credit
    -       360  
Other receivables
    666       1,048  
Other
    46       286  
    $ 2,087     $ 2,569  
Goodwill and Intangible Assets, Policy [Policy Text Block]
Other Intangible Assets, including Finite-Lived Intangible Assets
 
The Company allocates the cost of acquired companies to the identifiable tangible and intangible assets acquired and liabilities assumed, with the remaining amount classified as goodwill, if any. Since the entities the Company has acquired do not have significant tangible assets, a significant portion of the purchase price has been allocated to intangible assets and goodwill. The identification and valuation of these intangible assets and the determination of the estimated useful lives at the time of acquisition, as well as the completion of impairment tests, require significant management judgments and estimates. These estimates are made based on, among other factors, consultations with an accredited independent valuation consultant, reviews of projected future operating results and business plans, economic projections, anticipated highest and best use of future cash flows and the market participant cost of capital. The use of alternative estimates and assumptions could increase or decrease the estimated fair value of other intangible assets, and potentially result in a different impact to the Company's results of operations. Further, changes in business strategy and/or market conditions may significantly impact these judgments thereby impacting the fair value of these assets, which could result in an impairment of the intangible assets.
 
Finite-lived intangible assets are stated at cost less accumulated amortization.  Amortization of finite-lived acquired intangible assets is recognized on a straight-line basis, using the estimated useful lives of the assets of approximately two years to nine years in acquisition related amortization expense in the consolidated statements of comprehensive loss.
 
The Company reviews the recoverability of long-lived assets and finite-lived intangible assets whenever events or changes in circumstances indicate that the carrying value of such assets may not be recoverable.  If the sum of the expected future undiscounted cash flows is less than the carrying amount of the asset, an impairment loss is recognized by reducing the recorded value of the asset to its fair value measured by future discounted cash flows.  This analysis requires estimates of the amount and timing of projected cash flows and, where applicable, judgments associated with, among other factors, the market price and physical condition of the assets at measurement date.  Such estimates are critical in determining whether any impairment charge should be recorded and the amount of such charge if an impairment loss is deemed to be necessary. 
 
During the quarter ended September 30, 2016 the Company recorded an asset impairment charge of approximately $3.4 million, resulting from a decline in market value of Pancreas and Biobank assets associated with the acquisition of certain assets from Asuragen.
Discontinued Operations, Policy [Policy Text Block]
Discontinued Operations
 
The Company accounts for business dispositions and its businesses held for sale in accordance with ASC 205-20, Discontinued Operations. ASC 205-20 requires the results of operations of business dispositions to be segregated from continuing operations and reflected as discontinued operations in current and prior periods. See Note 11,
Discontinued Operations
for further information.
 
Earnings Per Share, Policy [Policy Text Block]
Basic and Diluted Net Loss per Share
 
A reconciliation of the number of shares of common stock used in the calculation of basic and diluted loss per share for the three- and nine-month-periods ended September 30, 2016 and 2015 is as follows:
 
 
   
Three Months Ended
   
Nine Months Ended
 
   
September 30,
   
September 30,
 
   
2016
   
2015
   
2016
   
2015
 
Basic weighted average number of  of common shares
    18,163       15,654       18,029       15,301  
Potential dilutive effect of stock-based awards
    -       -       -       -  
Diluted weighted average number of common shares
    18,163       15,654       18,029       15,301  
 
The following outstanding stock-based awards were excluded from the computation of the effect of dilutive securities on loss per share for the following periods because they would have been anti-dilutive:
 
 
 
   
Three Months Ended
   
Nine Months Ended
 
   
September 30,
   
September 30,
 
   
2016
   
2015
   
2016
   
2015
 
Options
    -       -       -       -  
Stock-settled stock appreciation rights (SARs)
    1,027       1,028       1,027       1,028  
Restricted stock and restricted stock units (RSUs)
    1,151       1,745       1,151       1,745  
Performance contingent SARs
    -       188       -       188  
      2,178       2,961       2,178       2,961  
XML 35 R23.htm IDEA: XBRL DOCUMENT v3.5.0.2
Note 2 - Liquidity and Management's Plans (Tables)
9 Months Ended
Sep. 30, 2016
Notes Tables  
Contractual Obligation, Fiscal Year Maturity Schedule [Table Text Block]
   
Total
   
0 to 3
months
   
3 to 6
months
   
6 to 12
months
 
Note due Redpath Equityholders
  $ 4,001     $ 1,334     $     $ 2,667  
Severance obligations
    3,137       3,137       -       -  
DOJ settlement
    665       85       85       495  
Deferred Bonus - ERT salesforce
    800       185       308       307  
Total obligations
  $ 8,603     $ 4,741     $ 393     $ 3,469  
XML 36 R24.htm IDEA: XBRL DOCUMENT v3.5.0.2
Note 3 - Summary of Significant Accounting Policies (Tables)
9 Months Ended
Sep. 30, 2016
Notes Tables  
Schedule of Other Assets [Table Text Block]
   
September 30, 2016
   
December 31, 2015
 
Indemnification assets
  $ 1,375     $ 875  
Letters of credit
    -       360  
Other receivables
    666       1,048  
Other
    46       286  
    $ 2,087     $ 2,569  
Schedule of Weighted Average Number of Shares [Table Text Block]
   
Three Months Ended
   
Nine Months Ended
 
   
September 30,
   
September 30,
 
   
2016
   
2015
   
2016
   
2015
 
Basic weighted average number of  of common shares
    18,163       15,654       18,029       15,301  
Potential dilutive effect of stock-based awards
    -       -       -       -  
Diluted weighted average number of common shares
    18,163       15,654       18,029       15,301  
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]
   
Three Months Ended
   
Nine Months Ended
 
   
September 30,
   
September 30,
 
   
2016
   
2015
   
2016
   
2015
 
Options
    -       -       -       -  
Stock-settled stock appreciation rights (SARs)
    1,027       1,028       1,027       1,028  
Restricted stock and restricted stock units (RSUs)
    1,151       1,745       1,151       1,745  
Performance contingent SARs
    -       188       -       188  
      2,178       2,961       2,178       2,961  
XML 37 R25.htm IDEA: XBRL DOCUMENT v3.5.0.2
Note 4 - Other Intangible Assets (Tables)
9 Months Ended
Sep. 30, 2016
Notes Tables  
Schedule of Acquired Finite-Lived Intangible Assets by Major Class [Table Text Block]
           
As of September 30, 2016
   
As of December 31, 2015
 
   
Life
   
Carrying
   
Carrying
 
   
(Years)
   
Amount
   
Amount
 
Diagnostic assets:
 
 
 
 
 
 
 
 
 
 
 
 
Asuragen acquisition:
                       
Thyroid
    9     $ 8,519     $ 8,519  
Pancreas
    -       -       2,882  
Biobank
    -       -       1,575  
RedPath acquisition:
                       
Pancreas test
    7       16,141       16,141  
Barrett's test
    9       18,351       18,351  
Total
          $ 43,011     $ 47,468  
Diagnostic lab:
 
 
 
 
 
 
 
 
 
 
 
 
CLIA Lab
    2.3     $ 609     $ 609  
                         
Accumulated Amortization
          $ (6,400 )   $ (4,585 )
                         
Net Carrying Value
          $ 37,220     $ 43,492  
Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]
2016
   
2017
   
2018
   
2019
   
2020
 
$ 3,771     $ 4,272     $ 5,292     $ 5,292     $ 5,292  
XML 38 R26.htm IDEA: XBRL DOCUMENT v3.5.0.2
Note 5 - Fair Value Measurements (Tables)
9 Months Ended
Sep. 30, 2016
Notes Tables  
Fair Value, by Balance Sheet Grouping [Table Text Block]
   
As of September 30, 2016
   
Fair Value Measurements
 
   
Carrying
   
Fair
   
As of September 30, 2016
 
   
Amount
   
Value
   
Level 1
   
Level 2
   
Level 3
 
Assets:
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cash and cash equivalents:
                                       
Cash
  $ 1,693     $ 1,693     $ 1,693     $ -     $ -  
Money market funds
    -       -       -       -       -  
    $ 1,693     $ 1,693     $ 1,693     $ -     $ -  
Marketable securities:
                                       
U.S. Treasury securities
  $ -     $ -     $ -     $ -     $ -  
Liabilities:
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Contingent consideration:
                                       
Asuragen
  $ 3,247     $ 3,247     $ -     $ -     $ 3,247  
RedPath
    14,653       14,653       -       -       14,653  
    $ 17,900     $ 17,900     $ -     $ -     $ 17,900  
   
As of December 31, 2015
   
Fair Value Measurements
 
   
Carrying
   
Fair
   
As of December 31, 2015
 
   
Amount
   
Value
   
Level 1
   
Level 2
     
Level 3
 
Assets:
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cash and cash equivalents:
                                         
Cash
  $ 7,534     $ 7,534     $ 7,534     $ -  
 
  $ -  
Money market funds
    776       776       776       -         -  
    $ 8,310     $ 8,310     $ 8,310     $ -       $ -  
Marketable securities:
                                         
Money market funds
  $ 48     $ 48     $ 48     $ -       $ -  
Mutual funds
    58       58       58       -         -  
U.S. Treasury securities
    1,115       1,115       1,115       -         -  
Government agency securities
    131       131       131       -         -  
    $ 1,352     $ 1,352     $ 1,352     $ -       $ -  
Liabilities:
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Contingent consideration:
                                         
Asuragen
  $ 4,628     $ 4,628     $ -     $ -       $ 4,628  
RedPath
    13,921       13,921       -       -         13,921  
    $ 18,549     $ 18,549     $ -     $ -       $ 18,549  
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]
   
2016
 
                           
Adjustments
         
   
January 1,
   
Payments
   
Accretion
   
to Fair Value
   
September 30,
 
Asuragen
  $ 4,628     $ (450 )   $ 243     $ (1,174 )   $ 3,247  
Redpath
    13,921       -       732       -       14,653  
    $ 18,549     $ (450 )   $ 975     $ (1,174 )   $ 17,900  
XML 39 R27.htm IDEA: XBRL DOCUMENT v3.5.0.2
Note 7 - Accrued Expenses and Long-term Liabilities (Tables)
9 Months Ended
Sep. 30, 2016
Notes Tables  
Schedule of Accrued Liabilities [Table Text Block]
   
September 30, 2016
   
December 31, 2015
 
Accrued royalties
  $ 504     $ 111  
Self insurance and benefit accruals
    272       366  
Indemnification liability
    875       875  
Contingent consideration
    209       659  
Rent payable
    78       127  
DOJ settlement
    665       250  
Accrued professional fees
    1,320       775  
Taxes payable
    691       591  
Unclaimed property
    544       546  
Directors fees and insurance
    208       107  
All others
    1,539       1,554  
    $ 6,905     $ 5,961  
Schedule of Other Assets and Other Liabilities [Table Text Block]
   
September 30, 2016
   
December 31, 2015
 
Rent payable
  $ -     $ 52  
Uncertain tax positions
    3,556       3,425  
DOJ settlement (indemnified by RedPath)
    1,000       2,500  
Other
    59       201  
    $ 4,615     $ 6,178  
XML 40 R28.htm IDEA: XBRL DOCUMENT v3.5.0.2
Note 8 - Stock-based Compensation (Tables)
9 Months Ended
Sep. 30, 2016
Notes Tables  
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]
   
Nine Months Ended
 
   
September 30,
 
   
2016
   
2015
 
Risk-free interest rate
    -       1.02 %
Expected life (years)
    -       3.5  
Expected volatility
    -       54.47 %
Dividend yield
    -       -  
XML 41 R29.htm IDEA: XBRL DOCUMENT v3.5.0.2
Note 9 - Income Taxes (Tables)
9 Months Ended
Sep. 30, 2016
Notes Tables  
Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]
   
Three Months Ended
   
Nine Months Ended
 
   
September 30,
   
September 30,
 
   
2016
   
2015
   
2016
   
2015
 
Provision (benefit) from income tax
  $ 173     $ (180 )   $ (54 )   $ (430 )
Effective income tax rate
    (2.5% )     2.4 %     0.4 %     1.9 %
XML 42 R30.htm IDEA: XBRL DOCUMENT v3.5.0.2
Note 11 - Discontinued Operations (Tables)
9 Months Ended
Sep. 30, 2016
Notes Tables  
Schedule of Components of Loss from Discontinued Operations [Table Text Block]
   
Three Months Ending September 30,
   
Nine Months Ending September 30,
 
   
2016
   
2015
   
2016
   
2015
 
Revenue, net
  $ -     $ 34,119     $ 1,644     $ 104,408  
                                 
(Loss) income from discontinued operations
    (414 )     2,576       (1,006 )     6,615  
Gain on sale of assets
    -       -       1,326       217  
(Loss) income from discontinued operations, before tax
    (414 )     2,576       320       6,832  
Income tax (benefit) expense
    (117 )     2       219       4  
(Loss) income from discontinued operations, net of tax
  $ (297 )   $ 2,574     $ 101     $ 6,828  
Discontinued Operation, Schedule of Amounts Recognized in Balance Sheet [Table Text Block]
   
For the Nine Months Ended
September 30, 2016
   
For the Year Ended
December 31, 2015
 
   
CSO
   
DCA/TVG
   
Total
   
CSO
   
DCA/TVG
   
Total
 
Accounts receivable, net
  $ -     $ -     $ -     $ 3,296     $ -     $ 3,296  
Unbilled receivable, net
    -       -       -       16       -       16  
Other
    -       150       150       2,062       -       2,062  
Current assets from discontinued operations
    -       150       150       5,374       -       5,374  
Property and equipment, net
    -       -       -       190       -       190  
Other
    -       -       -       -       150       150  
Long-term assets from discontinued operations
    -       -       -       190       150       340  
Total assets
  $ -     $ 150     $ 150     $ 5,564     $ 150     $ 5,714  
                                                 
Accounts payable
  $ 947     $ -     $ 947     $ 3,767     $ -     $ 3,767  
Unearned contract revenue
    -       -       -       11       -       11  
Accrued salary and bonus
    1,686       -       1,686       3,036       -       3,036  
Other
    2,052       70       2,122       5,092       358       5,450  
Current liabilities from discontinued operations
    4,685       70       4,755       11,906       358       12,264  
Total liabilities
  $ 4,685     $ 70     $ 4,755     $ 11,906     $ 358     $ 12,264  
XML 43 R31.htm IDEA: XBRL DOCUMENT v3.5.0.2
Note 12 - Long-term Debt (Tables)
9 Months Ended
Sep. 30, 2016
Notes Tables  
Schedule of Debt [Table Text Block]
   
2016
 
2017
 
2018
Note
  $ 1,334       $ 4,001       $ 5,335    
XML 44 R32.htm IDEA: XBRL DOCUMENT v3.5.0.2
Note 13 - Supplemental Cash Flow Information (Tables)
9 Months Ended
Sep. 30, 2016
Notes Tables  
Schedule of Cash Flow, Supplemental Disclosures [Table Text Block]
 
 
Nine Months Ended
 
 
 
September 30,
 
 
 
2016
 
 
2015
 
Net cash (used in) provided by operating activities of discontinued operations
  $ (1,486 )   $ 7,466  
                 
Net cash (used in) provided by investing activities of discontinued operations
  $ -     $ -  
XML 45 R33.htm IDEA: XBRL DOCUMENT v3.5.0.2
Note 2 - Liquidity and Management's Plans (Details Textual)
1 Months Ended 3 Months Ended 9 Months Ended
Sep. 30, 2016
USD ($)
Sep. 28, 2016
USD ($)
Dec. 31, 2015
USD ($)
Sep. 30, 2016
USD ($)
Sep. 30, 2015
USD ($)
Sep. 30, 2016
USD ($)
Sep. 30, 2015
USD ($)
Nov. 14, 2016
USD ($)
Dec. 31, 2014
USD ($)
CSO [Member]                  
Proceeds from Divestiture of Businesses     $ 26,800,000            
Secured Note Payable to RedPath Equity Representative [Member]                  
Contractual Obligation $ 10,700,000     $ 10,700,000   $ 10,700,000      
Debt Instrument, Covenant Term, Net Cash Balance, Amount 400,000                
Debt Instrument, Periodic Payment, Principal $ 1,333,750                
Debt Instrument, Number of Periodic Payments, Principal 8     8   8      
Employee Severance [Member]                  
Contractual Obligation $ 3,100,000     $ 3,100,000   $ 3,100,000      
Obligations to Former Sales Representatives, Under the CSO Incentive Plan [Member] | Maximum [Member]                  
Contractual Obligation 1,000,000     1,000,000   1,000,000      
Obligations to Former Sales Representatives, Under the CSO Incentive Plan [Member]                  
Contractual Obligation $ 600,000     $ 600,000   $ 600,000      
Credit Agreement [Member] | SCM Specialty Finance Opportunities Fund, L.P. [Member] | Revolving Credit Facility [Member] | Prime Rate [Member]                  
Debt Instrument, Basis Spread on Variable Rate   2.75%              
Credit Agreement [Member] | SCM Specialty Finance Opportunities Fund, L.P. [Member] | Revolving Credit Facility [Member] | Subsequent Event [Member]                  
Long-term Line of Credit               $ 0  
Credit Agreement [Member] | SCM Specialty Finance Opportunities Fund, L.P. [Member] | Revolving Credit Facility [Member]                  
Line of Credit Facility, Maximum Borrowing Capacity   $ 1,200,000              
Debt Instrument, Interest Rate, Increase in Event of Default   5.00%              
Debt Instrument, Fee Amount   $ 12,000              
Debt Instrument, Percentage Used to Determine Monthly Unused Line Fee   0.083%              
Debt Instrument, Percentage Used to Determine Monthly Collateral Management Fee   0.1666%              
Debt Instrument, Percentage Used to Determine Termination Fee, Before First Anniversary   2.00%              
Debt Instrument, Percentage Used to Determine Termination Fee, After First Anniversary   1.00%              
Obligations to Former Sales Representatives, Under the CSO Incentive Plan [Member]                  
Restructuring and Related Cost, Number of Positions Eliminated, Inception to Date 343     343   343      
Payments for Restructuring           $ 100,000      
Net Income (Loss) Attributable to Parent       $ (7,493,000) $ (4,895,000) (14,613,000) $ (15,741,000)    
Net Cash Provided by (Used in) Operating Activities           (6,617,000) (13,536,000)    
Cash and Cash Equivalents, at Carrying Value $ 1,693,000   8,310,000 1,693,000 $ 8,955,000 1,693,000 $ 8,955,000   $ 23,111,000
Accounts Receivable, Net, Current 2,753,000   2,806,000 2,753,000   2,753,000      
Assets, Current 6,683,000   19,165,000 6,683,000   6,683,000      
Liabilities, Current $ 19,870,000   23,373,000 $ 19,870,000   $ 19,870,000      
Repayments of Long-term Debt     $ 21,600,000            
XML 46 R34.htm IDEA: XBRL DOCUMENT v3.5.0.2
Note 2 - Liquidity and Management's Plan - Contractual Obligations Due in the Next 12 Months (Details)
$ in Thousands
Sep. 30, 2016
USD ($)
Secured Note Payable to RedPath Equity Representative [Member]  
Contractual Obligations, Due $ 4,001
Contractual Obligations, Due in 0 to 3 Months 1,334
Contractual Obligations, Due in 3 to 6 Months
Contractual Obligations, Due in 6 to 12 Months 2,667
DOJ Settlement [Member]  
Contractual Obligations, Due 665
Contractual Obligations, Due in 0 to 3 Months 85
Contractual Obligations, Due in 3 to 6 Months 85
Contractual Obligations, Due in 6 to 12 Months 495
Employee Severance [Member]  
Contractual Obligations, Due 3,137
Contractual Obligations, Due in 0 to 3 Months 3,137
Contractual Obligations, Due in 3 to 6 Months
Contractual Obligations, Due in 6 to 12 Months
Interpace Diagnostics, LLC [Member]  
Contractual Obligations, Due 800
Contractual Obligations, Due in 0 to 3 Months 185
Contractual Obligations, Due in 3 to 6 Months 308
Contractual Obligations, Due in 6 to 12 Months 307
Contractual Obligations, Due 8,603
Contractual Obligations, Due in 0 to 3 Months 4,741
Contractual Obligations, Due in 3 to 6 Months 393
Contractual Obligations, Due in 6 to 12 Months $ 3,469
XML 47 R35.htm IDEA: XBRL DOCUMENT v3.5.0.2
Note 3 - Summary of Significant Accounting Policies (Details Textual) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2016
Sep. 30, 2015
Sep. 30, 2016
Sep. 30, 2015
Minimum [Member]        
Finite-Lived Intangible Asset, Useful Life     2 years  
Maximum [Member]        
Finite-Lived Intangible Asset, Useful Life     9 years  
Allowance for Doubtful Accounts Receivable, Current $ 1,300   $ 1,300  
Asset Impairment Charges $ 3,363 $ 3,363
XML 48 R36.htm IDEA: XBRL DOCUMENT v3.5.0.2
Note 3 - Summary of Significant Accounting Policies - Other Current Assets (Details) - USD ($)
$ in Thousands
Sep. 30, 2016
Dec. 31, 2015
Indemnification assets $ 1,375 $ 875
Letters of credit 360
Other receivables 666 1,048
Other 46 286
$ 2,087 $ 2,569
XML 49 R37.htm IDEA: XBRL DOCUMENT v3.5.0.2
Note 3 - Summary of Significant Accounting Policies - Reconciliation of the Number of Shares Used in Basic and Diluted Earnings Per Share (Details) - shares
shares in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2016
Sep. 30, 2015
Sep. 30, 2016
Sep. 30, 2015
Basic weighted average number of of common shares (in shares) 18,163 15,654 18,029 15,301
Potential dilutive effect of stock-based awards (in shares)
Diluted weighted average number of common shares (in shares) 18,163 15,654 18,029 15,301
XML 50 R38.htm IDEA: XBRL DOCUMENT v3.5.0.2
Note 3 - Summary of Significant Accounting Policies - Stock Awards Excluded from the Computation of the Effect of Dilutive Securities (Details) - shares
shares in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2016
Sep. 30, 2015
Sep. 30, 2016
Sep. 30, 2015
Employee Stock Option [Member]        
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount (in shares)
Stock Appreciation Rights (SARs) [Member]        
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount (in shares) 1,027 1,028 1,027 1,028
Restricted Stock Units (RSUs) [Member]        
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount (in shares) 1,151 1,745 1,151 1,745
Performance Shares [Member]        
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount (in shares) 188 188
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount (in shares) 2,178 2,961 2,178 2,961
XML 51 R39.htm IDEA: XBRL DOCUMENT v3.5.0.2
Note 4 - Other Intangible Assets (Details Textual) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2016
Sep. 30, 2015
Sep. 30, 2016
Sep. 30, 2015
Amortization of Intangible Assets $ 970 $ 986 $ 2,909 $ 2,825
Asset Impairment Charges $ 3,363 $ 3,363
XML 52 R40.htm IDEA: XBRL DOCUMENT v3.5.0.2
Note 4 - Other Intangible Assets - Identifiable Intangible Assets Carrying Value (Details) - USD ($)
$ in Thousands
9 Months Ended
Sep. 30, 2016
Dec. 31, 2015
Diagnostic Test, Thyroid [Member] | Asuragen [Member]    
Finite-lived intangible asset, useful life 9 years  
Finite-Lived Intangible Assets, Net $ 8,519 $ 8,519
Diagnostic Test, Pancreas [Member] | Asuragen [Member]    
Finite-lived intangible asset, useful life  
Finite-Lived Intangible Assets, Net 2,882
Diagnostic Test, Pancreas [Member] | RedPath [Member]    
Finite-lived intangible asset, useful life 7 years  
Finite-Lived Intangible Assets, Net $ 16,141 16,141
Diagnostic Test, Biobank [Member] | Asuragen [Member]    
Finite-lived intangible asset, useful life  
Finite-Lived Intangible Assets, Net 1,575
Diagnostic Test, Barrett's RedPath [Member] | RedPath [Member]    
Finite-lived intangible asset, useful life 9 years  
Finite-Lived Intangible Assets, Net $ 18,351 18,351
CLIA Diagnostic Lab [Member]    
Finite-lived intangible asset, useful life 2 years 109 days  
Finite-Lived Intangible Assets, Net $ 609 609
RedPath [Member]    
Finite-Lived Intangible Assets, Net 43,011 47,468
Finite-Lived Intangible Assets, Net 37,220 43,492
Finite-Lived Intangible Assets, Accumulated Amortization $ (6,400) $ (4,585)
XML 53 R41.htm IDEA: XBRL DOCUMENT v3.5.0.2
Note 4 - Other Intangible Assets - Future Estimated Amortization Expense (Details)
$ in Thousands
Sep. 30, 2016
USD ($)
2016 $ 3,771
2017 4,272
2018 5,292
2019 5,292
2020 $ 5,292
XML 54 R42.htm IDEA: XBRL DOCUMENT v3.5.0.2
Note 5 - Fair Value Measurements - Financial Instruments (Details) - USD ($)
$ in Thousands
Sep. 30, 2016
Dec. 31, 2015
Cash [Member] | Reported Value Measurement [Member]    
Cash and cash equivalents, fair value disclosure $ 1,693 $ 7,534
Cash [Member] | Estimate of Fair Value Measurement [Member]    
Cash and cash equivalents, fair value disclosure 1,693 7,534
Cash [Member] | Fair Value, Inputs, Level 1 [Member]    
Cash and cash equivalents, fair value disclosure 1,693 7,534
Cash [Member] | Fair Value, Inputs, Level 2 [Member]    
Cash and cash equivalents, fair value disclosure
Cash [Member] | Fair Value, Inputs, Level 3 [Member]    
Cash and cash equivalents, fair value disclosure
Money Market Funds [Member] | Reported Value Measurement [Member]    
Cash and cash equivalents, fair value disclosure 776
Money Market Funds [Member] | Estimate of Fair Value Measurement [Member]    
Cash and cash equivalents, fair value disclosure 776
Money Market Funds [Member] | Fair Value, Inputs, Level 1 [Member]    
Cash and cash equivalents, fair value disclosure 776
Money Market Funds [Member] | Fair Value, Inputs, Level 2 [Member]    
Cash and cash equivalents, fair value disclosure
Money Market Funds [Member] | Fair Value, Inputs, Level 3 [Member]    
Cash and cash equivalents, fair value disclosure
Reported Value Measurement [Member] | Fair Value, Inputs, Level 1 [Member]    
Cash and cash equivalents, fair value disclosure 1,693  
Reported Value Measurement [Member] | Fair Value, Inputs, Level 2 [Member]    
Cash and cash equivalents, fair value disclosure  
Reported Value Measurement [Member] | Fair Value, Inputs, Level 3 [Member]    
Cash and cash equivalents, fair value disclosure  
Reported Value Measurement [Member] | US Treasury Securities [Member]    
Investments, fair value disclosure 1,115
Reported Value Measurement [Member] | Marketable Securities, Money Market Funds [Member]    
Investments, fair value disclosure   48
Reported Value Measurement [Member] | Mutual Funds [Member]    
Investments, fair value disclosure   58
Reported Value Measurement [Member] | Government Agency Securities [Member]    
Investments, fair value disclosure   131
Reported Value Measurement [Member] | Asuragen [Member]    
Contingent consideration, deferred payments 3,247 4,628
Reported Value Measurement [Member] | RedPath [Member]    
Contingent consideration, deferred payments 14,653 13,921
Reported Value Measurement [Member]    
Cash and cash equivalents, fair value disclosure 1,693 8,310
Investments, fair value disclosure   1,352
Contingent consideration, deferred payments 17,900 18,549
Estimate of Fair Value Measurement [Member] | US Treasury Securities [Member]    
Investments, fair value disclosure 1,115
Estimate of Fair Value Measurement [Member] | Marketable Securities, Money Market Funds [Member]    
Investments, fair value disclosure   48
Estimate of Fair Value Measurement [Member] | Mutual Funds [Member]    
Investments, fair value disclosure   58
Estimate of Fair Value Measurement [Member] | Government Agency Securities [Member]    
Investments, fair value disclosure   131
Estimate of Fair Value Measurement [Member] | Asuragen [Member]    
Contingent consideration, deferred payments 3,247 4,628
Estimate of Fair Value Measurement [Member] | RedPath [Member]    
Contingent consideration, deferred payments 14,653 13,921
Estimate of Fair Value Measurement [Member]    
Cash and cash equivalents, fair value disclosure 1,693 8,310
Investments, fair value disclosure   1,352
Contingent consideration, deferred payments 17,900 18,549
Fair Value, Inputs, Level 1 [Member] | US Treasury Securities [Member]    
Investments, fair value disclosure 1,115
Fair Value, Inputs, Level 1 [Member] | Marketable Securities, Money Market Funds [Member]    
Investments, fair value disclosure   48
Fair Value, Inputs, Level 1 [Member] | Mutual Funds [Member]    
Investments, fair value disclosure   58
Fair Value, Inputs, Level 1 [Member] | Government Agency Securities [Member]    
Investments, fair value disclosure   131
Fair Value, Inputs, Level 1 [Member] | Asuragen [Member]    
Contingent consideration, deferred payments
Fair Value, Inputs, Level 1 [Member] | RedPath [Member]    
Contingent consideration, deferred payments
Fair Value, Inputs, Level 1 [Member]    
Cash and cash equivalents, fair value disclosure   8,310
Investments, fair value disclosure   1,352
Contingent consideration, deferred payments
Fair Value, Inputs, Level 2 [Member] | US Treasury Securities [Member]    
Investments, fair value disclosure
Fair Value, Inputs, Level 2 [Member] | Marketable Securities, Money Market Funds [Member]    
Investments, fair value disclosure  
Fair Value, Inputs, Level 2 [Member] | Mutual Funds [Member]    
Investments, fair value disclosure  
Fair Value, Inputs, Level 2 [Member] | Government Agency Securities [Member]    
Investments, fair value disclosure  
Fair Value, Inputs, Level 2 [Member] | Asuragen [Member]    
Contingent consideration, deferred payments
Fair Value, Inputs, Level 2 [Member] | RedPath [Member]    
Contingent consideration, deferred payments
Fair Value, Inputs, Level 2 [Member]    
Cash and cash equivalents, fair value disclosure  
Investments, fair value disclosure  
Contingent consideration, deferred payments
Fair Value, Inputs, Level 3 [Member] | US Treasury Securities [Member]    
Investments, fair value disclosure
Fair Value, Inputs, Level 3 [Member] | Marketable Securities, Money Market Funds [Member]    
Investments, fair value disclosure  
Fair Value, Inputs, Level 3 [Member] | Mutual Funds [Member]    
Investments, fair value disclosure  
Fair Value, Inputs, Level 3 [Member] | Government Agency Securities [Member]    
Investments, fair value disclosure  
Fair Value, Inputs, Level 3 [Member] | Asuragen [Member]    
Contingent consideration, deferred payments 3,247 4,628
Fair Value, Inputs, Level 3 [Member] | RedPath [Member]    
Contingent consideration, deferred payments 14,653 13,921
Fair Value, Inputs, Level 3 [Member]    
Cash and cash equivalents, fair value disclosure  
Investments, fair value disclosure  
Contingent consideration, deferred payments $ 17,900 $ 18,549
XML 55 R43.htm IDEA: XBRL DOCUMENT v3.5.0.2
Note 5 - Fair Value Measurements - Roll-forward of the Carrying Value of the Contingent Consideration (Details) - Contingent Consideration [Member]
$ in Thousands
9 Months Ended
Sep. 30, 2016
USD ($)
Asuragen [Member]  
Beginning Balance $ 4,628
Payments (450)
Accretion 243
Adjustments to Fair Value (1,174)
Ending Balance 3,247
RedPath [Member]  
Beginning Balance 13,921
Payments
Accretion 732
Adjustments to Fair Value
Ending Balance 14,653
Beginning Balance 18,549
Payments (450)
Accretion 975
Adjustments to Fair Value (1,174)
Ending Balance $ 17,900
XML 56 R44.htm IDEA: XBRL DOCUMENT v3.5.0.2
Note 6 - Commitments and Contingencies (Details Textual) - USD ($)
1 Months Ended 3 Months Ended 9 Months Ended 10 Months Ended 12 Months Ended
Feb. 28, 2017
Oct. 31, 2016
Oct. 13, 2016
Jul. 31, 2016
May 27, 2016
Jun. 16, 2015
Jun. 03, 2015
Oct. 31, 2014
May 31, 2016
Mar. 31, 2016
Mar. 31, 2016
Sep. 30, 2016
Oct. 31, 2016
Dec. 31, 2015
Former Owners of RedPath [Member] | Subsequent Event [Member]                            
Loss Contingency Accrual, Payments                         $ 170,000  
Former Owners of RedPath [Member]                            
Business Combination, Indemnification Assets, Amount as of Acquisition Date               $ 2,500,000            
DOJ [Member] | Subsequent Event [Member]                            
Loss Contingency Accrual, Payments   $ 85,000                        
DOJ [Member] | Scenario, Forecast [Member]                            
Loss Contingency Accrual, Payments $ 80,000                          
DOJ [Member]                            
Loss Contingency, Renegotiated, Amount                 $ 250,000          
Loss Contingency Accrual, Payments       $ 85,000                    
Subsequent Event [Member] | Companys Counter-claim Against Prolias [Member]                            
Litigation Settlement, Amount     $ 500,000                      
Loss Contingency, Damages Sought, Value     $ (621,236.16)                      
Loss Contingency, Interest on Settlement     10.00%                      
Loss Contingency Damages Sought, Value, Attorney Fees     $ 390,769.04                      
Other Accrued Expenses [Member]                            
Regulatory Liabilities                       $ 700,000    
Other Noncurrent Liabilities [Member]                            
Regulatory Liabilities                       1,000,000    
Companys Counter-claim Against Prolias [Member]                            
Loss Contingency, Damages Sought, Value             $ 500,000              
Notes Issued             $ 1,000,000              
Swann vs. Akorn, Inc, and Interpace Diagnostics Group, Inc. [Member]                            
Loss Contingency, Damages Sought, Value         $ 300,000                  
Continuing Operations [Member]                            
Severance Costs                     $ 500,000 2,300,000    
Discontinued Operations [Member]                            
Severance Costs                       800,000    
Letters of Credit Outstanding, Amount                       $ 300,000    
Business Acquisition, Equity Interest Issued or Issuable, Number of Shares           500,000   500,000   500,000        
Common Stock, Par or Stated Value Per Share               $ 0.01       $ 0.01   $ 0.01
Adjustments to Additional Paid in Capital, Other           $ (6,100,000)       $ (6,800,000)        
Stock Issued During Period, Value, Treasury Stock Reissued           $ 6,100,000       $ 6,800,000        
Litigation Settlement, Amount               $ 3,000,000            
Regulatory Liabilities                       $ 1,700,000    
Severance Costs                     $ 1,100,000 $ 3,100,000   $ 3,700,000
XML 57 R45.htm IDEA: XBRL DOCUMENT v3.5.0.2
Note 7 - Accrued Expenses and Long-term Liabilities - Accrued Expenses (Details) - USD ($)
$ in Thousands
Sep. 30, 2016
Dec. 31, 2015
Accrued royalties $ 504 $ 111
Self insurance and benefit accruals 272 366
Indemnification liability 875 875
Contingent consideration 209 659
Rent payable 78 127
DOJ settlement 665 250
Accrued professional fees 1,320 775
Taxes payable 691 591
Unclaimed property 544 546
Directors fees and insurance 208 107
All others 1,539 1,554
$ 6,905 $ 5,961
XML 58 R46.htm IDEA: XBRL DOCUMENT v3.5.0.2
Note 7 - Accrued Expenses and Long-term Liabilities - Other Long-term Liabilities (Details) - USD ($)
$ in Thousands
Sep. 30, 2016
Dec. 31, 2015
Rent payable $ 52
Uncertain tax positions 3,556 3,425
DOJ settlement (indemnified by RedPath) 1,000 2,500
Other Liabilities Noncurrent 59 201
$ 4,615 $ 6,178
XML 59 R47.htm IDEA: XBRL DOCUMENT v3.5.0.2
Note 8 - Stock-based Compensation (Details Textual) - USD ($)
$ / shares in Units, $ in Thousands
1 Months Ended 3 Months Ended 9 Months Ended 12 Months Ended
Oct. 14, 2016
Feb. 29, 2016
Sep. 30, 2016
Sep. 30, 2015
Sep. 30, 2016
Sep. 30, 2015
Dec. 31, 2015
Stock Appreciation Rights (SARs) [Member]              
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage             33.33%
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period             5 years
RSU's and Restricted Stock [Member] | Director [Member]              
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage   33.33%          
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period             3 years
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period   1,300,000          
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value   $ 0.25          
RSU's and Restricted Stock [Member]              
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period             3 years
Employee Stock Option [Member] | CEO, CFO, and Certain Employees [Member] | Subsequent Event [Member]              
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period 1 year            
CEO, CFO, and Certain Employees [Member] | Subsequent Event [Member]              
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 878,744            
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price $ 0.16            
Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized             2,450,000
Allocated Share-based Compensation Expense     $ 20 $ 300 $ 100 $ 1,000  
XML 60 R48.htm IDEA: XBRL DOCUMENT v3.5.0.2
Note 8 - Stock-based Compensation - Weighted Average Assumptions (Details)
9 Months Ended
Sep. 30, 2016
Sep. 30, 2015
Risk-free interest rate 1.02%
Expected life (years) 3 years 182 days
Expected volatility 54.47%
Dividend yield 0.00%
XML 61 R49.htm IDEA: XBRL DOCUMENT v3.5.0.2
Note 9 - Income Taxes - Income Taxes (Details) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2016
Sep. 30, 2015
Sep. 30, 2016
Sep. 30, 2015
Provision (benefit) from income tax $ 173 $ (180) $ (54) $ (430)
Effective income tax rate (2.50%) 2.40% 0.40% 1.90%
XML 62 R50.htm IDEA: XBRL DOCUMENT v3.5.0.2
Note 10 - Segment Information (Details Textual)
12 Months Ended
Dec. 31, 2015
Number of Reportable Segments 1
XML 63 R51.htm IDEA: XBRL DOCUMENT v3.5.0.2
Note 11 - Discontinued Operations - Results Included in Loss From Discontinued Operations, Net of Tax (Details) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2016
Sep. 30, 2015
Sep. 30, 2016
Sep. 30, 2015
Revenue, net $ 34,119 $ 1,644 $ 104,408
(Loss) income from discontinued operations (414) 2,576 (1,006) 6,615
Gain on sale of assets 1,326 217
(Loss) income from discontinued operations, before tax (414) 2,576 320 6,832
Income tax (benefit) expense (117) 2 219 4
(Loss) income from discontinued operations, net of tax $ (297) $ 2,574 $ 101 $ 6,828
XML 64 R52.htm IDEA: XBRL DOCUMENT v3.5.0.2
Note 11 - Discontinued Operations - Assets and Liabilities Classified as Discontinued Operations (Details) - USD ($)
$ in Thousands
Sep. 30, 2016
Dec. 31, 2015
Commercial Services [Member]    
Accounts receivable, net $ 3,296
Unbilled receivable, net 16
Other 2,062
Current assets from discontinued operations 5,374
Property and equipment, net 190
Other
Long-term assets from discontinued operations 190
Total assets 5,564
Accounts payable 947 3,767
Unearned contract revenue 11
Accrued salary and bonus 1,686 3,036
Other, liabilities 2,052 5,092
Current liabilities from discontinued operations 4,685 11,906
Total liabilities 4,685 11,906
Other Discontinued Operations [Member]    
Accounts receivable, net
Unbilled receivable, net
Other 150
Current assets from discontinued operations 150
Property and equipment, net
Other 150
Long-term assets from discontinued operations 150
Total assets 150 150
Accounts payable
Unearned contract revenue
Accrued salary and bonus
Other, liabilities 70 358
Current liabilities from discontinued operations 70 358
Total liabilities 70 358
Accounts receivable, net 3,296
Unbilled receivable, net 16
Other 150 2,062
Current assets from discontinued operations 150 5,374
Property and equipment, net 190
Other 150
Long-term assets from discontinued operations 340
Total assets 150 5,714
Accounts payable 947 3,767
Unearned contract revenue 11
Accrued salary and bonus 1,686 3,036
Other, liabilities 2,122 5,450
Current liabilities from discontinued operations 4,755 12,264
Total liabilities $ 4,755 $ 12,264
XML 65 R53.htm IDEA: XBRL DOCUMENT v3.5.0.2
Note 12 - Long-term Debt (Details Textual) - USD ($)
3 Months Ended 9 Months Ended
Nov. 14, 2016
Dec. 22, 2015
Oct. 31, 2014
Sep. 30, 2016
Sep. 30, 2015
Sep. 30, 2016
Sep. 30, 2015
Jun. 30, 2015
RedPath Integrated Pathology, Inc [Member] | Notes Payable, Other Payables [Member] | The Note [Member]                
Debt Instrument, Face Amount     $ 11,000,000          
Debt Instrument, Covenant Term, Net Cash Balance, Amount $ 400,000              
Debt Instrument, Covenant Term, Rolling Net Cash Flow Analysis 91 days              
Long-term Debt       $ 9,000,000   $ 9,000,000   $ 10,700,000
Debt Instrument, Interest Rate, Stated Percentage     5.00%          
Business Combination, Consideration Transferred, Liabilities Incurred     $ 7,500,000          
Interest Expense, Debt       200,000 $ 200,000 600,000 $ 600,000  
Debt Instrument, Unamortized Discount       1,700,000   1,700,000    
RedPath Integrated Pathology, Inc [Member] | Loans Payable [Member]                
Debt Instrument, Face Amount     20,000,000          
Proceeds from Issuance of Debt     $ 19,600,000          
RedPath Integrated Pathology, Inc [Member]                
Business Combination, Indemnification Assets, Amount as of Acquisition Date       1,500,000   1,500,000    
Regulatory Liabilities       1,700,000   1,700,000    
Interest Expense, Debt       539,000 $ 884,000 1,601,000 $ 2,616,000  
Regulatory Liabilities       $ 1,700,000   $ 1,700,000    
Payments for Other Fees   $ 1,600,000            
XML 66 R54.htm IDEA: XBRL DOCUMENT v3.5.0.2
Note 12 - Long-term Debt - Long-term Debt Future Principal Payments (Details)
$ in Thousands
Sep. 30, 2016
USD ($)
2016 $ 1,334
2017 4,001
2018 $ 5,335
XML 67 R55.htm IDEA: XBRL DOCUMENT v3.5.0.2
Note 13 - Supplemental Cash Flow Information - Supplemental Cash Flow Information (Details) - USD ($)
$ in Thousands
9 Months Ended
Sep. 30, 2016
Sep. 30, 2015
Net cash (used in) provided by operating activities of discontinued operations $ (1,486) $ 7,466
Net cash (used in) provided by investing activities of discontinued operations
EXCEL 68 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 69 Show.js IDEA: XBRL DOCUMENT /** * Rivet Software Inc. * * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved. * Version 2.4.0.3 * */ var Show = {}; Show.LastAR = null, Show.hideAR = function(){ Show.LastAR.style.display = 'none'; }; Show.showAR = function ( link, id, win ){ if( Show.LastAR ){ Show.hideAR(); } var ref = link; do { ref = ref.nextSibling; } while (ref && ref.nodeName != 'TABLE'); if (!ref || ref.nodeName != 'TABLE') { var tmp = win ? win.document.getElementById(id) : document.getElementById(id); if( tmp ){ ref = tmp.cloneNode(true); ref.id = ''; link.parentNode.appendChild(ref); } } if( ref ){ ref.style.display = 'block'; Show.LastAR = ref; } }; Show.toggleNext = function( link ){ var ref = link; do{ ref = ref.nextSibling; }while( ref.nodeName != 'DIV' ); if( ref.style && ref.style.display && ref.style.display == 'none' ){ ref.style.display = 'block'; if( link.textContent ){ link.textContent = link.textContent.replace( '+', '-' ); }else{ link.innerText = link.innerText.replace( '+', '-' ); } }else{ ref.style.display = 'none'; if( link.textContent ){ link.textContent = link.textContent.replace( '-', '+' ); }else{ link.innerText = link.innerText.replace( '-', '+' ); } } }; XML 70 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 72 FilingSummary.xml IDEA: XBRL DOCUMENT 3.5.0.2 html 193 256 1 false 57 0 false 4 false false R1.htm 000 - Document - Document And Entity Information Sheet http://www.interpacediagnostics.com/20160930/role/statement-document-and-entity-information Document And Entity Information Cover 1 false false R2.htm 001 - Statement - Condensed Consolidated Balance Sheets (Current Period Unaudited) Sheet http://www.interpacediagnostics.com/20160930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited Condensed Consolidated Balance Sheets (Current Period Unaudited) Statements 2 false false R3.htm 002 - Statement - Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) Sheet http://www.interpacediagnostics.com/20160930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited-parentheticals Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) Statements 3 false false R4.htm 003 - Statement - Condensed Consolidated Statements of Comprehensive Loss (Unaudited) Sheet http://www.interpacediagnostics.com/20160930/role/statement-condensed-consolidated-statements-of-comprehensive-loss-unaudited Condensed Consolidated Statements of Comprehensive Loss (Unaudited) Statements 4 false false R5.htm 004 - Statement - Condensed Consolidated Statements of Comprehensive Loss (Unaudited) (Parentheticals) Sheet http://www.interpacediagnostics.com/20160930/role/statement-condensed-consolidated-statements-of-comprehensive-loss-unaudited-parentheticals Condensed Consolidated Statements of Comprehensive Loss (Unaudited) (Parentheticals) Statements 5 false false R6.htm 005 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) Sheet http://www.interpacediagnostics.com/20160930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited Condensed Consolidated Statements of Cash Flows (Unaudited) Statements 6 false false R7.htm 006 - Disclosure - Note 1 - Basis of Presentation Sheet http://www.interpacediagnostics.com/20160930/role/statement-note-1-basis-of-presentation Note 1 - Basis of Presentation Notes 7 false false R8.htm 007 - Disclosure - Note 2 - Liquidity and Management's Plans Sheet http://www.interpacediagnostics.com/20160930/role/statement-note-2-liquidity-and-managements-plans Note 2 - Liquidity and Management's Plans Notes 8 false false R9.htm 008 - Disclosure - Note 3 - Summary of Significant Accounting Policies Sheet http://www.interpacediagnostics.com/20160930/role/statement-note-3-summary-of-significant-accounting-policies Note 3 - Summary of Significant Accounting Policies Notes 9 false false R10.htm 009 - Disclosure - Note 4 - Other Intangible Assets Sheet http://www.interpacediagnostics.com/20160930/role/statement-note-4-other-intangible-assets Note 4 - Other Intangible Assets Notes 10 false false R11.htm 010 - Disclosure - Note 5 - Fair Value Measurements Sheet http://www.interpacediagnostics.com/20160930/role/statement-note-5-fair-value-measurements- Note 5 - Fair Value Measurements Notes 11 false false R12.htm 011 - Disclosure - Note 6 - Commitments and Contingencies Sheet http://www.interpacediagnostics.com/20160930/role/statement-note-6-commitments-and-contingencies Note 6 - Commitments and Contingencies Notes 12 false false R13.htm 012 - Disclosure - Note 7 - Accrued Expenses and Long-term Liabilities Sheet http://www.interpacediagnostics.com/20160930/role/statement-note-7-accrued-expenses-and-longterm-liabilities Note 7 - Accrued Expenses and Long-term Liabilities Notes 13 false false R14.htm 013 - Disclosure - Note 8 - Stock-based Compensation Sheet http://www.interpacediagnostics.com/20160930/role/statement-note-8-stockbased-compensation- Note 8 - Stock-based Compensation Notes 14 false false R15.htm 014 - Disclosure - Note 9 - Income Taxes Sheet http://www.interpacediagnostics.com/20160930/role/statement-note-9-income-taxes Note 9 - Income Taxes Notes 15 false false R16.htm 015 - Disclosure - Note 10 - Segment Information Sheet http://www.interpacediagnostics.com/20160930/role/statement-note-10-segment-information Note 10 - Segment Information Notes 16 false false R17.htm 016 - Disclosure - Note 11 - Discontinued Operations Sheet http://www.interpacediagnostics.com/20160930/role/statement-note-11-discontinued-operations Note 11 - Discontinued Operations Notes 17 false false R18.htm 017 - Disclosure - Note 12 - Long-term Debt Sheet http://www.interpacediagnostics.com/20160930/role/statement-note-12-longterm-debt Note 12 - Long-term Debt Notes 18 false false R19.htm 018 - Disclosure - Note 13 - Supplemental Cash Flow Information Sheet http://www.interpacediagnostics.com/20160930/role/statement-note-13-supplemental-cash-flow-information- Note 13 - Supplemental Cash Flow Information Notes 19 false false R20.htm 019 - Disclosure - Note 14 - Recent Accounting Pronouncements Sheet http://www.interpacediagnostics.com/20160930/role/statement-note-14-recent-accounting-pronouncements Note 14 - Recent Accounting Pronouncements Notes 20 false false R21.htm 020 - Document - Note 15 - Other Subsequent Events Sheet http://www.interpacediagnostics.com/20160930/role/statement-note-15-other-subsequent-events Note 15 - Other Subsequent Events Uncategorized 21 false false R22.htm 021 - Disclosure - Significant Accounting Policies (Policies) Sheet http://www.interpacediagnostics.com/20160930/role/statement-significant-accounting-policies-policies Significant Accounting Policies (Policies) Uncategorized 22 false false R23.htm 022 - Disclosure - Note 2 - Liquidity and Management's Plans (Tables) Sheet http://www.interpacediagnostics.com/20160930/role/statement-note-2-liquidity-and-managements-plans-tables Note 2 - Liquidity and Management's Plans (Tables) Uncategorized 23 false false R24.htm 023 - Disclosure - Note 3 - Summary of Significant Accounting Policies (Tables) Sheet http://www.interpacediagnostics.com/20160930/role/statement-note-3-summary-of-significant-accounting-policies-tables Note 3 - Summary of Significant Accounting Policies (Tables) Uncategorized 24 false false R25.htm 024 - Disclosure - Note 4 - Other Intangible Assets (Tables) Sheet http://www.interpacediagnostics.com/20160930/role/statement-note-4-other-intangible-assets-tables Note 4 - Other Intangible Assets (Tables) Uncategorized 25 false false R26.htm 025 - Disclosure - Note 5 - Fair Value Measurements (Tables) Sheet http://www.interpacediagnostics.com/20160930/role/statement-note-5-fair-value-measurements-tables Note 5 - Fair Value Measurements (Tables) Uncategorized 26 false false R27.htm 026 - Disclosure - Note 7 - Accrued Expenses and Long-term Liabilities (Tables) Sheet http://www.interpacediagnostics.com/20160930/role/statement-note-7-accrued-expenses-and-longterm-liabilities-tables Note 7 - Accrued Expenses and Long-term Liabilities (Tables) Uncategorized 27 false false R28.htm 027 - Disclosure - Note 8 - Stock-based Compensation (Tables) Sheet http://www.interpacediagnostics.com/20160930/role/statement-note-8-stockbased-compensation-tables Note 8 - Stock-based Compensation (Tables) Uncategorized 28 false false R29.htm 028 - Disclosure - Note 9 - Income Taxes (Tables) Sheet http://www.interpacediagnostics.com/20160930/role/statement-note-9-income-taxes-tables Note 9 - Income Taxes (Tables) Uncategorized 29 false false R30.htm 029 - Disclosure - Note 11 - Discontinued Operations (Tables) Sheet http://www.interpacediagnostics.com/20160930/role/statement-note-11-discontinued-operations-tables Note 11 - Discontinued Operations (Tables) Uncategorized 30 false false R31.htm 030 - Disclosure - Note 12 - Long-term Debt (Tables) Sheet http://www.interpacediagnostics.com/20160930/role/statement-note-12-longterm-debt-tables Note 12 - Long-term Debt (Tables) Uncategorized 31 false false R32.htm 031 - Disclosure - Note 13 - Supplemental Cash Flow Information (Tables) Sheet http://www.interpacediagnostics.com/20160930/role/statement-note-13-supplemental-cash-flow-information-tables Note 13 - Supplemental Cash Flow Information (Tables) Uncategorized 32 false false R33.htm 032 - Disclosure - Note 2 - Liquidity and Management's Plans (Details Textual) Sheet http://www.interpacediagnostics.com/20160930/role/statement-note-2-liquidity-and-managements-plans-details-textual Note 2 - Liquidity and Management's Plans (Details Textual) Uncategorized 33 false false R34.htm 033 - Disclosure - Note 2 - Liquidity and Management's Plan - Contractual Obligations Due in the Next 12 Months (Details) Sheet http://www.interpacediagnostics.com/20160930/role/statement-note-2-liquidity-and-managements-plan-contractual-obligations-due-in-the-next-12-months-details Note 2 - Liquidity and Management's Plan - Contractual Obligations Due in the Next 12 Months (Details) Uncategorized 34 false false R35.htm 034 - Disclosure - Note 3 - Summary of Significant Accounting Policies (Details Textual) Sheet http://www.interpacediagnostics.com/20160930/role/statement-note-3-summary-of-significant-accounting-policies-details-textual Note 3 - Summary of Significant Accounting Policies (Details Textual) Uncategorized 35 false false R36.htm 035 - Disclosure - Note 3 - Summary of Significant Accounting Policies - Other Current Assets (Details) Sheet http://www.interpacediagnostics.com/20160930/role/statement-note-3-summary-of-significant-accounting-policies-other-current-assets-details Note 3 - Summary of Significant Accounting Policies - Other Current Assets (Details) Uncategorized 36 false false R37.htm 036 - Disclosure - Note 3 - Summary of Significant Accounting Policies - Reconciliation of the Number of Shares Used in Basic and Diluted Earnings Per Share (Details) Sheet http://www.interpacediagnostics.com/20160930/role/statement-note-3-summary-of-significant-accounting-policies-reconciliation-of-the-number-of-shares-used-in-basic-and-diluted-earnings-per-share-details Note 3 - Summary of Significant Accounting Policies - Reconciliation of the Number of Shares Used in Basic and Diluted Earnings Per Share (Details) Uncategorized 37 false false R38.htm 037 - Disclosure - Note 3 - Summary of Significant Accounting Policies - Stock Awards Excluded from the Computation of the Effect of Dilutive Securities (Details) Sheet http://www.interpacediagnostics.com/20160930/role/statement-note-3-summary-of-significant-accounting-policies-stock-awards-excluded-from-the-computation-of-the-effect-of-dilutive-securities-details Note 3 - Summary of Significant Accounting Policies - Stock Awards Excluded from the Computation of the Effect of Dilutive Securities (Details) Uncategorized 38 false false R39.htm 038 - Disclosure - Note 4 - Other Intangible Assets (Details Textual) Sheet http://www.interpacediagnostics.com/20160930/role/statement-note-4-other-intangible-assets-details-textual Note 4 - Other Intangible Assets (Details Textual) Uncategorized 39 false false R40.htm 039 - Disclosure - Note 4 - Other Intangible Assets - Identifiable Intangible Assets Carrying Value (Details) Sheet http://www.interpacediagnostics.com/20160930/role/statement-note-4-other-intangible-assets-identifiable-intangible-assets-carrying-value-details Note 4 - Other Intangible Assets - Identifiable Intangible Assets Carrying Value (Details) Uncategorized 40 false false R41.htm 040 - Disclosure - Note 4 - Other Intangible Assets - Future Estimated Amortization Expense (Details) Sheet http://www.interpacediagnostics.com/20160930/role/statement-note-4-other-intangible-assets-future-estimated-amortization-expense-details Note 4 - Other Intangible Assets - Future Estimated Amortization Expense (Details) Uncategorized 41 false false R42.htm 041 - Disclosure - Note 5 - Fair Value Measurements - Financial Instruments (Details) Sheet http://www.interpacediagnostics.com/20160930/role/statement-note-5-fair-value-measurements-financial-instruments-details Note 5 - Fair Value Measurements - Financial Instruments (Details) Uncategorized 42 false false R43.htm 042 - Disclosure - Note 5 - Fair Value Measurements - Roll-forward of the Carrying Value of the Contingent Consideration (Details) Sheet http://www.interpacediagnostics.com/20160930/role/statement-note-5-fair-value-measurements-rollforward-of-the-carrying-value-of-the-contingent-consideration-details Note 5 - Fair Value Measurements - Roll-forward of the Carrying Value of the Contingent Consideration (Details) Uncategorized 43 false false R44.htm 043 - Disclosure - Note 6 - Commitments and Contingencies (Details Textual) Sheet http://www.interpacediagnostics.com/20160930/role/statement-note-6-commitments-and-contingencies-details-textual Note 6 - Commitments and Contingencies (Details Textual) Uncategorized 44 false false R45.htm 044 - Disclosure - Note 7 - Accrued Expenses and Long-term Liabilities - Accrued Expenses (Details) Sheet http://www.interpacediagnostics.com/20160930/role/statement-note-7-accrued-expenses-and-longterm-liabilities-accrued-expenses-details Note 7 - Accrued Expenses and Long-term Liabilities - Accrued Expenses (Details) Uncategorized 45 false false R46.htm 045 - Disclosure - Note 7 - Accrued Expenses and Long-term Liabilities - Other Long-term Liabilities (Details) Sheet http://www.interpacediagnostics.com/20160930/role/statement-note-7-accrued-expenses-and-longterm-liabilities-other-longterm-liabilities-details Note 7 - Accrued Expenses and Long-term Liabilities - Other Long-term Liabilities (Details) Uncategorized 46 false false R47.htm 046 - Disclosure - Note 8 - Stock-based Compensation (Details Textual) Sheet http://www.interpacediagnostics.com/20160930/role/statement-note-8-stockbased-compensation-details-textual Note 8 - Stock-based Compensation (Details Textual) Uncategorized 47 false false R48.htm 047 - Disclosure - Note 8 - Stock-based Compensation - Weighted Average Assumptions (Details) Sheet http://www.interpacediagnostics.com/20160930/role/statement-note-8-stockbased-compensation-weighted-average-assumptions-details Note 8 - Stock-based Compensation - Weighted Average Assumptions (Details) Uncategorized 48 false false R49.htm 048 - Disclosure - Note 9 - Income Taxes - Income Taxes (Details) Sheet http://www.interpacediagnostics.com/20160930/role/statement-note-9-income-taxes-income-taxes-details Note 9 - Income Taxes - Income Taxes (Details) Uncategorized 49 false false R50.htm 049 - Disclosure - Note 10 - Segment Information (Details Textual) Sheet http://www.interpacediagnostics.com/20160930/role/statement-note-10-segment-information-details-textual Note 10 - Segment Information (Details Textual) Uncategorized 50 false false R51.htm 050 - Disclosure - Note 11 - Discontinued Operations - Results Included in Loss From Discontinued Operations, Net of Tax (Details) Sheet http://www.interpacediagnostics.com/20160930/role/statement-note-11-discontinued-operations-results-included-in-loss-from-discontinued-operations-net-of-tax-details Note 11 - Discontinued Operations - Results Included in Loss From Discontinued Operations, Net of Tax (Details) Uncategorized 51 false false R52.htm 051 - Disclosure - Note 11 - Discontinued Operations - Assets and Liabilities Classified as Discontinued Operations (Details) Sheet http://www.interpacediagnostics.com/20160930/role/statement-note-11-discontinued-operations-assets-and-liabilities-classified-as-discontinued-operations-details Note 11 - Discontinued Operations - Assets and Liabilities Classified as Discontinued Operations (Details) Uncategorized 52 false false R53.htm 052 - Disclosure - Note 12 - Long-term Debt (Details Textual) Sheet http://www.interpacediagnostics.com/20160930/role/statement-note-12-longterm-debt-details-textual Note 12 - Long-term Debt (Details Textual) Uncategorized 53 false false R54.htm 053 - Disclosure - Note 12 - Long-term Debt - Long-term Debt Future Principal Payments (Details) Sheet http://www.interpacediagnostics.com/20160930/role/statement-note-12-longterm-debt-longterm-debt-future-principal-payments-details Note 12 - Long-term Debt - Long-term Debt Future Principal Payments (Details) Uncategorized 54 false false R55.htm 054 - Disclosure - Note 13 - Supplemental Cash Flow Information - Supplemental Cash Flow Information (Details) Sheet http://www.interpacediagnostics.com/20160930/role/statement-note-13-supplemental-cash-flow-information-supplemental-cash-flow-information-details Note 13 - Supplemental Cash Flow Information - Supplemental Cash Flow Information (Details) Uncategorized 55 false false All Reports Book All Reports idxg-20160930.xml idxg-20160930.xsd idxg-20160930_cal.xml idxg-20160930_def.xml idxg-20160930_lab.xml idxg-20160930_pre.xml true true ZIP 74 0001437749-16-042352-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001437749-16-042352-xbrl.zip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

%3T[1?81YZS(4G MP.\TWW% L9 ?S3&1[DX9-_W?&02GQ+L'E[?WUS+^PU6/!70_>&'Y16!?^Z *MIFNZ8:1 E?KJH M!'^/F:Y'?_=L1^<.OIQ9YWCL?N1P?$/. ^BUD7SKTT5U^P@]>=7(/&I'&W'B M.'U%7N<4'N-IO-)T>GL$("DBV%H$-@+;J<#6)K 1V$X%M@Z!CL--^DK2&II5I#42JU6,1L/RP('^2G,%6#KI6I+^AMH"; $V(C81JF:Z]CYWDV^]AVL@\2=S[]\ MYGC<2=ZBQ2]=V:,QLR:*PS7< -,59@5[L(H!'QC."/=$M2%S!ARW0Q?VI&N7 M]>DFL<-=W_1P\+YCCQ2FZ%Q#GH U'&DVN2/F_(3GOV"I)CYS>H<<;AE_,>P> MLWY&^\#P'ULSQ"[OJ^$-!A!O1?84L5,L**P)+AB-=!LUQ,K$ZX*#DRG)KYFX,>V^(:A MPQIF] U1G#*=:EQLC-G,1^M-]!3\V(2?&"8L--P-RH*X7IHM0PX?P;*#:&(C MV\=5TH0OP3CX:U<9A.L!P Z(LR:7RA/@CXN?(CWBJ?$5>,ABP^LV>'H>O/?" M%=<86/!8C<$8"_268)F-?SS&0JA@612U4KX#2[>+Y4L&#(TC]#BWIA+4440K MA "\1^1?*L\Q$6I!C15^ 9=O%AO,Y0E/0D)T#H[(R+#B/U#XM(#+=WG?-T'> M+RAI+RAM PA,YS58[4LHUU=NFOC?8.Y'8Y-'SXPY+'B3F8N59T*<\P=)CRLP-<*Z.[Y+JB8ZRJ@<180 8Z<98\,+?H]TH)%?IZA&6,A[B%$1AT((@9R!QDOEJ^_@>"7T@:T!< &/FTK< M]>![?##!H7\%^D,QP03H1L#CB$WBZ .JHO$%Q&8(Q$%X+_HXW'!%% =@^SLH:64"H)@"*8M #*R7 =P@ M>@?K+'"(FO"Q2U&?]VJ'M;2@1%@2'%766G.AF<.7^9U6YP8QH;!\N'TNOB@$ M%V@#VA703(1,4.@F+&H1T&8K>'\] MZ%]ADO@+)AI>@LESXL92,QS /LPM.#_XAHY.!%KX<)W7HJ.;4S/G^F#7PF>C M_41'J!>CUN0KU>8V0"VL+U,'XVT\MW[Z,+BKH:^&;N)LE0/%$5H*-%GS-(6> M75PA2@LF%I&YH'H]%+/N:Y&:37,K<4L>9EG0 <.LQ M*83G(=:W6\RP CH3B$K-%.K&3["2$S[Z]I#CP0 MGPT8C-Q/Y!-8$92A,BRGN-RA6$][/)X0T^,BBP :_D X]ZOPH'.@63C8/3R$ M .!WF3.YS"H^*XXURRS#65J;XI0MJYG6ZZVRHPL9SH7,J ,J\>#8?<-;F?IL M+:8^0:H@?]/]=%&NQ1.A#;5S 4;<"'YNN':]JK;*OJM??%;K+2S(BQ$[&W0' M:AHS:AH;J:E6DJAI55HI$+,J*YQ,C)I$3*/228.:QHR:+41339PHE-M6U-Q: MX +R._CT*X#_"N@Q+!]T[_LT.CL03:U$(LLMM=.>V1MW;]X@RH.E MS;# P;B%)="]MRUDT;%AW;(&MUA$C&F>P]2EF3QIK4JUMB/7>W.1H;AV4M!F M,DI:S?JN(,FCN'8R"_Y>X3'!@5W/9KLK"Y7JM7>(RP>=>]_[ MH/M=SW.,GB^JQ9[M1R[V%*W!#>Y93@[R(5K51K+76EV(4E(C^622V,$] $DD M>E-5<(]S+HD=5GZ01**CI%;4G MBAR4=!)'H C7;U74.4":22'4A[R38A=7& MOY)H_'<@^6B<[[BX)]B!%9Q7+M6FS(SON-XGJ/U*QBNJS(SOZ (DJ/E*QNN- M(S$.WUE1TKI]::I;:U?4>N=8A:FI=Q*"E>2D78+"88.-DL7*?\\>[W<@/+A> M=/-Q\,4622>K/MP&#,L7@W:VW]%8>4*#Y+M>OK?W5]^_W2C/W?]W\[2/I->= M(\EG$6P^#W?\QBTP]*9HVJ>)B@#-,0SA.U7 M/,SP*)QIP^D6ZK0/GC?DAC/=2Y^64O3[00L__*V"56_3!GM]WS1%!5!0 LA\ M;V@[AA=4_PU\0\?*#_'M&,U+Q##1CR\J(!0UH[ \.=S#@@AXHB[*3!3#B_B! MGR@][HGMWQBQLX=&M4:7RK7/E^O]9N678FA!Y-B."DUA',-=^$7TZ:QV99'$ M&&DC&PLF-,T7LEI/851BX(@DW*HO1+*.FA1&LS:MZ!V#O\"MH)(KVAU?H"Y6 M>J!T ]YPUI#H ?S:Y6&5QFR_O(]5CJ(\94I_'":BN"/8WYXO\NE- FPA!W_Z MCN'JAK90[2:@$C1A%.0&R[T_&C$'G $W+H-W/4!]W_#>3Z6!/2&QRD)LBFO3 M3$BL;G-:M+$&MT'O3/'-??I:9M4!L6P'?-)5YPLG'*=B[7FX M]3T@<[P&S!R*M)W.3F.Q?66P>LP[#XV\M*\L?INGM4VB7-RMFNV?B/V2V<[*B1%#;2\/KV%)L^VEVJH5LNFE+&"0G\)0@K=>*9$JW#BSZXG^I!Q8[(&:1@IP$$S?3*JI8 M798HILI%#!&3NJ26) L*#SZ1B<7!XKF7/;MZOMSP=?M MZC,VX4[(H4= 7IF+34SQK(HY4?39Z2*'1W< A(WR[;YR]?0=V]7KL>.ZJPZJ M(*E,1X&N[*H:G#E:?/YBQ'5,D5XJ,:&F(LC&:D%:W(MUNL>#/DB(:#TOVKK; M_3XV[^Q-%.SH.O)'0>/HX,8&&SN^BA-E.U[]L^Y4=,+YZ9L 65]"61S6&45- M;/Z@ME;U5EL:?T\B=VI:HB8WG5+;E2-2N5-#$;6=2&5C56>5%$6Y?;./Y%:F MY7IM/U&*JQ.NPRL4;JUN<-K2?6 3<:[IH/YLS?J:?I/-I38MZTDYF/)=.J4U MZ\F==BI+@DZ'\$>N<>,E!:G7DIL(UINUI29O&\E)@X&=A%]+-&OU:F.IX5,: M]#NPP-[%+NXY$/9KU+2Q#>X7R$F#@9TFH)'8I+CAJMI(F?)KWN>.P_5'O(#!/]C2)]L<=1/@%R@Y MF/#=1)YH:VK+W9P/(UQ<,7<5',8/.J ?:NB3[8Q:;54W4+],3AH,[";\9#NC M5MI+;E$[<#/#PN^::)UBQRI@^W5FDAPDZU=04TJ M#.SFF"8'B:W*)GN[!0=!=^0P8KOFO:WR W]\"6^6Z\XN ^F^&6[YD>MCY@WQ ML0/<=]QY*M(R[1 M;,!*NQB0'<=NK*,N,7"I-I<\@2VI>V"&OGTGTG!!;R59"^7-_6 9YJ<+T$1^ M\>LN0^[D421?)P01_Z*O.AMUD9X7'FX!?66&\SO>)C;;D9BCT(@OA-,O?YE\ MFUV8ARU@76%6KL(;#8/VSUSOBLOL5@P1VJ89'5/+]./IV1&/GCQQ<$&%XQD9 MI9D8.HD7>6R8A^/P?1,VKOO>GW[S*$PG&9!C,SU]^;\-[C!'&T[N^ LW!>W3 MSVZML>^YX@/U<%:3S)%LK%8/9S7)MLG&:NU@5EM)Z9M466V4U6JYII["6GT3 MUS&BYQ3CV[;X)/C@JV_I*URJ>9/>2;J3Y.)S?3%SODX0IQ':H:8N'8DE+H+9 M2BQ%.YF.G!*W4_,EIS5&=AY0%TG50@N:2ZMI@WS[_]/$10B1YFQH)*T8@>(I[D#9A\ MB6>-)=TLGKA "N"![L2PFF>'= VRU607L]98+(+)EXE.UNDHO<^;8S1._EZMV)ZX\<[_WKQRN&]YW& &O?P-S$)B!Q/VE-94C ME>13#K6%RI%-PR\0FU XF437W(Y^/7$G^7.]5:_/[Z@G%D.N)2& MX+/ZSB1T+?W)L[6?0]O408PW?_F+UT9O)9I&HIO_N=[H-!/I6CG\H<1N$F(C MV0]OMEIJ-1UBP^+QW6793,RZ?U8[[58EB;QPP-T)V@BZ-24UM5HK$?>;"/K> M!R,WMEUF_N;8_OC6TDP?%7?E1<+)V]3!:<0G/'(;K,XF7OKW-.3<@QGKZKJH MDF/FS**Z7R9S([OKAPZ=''LTXHYF,/.).R^&MME/KR4?EJLO'A;:5RP%$:XH M+%S]^68I)VISLJ[().-UK"5:^WJK(3> (A]%8NU,CJ+53J5)TDU)/9-=N87] M,4F%O(:WY#-F:K6:[/5DP-TF;T1B/:TF BBU53153T4641^DM(G 3FE-/:G$ MUS&:7%"7U@I[&E9SL-ZNV1I-:[TMI*P/4N3$=%M:J^])1;Z.T\2N*NFMQ1MY MQ9EZ'C(K?I)J=D!V#P.E-I+K,IMJLH%:3TAZ#&R<%[61."]-M94,P7T8F'RU MG1^@@8['#.N9O3W8P0FYG7(Q"^17$V/X=FNU^#=1D1;MFT5?38R,3T3[8=!/ M/CY8:S16KQ=;4)(B"YMG(+GI2JU>W7$*DEFP>)3^7B5F52VK]3^"S[\R38P1 MGAE]LQVN[N(7S*D]]S^5\^//;F);XMNO#^ID.GS68[T=[,"7M&<[(TIQ)A M;]C6[XOM./8KRHN-X9/$/'FU+;NTU\BO54W>H%L\M;N+K!:E[!D#L:0^<<\S M!8,KMHO$F<=Z6:V@MS5[N6[GJ)DX_<'.T1SY243L3VP3*51K\9>SGU\QET?> M\YA9$_<*'P)NM,F,47< ^NYZ#XYM&LQ-5RM:E37%[/M*!1;FYW!A7F4:*\W< MG5=O)J=S*JU%,<78WT4P^6P4D9B"Z2PIU59RV7MSK)[L3M9:BT[!\H![4+1Y M=RQYNTY=C#MVH>@;\\("H$<^9A-1'O"]_^ 8EF:,F7EK_9=@G\=%. M-/.-6JV12/7V1!W*V*N]%UO)Q_TJ"[T)]B%I;Z8>^0C,N\Z=[_VO$%DR$Q^X M%X-K*J1JR6C;A[QD9G?TZQ=*&!*GJ%%MMA(Y2'1_MZ1K6.ZSD6'"FY[HFFWQ5\7!KMGAIZ[Q-P^:;$][ MG8NS@.GVZ\>&_:(7^^W]]86_+A2-FWC1L0:>H9 _ M_CUFNA[]W;,=0"&^G#6XC]^F-6W:'PX;]'1?[+SOV>/]KE$V>7^K2ZZFWWD, MWHN+]MCM\3>"X97CE0AX_X"I?PRN/ZANU7P\^8H$$O!Z =]]O_^M_'SS^$VY MOOGRO/X2L@1AK[O3(?WK#@ITM<)W2_FN>;;HXZ^*/O[UDK@#((RR1!]^T> & M[ Y7[NZN2@H7_6YTH,&SX7.%15$V]OMGZ)([7'D,G&_E'3[LV6&6RS3TT]_C MS0-HR2TN_H[N0YC[TCP)\^,I%KCBLU]%XP0%94%U&;PY=K@+OV-XS5U)@6%Z M?,C,/E[A@+_JV\X(OL>#(KBP)@T_#!]74G1Q6<.B; )V,!AXGV@4\@F$U:#. M/U_/X7PIAJO\2U4O*PHL]J; F!'V;2KW,0Q H(_#%O6&I0@KA0!A)J+5Y9HO MKDR$-QSXF3E1,.' 3#.XX*/'!X9EX147(61F\@R@T[Q40-?F;\U8U+,M\:RP M47 '1X1%U#OPBWCX"+QY ^$[!;OAN%Z<7/S^O?T2$#(E;W8MY +JF^E2VO<= M#*#WI[A:B4ETQDL&3 MF&%BJ7KXX(AV^"'&%9C)!JL7W8Z"]ZEHS!TJO6##5.F#LQJ_@@:>8MG@*K@N MWC)C*?^"N*8$#CC8[;=P>TX9.[;&N>X&/^Z)="-P/L*F%B6%!60AX_ P(-F9 M**^<_PRD&;*C..*\"C[-X<+D"QE$5\C$F(#!7@Q]>JO.M@:;B3%!SWIX8@2H M4M1:69 AV.^;]BN.QN$O#%A&,#PZQC&85".8S!)^2A2^X0C3B6:.H*['0>! M:/A1,,$ZFP@I, W&%-%=9 )*,:6'GW3'CF&&VM2Z3/1B\FE%B[HZW 93#=;= M!FR'$XOSC3%O*82!!7/^:CL_<:(U-C9 X6.7.XEKCQ W)5 $W1<8Q-]%^AEJ M=611V!CTX4TF%ZM#0;&8F,#)QK!_=/15_'9[HSF_!J^Z:.7I8R9"^18@#9 MI@&_94&B??;@:,D,V27@YX,O=(LB_R>X^_D50(@SW;BL_((.D%@"HN6*31^W2^2I$/Y"@O>,YNSF"&5BKRNPP7Y:T% MYNQ?K@\1"RQN:\357_N$DS"S\=&HT(%_,P+R-KEQ6HW&"&'0Z+>%M MA&CYW7'@/)L@9G2"A,,07)DW1QQ>J*>("_52I*]Y('U=H;?+A)025S*(IA:H MZ,Q"JZG;[5MLA$[BWT"TCC5AN.TK K'8JI=H6(/_40IG@RF?[D/,G%N,51QN M"CL4ZK5I6X,R;FN")>^!TKDSGSC\AG /1K$W I<%/054M[DLC+TB\ *O_26T M]1;$3<$MDLJ$,]!$M/OPC#[8:_O5_9#^6JJV9?01Y/!,9BGIM/'WS.-V1^%]!P8*BCM\@BC - M?7Y_0A,V8OG.9IA-&R?7^G117[WSD?R4I#V.DV@VFK7=]WL(!85#08M00"A0 MV[MN1P:+5$32BHOK-8WS?O\B[2F,]O<[E_5?UDSH9GHV[4YOWHL^R=R@IWIB M#8TJ-];)-U%A-LG^Z#I^(/6+2KV)GW\=F8WFGGS$38V#&WZ[LZ:6:K5Z_F=) ML>Q7AXT_703_E76ER;OBY)MZ4OLI:_52I:+F?Y9([4GM2>VW9ZT!JWTC_[-4 M>+5?5P^:[VR_;,GF8]<39\]AOO'R'-M #(]:F!-E&)2CX:F5D67T#2WHXB0V MDG&?[U_J;&\UV$D2^Y?!OM#U]_^! :+CC;-2W+"HUGZUYHMI9WM(#M,X<->WN[BJH8\%VYM[[Z8:ZB24##F+;\00\'2[V^S<5U$<% M/6P 8PZPFF(\W34.L"VTOEJ);>*+\>]LAB7[J(ZCX!3<9*X*%C\7JKU4]AQ4 MP,(3E;@) @O C1<0!M:Q3DO.L,)HH2ZN$RMJ"+:-1>%JH-/X@[#)@]+G6$ # M\@F+'=PD<2Q*G4K5\L'7CW%HE7>J?413/JNE#$J!%^II?%=46XDRYF#Y"6H7 MO(7Z:'S7B^D2UC2SR:K2&'O60%LQ;;:/VI6"!EW0RIK2JF"_242S=6JQY6ZRX$Y8NJ%/%:KB(Y&!1 M7IK)I:JA;#4K_GKU2=?I*=;%@ZZN>R5:98E[*[J:YOC,?(A,GZY\76D&NI/)2C:8>2Z.5ZCM+KZY%\Q_L) M^6^5*U7L>A-[N8G_J&?>D\8M4"8[X#[\XVMX)F(+]A.[0;07VU(<<_IC1[C7 M3/]7$5Q\%['%]W[8Z"-U0"1WHUALW;F_2*[9B VX^V3[@Z$GKI98EHKH %.I MQ5\>T EG'MML8N-@KJ7M_Y,HHW*SJE9KS4NU>5HY51KE:BO^18*%R\MW?JSM !'V,TML2['V5I9#"&K,"&IL MZ$<"_TL&5FV^F,[M-3#+HU5JCUDR+FZ#!,-JB0Z6? M:/C*:KVI+F%I-O!.-.TDQ.1;S\IJHU574Z))Q!A;RJG13NP 5V[5.RF*J;6M MF!K)#9_*]7:GL3U)K^#AH;\!D ,L6O!2$RXXWFMT-62PT+FW5OP[(LPWN;MW M]Z(.=2^B[D4I="^J[[9KD?"8;1(?R?O&-$F[27>/1SS>7('F*=VKJ^\_[I]O M[W]3'AZ_W\/KJYMO\,'3/A.X;5>E+2J#SW)O/-]Y]UM+Z?H#H"[6%2J,-S A M/%WKE"=,>3-'=Y4O-OQ'>1<_?/VU^_1EX:BUZ_I<5P:^H0>Y2H5T- GAOER-Q@_PG7 M13>D,VI8@FT;+(A,HS./X%/B%G9P?-88A8EX"X]0X\:XZX:=0_HB/0\#>Y,9 M9YV/KA)M47M!]TV\_D#T?0E(5R+2,2V/27$K.!T9)<#%MEH2%^($92"Y2Z4; M#:^,<'JB!BM1MEV?W9BA&'T<-MB5!-*=X$B_JSC, )'&=E(4W?9['K!@^U'[ MEVT9S$;M%J0:3/,45$&_"K'WCQM$@ADCW"@T7(5/>QWA6>APDH/3T.)8-CZ8 M];$7R'3G 7>/@F.NXADA1J+?B*U8\8M2L.T"$XN;4[H]%KLN8\2WY^'LQ;=# MD10\]1[65\ G8]OCP808\!7-FVU+OATWXQ3%TWPQ4*-:Q"$F-:CUBV*4&:[G@"Y:)K[SG !0GL9X! M:/8C2]]]^J$$,4ZUI-QQAON8[Y[ML:$I[7KU/2C,T-"&@>&?*:;H1Q)::C!< M V89?T>M*K">R,0'A:TOE'?\G3+M8B2K1X.-XJPP-5-V;M2\)QHAJAZ(M81=O,@);+5IQ\5E_ ME9 E?6M"PL<'F[E@1D+^^1MN42O>*S=?HHX2@7&9KG-B2+&;&LDQOC3 ^$-N MC@$(F.:RG6#T%8L/;I0[V.(.+XL..GF((<*N >@&E##\%$83WIXMS:)UUK1= M%RYBAHO?$MOJ 5\!R7-+ENAB(MIX@!18T)LMZ,Z$5CQX(]9S#- 8K(!B_.F] M4? <7,W#PK;ILA;0&RM%V^@Z3*WNIG5CU@YL]=+17KUTA.Z -T0G9_Z1E\K- M_#(")"2O)+/ROH4U);Z2P/>F^ B7D0UF.[3/*RSW(:T[)#K966#+_(UM-,HJ M&.69?7Q$_] /NPKB'HZ#R!&VYPKXM$=H"S=N8ZP9^,!M"5*D$W?*FI,VF8#6-E8TTNLM$WNKH2?4GJ 8/@6\O M]/A[S)0CN7<&@!'MT@*-WY@#R]*F-:V]A_AF+5M>X W?#8M?X K51<_]S<&<:/BC>^Z]7Q3K-&!K)-+<**MU;.?%G6E3HIE9"X(0>QKW+-NK M4#23>%2X/$B]7.GL/&=Q9M"V@86>5DR949$5&$D8(PB(Q$(X#<9@R16MZV:K MJA..BF$D!W_#F]5R]8,^?X#\DE$$.=,YPQZ<5E2S)89U M>!\;; 65QUI\YO"7@4LSBZ-$!9<6%"/WPC?-8/6!A5PDD$.O(PAU%X@)Y#'M MT"/HB6DP+#@X@6#0S< EL81^@E<1#!K&$-%*AMU_@#H,345<&\% LT7/L"C* MTQP#9SZJL9X%_$BH-IU#(0W=%AT#1^#S!(^*?HN+<]0Z+*@^"]H-"I]*](%U MP7,P(0SVV)O86Q(TX$J$4)G.0 F>;Y6%+S$G[&!-C:@!/TB?EK.[HGT83K98 MQR[C]D318$CX)L[SJYTD*+#%,1LRCMD0>\&&"#\PLB.XX ;%\2P8..JV9T4R MB)D/7+FQACZ,JXN7*\5)7F#&QV&PJ@S76TQS/_%!0KW:W"[MTJ4H"^15YRZ1?.L!H,MC M"'* NAA=B://4SG=\[Z)BH$/VZY-OEZQU5FXWG9IZ)TIVVG7MIY8NM$2Y0&I M4K9+*4"CD7S)6;O:.H+0MJX(:#02M[KAQ<+50-N2EEII0".Y7*%9;R?(+6DW M?BOR=@)<\CW!9?BT=@3R=D/=NHH9M:T>1WP[0"^Y0 9^OW#1\F;Z8KF^JVEJ M J_XL_2'F"^)MVV%N8II1;0[NRU\W\*+*A5>4.%%&H47=&O44>7[I?MT^Z1\ M_ZH\/-X\ ?:[S[??[X]Z>93\90[YSE>*%(>F!5$!!FR^Q7S=\/@LJ,.];'18 M]*2D=7S'/+:M:*'O'YQHC1ZUZC?OHQ22V*=A>GB4]$^(EN8/U&T>'8+2V;59 ML7I[113>\:L O:[-LQXLX,?ET^7RE/0W#\J1KB)LG] S/_Q[>X@FE986^)C%IQH%PKK!%DGP>> 6WA@U!3MZK&A_%SF<)K,G9;L_+"$ M@@L/#C3TMV[WX;V0]#)ILR*'*.-FB'ND%!M%<_7_B&UWXL@8>EUH)6DL, M?#- ZE/Y_ZV435?P @-@DWQX_B1*:T9;DK&SQG.[B[AO:MM>@+3I!F]OHB [ M8;H44W5>PC[C@1,5)\]"JE!6N!L8[(A&-]4$J=I2)/D_?7T0'::?%4*51&+= MXEA$@EOZ8I\SN)YA*9&+2>1UA*T6,A#I&H.@ZPA>!R!R/R'&PLWS,*^+."UX",A:FX\DV_7 ?YV'(8%)^VM;[CX*QY]]_"Q> =^(EF#_@ MX25F3Z;'JM]/;3/:!Q 42O@IVJ)X=_7T_?WLR#O&8)?*405\4BL^#16GV\^1 M"19W"Y0%$WBA1EF4/\0+N!+NU4!H@SY'\#;$-7ZZV"]XF9[BCP83&QO8+08W M;,3V#2[V"XL 4I>X"C1WS-.F'?HN!-:XW2).JG+];E9DLLMU\O/W::OUY/NT M&[7.?-B_=O##"%V1B%TD-#'_I#8:]0,)#4IW=A9?LUU+S.O4FRMH$N/L0, F ML0 !B8F;:GMW"O8&$A"2F,:O5MJM)$HVS@ &"6HD$-9JKD+T500==_5Y/ MSCU7*FH224DWK&])U<:+WY--0*W::.Q%%001X!$;$(:'7^;[B*N6N+U1:U6K ME67*5@R[+W$;I59+W.&HU^J=ZK[$Q>S5X8G0>IT2H90(/3Q1UZ)$Z%'EV[VZ M>OQQE>W^MW'V__ZW\?//X#=CK?KF]NWV^O3GS,V#Y3HX* M^RZN ,0PEL?VC%W#%5VRHIOMHUYY+.%2/Q$U)2>NEBYGDWBV9"HBWNOY3\__ MO8-W@J3-JG;'$X[3N?X([MJ[#&<&->U%M[-T^5NS%M/ZW-W^=HHNV+)VVEYU M@Y,X_!*[KJFZWZJ[OK6UBX MHP]A9@B5YX#*Q;QO(]>@E.3ZL^;:BR(*<_E9F*N$H'O"3 S]3XR=;>ZMD/_^ MDTQO-%EW2]^*6TLVW%%2J2O9"5+Z:T@(KG+!55750L)UZT6P+_Z7^B*X W06 M*M66W9C0F%A,2A,=QNQVBHD;BDL//8B M>/W]?^ OSPLZ*:[O("*+NI)7?7RONBE]GHFBP6)0F&X6HU$I)&XI&CSV0A@5 MDHX=N\]%)QIF*GU.!:4YIC!='[M4JTIO7"@Z+ :%Z28U:-.0HL/]FA**6PGR ME",E'_OXL6%'^IIUB@V+06&JN&T4%+<4&QY[&?QAB>LY@NAPS!VJ(\TQA>D> M-ZS3<<-"H$)^"E/&K?1'*R@DE'(MO#87.A*VX7[4+BQ"98D/*RS-GMT\MJ\ MY=BH95G=OF-C+ I(25TR5I=&END8B=0EZSA8$N]0?O]U=PVI@8;HMM\S^28F MLNR$M07QNV\\ECJ5+"L9=M'OVM;Z39$HZ4FZ>M(H=9I9;G5*I"?K&O@G-EF7 M.,X\0H/_E7= S/4LQ\[_)^'NSK8&98\[HVG#'KPHDKK\4Y=_ZO*?FU[GI_$+ MT@DK ^4J7$-U:O-/L)00EM3G_PB.^)GT^:=F'<>D,%<]T\NR[]'2!@>!=5IH M)WWK[5SN+Q2_SNZ'I7''8X:E>.Q-&=NN(6ZJS\7:)UN"6 X*T^V-7FHTI"_A MI:V-8E"8,G+K5>G/(U.9G92+XD*WJG=&U.>?ZTIOHCQR_8%YP_>Y6"1SY7/G MR-3,%01ADDUR4T/18C$H3!6YU5*CH,BER/'8B^1WK$//Q1(HF[>]3UVM;/YX M6G6U\7JBXM6@4V1*NG(47:E6\E)Y=V1ER3H8EL0KE-]O3;VR5I*MFM0J:V/\ MU$M-M7@5Z!2!DIZDJR?-DIKI31H2ZCQU__YU7?+ \;&'T0<=S^>;!CQYY_].%\0=6!)8K MG7*M=& M!P"23.=LV/W):Y35:KFFKB.OFD0>_'Q_^O!#Y@YO+\9NW,;=>'DI/ MA7^V$62S64NDM+Y,YZKQ]R:S,2.S$9$9)ZR60)CRYGZP#//3A>?X_.+7U>-C M(S2&5PINEE5K6UDUFI7=9+6:B,,(;LP(;FPF.%%+RJI:/1G-NP"RT4P$I'I2 M*2]A,YGB)*1^+E>;[<-H?N0:-U[0+KN[F\EF.UF[0<.6*8N-MBLMFVPBT)(H M)K527R&F1&(>V 0WV-ROMO.5+]"B3VFI5F,OXV3=WG^-V^I:JYU(5U-X&S.Z M%D9.).N1CWU'&S*7?^]?V:.1;3UYL"!NIQDQ&YBHOVMMX#Z$[ +X9K**UEI) M\DJ@9 WE+O"F>;Z#1ZFV$-P?<[]X,)G5?3/<\O>>:0R8J$YZMN&Y(^X\,8 4 MT.-P%P:#SUZX^\/2N?,\Y%>N#2H);\.;^(QOHB8\&3ZPUB?#)QD]<[2NEL&S MW=7^\@V'/X1=/9$+3HF&P#IT;S$#CM0]!.L&JT$GVZ=FVE)#>3 MM,"*P_L[%Y\KEQ4UQLM6-*7#QPHCO<1' D9.P(?X@MOUO:'M&']S?;]YB(-H MGMY&95$AUPY_&*G;B+I].E)O7=??5Z*=1#(W$!@,NC]Q6\BP73DV<=]]S_68 MI2\N0]N*KZWN2V%LY /)W$:0U2.3* @>%ZYK[FJ.,<8W=UWG6^WVQ>=-^_A] M>&:YST:&"6]Z(J=E\5?%P9Q6^*D+IB5(@6U5&4!/+.P3-[9IF/Z+W1AD[0 0 M,(H?PGL>,PWM8WAZ;UX)UQ]C6-V889N2&TEZ<.1R;B$T4ZZ>OBL]WX7GN:Z" M1T_@/6_H<%X6'34L^* ,<:4W5,;"N+H*AZA.7^[ T5 @#E5ZG%N*,YU[^*)G M*T X6EO#0H+\/\2.^Q)&C[' PEC*+)FWK K1^I=0Y(F9EBB^$XOG'T%&2[C^.-X79F+S[:BCBX7E8K*)S8R^BQ(H(-SD\)QAZY M/F;>\!:>,' P?L*B<=NT!Q,02\#R']B*!CO1X&#/DS$7/[RSF>4^!(>0-XFF M54N*\RX^JYVEM%\OG5=JYMO^?U?;.K:;9O>2MT<*?MGFKR%D:[NDAN(A&'D+M32JB: MN(%1K>Q+[B,?^";S;&?2!:7V]LJK5Y.3?K568XZPQ>%V)69S8KW:22*FO25N55K)6M!9LR\I!#Z'KC_B*'ZY](!>.N0GB3;KCCXFXTE)7D M[8&L69EM%<<>M@5#B7!1%[-.1^!H_U5O[6J6&)BG [C)8=4*]4-$/DDJ"=B1 MS"VJ%A(7AVKC$#+'8;K^>Q\=E^?0<=G&FUSKW"4J9G5IXRZ)AD5*725XSF0L7*6BH.(GBGVH'D564%9H]%\4Z5 [5$^*JUV@EE MO'WE0"W1O5&;]>8!%,\V%^'[C]Q$BWIEN]Z]CY;T>_\AZMAP8QHCP\*/<=M3 MA(7/]C7\G6S"L]IGK2\EJ,<0GUU\KM5K6.HTTD,Q\JJ"D17#R(Y!,L+ MAUA_,13;W=I6$AW06DV=5ZR%@7>D:B>36DE>L1J5-*G:R6Q6$@U]I].LI2NK M[4VCFFC,F^W6+K+2AESW3?Z]'WK^,:_O&5,ETW+5';99RM7ZL798I.H2>VB; MV.!X3;HEUM2.^&Z<5*36$*E?*BD'K'4(W;O2_@"]P/6_PDST?O(11,$ MVFQ6ZG)W@FANX0HA?2+A2QY_CN_)F?W8+NRC5Z7&+]PU/8;@F M0O2?BZ50MAXGD;4E-OGF)0F&[7V&8QNQUG'2$6/RJ\C7K$!L4= MTZOE)KE8$G/E;N?(M,2H;K>D;T=-86(Q*"3<4KPHP9)X)2K^!V$-FVOH8=U_ M+E9$$9 M49CN-F*U54C<4EAX[$5PX7:M7*R#Y%4?WZMN2I]GHFBP&!2FF\5H2'^#%D6# M4BZ$42'IV+'[W'5%,Q6ESZF@-,<4IGRQ9*TJO7&AZ+ 8%*:;U*!-0XH.]^L/ MQ][@&WG*D9*/??S8L"-]S3K%AL6@,%7<-@J*6XH-C[T,_K TD\&;(CH4W09S ML1:2:WUTU[I1I^.&A4"%_!2FC%OICU902"CE6GAM.%SS;,<5R5%Q[G!Z"C$7 MJR)YVB>H)96^C(8BQ&)0F"INU8KT9304(4JY*G9-4[&Q>S1M%Z9WEWJL"98D M/.QQI_JZ3EZ;MQP;M2RKVW=LC$4!*:E+QNK2R#(=(Y&Z9!T'2^(=RN^_[JXA M-= 0W?9[)M_$1):=L+8@?O>-QU*GDF4EPR[Z7=M:ORD2)3U)5T\:I4XSRZU. MB?0DO@[^*IJ +\9EL8;G6_P+@1@":O%^\/O8!_++N9G]HQ_K\@3);X)^! M7;TS^J?=VR?4% U5\QQ)N"=$W((.?E'#BV2%)X<*/UW_^7,<=]+[P\2WHJ! MM^[(]BV/X$9P([C)4PP7)L?KYW$_VU9;%:\L,6-)"'N7R@EK1SOKS,'E;VY^'$\R MDR>=TLR>PF.?.=D6K-O=.EEJJ-+?LD6 )< 6'["R)F&V\]URFI=Y8);F<):/ MWAZRGOBH3:HF%"?@I316VUU&Y7"XEP>LW[FPI7+58 HG779+@\G_:)(>8UB4)AJ@H-06PA,R$]AJJA52PVZ MBHQJH_;RVQZY_L"\(95&R5#^L%V6K.@2.>_A"U,.0\,3&N1/RA0G Q/MIBD> M=T]]7#0_CK?\%*:;AVD5,2PX.TS(3V&Z 6VSI-:EOU64H%L,"@FZE(R1PX7[ MPAR'>]Z_<^3#T4[]\.G7BM5U+RL;=O?R46915*4E!6E5:HWVZ0HE,<\A1.XZ?F; MN].:K"=9:]IXI+@?>UDWM,L9!SN7ON2 )^* ."#-*.:L$ ?9FN:/?)-Y7%>Z(]OQC+\9'E_/?JN MBD_.5R#D\LGE\KUKENJ52GZ=OO>RHH!PFBY.ZZ5&NU$@G%),DMH35A9)RT#8 M*4KN,QAC0[-@AV3WWE"OF.!/#&BB_,]/G%(R==3!&)P&HP/DT M!IP_:MA&1Z_,UZX?FMYS!H8\("NZW+/_3+YQOZTG2N3N>XS M?_.^F+;V\_,__Z$H_UGQ/,LS=,/T/7C2$]=\Q_ ,[MZ\:::OPRB./;JR1V/? M$]GM[_T;YEC@7[D/W'D:,H=/GZ]HMN7!'X^\#[[=']6*VBQ75/@G?-DIURH7 MBJ%_NM#*:N?B\R9O4)2.]=G(,.%-3\R[!?/NX+R'G[K&WSR R=2_%&),$TN= MRB\+&*@U8S[O8^CCXK>$,MS>7]_<"Z2\??RHO!JZ-_R@M"KXYX6B<=-TQTP# M 7ZZJ 1_CYFN1W_W;$?G#KZ,A0I'4I)Z_9<3FTF9"Z-@+FR<&NO317/[P&=5 M@94DP=#ST.%<^09J,G25&PM4^<3!4$;33B@[:<@-3\D#R.:3+V11,^X<4E!M M>.)CCX]ZW%%JE5)6FK!SQQ/"+&&V8)@E12)>^ MGB04$NHS1^%A%I";?XH)-1*WP=USZ!CD9J.UPS1&%7@$17>??4?73?YR(VV?&@QYE0>+CEB5&MEBK5ENS6)Z0W1VLF M(?-4@YOC.B,&7DMNH-0FX1<"$_A61S";GYI)!L M+NVM2!>O/'"G;SOPF<;%(7C#&G#+4W G)1>!B6RID;SC>Q6Z94LMX$E MND2=5(5496,FLIV7RV9)64A9:%TA52%5R8.JT+HBX8:8)*D)^9,GQ^Q3*+/& M']2PL%I26WE1>FKL20HC@<)TFEGN!Y#"D,+D3&%HA2&%(86A%>9D+:13:OF< MU%+ZBKG#KZ;]^N2/QR8?<T[@Q@:19V8/_O_VOK2Y;21)^_L;\?X' MA+V,_.8I D4(;!#@H0!+GUV]F5N$B 8JD M> !D=+%&+#[(\,HDJ26J[VSV*O9[8L]5DXM%X M'PINP6,_&!/?>[+!O3,&4\.;<)]A0;7!S,!^HCB5X0T-H$-66H=PG;I(GZFY M!0JWW7]PT0Z!U;O8-VKM\^[^6+GQ+O9E08'&Z49Q>E9K=[MZXU'^XEF*YO;Z M"95_PK[MN*.WW6SWB0MMN^DU\8@/.2T+%,I/H0;KWL&Z7C')2L4>114C5WP0 MO*$LI%Z9LI#SN;*01NJ;RE6%%,%T-TJG?.]>+Q0]+]2IX'0[WRXL?LJ^VR+M MNH&71D$947"F4:!1T#A?%@7[]M;5\MRZ.#V.,S:_>0$OH<==*#"5<' 64+^* MU;X+=VAA=G'!.') @'')SC5IEZ+?3RT=JU>;U1_EK38 M:['78K_\T#JPVG>J/TL'+_;K!7_GX[9%$=Y/PR''-""_=DUOS!_8RST+^#TW M/=>T'=F$;/T(QM$JFQ(W/S&%6R$TZC3J2H0ZK6;U/K;JE1!H M[7K$8%N\^U&--:S8-MBJ"K?R:K21E/^WSHRCZN$%&),W O:R8\3HC0UO)JR^R8T-C;/606YM* L8RD]AI>#ZOG%>KRY< M]7;_(T%I9X_ECAJD&J1+@;3=.B15NN\.N(??]38NZ$EY#X;/ K[;M.^A=%PK M!X5O5RDIJM\W3SM_*[E.6=#]K%PKG\;KUO':/"V[G;8 K7_;H]]>$C"4G\*- MPK6NX5II,)2?PHW"M7%Z<4AP7:]>?O4J^*)Z^MO@D?L](7@@>JY%?]W8; / MP7.VWE!)WZE.)?W<62K=UGPE?74.4]&)V:-(S&8*^HP]U 2L=>2VAN6!P_** MFPJ5#4+EKHL'-HO*DA06',DI[O< 96/"IF0&52'ZI_,(^FA$73]P]&#M- \2 MK3KYM>T%[[MKV[ =QSZT[%CQ^J,0B M62F;NT*J)G,.) ;92JYJM+=X&!1N%+G-6N= D:L]QVTODI2IK<026#9K^]4D M34G&L/ \94R34M9[)V+?9;2K):TT9ZIEI5]RDJSWM#"4@9GN"168?GMUM7E MHP7R87GAP.%E3M4L0?S*9GF[UFWL,W:UBGRW*G$ L9:30Y23;JUQ=J[E9'8= M7+Z*=Y7:VR7J=]]UBAM^]ZW.K6W#:/ MHN;V.LJNF@QKCPQ&MD0E(LME_&QZ N28,;VB8/K?LH!)+7]D21>6@\.TJ)45UZ7>@Z/3F85"X4=2VNJ6O M**IDIO'P'4&*)!L^-[G]A%%;[0-6E\*-VM;=[C[WH*R2Y:GK;.B14;CAJ$>] M796$YI:AKOW.G2RWE5ABRV:U5Z4H<;UNZ6L7);:KLDKK EXM*WN6E>:Y%I92 MN-4E,2/+;^A6N3!Q#>%^4V%BLU8_/]NC?.LB72T+Y9&%3G>?.[NJ5HB[7-5M M_Y'Y_",3>!3!%$\IZ#TSW^H'<,OMA([P^9,Y(174P&/#L?SN#:?I=JMQCXSA28[SBJN,T3=ZL'U$H+PV&4O.NST#40RP+$0SK^?$ONXY%LM+BWQ<^3 MH<^QT2& E(N VAQ6(@58MBA/.2C<:/%!Z\.5#PYL@ M=0XZ#IX\AP5XKLVT$HN!-ARUNZ/=G<.@<*.H[;1/ MVV?5!:[V=S9]N([]9%OF1/"B,ULBV,JI$.SH L&R M)/./H(#JX1$SLV6M$*S,.XX:0[K(]JXM,1X=49*H1J1%9+D1J]:RK3=]> M;:K+GC402P'$:I<]:R >#!"U1M1 + 40JZT1]WU.S&O'"\@P\L7"E/A,./GD M0L6XJY1P_LB$;1K/*H5@,)E#,%Q*(AC>,)E!.M#<&X\]UQ"46JA$=EK7L.11 M6-]HR?YYK=%ME3W9I\NO#H/"S4*W4^MVVAJZAP",\E.X::U;;^[S("8-W2.B M<--:M[77AO?ZF.OJ5LC>>0&XXC9S#,MVPL!^X@9,$S<#]$\$%E2=#+#.RF!8 M854-)Z5LQ8A5.>1WD5;:PB&_^RQH+-$1OUI4M*AH4=&BHD5%BXH6%2TJ6E2. MK,>"SIU%FS7! 05/LSA[IA-F6U*%RY^_7V9=^*:#^/>>=EM%(^J.%5IB]B\Q M^\[V:8G1$E,MB=EWDE%+C):8:DG,OG.;)9*8]8Y*6.$X@_P3$;SA9]NU WYC M/W'KV@V8.[+A+MF.Z7,8A#[OC3T_L/_%\)0%/%/.%?P-O90:E3DH(:>74NH; M=4Y"HS*=E-8//AUB0?BN=R;HW0='O/O@3(--@VU78#O78--@VQ78+C38--AV M!+9FO?1@VW>R\T-I&-FLES\1&>('[/)WB;.[JRA>EX AZT M1OI*M,[KC4YU,EB->FYVZHW)J>+LE'JM/$]\%G&!-UDO$.'P8;!,&&(V-9=F M[38C$TN!09:]HMPYUM]E\KM^NC">\6IL0S-X,8/[G[Y\!3D;8:-0-/^:H9P2,W+KWQA+E3XY$)PW.YX4?*'YY&J\%OZ'B6R9%6 M6Z0(88[CP7-M%R?.\P5R9, #G-#0A65-!/BH:'923ZI%E\G7&!/?$]A042"C MC"$9(X;)Q*,QQ#?4B"0D&."$#'#Q03#-*9H'7IB9AL(%H)H2>JB:YV$%99'P M8.B9(8(39-?B3]SQ)HA@! GN<^&^:8,B^!=^E_=$(P"X A4.I\HNO R!XS#\ M'GXT'UW/\493>B"@5G@N/@[PAD5L)O9"0)@J"$] ?%#&U/-MH< :"1]*C>^% MH\<5%6-:VS)[3,(%ZL%K_!0MS FXU(JH+QCH,)1S(3QX&VTQPC>,&.@ #S4HO 5X0T_B MKN69/C+'1!'W80C/C[;Y2$^8P ^F/0&%,37DY%DX>9SY\(6B3"KB1S UC$E\ MM@:,>.0#/Y1VD8\^-2X!SQY,-"J?I?@::5'P1V"* B1HS'SP(?"="3MKQB-H M(CM@CN2L"2B'VZ66!M0^V29JW"''Y0$Y1#,;J9[H)8\,]+*PP44!*AS/'9T M4\?QKJP1:#M4SSY #]Z(+I+/CA2+WY:/-ASH) MBM=/UA#;!UI$Z 0D?PQ%;F#CHCM@P-JE#.^4=_JZ#SGK=#K#:Q?78$#"/<I2W?!*!_AD*B]_\ M%AI?%_M6LQ">2.*:-.(*!,KA$E9%T7AEHNNBFM_T'T/X'X0ENY%*&!I!D,R\&T3 M_ KJ$AN!*(6:L\:[/^Y:__O:X-8CO#(L^?%@![AM[-JUL'=ZR!RZY%/.4WV&%=/ZX4#P?X;PND]/\*_XCIGO M%[+XDGN70P_FY5*&:Z.WB1R>7R#/&^7F^:=_AG8P!4\N\$/R\6\Q2//PR%S5 MHOD+/"(0UZY\;:Y>;29ZM7G2O-@\CHL7D;.THGX9^(Y](H^= 34XMU#NB$?[ MF9F9':3TXQ4LY)^9[6.;[7RW<)]35[" G8 -<9*=ROIIL[/[>7R5HQN:Z/AY MJ2;HZ)HBPZ^0MQRF -Z[PO9]#V.Q MW=-.CZE9K^>/Z8]-"/JR0]@!Q_[T''@,^-?3]:;^K"Q3_]I 5IC\QL5YT>2? M=MKMLRTC(#N2+;+NWA8_/_N<7^/&'="]ZR&@M6\$+#>,E>9_?K6/YK_>J#>W M-/]YX]@0VZ)S'GJ69>,MS)$G/O3"X-'S*0WXQKA9=UX11*MJLST;W-O>,#;$ MK]QU^@NEN)9Q%';B !3/Q<7\VA7-Q?G9^5F[O8&I*.;0BE,@5GK#C*WTZ07S MXH+?^9C#K,+4%(0Y%B=H<'W,F,MF25H:=):S$'9&: M9QZF2>U26+-QWKS:P R]2M\L'SP_P.^OJ2A1EGT6IXB3X'V[,,?^"M^7>5^. M43CS\L)4:J,^D]_/>>$,22A+U\ M<)!#/XY.$A,??,Y$Z$_IFGMNTU6Y,PQ& M0#?U<<%"7>\4ICVZ.2\_0<+)N50;&E M*ALR,.K4"W.P8,^=7I.1 MWF2T@4U&G;E:QS6>HON<0O>&6XD:M,^HF[-^ >W71_+U:]\6)_A/KCQ[O'TZK2&U#!7W\7ZIVR*(4*M#VLLYXX4WGG-R8L]D_CQB:_SK@/8=WI=.N=]^:' M]^T/[S]^J&%M=C3(3C3(])X"UX/)L6%4WWK]J]Y_4[5_30Y1EG='0WQB6'4_ MQ0?BG[W0L@-\RM@. LZSC'B/'Y.1F'^?N3KYR?K[!\,$LPCKU0?3)5E1RZ? M=>2&M.#94],CXJKV:+BVP!'C=@'BHXVU2Z_SLOGA?>]#M)'!Y[@OC(M<(@:< M'NS;M+5A:+ ="K#_22//ORLR"(8P",F'A;:JJUHBL3LJ'%Z<*.4FAUESC)X M*.TZR=Z:GNRNG&R#F3]=[]GA5KS!9<%[Y%X/&!"QB?8LP*-RF(7/831T,QZZ MXHOT?00/<+L)7 IWO\I:X@=NUI/#BH<;@S,]R(A&@".\TXD1:>)NL8D,/:@= M,H2IQ4(2;T^1F]C2+PK=P';H&]R@8DMI?V]_($I=L#0!76[(')A5N9$BZOBJ MK%?#\^%RN#Z:$[E;\4SN&!RQ#%]!4F'( M-%B<6H ++ Y>O24W0LG85X11J1F4$LL3'1":Y&KN6I%*28\B M8+31Z,H+!T$/-Q%^P0V;EQ[N,W+7=3%:VL70+L8&S->F]C#*/D4;F*";Z__^ M?GUU_?"_1N_;%8S^6^_+)SQ=X=_[QMU-[UO?. I?(SV6Q._(]4"JZ75\]N0Y M!R[ND1T#%!X%KG9@J\R["UE3W7;I6 T_UPPKQS,K<,:^4NC?=HU8 %Q(B^! MMLS3YEHP,9*=G"S>*V \@YG\2S>Y[=1(6)Q>\2W;(GO99V#0&OB-R6A?+-HV M1 ]].0QI !8?P+I/44\B?&C[8'.D!PKDRG$-0K+A\/DG:! F MO&R>1Y:P *%Z=L#('48^K3E><#![",O29J!=D N!(YY"CRV?/;L9HT@Y@@@ M%*P%W,@<9,Y.P!GAFON@:V@'.QV6 M3=,])"%%K(IHTY*0.^(''#R3B<\GS)?;_YG<,JX.&L#\'E=_I+7?,VBJ1*XH M0"$/53&ED:Y%2U#-X8?/T/+DP/I!&#A%_[R8/DF]3 MEZ2'22^\.+U(+19%F);_5,RXJ+Q0]N:C=8)) (C$MW5P[7)RSU2RTV^C0)8ISQ9$7AB=F/*GE=PA7 MD>!,X4T@DSXNELXT.[(QFT9/24=/XG>XRF"AY1:F[-5KS^C: 9^",J98&KGA MR'!O0"=7B1"F);J'^ W6$K%K5ANF:1SP9+ T>9DSG] $9 8=V"%5(STN?^5/ M0W(.?8"/9P[/8]G;O>?D7CKHR2Q[B5LHEA%!&A M,J4M1P!?3M L= .",%BO-Y?SL?,E[LR,AZ+W?N;W:%BOL;%&QB\MT/PED%Z) MH"V^CHI-T=EG--%@2M*A/VC&XI*/CXD"G8U:@F *)3_39;&.:447A*Z#"(BL M\>BEQ%-YQ)GK&:.0824F5^'I'"D@*0$X8D@80C;HOT#/1-82N23\9>*@ND(Q%#.&SA.(@!>B<>Z$ M,G_EHM_GGL1?1.H7[D->P,MJZ/\Y(3D#"E!X%^%=&7_DRB3*&G0&19S5T7)X MQ)0K=7_HQ'M>B$,#R* MB$=')Y')&1EG$7!AD)R-\90HU",IK^9ZB&=)/:,,S3CSL"BZ@ %@AQB&I,BE MKI;/3S0U?P&Z@L@] \,A!;B8:VF7,ZW1GS$+X,)ZC?9Y,E\16!-A4 R)UV/) M]905J#(*X!^KE0%H,*6"%IS,B@A1:)GPG[@81N=YT2F ]-+OI_U3XR-S?_KA M)#"GP V+,A^I!U(@P+$!49:RR?TY*P8#!IZ?69"0^N2,R/0,2*. LT@1@.LVRN1P&:0P:!XE5*A>$4X(A"]032D, 77BJESRHRXZ+!$FS KGH MT7AX.%LJ^H#Q 8KSI-A-G6>#^7,59P8H39X,#.<]M.7/8BR-PY#OQ1^0ZW"U M5+0NJV%!9[HF^00C+[#5&D@V=710:J1>*9CGJ32\,CZD L[:)R*MZ9ZD\IX5 M[O1IJHD#L82]B9_'["\P6*3__ZKW(RTZT%\3#\V(K*(<3&<$&'4J#<@*3=*D MD1D3\572.9QE3HIR"IW "B&CM+%)C8MVO+#^BB>B>O[(EIZ&O(3"&S[WAJ?& M/Z)%!JDB39&E6VGM)#^;55@D^?3Z.8LD&_X<< >\G21 8XL"3DE#AGPC7'S( MCD$=164:]A@S]')BI:['86)0F,*KT0&7!$N'O]A*OZ2.A556R*GQS:.8D2^3 MZ/%:JTQ!X!?EP97UE8'L#,@*M5NR**; %MEER1*^0@BSY/IMEV&8RFO07K!4 M/$^Z7UAD(@_5!$BEX105M<3^%]I0I$$R(/VM>A!;;N$\E(*&3COBZQ)-7")2 MSS=:!#$C*65,LC<6%_)LMP*A OR1?5BB<%*4:'#ERCQGZ/S2J*>B^&EW!I^0 M#AF\%O]9>EHJ5U:P7#I.:Z%CDK+YLBJMA=+\B0]WS%HJ7JQ&$G_M_2^MTT:2 M:$Q%FM@+%Q^T7M%ZY4CJ!UO[5"IE9\YM2H^H)CP+HT))X!@#-J!5X"<,OF(4 MW'B/X4T/K)_8])E3.\:#1[FIFM%JMQ:_BDI39)(EN]\@&PN@I@_4@X--*6'( M)A/?>[''\!9G:OQ23R6^;1!(D\^C<+$L)DC%X5[9B72P.E7'BS=104N5+:EVB93O62P71C:EYFJ MN2=E,=,>TD8SRN7*!FXJ!2$JF$=8(Q6_/=/NHO.WF<;>$D)9MZJS4_-OPQS> M=*_TW;2V+^QG?WM_]>D^AO&_T:E-=:,Q>3%HST+64#)I3Q+,A8=3X_[^KKF> M/RZ?LXQ'OINEQP,W='4C]4T3,L-X+&<*QUA;"..YZUU=77_[$O_8B$Q1C<0# M1V(=0RBMMQ5,E'AX]0;*&D=;6D:4G3DK9=*'91TL#ATJ)66E'[ M->TX^1&!'WN7__7E_O;[MZN3R]N;VWL L&ER/AR^V_1HE/?8/O_; EEZG9H5 M_?-] >8;5B!AFN^>6Y/9_12[!E*4-UB;\UM7KF^F\)Q) M&?BI4;M_"BN%VF:MVST[2#6[M/,QI'\V[GRL )Y9"BKB<.06+%?"ST@QO*3Z M9!\4OEVQI*ANU1JMTBL616^%5D*-7(U#0:;>5\#LJ%<>HD#9)4=WM=LJN3W3\[3 HW"ANSS5L M#P(4Y:=0PU;#MH(4;K8@CYX;"N/$@!'+,P[HN-E* MN"%E"VJ\6LY:DC$L4D&KU>0N%1@YA_M+,RNOE8+J"* 6EGT*2V.OEJ@6%BTL M%1*65OU<"XL6%BTLRPG+/JL!2B0L94UI16R00[Y8[$]7S=^D0P0J5V!7MA!6 MOE9H@5; ABL.+W--[Q+$KQZVK77KK8IHM=;26DV'>K6<;%9.VK6S]CZWS6DY MT7)2!3EI7;1*,QM:2$I"H1:2&2&IM;L7>C%)NY+JC\PQK9GNYAMUK]Y%CYWU M_XJ/ 7F3[S?TW.#DF0X?QUEPK+_'MRT^43'#AD7$EO:8S5LW=:)Z\UR=J#[7 M;/G2\:@-WA4+9KLJI\]D9:I[]O.CYSC3$^_9Q5;/ML]-V2G.=M4?V$K3MFSF M4PM5[%+M3YC)C:ND-[EJ^YRF(KD.?III5@U/SWT,T.9//'FZ\8&I\IE["W+B=8-/#T)5'.W\.70L8=WIW.O^*&SQ W\\\^-2X MP[:J3'9SIA[RX> OG"#5&2ENRTRS/$.CG'OY6(/AM]1[*>I2R R?/WD.-69T M/.Q,,$<1?)L=:+:'\1+-ID9=0^[*4:='E/0SD=S>IX-9OX$S>EP:P2CI8;-\7:YPZ-E=]LI!K M-D%84$=,YC@1"+ M>(@-&T".N?U$)\B^1W*B[EMP'W-'-IY7_F'F[-X"CJXP M%DDNT(C]P_/IK2&&J?%WNAF8'&XM&DS!2,3;AD+MB*-.H;4,X_'6@CE?OKGR M"I,ENX/+5N:K3$(*%JXG7T+*!QX^47J!NJBF7R [H8Y9(&F)NM[3XU#N;3&_ MQIS+F^CW 6>^2(: G>9A%*Z+9SACDW35+D1Q\*^;W Q]2JGL[LFM-$.]6B98:B4^/3D^QX,ESB:D"S-R9V)@?SIW1T=+R_27WQJ$^* MB/I,H08>,MNA)JZJ,XN/%V'#EVS35FQA;H5*_8W93]7ZG.&DPD.Q#[PMTJUA M9!O>M&#)WNGX6=TXL&&!8+YL9<#I)/@\ O!9LQ(]:^V5H&M6A8XAK[QYG&[Q MG+)P0)3BMM5A<.(-3R:>^9/C\?,BB+IVJRX<((PA%2*J%ME*PZ+0>JX+ M#_#G2/&&;HCZ%"<+?\YJ>F7D2<4'[P('^ 0L(6<(O )"X4_49B;95_73^GGK M;_$J;=G8D K[L@C6ZWFXR4 MX=D>(WPSJL-H0,4+2K8?1N%8I3OTWD*Z4T/)4DDL??82XIH)71GNV/D.!$YJ M]' 4$ ZP5-W-R<8!&P#,'E^DNT"DK/5YJ_HSW=9+;IMQRP#L-'T9CC;>1#0; M!HK3@)VC\ X"F[:0T0)QO8#:VW,?,&?Q"P0-I."O+1 MB!<%96.J)6/P7&DR0H>J>:JTI,!B\P-:K8'6L8I6).'41%9P/*?&)[">36+2 MK1EXQ'Y%S):X#^2&/MPQ-P?$WX1?,QQJUG?%HE,#T)C,3'?+W+"'2S/C"FRS M<7J*]H"73-A3/B4[ +)[Z4^1&0GW70/KB&%H4$Z/'J/#53 03;APSFXP& M=*O "<;L@(O^-T;U(B>(^EQZ26M+> K&-+&9)1C9KO%+NUY')[6&AK-JN*E" M1*I)9KRL@(!RF&'5@A"9#P_#8Q6G!CB7/Z6EGSOHV+C!= BF:F0+3<""K_P^ MQ?C4X*(,BIJ_)0 D ]M$"WF! ALI,J/1.L&O)%N&CO>,;^/P%QI=8W@]ME=+ MB5-3(JC82C?RDKW+-- ]!HOE>T8JLH:*+:))MR1\?W+5[3K5!3L2-I&1MIJ, M#G%F/L;2&+O@O^#YVZW:60=0G$U>1NU@&6D*:H*=I$C MP6J(MBN+/%16,>! MR['%-FH1 &"T6$1K1:0!Y1NBY]J86GB.[IE37Z<4@(4!9AC"9!![@.%IBT?A M%OE@BU%X@!@TM(4)Y*K1U. &H-.ED+1K]& \CJ+N; 4K4.-[+AA*,4TW<*91 MJFC,&2BY"-I+KR1%*)#+IPK!K+=($[3-;<&OY_)WIA8XE5;#CB1C%N9U-96JM9E"D=B8ICH*027!0II$KFG%= ML2@;V3--2H2.,"^2?D34^5E(:V+B8-R--L=3^D2F#7$"GE1W:@O681H"?NEZ M[DG\A0##S93WH=]%7G;2OUKQ#^\B!BI?F_QN"ER#>)J8L;1QQ9;O9 Y,JDL< M@ZL&H0#P"DST/7''FTC3!:]3* MJZ2"^ NWWO/A[^_L'XCGD_K%2:O^#A-@]A@,@]_?G;3>&;;U^SNST>ATSQJM MSCL#JSCD/<)K-QMG)Z&PWOW1O6B D9)0_=K;WTIKYZ31/&DU%M':+:*U\S9: ML=LY_'Z+,]M3Z?G[./9XYSFV.# M+P/2A"YH0A\UH?I5V/_B4G$N7U.FGWB(3ZS&:KT4&^A'^ X6-=N458_WZ5@_ MJ-D>=L:6_A2L-*0GL==Z))Y+J=SJ!?>+**_$U#\4&A4YQ5MH68^XBUXR&$DA M9=>P#$+F<'B X?@ G :126=EGPNO?K)-E1P"= QM!]/!X<3#0/QXXO!T=CD@ M%\3G3S:,066JL:XF_3L6'(5.($NJ0./_%;JI3+EZAT[WWCT!)ESV3P=L,8;N: \MD59=71!I,D"!*,KV!SF3#\ M6OS)Z%E/8%RPD4JD1:\3Y*N[TD$#8U)YZQB^P+*95 -[9B'$I,5#-3J8.>9F M$*7UR*EDPG.!LBF:;1B2/(61Y#U")$F5HA0Y?NW8Z*KY=F2-R;H>>SP $U,& M+*@F"BQ$-*CCL>*E>0-7!KO,8PIBF61>S(UY[OL6180*%$\\*?CM'?SNLR]< MEI'Z?/3W^,&@T 6F9N-9&E#IEK*Y%2<148\P8B_*, -+"1_@A=KXZE<&"-[/ M$[HC+]S*X9*$(UQ/_L*KFA0FT#-M0E=4#R*X)&>^$$FKUGVKUBA,EU)_6)&' M<36?THFV"P))\PV@ 57J4PG<"-.(+F($+H%'C'PV%C+K;WGD5A*F6*P),-L) M@U"PR57-JD9F+$O\\#^4%..4T4QJCP27I3J80N4O 'L9BTS#=H(V]GPI:UJK M6AY7GC6&DZ0[&M7X1RDV(1$\ ;^,_J+A(6ML4C[CJ(J*V(A!T61UP!*J]$J0 M5QX!?]K^0E87<3JA'E^?'E;$W&@RB0.DNP:"JR(AU-IQVCJNV5*CK"5A Q/6 M,XQ+J$(K6C@VEU*^@>UD(B M%;0F1A:IEN3%QCI47.*PW+\5I^18AF1K;H5@%):8SR$N5*:;_IQRAI=Q;W,\ MXI1%_@_N6)\]O\\<_HT'W[S@#DR:V^$5J#E/,.>+[X63PNC#CVL7)H_W V F MSM-'F2?I/W*.7GE/23MSX'$8H )K0GR<9IXMKJ/0#EZCHDC6;9QCZ8%6.;F, M$=)7LO25^)^.(30[9P4Q!.-%_.;:SN_O C_D[WX] '[0?.?_GL>8\[TS)DO/ MQ?[H4:&H_0.W*!36[-:+0F&MYD4W&PM;@R4'P-35T-]M[!UMBV:[N=/9!M\N M]*?]P#-_]A_![Q!+!9:OOWU.QS\[]31+7P:^8Y\(>MJ[/SKM9J?=2A,]]\HU M:,KAXQQ-S4*:&O4W$?4G+V19&:^Z/1;;=FIG;V?:O3D\.C>I9# MA8KEO-UJKD3/=\%OAY_ VD&/;K6L753W(]*; M?>(2H%@K4^9;B' \D<5J%.=@5(>9B:!F\_..+6/!&-&1Y66JXL>*C;8HJ R MI**T_)M595MZ[V[N().06>V$PV2&'B5JKEBEP MB/W4'6#*(_H: M>2FX3&]0)!ZA-0Z=P)[ 2[FC-@;B;@C)*,#N$RS[$JMQ4$2DO%F@2A M88\GS/837 WE[BN)95"H(U<.5#WNU$BXF0G#$I80#,Y4996$BG8"-P,,G